WO2006036817A2 - Fungal variants and uses thereof - Google Patents

Fungal variants and uses thereof Download PDF

Info

Publication number
WO2006036817A2
WO2006036817A2 PCT/US2005/034219 US2005034219W WO2006036817A2 WO 2006036817 A2 WO2006036817 A2 WO 2006036817A2 US 2005034219 W US2005034219 W US 2005034219W WO 2006036817 A2 WO2006036817 A2 WO 2006036817A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
fungal
spp
mammal
candida
Prior art date
Application number
PCT/US2005/034219
Other languages
French (fr)
Other versions
WO2006036817A3 (en
Inventor
G. Todd Milne
Original Assignee
Microbia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia, Inc. filed Critical Microbia, Inc.
Publication of WO2006036817A2 publication Critical patent/WO2006036817A2/en
Publication of WO2006036817A3 publication Critical patent/WO2006036817A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Definitions

  • This invention relates to variant fungal cells, and more particularly to uses of the cells to treat or prevent fungal infections in mammals.
  • the invention features a method for treating or inhibiting a fungal infection in a mammal.
  • the method includes, for example: administering to the mammal a composition comprising cells of a fungal strain or an extract thereof, wherein the cells are genetically modified (e.g., recombinantly genetically modified) to have an altered filamentation property, thereby treating or inhibiting the fungal infection in the mammal.
  • a composition comprising cells of a fungal strain or an extract thereof, wherein the cells are genetically modified (e.g., recombinantly genetically modified) to have an altered filamentation property, thereby treating or inhibiting the fungal infection in the mammal.
  • An altered filamentation property refers to a filamentation property which is altered relative to, for example, a wild type form of the strain; a strain which lacks the recombinant genetic modification and is otherwise identical to the strain that is administered; or to a reference strain.
  • the cells having the altered filamentation property are hypofilamentous.
  • the cells can be genetically modified (e.g., by recombinant means) to alter the expression or activity of at least one polypeptide that regulates filamentation such that the genetically modified cells are hypofilamentous, e.g., relative to non-modified cells.
  • the cells can be genetically modified to increase or decrease the expression or activity of at least one polypeptide that regulates filamentation.
  • the fungal cells can be of the same genus and species as the fungus of the fungal infection, or can be of a genus and/or species other than the fungus of the fungal infection.
  • the genetic modification of the cells can include a deletion, insertion, rearrangement or mutation in one or more nucleotides of the cell. Genetic modifications include modifications arising spontaneously or resulting from mutagenic treatments (e.g., fungal cells may be mutagenized and clones of mutagenized cells may be screened or selected for clones exhibiting altered filamentation properties) and modifications introduced by recombinant DNA methodologies.
  • the deletion, insertion, rearrangement, or mutation of DNA sequences can cause an amino acid change, deletion, insertion, or a premature truncation of a polypeptide encoded by a nucleic acid in the cell, (e.g., a polypeptide that regulates filamentation).
  • the polypeptide that regulates filamentation is a Crvl polypeptide or a fungal homolog thereof (e.g., wherein the fungal homolog is a fungal polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to Crvl).
  • the polypeptide is selected from: CdclO,
  • the fungal cells can be cells of a dimorphic fungus, e.g., cells of a dimorphic ascomycete.
  • the fungal cells can be cells of the genus Candida, e.g., Candida albicans cells.
  • the composition can include live fungal cells, or can include primarily killed cells (e.g., wherein at least 80%, 90%, 95%, or 99% of the fungal cells of the composition are killed).
  • the fungal cells can be killed by heat, ultraviolet radiation, mechanical disruption, or chemical inactivation.
  • the composition can further include an adjuvant.
  • the composition is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally. In one embodiment, the composition is administered orally.
  • the composition can be administered one, two, or more times (e.g., 3, 4, or 5 times) to the mammal.
  • the method elicits an immune response to the fungus of the fungal infection in the mammal, e.g., a protective immune response, a cell- mediated immune response, a humoral immune response, or both a cell-mediated immune response and a humoral immune response.
  • an immune response to the fungus of the fungal infection in the mammal e.g., a protective immune response, a cell- mediated immune response, a humoral immune response, or both a cell-mediated immune response and a humoral immune response.
  • the method further includes evaluating the immune response to a fungus (e.g., the fungus of the infection, and/or the fungus of the strain that is administered) in the mammal, e.g., evaluating a cell mediated immune response or a humoral immune response to the fungus, e.g., evaluating a cell mediated delayed- type hypersensitivity response and/or an antibody response to the fungus.
  • a fungus e.g., the fungus of the infection, and/or the fungus of the strain that is administered
  • evaluating a cell mediated immune response or a humoral immune response to the fungus e.g., evaluating a cell mediated delayed- type hypersensitivity response and/or an antibody response to the fungus.
  • the mammal can be at risk for infection by a fungus before the administering.
  • the mammal at risk can be immunocompromised or at risk for becoming immunocompromised, e.g., the mammal has impaired neutrophil function, e.g., the mammal is a human with HIV, e.g., suffering from AIDS, or is taking an immunosuppressive drug.
  • the mammal may be suffering from a fungal infection prior to the administering, e.g., a fungal infection caused by a fungus of a genus that is the same as the genus of the fungal cells (or extract thereof) administered to the mammal, e.g., an infection caused by the same species as the species of cells administered.
  • the mammal may be suffering from a fungal infection caused by a fungus of a species (and possibly, genus) other than the species of the fungal cells administered to the mammal.
  • the fungal cells may be cells further genetically modified (e.g., recombinantly genetically modified) to increase expression of a cell-surface or secreted molecule, or a portion thereof, e.g., relative to a wild-type strain, a strain that is identical but for the recombinant genetic modification, or a reference strain.
  • recombinantly genetically modified e.g., recombinantly genetically modified
  • the cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, hi one embodiment, the cell-surface molecule is a mannoprotein, e.g., mp58, a homolog of mp58 (e.g., wherein the comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof.
  • a mannoprotein e.g., mp58
  • a homolog of mp58 e.g., wherein the comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58
  • the cell-surface or secreted molecule is selected from the polypeptides of Table 9 and homologs thereof (e.g., wherein the homolog is a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the polypeptide of Table 9).
  • the method can further include administering cells or an extract of cells of a second fungus (e.g., wherein the second fungus is of the same genus as the first fungus, the same genus and species, the same genus and a different species; or wherein the second fungus is of a different genus from that of the first fungus).
  • the cells of the second fungus have been genetically modified to increase the expression of a cell surface or secreted molecule, or a fragment thereof.
  • the cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof.
  • the cell-surface molecule is a mannoprotein, e.g., mp58, a homolog of mp58 (e.g., wherein the homology comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof.
  • the cell- surface or secreted molecule is selected from the polypeptides of Table 9 or a homolog thereof (e.g., wherein the homolog is a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the polypeptide of Table 9).
  • the mammal can be, e.g., a mouse, human, goat, cow, pig, dog, cat, rabbit, rat, or horse.
  • the method can further include isolating a composition comprising antibodies from the mammal (e.g., isolating antisera from the mammal).
  • composition comprising antibodies can then be administered to a second mammal (e.g, a human), e.g., wherein the second mammal is infected by a fungus or is at risk for infection by a fungus (e.g., wherein the fungus is chosen from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Paracoccidioides spp., and Coccidioides spp.).
  • a second mammal e.g, a human
  • the second mammal is infected by a fungus or is at risk for infection by a fungus
  • the fungus is chosen from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma
  • the cells are genetically engineered to decrease expression or activity of a polypeptide that alters a filamentation property of the cells, e.g., wherein the polypeptide is a gene product of a gene selected from:
  • the invention features a method for eliciting an immune response to a fungus in a primate.
  • the method includes, for example: administering to the primate a composition comprising cells of the fungus or an extract of the cells, wherein the cells have decreased expression or activity of CRVl or a fungal homolog of CRVl, thereby inducing an immune response to the fungus in the primate.
  • the method can include other features described herein.
  • the invention features a method for eliciting an immune response to a fungus in a mammal.
  • the method can include, for example: administering to the mammal a composition comprising cells of a Candida species or an extract thereof, wherein the cells are genetically modified to be deficient for expression or activity of at least one polypeptide that regulates filamentation growth, thereby inducing in the mammal an immune response to the Candida strain and, e.g., a second fungal species selected from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Paracoccidioides spp., and Coccidioides spp.
  • the second fungal species can be chosen from, e.g.,: Aspergillus fumigatus,
  • the invention features a composition including: (a) cells of a fungus or an extract of the cells, wherein the cells are of a strain genetically modified (e.g., modified by recombinant means) to have at least one altered f ⁇ lamentation property; and (b) a pharmaceutically acceptable carrier.
  • the cells can be genetically modified to decrease expression or activity of at least one polypeptide that regulates filamentation.
  • the cells are genetically modified to decrease expression or activity of Crvl polypeptide or a fungal homolog thereof (e.g., a fungal homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to Crvl).
  • the cells are further genetically modified to increase expression of a cell surface or secreted molecule, or a portion thereof, e.g., relative to a wild-type strain.
  • the cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, e.g., a mannoprotein, e.g., mp58, a homolog thereof (e.g., wherein the homolog comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof.
  • the composition can further include an adjuvant, and/or an extract of cells or cells of a second fungus.
  • the cells of the second fungus are genetically modified to increase expression of cell-surface or secreted molecule (e.g., a mannoprotein such as mp58, or a homolog thereof, or a polypeptide listed in Table 9, e.g., wherein the homolog comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the protein or polypeptide), or a fragment thereof, e.g., relative to a wild-type strain.
  • the invention features a method for treating or inhibiting a fungal infection in a mammal.
  • the method includes, for example: administering to the mammal a composition comprising cells of a fungus or an extract thereof, wherein the cells are genetically modified to have increased production of a cell surface or secreted molecule, thereby treating or inhibiting the fungal infection in the mammal.
  • the fungal cells can be of the same genus and species as the fungus of the fungal infection, or can be of a genus and/or species other than the fungus of the fungal infection.
  • the fungal cells can be cells of a dimorphic fungus, e.g., cells of a dimorphic ascomycete.
  • the fungal cells can be cells of the genus Candida, e.g., Candida albicans cells.
  • the composition can include live fungal cells, or can include primarily killed cells (e.g., wherein at least 80%, 90%, 95%, or 99% of the fungal cells of the composition are killed).
  • the fungal cells can be killed by heat, ultraviolet radiation, mechanical disruption, or chemical inactivation.
  • the composition is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally. In one embodiment, the composition is administered orally.
  • the composition can be administered one, two, or more times (e.g., 3, 4, or 5 times) to the mammal.
  • the method elicits an immune response to the fungus of the fungal infection in the mammal, e.g., a protective immune response, a cell- mediated immune response, a humoral immune response, or both a cell-mediated immune response and a humoral immune response.
  • the method further includes evaluating the immune response (e.g., to the fungus of the fungal infection and/or to the fungus of the composition that is administered) in the mammal, e.g., evaluating a cell mediated immune response or a humoral immune response, e.g., evaluating a cell mediated delayed-type hypersensitivity response and/or an antibody response.
  • the mammal can be at risk for infection by a fungus before the administering.
  • the mammal at risk can be immunocompromised or at risk for becoming immunocompromised, e.g., the mammal has impaired neutrophil function, e.g., the mammal is a human with HIV, e.g., and is suffering from AE)S, or is a human taking an immunosuppressive drug.
  • the mammal may be suffering from a fungal infection prior to the administering, e.g., a fungal infection caused by a fungus of a genus that is the same as the genus of the fungal cells (or extract thereof) administered to the mammal, e.g., an infection caused by the same species as the species of cells administered.
  • the mammal may be suffering from a fungal infection caused by a fungus of a species (and possibly, genus) other than the species of the fungal cells administered to the mammal.
  • the cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, hi one embodiment, the cell-surface molecule is a mannoprotem, e.g., mp58, a homolog of mp58 (e.g., a homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof, hi one embodiment, the cell-surface or secreted molecule is selected from the polypeptides of Table 9 or a homolog thereof (e.g., a homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the sequence of the polypeptide of Table 9).
  • a homolog of mp58 e.g., a homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the
  • Treating refers to an administering that improves a mammal's condition due to a fungal infection or decreases the severity or incidence of infection of the mammal.
  • Methods that treat or inhibit a fungal infection may alleviate, improve, or otherwise affect the infection, the symptoms of the infection, or the predisposition toward the infection.
  • Genetically modified includes genetic modifications induced by chemical (e.g. MMS (methyl methane sulfonate), EMS (ethyl methane sulfonate), NTG (nitrosoguanidine), or other artificial means (e.g., induced by DNA- modifying enzymes, Ultraviolet (UV) crosslinking, gamma irradiation, X-ray treatement), spontaneously-arising genetic modifications, and modifications due to the introduction of recombinant DNA episomally and/or into the genome of the cell.
  • Genetically modified cells are modified relative to a wild-type or parental strain.
  • Recombinantly genetically modified refers to genetic modifications introduced using recombinant DNA methodologies.
  • Gene includes coding, promoter, operator, enhancer, terminator, co-transcribed, and other regulatory sequences associated with a particular coding sequence.
  • “Homolog” is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity (e.g., percentage of amino acid or nucleotide identity) and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms “ortholog”, meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog” meaning a functionally similar sequence when considered within the same species.
  • substitutions of one amino acid for another may be tolerated at one or more amino acid residues of a wild-type enzyme without eliminating the activity or function of the enzyme.
  • conservative substitution refers to the exchange of one amino acid for another in the same conservative substitution grouping in a protein sequence.
  • Conservative amino acid substitutions are known in the art and are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
  • conservative substitutions typically include substitutions within the following groups: Group 1 : glycine, alanine, and proline; Group 2: valine, isoleucine, leucine, and methionine; Group 3: aspartic acid, glutamic acid, asparagine, glutamine; Group 4: serine, threonine, and cysteine; Group 5: lysine, arginine, and histidine; Group 6: phenylalanine, tyrosine, and tryptophan.
  • Each group provides a listing of amino acids that may be substituted in a protein sequence for any one of the other amino acids in that particular group. There are several criteria used to establish groupings of amino acids for conservative substitution.
  • hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, MoI. Biol. 157:105-132 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. Amino acid hydrophilicity is also used as a criterion for the establishment of conservative amino acid groupings (see, e.g., U.S. Patent No. 4,554,101).
  • the sequence of a nucleic acid and/or a polypeptide will be compared to a second sequence (e.g., a second sequence from a second organism or from a related sequence in the same organism), and the homology can be determined. Homology comparisons can be used, for example, to identify corresponding amino acids.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • the percent identity between two nucleotide sequences can be determined using the algorithm of Needleman and Wunsch ((1970) J. MoI. Biol. 48:444-453) which has been incorporated into the GAP program in the GCG software package, using either a Blosum 62 matrix and a gap weight of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid or amino acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • the length of a test sequence aligned for comparison purposes can be at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence.
  • the nucleotides or amino acids at corresponding nucleotide or amino acid positions are then compared. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein "identity" is equivalent to "homology").
  • the protein sequences described herein can be used as a "query sequence" to perform a search against a database of non-redundant sequences, for example.
  • Such searches can be performed using the BLASTP and TBLASTN programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10.
  • BLAST protein searches can be performed with the BLASTP program, using, for example, the Blosum 62 matrix, a wordlength of 3, and a gap existence cost of 11 and a gap extension penalty of 1.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information, and default parameters can be used.
  • Sequences described herein can also be used as query sequences in TBLASTN searches, using specific or default parameters.
  • nucleic acid sequences described herein can be used as a "query sequence" to perform a search against a database of non-redundant sequences, for example.
  • Such searches can be performed using the BLASTN and BLASTX programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10.
  • Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402.
  • the default parameters of the respective programs e.g., BLASTX and BLASTN
  • Alignment of nucleotide sequences for comparison can also be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. MoI. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr.,
  • Nucleic acid sequences can be analyzed for hybridization properties.
  • hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions describes conditions for hybridization o and washing.
  • Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1- 6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used.
  • Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) 5 at about 45 0 C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55 0 C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 6O 0 C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one, two, three, four or more 0 washes in 0.2X SSC, 0.1 % SDS at 65°C) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65 0 C.
  • SSC sodium chloride/sodium citrate
  • FIG. IA is a graph depicting the percentage survival of mice injected with a crvl/crvl C. albicans strain (ovals) or saline (squares), followed by challenge with a virulent strain of C. albicans.
  • FIG. IB is a graph depicting the percentage survival of mice injected with a crvl/crvl C. albicans strain (triangles) or saline (squares), followed by challenge with a virulent strain of C. albicans.
  • FIG. 2 is a set of pictures showing the histology of kidneys of mice injected with a virulent strain of C. albicans (upper panels) or mice injected with a crvl/crvl strain of C. albicans followed by challenge with a virulent strain (lower panels).
  • Gomori methenamine silver (GMS) was used to stain fungi in the tissues.
  • the invention is based, in part, on the observation that exposure to attenuated strains of fungi with one or more altered filamentation properties can protect against subsequent infections with other fungi.
  • inoculation of cells of a hypofilamentous strain of Candida albicans (C. albicans) protects animals from lethal challenge with virulent strains of C. albicans.
  • attenuated fungi, or extracts thereof can elicit responses that prevent or decrease disease due to infection by both homologous and heterologous strains, i.e., exposure to an attenuated Cryptococcus neoformans can stimulate responses that provide protection from infection with Candida albicans.
  • Attenuated fungi, or extracts thereof can be administered alone or in combination with other fungal components such as crude or purified fungal cell wall extracts, and cell surface and secreted components (e.g., from the same or a different strain from the attenuated fungal compositions). These combinations can further promote immune responsiveness to fungi by activating innate immune mechanisms and/or by increasing the exposure of the patient or animal to protective and/or immunodominant epitopes. In certain embodiments, attenuated fungi may also have beneficial effects on subjects that have already been exposed to other fungi. Attenuated fungi or extracts thereof can be administered in combination with an antibody that specifically binds to a fungal component (e.g., a fongal polypeptide or carbohyrated) or an antigen binding portion thereof.
  • a fungal component e.g., a fongal polypeptide or carbohyrated
  • C. albicans crvl/crvl mutant strains are profoundly avirulent in animal models of infection. These strains grow vigorously in vitro and are able to initially colonize mouse tissues in vivo. However, despite relatively high initial tissue cell counts, crvl/crvl strains cause relatively little tissue damage and do not kill the infected host. The avirulent crvl/crvl cells are cleared from the host tissues over a period of weeks, hi contrast to clinical isolates of C. albicans that grow predominantly as filamentous forms in vivo, crvl/crvl strains grow as ovoid, yeast form cells (U.S. Pat. Pub. 20030176367).
  • This altered morphology may facilitate the phagocytosis of yeast form crvl/crvl cells relative to their filamentous, wild type counterparts.
  • Transcriptional profiling reveals that the expression pattern of many of the genes associated with infection and virulence are differentially expressed in crvl/crvl strains relative to wild type controls (when grown under conditions that mimic the host environment (e.g., 37°C, pH 7, serum)).
  • HWPl a hyphal wall protein associated with adherence and virulence, is highly induced in wild type strains upon transfer to Yeast Nitrogen Base (YNB), pH 4.5, 30°C to YNB, pH 7, 37°C.
  • HWPl is not induced in crvl/crvl strains when handled similarly.
  • a number of genes are similarly regulated in both crvl/crvl and wild type including PRAl, the gene encoding mp58, a conserved and highly immunogenic C. albicans cell surface protein.
  • Attenuated fungal strains can be generated by reducing or increasing activity or expression of polypeptides that regulate filament formation and/or invasiveness.
  • the CR Vl gene of C. albicans is required for hyphal growth and invasion under physiological conditions (U.S. Pat. Pub. No. 20030176367). Strains in which this gene is deleted, mutated, or in which expression is decreased or otherwise inhibited can be used in methods for inducing an immune response in mammals.
  • homologs of CRVl in both C. albicans and in other species can be targeted to generate attenuated strains.
  • Attenuated strains include those in which one identifies variant cells with increased or decreased expression or activity of a polypeptide known to be indicative of filamentation (or a non- filamentous state). Such variants may arise from chemical or genetic procedures and may be due to rearrangements, deletions, or insertions in the genome of the cells. Attenuated strains suitable for the methods described herein include strains with altered filamentation properties, which can include changes in growth patterns of individual cells as well as overall changes in filament shape or structure.
  • cell properties include, without limitation, cell volume, cell length, cell width, cell- cell adherence, axial ratio (e.g., lengthr.width ratio), budding pattern (e.g., unipolar, bipolar), and overall cell shape (e.g., round, ovoid, ellipsoid, elongated, irregular).
  • Filament properties include, without limitation, spacing between septae, branch frequency, branch polarization (e.g., in the same or different direction relative to the main filament), planarity, type of growth (hyphal versus pseudohyphal), frequency of yeast form or non-filamentous cells within the filament, and overall macroscopic characterization (e.g., "bushy", "cables").
  • ovoid non-filamentous cells are less able to invade substrates as compared to elongated filamentous cells. Genetic or chemical modifications can be defined as inducing/causing a hypofilamentous phenotype if they reduce cell or filament length of the fraction of elongated versus ovoid cells.
  • the nucleic acid and amino acid sequences and GenBank ® Accession numbers and for CRVl and homologs of CRVl are provided in Tables 1, 2, 3, and 4, below.
  • the predicted protein sequences encoded by other genes that are not homologs of Crvl, but which can also be targeted to generate attenuated strains, are provided in Table 5, with their corresponding DNA sequences in Table 6.
  • Fungi also contain genes, often characterized as transcriptional regulators that, when mutated or deleted, cause the strain to become hyperfilamentous.
  • overexpression of one (or more) of these genes has been shown to lead to a hypofilamentous phenotype and reduced virulence.
  • overexpression of any of these genes or their homologs from other fungal species can generate hypofilamentous strains that provide protection against subsequent infection by virulent strains of the same or different fungal genera or species.
  • the SPT3, SSN6, RBFl, RFGl, TUPl, and NRGl amino acid and nucleotide sequences are provided below in Tables 7 and 8, respectively.
  • Fungal species suitable for preparation of the compositions described herein include, but are not limited to: Absidia corymbifera, Absidia spp., Acremonium falciforme, Acremonium kiliense, Acremonium recifei, Acremonium spp., Ajellomyces capsulatus, Ajellomyces dermatitidis, Ajellomyces spp., Allescheria boydii, Alternaria alternata, Alternaria chartarum, Alternaria dianthicola, Alternaria geophilia, Alternaria infectoria, Alternaria spp., Alternaria stemphyloides, Alternaria teunissima , Anthopsis deltoidea, Aphanomyces spp., Apophysomyces elegans, Armillaria spp., Arnium leoporinum, Arthroderma benhainiae, Arthroderma fulvum, Arthroderma gyp
  • Chrysosporium inops Chrysosporium keratinophilum, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium parvum , Chrysosporium queenslandicum, Chrysosporium spp., Chr ⁇ sosporium tropicum, Chrysosporium zonatum, Cladophialophora carrionii, Cladophialophora spp., Cladosporium cladosporioides, Cladosporium elatum, Cladosporium herbarum, Cladosporium sphaerospermum,
  • Cladosporium spp. Coccidioides immitis, Coccidioides posadasii, Coccidioides spp., Colletotrichium spp., Conidiobolus coronatus, Conidiobolus incongruus, Conidiobolus lamprauges, Conidiobolus spp., Cryptococcus neoformans, Ciyptococcus spp., Cryptoporiopsis spp., Cunninghamella bertholletiae, Cunninghamella spp., Curvularia brachyspora, Curvularia clavata, Curvularia geniculata, Curvularia lunata, Curvularia pallescens, Curvularia senegalensis, Curvularia spp., Curvularia verruculosa, Cylindrocladium spp., Dactylaria spp., Debaryomyces hansenii, Diplodia spp., Emmonsia parva
  • Exophiala jeansehnei var. heteromorpha Exophiala jeanselmei var. lecanii-corni, Exophiala moniliae, Exophiala salmonis, Exophiala spinifera, Exophiala spp., Exophila pisciphila, Exserophilium spp., Filobasidiella neoformans, Fonsecaea compacta, Fonsecaea pedrosoi, Fonsecaea spp., Fulvia spp., Fusarium chlamydosporum, Fusarium oxysporum, Fusarium solani, Fusarium spp., Geotrichum candidum, Geotrichum clavatum , Geotrichum fid, Geotrichum spp., Guignardia spp., Helminthosporium spp., Histoplasma capsulatum, Histoplasma capsulatum var.
  • capsulatum Histoplasma capsulatum var. duboisii, Histoplasma spp., Hortaea wasneckii, Issatschenkia orientalis, Kluyveromyces lactis, Lacazia loboi, Lasiodiplodia spp., Lecythophora spp., Leptosphaeria australiensis, Leptosphaeria senegalensis, Leptosphaeria spp., Macrophomina spp., Madurella grisae, Madurella mycetomatis, Madurella spp., Magnaporthe grisea, Magnaporthe spp., Malassezia furfur, Malassezia globosa, Malassezia obtuse, Malassezia pachydermatis, Malassezia restricta, Malassezia slooffiae, Malassezia sympodialis, Malbranchea
  • rhizopodiformis Rhizopus oryzae, Rhizopus spp., Rhodotorula rubra, Rhodotorula spp., Saccharomyces cerevisiae, Saccharomyces spp., Saksenaea vasiformis, Sarcinomyces phaeomuriformis, Scedosporium apiospermum, Scedosporium prolificans, Scedosporium spp., Scerotium spp., Schizophyllum commune, Schizosaccharomyces pombe, Sclerotinia spp., Scopulariopsis brevicaulis , Scopulariopsis spp., scytalidium spp., Sphaerotheca spp., Sporobolomyces salmonicolor, Sporobolomyces spp., Sporothrix schenckii, Stachybotrys chartarum, St
  • Venturia spp. Verticillium spp., Wangiella dertnatitidis, Wangiella spp., Whetxelinia spp., Xylohypha spp., and Yarrowia lipolytica.
  • Fungal cell wall components are immunogenic in mammals and can be used to enhance immune responsiveness to fungi. Furthermore, cell wall components have been shown to induce cross-species protection. Immunization with an extract containing a Cryptococcus neofonnans mannoprotein, mp65, provides protective immunity to subsequent infections with both Cryptococcus neofonnans and C. albicans (Pietrella et al., Infect Immun, 70, 6621-27 (2002)).
  • Cells that overexpress cell surface proteins can be used for vaccination methods.
  • Examples of polypeptides and their corresponding nucleic acid sequences which can be overexpressed are provided in Tables 9 and 10, respectively. These genes include the C. albicans mp58 gene and other C. albicans cell surface proteins.
  • One way to achieve overexpression of a nucleic acid sequence in fungal strains such as C. albicans is to express the sequence under the control of a highly active promoter, such as a promoter of one of the following genes: ACTl, TEFl, TEF2, ADHl, MAL2, HWPl, PHRl, GALl, MET3, saa ⁇ PCKl.
  • a highly active promoter such as a promoter of one of the following genes: ACTl, TEFl, TEF2, ADHl, MAL2, HWPl, PHRl, GALl, MET3, saa ⁇ PCKl.
  • These promoters, or others can be further modified so as to be regulatable, e.g., by a compound such as an antibiotic, e.g., tetracycline (or a derivative thereof such as doxycycline), by the addition of tetR binding sites.
  • promoters from heterologous species e.g., promoters from the following genes of S. cerevisiae: ACTl, TEFl, TEF2, ADHl, GALl, GALlO and FBPl
  • ACTl ACTl
  • TEFl TEF2
  • ADHl GALl
  • GALlO GALlO
  • FBPl FBPl
  • Candida strains for inoculation are maintained under a variety of conditions including on solid media or slants at 4 0 C or room temperature for short term storage or at -8O 0 C in glycerol or other cryopreservatives for longer-term storage.
  • Exemplary Candida strains for inoculation include CAI4 (ATCC ® No. MYA-682), SC5314 (ATCC ® No. MYA-2876) and BWP17 (Wilson et al., J Bacterial, 181(6):1868-1874, 1999) and derivatives thereof (e.g., derivatives made by genetic modification (e.g. recombinant derivatives)).
  • Live cultures for inoculations are prepared as follows.
  • Cultures are incubated for 24 hours on appropriate agar at 37°C, inoculated into broth, and incubated at 37 0 C on a gyratory shaker operating at 165 rpm.
  • the cells are harvested after approximately 18 hours and washed three times in nonpyrogenic saline (NPS).
  • NPS nonpyrogenic saline
  • the final pellet is resuspended in NPS, cells are counted in a hemocytometer and diluted to the appropriate concentration in NPS.
  • the viability of the culture can be determined by plate count.
  • the cell suspension can be heated at 6O 0 C for
  • the lack of viability of the heated preparation can be confirmed by plating 10 9 cells on agar and incubating them at 37°C overnight.
  • Fungal cell extracts enriched for cell wall components can be prepared by methods described in Staab et al. ⁇ J Biol Chem. 279(39):40737-47, 2004). Briefly, cells are suspended in a lysis buffer (50 niM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM EDTA) with protease inhibitors and broken with glass beads ((425-600 microns, Sigma- Aldrich). The broken cells are centrifuged at low speed (1000 x g for 10 minutes at 4 0 C), the supernatants are transferred to new tubes and re-centrifuged at high speed (15,000 x g for 10 minutes at 4°C).
  • a lysis buffer 50 niM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM EDTA
  • the broken cells are centrifuged at low speed (1000 x g for 10 minutes at 4 0 C), the supernatants are transferred to new tubes and
  • the pelleted cell walls from the initial 15,000 x g spin are washed in 25 mM Tris-Cl, pH 7.5, 1 M NaCl, 0.5 mM EDTA with protease inhibitors as above.
  • the washed walls are boiled twice for 5 min in 100 ⁇ L of SDS lysis buffer (50 mM Tris-Cl, pH 7.5, 150, mM NaCl, 2% SDS, 10 mM DTT, 5 mM EDTA with protease inhibitors at 40 ⁇ g/mL, and 0.1 mM Pefabloc) to remove noncovalently-bound wall proteins.
  • the SDS-boiled cell walls are washed twice in buffer (25 mM Tris-Cl pH 7.5, 1 M NaCl, 0.5 mM EDTA with protease inhibitors), and suspended in 25 mM Tris-Cl pH 7.5, 40 mM 2-mercaptoethanol, 1 niM EDTA with protease inhibitors, and 75 units of Quantazyme ylg (Quantum Biotechnologies, InterSpex Products, Inc., Foster City, CA). The mixture is incubated at 37°C for 1 h with rocking and residual undigested cell wall material is removed by centrifugation at 15,000 x g at 4°C. The supernatants
  • mannoprotein extracts A method for preparation of mannoprotein extracts is described in Pietrella et al. (Infect Immun, 70, 6621-27 (2002)). Briefly, fungi are cultured in a defined medium for approximately 5 days at 35 0 C. The culture supernatant (which contains o mannoproteins) is concentrated by ultrafiltration and purified by a combination of affinity chromatography (concanavalin A (ConA)) and anion-exchange chromatography (DEAE). The extract includes a mix of protein and carbohydrate.
  • ConA concanavalin A
  • DEAE anion-exchange chromatography
  • Fungal compositions can also be administered in combination with purified protein preparations, e.g., an antibody or antibodies that specifically bind to fungal 5 polypeptides or antigen-binding portions thereof (e.g., recombinant fungal polypeptides or fragments thereof), hi certain embodiments the fungal polypeptides include C. albicans mp58 mannoprotein and fragments thereof described in U.S. Pat. Pub. No. 20040142385. hi certain embodiments the fungal polypeptides include those disclosed in Table 9 of the instant specification and fragments and homologs 0 thereof (e.g., homologs having sequences at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identical to a sequence in Table 9).
  • purified protein preparations e.g., an antibody or antibodies that specifically bind to fungal 5 polypeptides or antigen-binding portions thereof (e.g., recombinant fungal polypeptides or fragments thereof)
  • Methods for treating (e.g., prophylactically and/or therapeutically) a patient at 5 risk for or having a fungal infection are provided herein, hi certain embodiments, the methods are useful for the prevention or treatment of candidiasis.
  • the methods include administering to a patient at risk of developing a fungal infection a composition that includes fungal cells (e.g., living or killed cells) that exhibit one or more altered filamentation properties due to one or more genetic alterations. 0 Alternatively, or in combination, extracts of fungal cells are administered.
  • Fungal compositions can be administered by conventional approaches, including administration via e.g., intravenous, intraperitoneal, intramuscular, intranodal, subcutaneous administration, transdermal delivery, inhalation (e.g., aerosol), or oral routes or via direct injection into a tissue.
  • administration via e.g., intravenous, intraperitoneal, intramuscular, intranodal, subcutaneous administration, transdermal delivery, inhalation (e.g., aerosol), or oral routes or via direct injection into a tissue.
  • Fungal compositions can, but need not be administrated with an adjuvant or a carrier.
  • Adjuvants include, Freund's adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; other bacterial-derived preparations; gamma interferon; block copolymer adjuvants, RIBI adjuvants (available from Ribi ImmunoChem Research, Inc., Hamilton, Mont.); and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark).
  • Carriers include polymeric controlled release formulations, biodegradable implants, liposomes, oils, esters, and glycols.
  • Fungal compositions of the present invention can also include one or more pharmaceutically acceptable excipients.
  • a pharmaceutically acceptable excipient refers to a substance suitable for delivering a fungal composition to a site in vivo or ex vivo. Excipients can maintain a fungal composition in a form that is capable of eliciting an immune response at a target site.
  • Examples of pharmaceutically acceptable excipients are saline, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols.
  • Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.
  • auxiliary compounds include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer.
  • Auxiliary substances can also include preservatives, such as thimerosal, m- or o-cresol, formalin and benzol alcohol.
  • the administration of fungal compositions can be performed ex vivo or in vivo.
  • Ex vivo administration refers to performing a step of a method for administration outside of the subject, such as administering a composition of the present invention to a population of cells (e.g., peripheral blood lymphocytes) and returning the cells to the subject.
  • Suitable dose sizes are doses capable of eliciting antifungal responses in a subject when administered one or more times over a suitable time period.
  • a suitable single dose of a fungal composition can be a dose that is capable of effectively providing fungal antigens to a given cell type, tissue, or region of the subject body in an amount effective to elicit an antifungal immune response, e.g., when administered one or more times over a suitable time period.
  • the fungal compositions described herein can be administered to mammals including primates, rodents, livestock and domestic pets.
  • Livestock include mammals to be consumed or that produce useful products (e.g., sheep for wool production).
  • Mammals to protect include humans, dogs, cats, mice, rats, goats, sheep, cattle, horses and pigs.
  • Fungal infections which may be treated or inhibited by agents described herein include, without limitation: Aspergillosis, Blastomycosis, Candidiasis, Chromoblastomycosis, Coccidioidomycosis, Cryptococcosis, fungal eye infections, Histoplasmosis (capsulati and duboisii), Lobomycosis, Mycetoma, Otomycosis, Paracoccidiomycosis, Phaeohyphomycosis, Rhinosporidiosis, Sporotrichosis, Zygomycosis, Occulomycosis (including Mycotic keratitis), infection by Penicilliosis marneffei and various fungal hair, skin and nail infections (including Onychomycosis (Tinea unguium), Piedra, Pityriasis versicolor, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruri
  • the compositions described herein are administered to patients at risk for fungal infections. These include patients with impairment of neutrophil function due to decreased neutrophil production in the bone marrow, increased neutrophil destruction, or qualitative defects in neutrophil function.
  • Factors that can cause a decrease in neutrophil production include, but are not limited to (1) administration of cytotoxic drugs, including alkylating agents such as cyclophosphamide, busulfan, and chlorambucil, and antimetabolites such as methotrexate, 6-mercaptopurine and 5-flurocytosine; (2) administration of other drugs known to inhibit neutrophil production including, but not limited to, certain antibiotics, phenothiazines, diuretics, anti-inflammatory agents, and antithyroid drugs; (3) bacterial sepsis infections, viral infections such as HTV, EBV or hepatitis; typhoid, malaria, brucellosis, and tularemia; (4) primary hematologic diseases resulting in bone marrow failure, as well as both heredit
  • Factors that can cause an increase in destruction of neutrophils, thereby rendering an individual susceptible to fungal infections include, without limitation, the presence of antineutrophil antibodies, autoimmune disease (such as Felty's syndrome, rheumatoid arthritis, or systemic lupus erythematosis), or idiosyncratic reactions to drugs that, in an idiosyncratic way, act as haptens at the surface of neutrophils, initiating immune destruction of neutrophils.
  • autoimmune disease such as Felty's syndrome, rheumatoid arthritis, or systemic lupus erythematosis
  • idiosyncratic reactions to drugs that, in an idiosyncratic way, act as haptens at the surface of neutrophils, initiating immune destruction of neutrophils.
  • neutrophil function is also compromised by administration of corticosteroids used in the treatment of a wide variety of diseases. Thus, patients treated with corticosteroids are at increased risk of fungal infections.
  • Additional factors increasing individual susceptibility to fungal infections include: (1) treatment with broad spectrum antibiotics, especially in the hospital setting and in Intensive Care settings in particular; (2) application of intravenous catheters, particularly central venous catheters;(3) surgical wounds, particularly those associated with intra-abdominal surgeries; (4) tissue, bone marrow or solid organ transplantation; (5) cancer chemotherapy; (6) Acquired Immune Deficiency Syndrome; (7) Intensive Care Unit stay; and (8) diabetes.
  • neonates and aged patients are at increased risk.
  • Immunosuppressed patients e.g., patients with acquired immunosuppression, e.g., due to HIV infection or immunosuppressive medical treatments such as chemotherapy; or with an inherited immunosuppressive disorder
  • patients with acquired immunosuppression e.g., due to HIV infection or immunosuppressive medical treatments such as chemotherapy; or with an inherited immunosuppressive disorder
  • Fungal compositions can be administered to provide a beneficial effect (e.g., a prophylactic or therapeutic effect) specific to the strain administered, or which also is beneficial towards one or more additional strains (e.g., by inducing a cross-reactive response).
  • a beneficial effect e.g., a prophylactic or therapeutic effect
  • additional strains e.g., by inducing a cross-reactive response.
  • compositions derived from one particular strain to induce a beneficial effect in a subject at risk for infection with a second strain.
  • compositions described herein including, without limitation: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Saccharomyces spp., Paracoccidioides spp., and Coccidioides spp.
  • agents that can be used in combination therapy are polyenes (e.g., Amphotericin B (including lipid or liposomal formulations thereof), Mepartricin, Nystatin (including liposomal formulations thereof), Pimaricin, SPA-S-843), candins (e.g., Anidulafungin (also called LY303366, VER-002, V-echinocandin) Caspofungin, Cancidas (caspofungin acetate), Micafungin (FK463), and Cilofungin), aminocandins, sordarins (e.g., Azasordarin, GM 222712, GM 237354), azoles (e.g., Azaconazole, Azoline, Albaconazole, bal 8557, Bispyrithione Magsul
  • sordarins e.g., Azasordarin, GM 222712, GM 237354
  • azoles e.g.,
  • Ethonam Nitrate Ethonam Nitrate; Filipin; FK 463; Fungimycin; Gentian violet; Glutaraldehyde; Hamycin; Hydroxystilbamidine; Iodine; Kalafungin; Lomofungin; Lydimycin; MK
  • Oxifungin Hydrochloride Partricin; Potassium Iodide; Prednisone; Proclonol ;
  • Undecylenate Undecylenic Acid
  • Zadaxin beta-amino acids, e.g., PLD-118 or derivatives thereof).
  • the antifungal agents that are administered in combination may act, for example, by blocking ergosterol synthesis (e.g., azoles or allylamines), by interfering with the cell wall (e.g., candins), by interfering with the cell membrane (polyenes) or by interfering with protein translation (e.g., sordarins).
  • ergosterol synthesis e.g., azoles or allylamines
  • cell wall e.g., candins
  • polyenes cell membrane
  • protein translation e.g., sordarins
  • Fungal compositions may also be administered in combination with an antibody (or antigen-binding portion thereof) that specifically binds to a fungal component (e.g., a fungal polypeptide or carbohydrate, e.g., a mannoprotein).
  • a fungal component e.g., a fungal polypeptide or carbohydrate, e.g., a mannoprotein.
  • the antibody (or antigen-binding portion thereof) can be a monoclonal antibody, e.g., a human or humanized monoclonal antibody.
  • Example 1 Mice are protected from lethal infection with Candida albicans by pre- inoculated with a hypofilamentous mutant strain.
  • mice Fifteen Balb/c mice (female, 6-7 weeks old) were inoculated in the tail vein with 2.O x IO 6 cells of C. albicans strain MCl 91 (crvlA::ARG4/crvlA::HIS3 ade2:: URA3/ADE2 ura3 ⁇ ::imm434/ura3 ⁇ ::imm434 hisl ::hisG/hisl::hisG arg4: :hisG/arg4: :hisG) or saline control.
  • MC191 is a strain of C.
  • mice were challenged by inoculation with 2 x 10 6 cells of strain MC243, a virulent C. albicans strain. Survival was measured for 22 days, at which point the surviving animals were sacrificed. The results are depicted in FIG. IA. All of the mice that were pre- inoculated with saline died within 2 days, suggesting that the inoculum of MC243 was a particularly strong challenge and might obscure the magnitude of the significant difference observed. Therefore, the experiment was repeated with a lower inoculum of a different virulent C. albicans strain, CAF-2.
  • mice Ten Balb/c mice (female, 6-8 weeks old) were inoculated in the tail vein with 1.9 x 10 6 cells of strain MC191 ⁇ crvl) or saline control (8 mice). Fourteen days post-inoculation, mice were challenged by inoculation with 4.4 x 10 cells of CAF-2, a virulent C. albicans strain. Survival was measured for 28 days, at which point the surviving animals were sacrificed. The results of this experiment are shown in FIG. IB.
  • Kidneys were removed from both control mice and crvl /crvl pre-inoculated mice at the time of sacrifice. Colony forming units (CFU) of bacteria were determined by homogenizing one kidney from each mouse and plating the homogenate on YPD media or serum-containing plates, crvl /crvl strains were readily identified on serum plates as round colonies of non-filamentous cells while CAF-2 clones grew as invasive colonies of filamentous cells. The remaining kidney was retained for histologic analysis. Results Pre-inoculation of a crvl/crvl strain was found to confer resistance to subsequent challenge with a wild type isolate of C. albicans, as shown in FIGS. IA and IB.
  • hi experiment #1 crvl/crvl pre-inoculated mice survived up to 8 days while mice pre-inoculated with a saline control died within 2 days (FIG. IA).
  • mice previously inoculated with crvl/crvl cells showed no outward signs of infection when challenged with a virulent C. albicans strain and 100% survival throughout the experiment (24 days post-CAF-2 infection) (FIG. IB).
  • mice pre-inoculated with saline had large numbers of filamentous C. albicans cells in the kidneys (FIG. 2, upper panels).
  • mice pre-inoculated with the crvl/crvl strain were characterized by the presence of non-filamentous C. albicans in the tissue with few or no filamentous organisms (FIG. 2, lower panels).
  • Phenotypic characterization of fungi growing on serum plates onto which kidney homogenate was plated revealed that essentially all of the C. albicans isolated from the crvl/crvl pre-inoculated mice were in fact avirulent crvl/crvl mutants with few or no virulent CAF-2 cells observed ( ⁇ 1%) (data not shown).
  • ATTTCAACTTCCTGAATTGGCAATGA unnamed ATGAAGCGAGAGATGTACTCTGGGCAGTCAGACGTTGCTGATACTGGAT 40 protein GGAGTGCTCCAAAGCCAGGTCATATGTCGCTAGAAAGGTCGAGGATGTT product; GCAGGCCGCGCGGCGGCCGCAGCCGCTGCTGGTGGTGGGAGTACTCCAAAC Kl uyveromyces CATAATCAAAATTATAACAGACCTCCGAATATCAATACAAACAATAACA lactis; GCAGCAACAGCAACTCGTATGGTACTGGCAKGCCGGGAAACGCACCTGG XM_454887 ; ATTGGCAGGTACACCGGTGGGCATGGTTTCTGATCCTTCGCCTGTTCAG 50309748 GACACTATGGTGTTTAATGCAAGCGAGTACGACGATTTGCGAACCAAGA
  • XM_327362 AAGCGGATTTACAGCAGTTCGACGTCAACCAGATGCCTACCGGTAGCAT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for treating and inhibiting fungal infections are described herein.

Description

FUNGAL VARIANTS AND USES THEREOF
TECHNICAL FIELD
This invention relates to variant fungal cells, and more particularly to uses of the cells to treat or prevent fungal infections in mammals.
BACKGROUND
Systemic fungal infections account for 40% of nosocomial infection-related deaths. Of these, infection by Candida albicans is the most common - it is the third most prevalent causative agent for hospital-acquired infections. Despite more than 50 years of modern pharmaceutical research and discovery, there are relatively few safe and effective antifungal drugs available. Even with aggressive therapy, mortality rates for systemic fungal infections remain unacceptably high at 40-70%. As a result of the high mortality rate, prophylactic antifungal treatment is desirable for high-risk patients. Prophylaxis with antifungal dugs can decrease the incidence of fungal infection. However, this approach leads to the appearance of drug resistant isolates or species of fungi. In vitro data has also suggested that prophylactic treatment with an antifungal drug such as an azole can impair the subsequent efficacy of a second drug such as amphotericin. Thus, there is a clear medical need for agents that can reduce the frequency of fungal infections without compromising available treatment options.
SUMMARY In one aspect, the invention features a method for treating or inhibiting a fungal infection in a mammal. The method includes, for example: administering to the mammal a composition comprising cells of a fungal strain or an extract thereof, wherein the cells are genetically modified (e.g., recombinantly genetically modified) to have an altered filamentation property, thereby treating or inhibiting the fungal infection in the mammal.
An altered filamentation property refers to a filamentation property which is altered relative to, for example, a wild type form of the strain; a strain which lacks the recombinant genetic modification and is otherwise identical to the strain that is administered; or to a reference strain.
In various embodiments, the cells having the altered filamentation property are hypofilamentous. In some embodiments, the cells can be genetically modified (e.g., by recombinant means) to alter the expression or activity of at least one polypeptide that regulates filamentation such that the genetically modified cells are hypofilamentous, e.g., relative to non-modified cells. For example, the cells can be genetically modified to increase or decrease the expression or activity of at least one polypeptide that regulates filamentation. The fungal cells can be of the same genus and species as the fungus of the fungal infection, or can be of a genus and/or species other than the fungus of the fungal infection. The genetic modification of the cells can include a deletion, insertion, rearrangement or mutation in one or more nucleotides of the cell. Genetic modifications include modifications arising spontaneously or resulting from mutagenic treatments (e.g., fungal cells may be mutagenized and clones of mutagenized cells may be screened or selected for clones exhibiting altered filamentation properties) and modifications introduced by recombinant DNA methodologies. The deletion, insertion, rearrangement, or mutation of DNA sequences can cause an amino acid change, deletion, insertion, or a premature truncation of a polypeptide encoded by a nucleic acid in the cell, (e.g., a polypeptide that regulates filamentation).
In one embodiment, the polypeptide that regulates filamentation is a Crvl polypeptide or a fungal homolog thereof (e.g., wherein the fungal homolog is a fungal polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to Crvl). In one embodiment, the polypeptide is selected from: CdclO,
Cdc24, Chk2, Chs3, Cla4, Crkl, Cyrl/Cdc35, Efgl, Erg24, Fas2, Hogl,Hwpl, Ml, Kex2, Nag5, Nikl, Pldl, Pmtl, Slnl, Sskl, Tpsl, and Vps34, or a homolog (e.g., a fungal homolog) of one of these polypeptides (e.g., wherein the homolog is a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the polypeptide). The fungal cells can be cells of a dimorphic fungus, e.g., cells of a dimorphic ascomycete. The fungal cells can be cells of the genus Candida, e.g., Candida albicans cells.
The composition can include live fungal cells, or can include primarily killed cells (e.g., wherein at least 80%, 90%, 95%, or 99% of the fungal cells of the composition are killed). The fungal cells can be killed by heat, ultraviolet radiation, mechanical disruption, or chemical inactivation. The composition can further include an adjuvant.
In various embodiments of the method, the composition is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally. In one embodiment, the composition is administered orally. The composition can be administered one, two, or more times (e.g., 3, 4, or 5 times) to the mammal.
In one embodiment, the method elicits an immune response to the fungus of the fungal infection in the mammal, e.g., a protective immune response, a cell- mediated immune response, a humoral immune response, or both a cell-mediated immune response and a humoral immune response.
In various embodiments, the method further includes evaluating the immune response to a fungus (e.g., the fungus of the infection, and/or the fungus of the strain that is administered) in the mammal, e.g., evaluating a cell mediated immune response or a humoral immune response to the fungus, e.g., evaluating a cell mediated delayed- type hypersensitivity response and/or an antibody response to the fungus.
The mammal can be at risk for infection by a fungus before the administering. The mammal at risk can be immunocompromised or at risk for becoming immunocompromised, e.g., the mammal has impaired neutrophil function, e.g., the mammal is a human with HIV, e.g., suffering from AIDS, or is taking an immunosuppressive drug.
The mammal may be suffering from a fungal infection prior to the administering, e.g., a fungal infection caused by a fungus of a genus that is the same as the genus of the fungal cells (or extract thereof) administered to the mammal, e.g., an infection caused by the same species as the species of cells administered. The mammal may be suffering from a fungal infection caused by a fungus of a species (and possibly, genus) other than the species of the fungal cells administered to the mammal.
The fungal cells may be cells further genetically modified (e.g., recombinantly genetically modified) to increase expression of a cell-surface or secreted molecule, or a portion thereof, e.g., relative to a wild-type strain, a strain that is identical but for the recombinant genetic modification, or a reference strain.
The cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, hi one embodiment, the cell-surface molecule is a mannoprotein, e.g., mp58, a homolog of mp58 (e.g., wherein the comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof. In one embodiment, the cell-surface or secreted molecule is selected from the polypeptides of Table 9 and homologs thereof (e.g., wherein the homolog is a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the polypeptide of Table 9).
The method can further include administering cells or an extract of cells of a second fungus (e.g., wherein the second fungus is of the same genus as the first fungus, the same genus and species, the same genus and a different species; or wherein the second fungus is of a different genus from that of the first fungus). In one embodiment, the cells of the second fungus have been genetically modified to increase the expression of a cell surface or secreted molecule, or a fragment thereof. The cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof. In one embodiment, the cell-surface molecule is a mannoprotein, e.g., mp58, a homolog of mp58 (e.g., wherein the homology comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof. In one embodiment, the cell- surface or secreted molecule is selected from the polypeptides of Table 9 or a homolog thereof (e.g., wherein the homolog is a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the polypeptide of Table 9). The mammal can be, e.g., a mouse, human, goat, cow, pig, dog, cat, rabbit, rat, or horse. The method can further include isolating a composition comprising antibodies from the mammal (e.g., isolating antisera from the mammal). The composition comprising antibodies can then be administered to a second mammal (e.g, a human), e.g., wherein the second mammal is infected by a fungus or is at risk for infection by a fungus (e.g., wherein the fungus is chosen from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Paracoccidioides spp., and Coccidioides spp.).
In one embodiment of the method, the cells are genetically engineered to decrease expression or activity of a polypeptide that alters a filamentation property of the cells, e.g., wherein the polypeptide is a gene product of a gene selected from:
SPT3; SSN6; RBFl; RFGl; TUPl; NRGl; and homologs (e.g., fungal homologs) of SPT3; SSN6; RBFl; RFGl; TUPl; and NRGl (e.g., wherein the homolog comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the sequence of the gene product). In another aspect, the invention features a method for eliciting an immune response to a fungus in a primate. The method includes, for example: administering to the primate a composition comprising cells of the fungus or an extract of the cells, wherein the cells have decreased expression or activity of CRVl or a fungal homolog of CRVl, thereby inducing an immune response to the fungus in the primate. The method can include other features described herein.
In another aspect, the invention features a method for eliciting an immune response to a fungus in a mammal. The method can include, for example: administering to the mammal a composition comprising cells of a Candida species or an extract thereof, wherein the cells are genetically modified to be deficient for expression or activity of at least one polypeptide that regulates filamentation growth, thereby inducing in the mammal an immune response to the Candida strain and, e.g., a second fungal species selected from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Paracoccidioides spp., and Coccidioides spp. The second fungal species can be chosen from, e.g.,: Aspergillus fumigatus,
Aspergillus terreus, Aspergillus flavus, Aspergillus niger, Candida albicans, Candida ciferrii, Candida dubliniensis, Candida famata, Candida glabrata, Candida guilliermondii, Candida inconspicua, Candida kefyr, Candida krusei, Candida lambica, Candida lipolytica, Candida lusitaniae, Candida norvegensis, Candida parapsilosis, Candida pelliculosa, Candida rugosa, Candida tropicalis, Candida viswanathii, Candida zeylanoides, Coccidioides immitis, Cryptococcus neoformans, Fusarium chlamydosporum, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum var. capsulatum , Histoplasma capsulatum var. duboisii, Paracoccidioides brasiliensis, Pneumocystis carinii, and Trichophyton rubrum,
In still another aspect, the invention features a composition including: (a) cells of a fungus or an extract of the cells, wherein the cells are of a strain genetically modified (e.g., modified by recombinant means) to have at least one altered fϊlamentation property; and (b) a pharmaceutically acceptable carrier. The cells can be genetically modified to decrease expression or activity of at least one polypeptide that regulates filamentation. In one embodiment, the cells are genetically modified to decrease expression or activity of Crvl polypeptide or a fungal homolog thereof (e.g., a fungal homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to Crvl).
In one embodiment, the cells are further genetically modified to increase expression of a cell surface or secreted molecule, or a portion thereof, e.g., relative to a wild-type strain. The cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, e.g., a mannoprotein, e.g., mp58, a homolog thereof (e.g., wherein the homolog comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof. The composition can further include an adjuvant, and/or an extract of cells or cells of a second fungus. In one embodiment, the cells of the second fungus are genetically modified to increase expression of cell-surface or secreted molecule (e.g., a mannoprotein such as mp58, or a homolog thereof, or a polypeptide listed in Table 9, e.g., wherein the homolog comprises at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the protein or polypeptide), or a fragment thereof, e.g., relative to a wild-type strain. In another aspect, the invention features a method for treating or inhibiting a fungal infection in a mammal. The method includes, for example: administering to the mammal a composition comprising cells of a fungus or an extract thereof, wherein the cells are genetically modified to have increased production of a cell surface or secreted molecule, thereby treating or inhibiting the fungal infection in the mammal.
The fungal cells can be of the same genus and species as the fungus of the fungal infection, or can be of a genus and/or species other than the fungus of the fungal infection.
The fungal cells can be cells of a dimorphic fungus, e.g., cells of a dimorphic ascomycete. The fungal cells can be cells of the genus Candida, e.g., Candida albicans cells.
The composition can include live fungal cells, or can include primarily killed cells (e.g., wherein at least 80%, 90%, 95%, or 99% of the fungal cells of the composition are killed). The fungal cells can be killed by heat, ultraviolet radiation, mechanical disruption, or chemical inactivation.
In various embodiments of the method, the composition is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally. In one embodiment, the composition is administered orally. The composition can be administered one, two, or more times (e.g., 3, 4, or 5 times) to the mammal.
In one embodiment, the method elicits an immune response to the fungus of the fungal infection in the mammal, e.g., a protective immune response, a cell- mediated immune response, a humoral immune response, or both a cell-mediated immune response and a humoral immune response. In various embodiments, the method further includes evaluating the immune response (e.g., to the fungus of the fungal infection and/or to the fungus of the composition that is administered) in the mammal, e.g., evaluating a cell mediated immune response or a humoral immune response, e.g., evaluating a cell mediated delayed-type hypersensitivity response and/or an antibody response. The mammal can be at risk for infection by a fungus before the administering.
The mammal at risk can be immunocompromised or at risk for becoming immunocompromised, e.g., the mammal has impaired neutrophil function, e.g., the mammal is a human with HIV, e.g., and is suffering from AE)S, or is a human taking an immunosuppressive drug.
The mammal may be suffering from a fungal infection prior to the administering, e.g., a fungal infection caused by a fungus of a genus that is the same as the genus of the fungal cells (or extract thereof) administered to the mammal, e.g., an infection caused by the same species as the species of cells administered. The mammal may be suffering from a fungal infection caused by a fungus of a species (and possibly, genus) other than the species of the fungal cells administered to the mammal.
The cell-surface or secreted molecule can be a lipid, a carbohydrate, a polypeptide, or a portion thereof, hi one embodiment, the cell-surface molecule is a mannoprotem, e.g., mp58, a homolog of mp58 (e.g., a homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to mp58), or a portion of mp58 or the homolog thereof, hi one embodiment, the cell-surface or secreted molecule is selected from the polypeptides of Table 9 or a homolog thereof (e.g., a homolog comprising at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identity to the sequence of the polypeptide of Table 9).
"Treating or inhibiting", as used herein, refers to an administering that improves a mammal's condition due to a fungal infection or decreases the severity or incidence of infection of the mammal. Methods that treat or inhibit a fungal infection may alleviate, improve, or otherwise affect the infection, the symptoms of the infection, or the predisposition toward the infection.
"Genetically modified", as used herein, includes genetic modifications induced by chemical (e.g. MMS (methyl methane sulfonate), EMS (ethyl methane sulfonate), NTG (nitrosoguanidine), or other artificial means (e.g., induced by DNA- modifying enzymes, Ultraviolet (UV) crosslinking, gamma irradiation, X-ray treatement), spontaneously-arising genetic modifications, and modifications due to the introduction of recombinant DNA episomally and/or into the genome of the cell. "Genetically modified" cells are modified relative to a wild-type or parental strain. "Recombinantly genetically modified" refers to genetic modifications introduced using recombinant DNA methodologies.
"Gene", as used herein, includes coding, promoter, operator, enhancer, terminator, co-transcribed, and other regulatory sequences associated with a particular coding sequence.
"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity (e.g., percentage of amino acid or nucleotide identity) and/or similarity between the sequences being compared as hereinbefore described. Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species. As known to those skilled in the art, certain substitutions of one amino acid for another may be tolerated at one or more amino acid residues of a wild-type enzyme without eliminating the activity or function of the enzyme. As used herein, the term "conservative substitution" refers to the exchange of one amino acid for another in the same conservative substitution grouping in a protein sequence. Conservative amino acid substitutions are known in the art and are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. In one embodiment, conservative substitutions typically include substitutions within the following groups: Group 1 : glycine, alanine, and proline; Group 2: valine, isoleucine, leucine, and methionine; Group 3: aspartic acid, glutamic acid, asparagine, glutamine; Group 4: serine, threonine, and cysteine; Group 5: lysine, arginine, and histidine; Group 6: phenylalanine, tyrosine, and tryptophan. Each group provides a listing of amino acids that may be substituted in a protein sequence for any one of the other amino acids in that particular group. There are several criteria used to establish groupings of amino acids for conservative substitution. For example, the importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, MoI. Biol. 157:105-132 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. Amino acid hydrophilicity is also used as a criterion for the establishment of conservative amino acid groupings (see, e.g., U.S. Patent No. 4,554,101).
Information relating to the substitution of one amino acid for another is generally known in the art (see, e.g., Introduction to Protein Architecture: The Structural Biology of Proteins, Lesk, A.M., Oxford University Press; ISBN: 0198504748; Introduction to Protein Structure, Branden, C-L, Tooze, J., Karolinska Institute, Stockholm, Sweden (January 15, 1999); and Protein Structure Prediction: Methods and Protocols (Methods in Molecular Biology), Webster, D.M.(Editor), August 2000, Humana Press, ISBN: 0896036375).
In some embodiments, the sequence of a nucleic acid and/or a polypeptide will be compared to a second sequence (e.g., a second sequence from a second organism or from a related sequence in the same organism), and the homology can be determined. Homology comparisons can be used, for example, to identify corresponding amino acids. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Needleman and Wunsch ((1970) J. MoI. Biol. 48:444-453) which has been incorporated into the GAP program in the GCG software package, using either a Blosum 62 matrix and a gap weight of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
Generally, to determine the percent identity of two nucleic acid or protein sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid or amino acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a test sequence aligned for comparison purposes can be at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or amino acid positions are then compared. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein "identity" is equivalent to "homology").
The protein sequences described herein can be used as a "query sequence" to perform a search against a database of non-redundant sequences, for example. Such searches can be performed using the BLASTP and TBLASTN programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10. BLAST protein searches can be performed with the BLASTP program, using, for example, the Blosum 62 matrix, a wordlength of 3, and a gap existence cost of 11 and a gap extension penalty of 1. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information, and default parameters can be used.
Sequences described herein can also be used as query sequences in TBLASTN searches, using specific or default parameters.
The nucleic acid sequences described herein can be used as a "query sequence" to perform a search against a database of non-redundant sequences, for example. Such searches can be performed using the BLASTN and BLASTX programs (version 2.0) of Altschul, et al. (1990) J. MoI. Biol. 215:403-10. BLAST nucleotide searches can be performed with the BLASTN program, score = 100, wordlength = 11 to evaluate identity at the nucleic acid level. BLAST protein searches can be performed with the BLASTX program, score = 50, wordlength = 3 to evaluate identity at the protein level. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTX and BLASTN) can be used. Alignment of nucleotide sequences for comparison can also be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. MoI. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Natl Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr.,
5 Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et ah, eds. 1995 supplement)).
Nucleic acid sequences can be analyzed for hybridization properties. As used herein, the term "hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions" describes conditions for hybridization o and washing. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1- 6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) 5 at about 450C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 550C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 6O0C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one, two, three, four or more 0 washes in 0.2X SSC, 0.1 % SDS at 65°C) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 650C. Very high stringency conditions (at least 4 or more washes) are the preferred conditions and the ones that should be used unless otherwise specified. 5 The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. DESCRIPTION OF DRAWINGS
FIG. IA is a graph depicting the percentage survival of mice injected with a crvl/crvl C. albicans strain (ovals) or saline (squares), followed by challenge with a virulent strain of C. albicans. FIG. IB is a graph depicting the percentage survival of mice injected with a crvl/crvl C. albicans strain (triangles) or saline (squares), followed by challenge with a virulent strain of C. albicans.
FIG. 2 is a set of pictures showing the histology of kidneys of mice injected with a virulent strain of C. albicans (upper panels) or mice injected with a crvl/crvl strain of C. albicans followed by challenge with a virulent strain (lower panels). Gomori methenamine silver (GMS) was used to stain fungi in the tissues.
DETAILED DESCRIPTION
The invention is based, in part, on the observation that exposure to attenuated strains of fungi with one or more altered filamentation properties can protect against subsequent infections with other fungi. We have shown that inoculation of cells of a hypofilamentous strain of Candida albicans (C. albicans) protects animals from lethal challenge with virulent strains of C. albicans. Furthermore, attenuated fungi, or extracts thereof, can elicit responses that prevent or decrease disease due to infection by both homologous and heterologous strains, i.e., exposure to an attenuated Cryptococcus neoformans can stimulate responses that provide protection from infection with Candida albicans.
Attenuated fungi, or extracts thereof, can be administered alone or in combination with other fungal components such as crude or purified fungal cell wall extracts, and cell surface and secreted components (e.g., from the same or a different strain from the attenuated fungal compositions). These combinations can further promote immune responsiveness to fungi by activating innate immune mechanisms and/or by increasing the exposure of the patient or animal to protective and/or immunodominant epitopes. In certain embodiments, attenuated fungi may also have beneficial effects on subjects that have already been exposed to other fungi. Attenuated fungi or extracts thereof can be administered in combination with an antibody that specifically binds to a fungal component (e.g., a fongal polypeptide or carbohyrated) or an antigen binding portion thereof.
Attenuated Fungal Strains We have shown that C. albicans crvl/crvl mutant strains are profoundly avirulent in animal models of infection. These strains grow vigorously in vitro and are able to initially colonize mouse tissues in vivo. However, despite relatively high initial tissue cell counts, crvl/crvl strains cause relatively little tissue damage and do not kill the infected host. The avirulent crvl/crvl cells are cleared from the host tissues over a period of weeks, hi contrast to clinical isolates of C. albicans that grow predominantly as filamentous forms in vivo, crvl/crvl strains grow as ovoid, yeast form cells (U.S. Pat. Pub. 20030176367). This altered morphology may facilitate the phagocytosis of yeast form crvl/crvl cells relative to their filamentous, wild type counterparts. Transcriptional profiling reveals that the expression pattern of many of the genes associated with infection and virulence are differentially expressed in crvl/crvl strains relative to wild type controls (when grown under conditions that mimic the host environment (e.g., 37°C, pH 7, serum)). For instance, HWPl, a hyphal wall protein associated with adherence and virulence, is highly induced in wild type strains upon transfer to Yeast Nitrogen Base (YNB), pH 4.5, 30°C to YNB, pH 7, 37°C. In contrast, HWPl is not induced in crvl/crvl strains when handled similarly. However, a number of genes are similarly regulated in both crvl/crvl and wild type including PRAl, the gene encoding mp58, a conserved and highly immunogenic C. albicans cell surface protein.
Attenuated fungal strains can be generated by reducing or increasing activity or expression of polypeptides that regulate filament formation and/or invasiveness. For example, the CR Vl gene of C. albicans is required for hyphal growth and invasion under physiological conditions (U.S. Pat. Pub. No. 20030176367). Strains in which this gene is deleted, mutated, or in which expression is decreased or otherwise inhibited can be used in methods for inducing an immune response in mammals. Likewise, homologs of CRVl in both C. albicans and in other species can be targeted to generate attenuated strains. Other methods to generate attenuated strains include those in which one identifies variant cells with increased or decreased expression or activity of a polypeptide known to be indicative of filamentation (or a non- filamentous state). Such variants may arise from chemical or genetic procedures and may be due to rearrangements, deletions, or insertions in the genome of the cells. Attenuated strains suitable for the methods described herein include strains with altered filamentation properties, which can include changes in growth patterns of individual cells as well as overall changes in filament shape or structure. Relevant cell properties include, without limitation, cell volume, cell length, cell width, cell- cell adherence, axial ratio (e.g., lengthr.width ratio), budding pattern (e.g., unipolar, bipolar), and overall cell shape (e.g., round, ovoid, ellipsoid, elongated, irregular). Filament properties include, without limitation, spacing between septae, branch frequency, branch polarization (e.g., in the same or different direction relative to the main filament), planarity, type of growth (hyphal versus pseudohyphal), frequency of yeast form or non-filamentous cells within the filament, and overall macroscopic characterization (e.g., "bushy", "cables"). In general, ovoid non-filamentous cells are less able to invade substrates as compared to elongated filamentous cells. Genetic or chemical modifications can be defined as inducing/causing a hypofilamentous phenotype if they reduce cell or filament length of the fraction of elongated versus ovoid cells. The nucleic acid and amino acid sequences and GenBank® Accession numbers and for CRVl and homologs of CRVl are provided in Tables 1, 2, 3, and 4, below. The predicted protein sequences encoded by other genes that are not homologs of Crvl, but which can also be targeted to generate attenuated strains, are provided in Table 5, with their corresponding DNA sequences in Table 6. Fungi also contain genes, often characterized as transcriptional regulators that, when mutated or deleted, cause the strain to become hyperfilamentous. In some cases, overexpression of one (or more) of these genes (e.g., NRGl) has been shown to lead to a hypofilamentous phenotype and reduced virulence. In general, overexpression of any of these genes or their homologs from other fungal species can generate hypofilamentous strains that provide protection against subsequent infection by virulent strains of the same or different fungal genera or species. The SPT3, SSN6, RBFl, RFGl, TUPl, and NRGl amino acid and nucleotide sequences are provided below in Tables 7 and 8, respectively.
Techniques common to the fields of molecular biology, genetics and microbiology can be employed for generating the fungal strains described herein. Useful laboratory references for these types of methodologies include Molecular Cloning, A Laboratory Manual, 3rd edition, edited by Sambrook, J., MacCallum, P., and Russell, D.W. (2001), Cold Spring Harbor Laboratory Press (ISBN: 0-879-69576- 5); Current Protocols In Molecular Biology, edited by Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Struhl, K. (1993), John Wiley and Sons, Inc. (ISBN: 0-471-30661-4); PCR Applications: Protocols for Functional Genomics, edited by Innis, M. A., Gelfand, D.H., Sninsky, JJ. (1999), Cold Spring Harbor Press (ISBN: 0-123-72186-5); and Methods In Yeast Genetics, 2000 Edition: A Cold Spring Habor Laboratory Course Manual, by Burke, D., Dawson, D. and Stearns, T., Cold Spring Harbor Press (ISBN: 0-879-69588-9). Fungal species suitable for preparation of the compositions described herein include, but are not limited to: Absidia corymbifera, Absidia spp., Acremonium falciforme, Acremonium kiliense, Acremonium recifei, Acremonium spp., Ajellomyces capsulatus, Ajellomyces dermatitidis, Ajellomyces spp., Allescheria boydii, Alternaria alternata, Alternaria chartarum, Alternaria dianthicola, Alternaria geophilia, Alternaria infectoria, Alternaria spp., Alternaria stemphyloides, Alternaria teunissima , Anthopsis deltoidea, Aphanomyces spp., Apophysomyces elegans, Armillaria spp., Arnium leoporinum, Arthroderma benhainiae, Arthroderma fulvum, Arthroderma gypseum, Arthroderma incurvatum, Arthroderma otae, Arthroderma vanbreuseghemii, Arthrographis cuboidea, Arthrographis kalrae, Aspergillus clavatus, Aspergillus βavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus spp., Aspergillus terreus, Aspergillus ustus, Aspergillus versicolor, Aureobasidium pullulans, Basisdiobolus ranarum, Beauveria bassiana, Bipolaris australiensis, Bipolaris hawaiiensis, Bipolaris spicifera, Bipolaris spp., Blastomyces dermatitidis, Blastoschizomyces capitatus, Botrytis spp., Candida albicans, Candida ciferrii, Candida dubliniensis, Candida famata, Candida glabrata, Candida guilliermondii, Candida inconspicua, Candida kefyr, Candida krusei, Candida lambica, Candida lipolytica, Candida lusitaniae, Candida norvegensis, Candida par apsilosis, Candida pelliculosa, Candida rugosa, Candida spp., Candida tropicalis, Candida viswanathii, Candida zeylanoides, Centrospora spp., Cephalosporium spp., Ceratocystis spp., Chaetoconidium spp., Chaetomium atrobrunneum, Chaetomium spp., Chlamydia trachomatis,
Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium parvum , Chrysosporium queenslandicum, Chrysosporium spp., Chrγsosporium tropicum, Chrysosporium zonatum, Cladophialophora carrionii, Cladophialophora spp., Cladosporium cladosporioides, Cladosporium elatum, Cladosporium herbarum, Cladosporium sphaerospermum,
Cladosporium spp., Coccidioides immitis, Coccidioides posadasii, Coccidioides spp., Colletotrichium spp., Conidiobolus coronatus, Conidiobolus incongruus, Conidiobolus lamprauges, Conidiobolus spp., Cryptococcus neoformans, Ciyptococcus spp., Cryptoporiopsis spp., Cunninghamella bertholletiae, Cunninghamella spp., Curvularia brachyspora, Curvularia clavata, Curvularia geniculata, Curvularia lunata, Curvularia pallescens, Curvularia senegalensis, Curvularia spp., Curvularia verruculosa, Cylindrocladium spp., Dactylaria spp., Debaryomyces hansenii, Diplodia spp., Emmonsia parva, Emmonsia parva var. crescens, Emmonsia parva var. parva, Emmonsia pasteuriana, Epidermophyton floccosum, Epidermophyton spp., Exophiala castellanii, Exophiala dermatitidis,
Exophiala jeansehnei var. heteromorpha , Exophiala jeanselmei var. lecanii-corni, Exophiala moniliae, Exophiala salmonis, Exophiala spinifera, Exophiala spp., Exophila pisciphila, Exserophilium spp., Filobasidiella neoformans, Fonsecaea compacta, Fonsecaea pedrosoi, Fonsecaea spp., Fulvia spp., Fusarium chlamydosporum, Fusarium oxysporum, Fusarium solani, Fusarium spp., Geotrichum candidum, Geotrichum clavatum , Geotrichum fid, Geotrichum spp., Guignardia spp., Helminthosporium spp., Histoplasma capsulatum, Histoplasma capsulatum var. capsulatum , Histoplasma capsulatum var. duboisii, Histoplasma spp., Hortaea werneckii, Issatschenkia orientalis, Kluyveromyces lactis, Lacazia loboi, Lasiodiplodia spp., Lecythophora spp., Leptosphaeria australiensis, Leptosphaeria senegalensis, Leptosphaeria spp., Macrophomina spp., Madurella grisae, Madurella mycetomatis, Madurella spp., Magnaporthe grisea, Magnaporthe spp., Malassezia furfur, Malassezia globosa, Malassezia obtuse, Malassezia pachydermatis, Malassezia restricta, Malassezia slooffiae, Malassezia sympodialis, Malbranchea pulchella, Malbranchea sclerotica, Malbranchea spp., Microsporum audouinii, Microsporum canis, Microsporum cookei, Microsporum distortum, Microsporum eguinum, Microsporum ferrugineum, Microsporum fulvum, Microsporum gallinae, Microsporum gypseum, Microsporum nanum, Microsporum spp., Microsporum vanbreusegh, Monilinia spp., Mucor circinelloides, Mucor spp., Mycocentrospora acerina, Nectria haematococca, Nectria spp., Neotestudina rosatii, Neotestudina spp., Neurospora crassa, Nigrospora sphaerica, Nigrospora spp., Nocardia asteroides, Nocardia brasiliensis, Nocardia otitidiscaviarum, Nocardia spp., Ochrononis spp., Onychocola canadensis , Onychocola spp., Oospora spp., Ophiobolus spp., Paecilomyces lilacinus, Paecilomyces spp., Paecilomyces variotii, Paracoccidioides brasiliensis, Paracoccidioides spp., Penicillium marneffei, Penicillium spp., Penicillium verrucosum, Phaeoannellomyces spp., Phaeosclera dematioides,
Phialemonium obovatum, Phialophora europaea, Phialophora spp., Phialophora verruceosa, Phlyctaena spp., Phoma spp., Phomopsis spp., Phymatotrichum spp., Phytophthora spp., Pichia anomala, Pichia guilliermondii, Pichia ohmeri, Pichia spp., Piedraia hortai, Piedraia spp., Pneumocystis carinii, Pneumocystis jiroveci, Pneumocystis spp., Pseudallescheria boydii, Pseudallescheria spp., Puccinia spp., Pyrenochaeta romeroi, Pyrenochaeta spp., Pyrenochaeta unguis-hominis, Pythium insidiosum, Pythium spp., Rhinocladiella aquaspersa, Rhizoctonia spp., Rhizomucor pusillus, Rhizomucor spp., Rhizomucor variabilis, Rhizopus microsporus var. rhizopodiformis, Rhizopus oryzae, Rhizopus spp., Rhodotorula rubra, Rhodotorula spp., Saccharomyces cerevisiae, Saccharomyces spp., Saksenaea vasiformis, Sarcinomyces phaeomuriformis, Scedosporium apiospermum, Scedosporium prolificans, Scedosporium spp., Scerotium spp., Schizophyllum commune, Schizosaccharomyces pombe, Sclerotinia spp., Scopulariopsis brevicaulis , Scopulariopsis spp., scytalidium spp., Sphaerotheca spp., Sporobolomyces salmonicolor, Sporobolomyces spp., Sporothrix schenckii, Stachybotrys chartarum, Stachybotjγs sp., Stemphylium macrosporoideum, Syncephalastrum racemosum, Taeniolella boppii, Taphrina spp., Thielaviopsis spp., Torulopsis spp., Trichoderma spp., Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton spp., Trichophyton verrucosum, Trichophyton violaceum, Trichosporon asahii, Trichosporon cutaneum, Trichosporon inkin, Trichosporon mucoides, Trichosporon spp., Ulocladium botrytis, Ulocladium chartarum, Ustilago maydis, Ustilago spp.,
Venturia spp., Verticillium spp., Wangiella dertnatitidis, Wangiella spp., Whetxelinia spp., Xylohypha spp., and Yarrowia lipolytica.
Overexpression of Cell Surface or Secreted proteins and components Fungal cell wall components are immunogenic in mammals and can be used to enhance immune responsiveness to fungi. Furthermore, cell wall components have been shown to induce cross-species protection. Immunization with an extract containing a Cryptococcus neofonnans mannoprotein, mp65, provides protective immunity to subsequent infections with both Cryptococcus neofonnans and C. albicans (Pietrella et al., Infect Immun, 70, 6621-27 (2002)).
Cells that overexpress cell surface proteins (or fragments thereof) can be used for vaccination methods. Examples of polypeptides and their corresponding nucleic acid sequences which can be overexpressed are provided in Tables 9 and 10, respectively. These genes include the C. albicans mp58 gene and other C. albicans cell surface proteins.
One way to achieve overexpression of a nucleic acid sequence in fungal strains such as C. albicans is to express the sequence under the control of a highly active promoter, such as a promoter of one of the following genes: ACTl, TEFl, TEF2, ADHl, MAL2, HWPl, PHRl, GALl, MET3, saaά PCKl. These promoters, or others, can be further modified so as to be regulatable, e.g., by a compound such as an antibiotic, e.g., tetracycline (or a derivative thereof such as doxycycline), by the addition of tetR binding sites. Additionally, a number of promoters from heterologous species (e.g., promoters from the following genes of S. cerevisiae: ACTl, TEFl, TEF2, ADHl, GALl, GALlO and FBPl) function in a filamentous strain such as C. albicans. Compositions for administration
Strains for inoculation are maintained under a variety of conditions including on solid media or slants at 40C or room temperature for short term storage or at -8O0C in glycerol or other cryopreservatives for longer-term storage. Exemplary Candida strains for inoculation include CAI4 (ATCC® No. MYA-682), SC5314 (ATCC® No. MYA-2876) and BWP17 (Wilson et al., J Bacterial, 181(6):1868-1874, 1999) and derivatives thereof (e.g., derivatives made by genetic modification (e.g. recombinant derivatives)). Live cultures for inoculations are prepared as follows. Cultures are incubated for 24 hours on appropriate agar at 37°C, inoculated into broth, and incubated at 370C on a gyratory shaker operating at 165 rpm. The cells are harvested after approximately 18 hours and washed three times in nonpyrogenic saline (NPS). The final pellet is resuspended in NPS, cells are counted in a hemocytometer and diluted to the appropriate concentration in NPS. The viability of the culture can be determined by plate count. To kill cells prior to inoculation, the cell suspension can be heated at 6O0C for
2 hours. The lack of viability of the heated preparation can be confirmed by plating 109 cells on agar and incubating them at 37°C overnight.
Fungal cell extracts enriched for cell wall components can be prepared by methods described in Staab et al. {J Biol Chem. 279(39):40737-47, 2004). Briefly, cells are suspended in a lysis buffer (50 niM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM EDTA) with protease inhibitors and broken with glass beads ((425-600 microns, Sigma- Aldrich). The broken cells are centrifuged at low speed (1000 x g for 10 minutes at 40C), the supernatants are transferred to new tubes and re-centrifuged at high speed (15,000 x g for 10 minutes at 4°C). The pelleted cell walls from the initial 15,000 x g spin are washed in 25 mM Tris-Cl, pH 7.5, 1 M NaCl, 0.5 mM EDTA with protease inhibitors as above. The washed walls are boiled twice for 5 min in 100 μL of SDS lysis buffer (50 mM Tris-Cl, pH 7.5, 150, mM NaCl, 2% SDS, 10 mM DTT, 5 mM EDTA with protease inhibitors at 40 μg/mL, and 0.1 mM Pefabloc) to remove noncovalently-bound wall proteins. The SDS-boiled cell walls are washed twice in buffer (25 mM Tris-Cl pH 7.5, 1 M NaCl, 0.5 mM EDTA with protease inhibitors), and suspended in 25 mM Tris-Cl pH 7.5, 40 mM 2-mercaptoethanol, 1 niM EDTA with protease inhibitors, and 75 units of Quantazyme ylg (Quantum Biotechnologies, InterSpex Products, Inc., Foster City, CA). The mixture is incubated at 37°C for 1 h with rocking and residual undigested cell wall material is removed by centrifugation at 15,000 x g at 4°C. The supernatants
5 containing the cell wall material are centrifuged at 20,000 x g for 20 min at 40C before being transferred to new tubes for use.
A method for preparation of mannoprotein extracts is described in Pietrella et al. (Infect Immun, 70, 6621-27 (2002)). Briefly, fungi are cultured in a defined medium for approximately 5 days at 350C. The culture supernatant (which contains o mannoproteins) is concentrated by ultrafiltration and purified by a combination of affinity chromatography (concanavalin A (ConA)) and anion-exchange chromatography (DEAE). The extract includes a mix of protein and carbohydrate. Fungal compositions can also be administered in combination with purified protein preparations, e.g., an antibody or antibodies that specifically bind to fungal 5 polypeptides or antigen-binding portions thereof (e.g., recombinant fungal polypeptides or fragments thereof), hi certain embodiments the fungal polypeptides include C. albicans mp58 mannoprotein and fragments thereof described in U.S. Pat. Pub. No. 20040142385. hi certain embodiments the fungal polypeptides include those disclosed in Table 9 of the instant specification and fragments and homologs 0 thereof (e.g., homologs having sequences at least 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% identical to a sequence in Table 9).
Methods for Administration
Methods for treating (e.g., prophylactically and/or therapeutically) a patient at 5 risk for or having a fungal infection are provided herein, hi certain embodiments, the methods are useful for the prevention or treatment of candidiasis. The methods include administering to a patient at risk of developing a fungal infection a composition that includes fungal cells (e.g., living or killed cells) that exhibit one or more altered filamentation properties due to one or more genetic alterations. 0 Alternatively, or in combination, extracts of fungal cells are administered. Fungal compositions can be administered by conventional approaches, including administration via e.g., intravenous, intraperitoneal, intramuscular, intranodal, subcutaneous administration, transdermal delivery, inhalation (e.g., aerosol), or oral routes or via direct injection into a tissue.
Fungal compositions can, but need not be administrated with an adjuvant or a carrier. Adjuvants include, Freund's adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; other bacterial-derived preparations; gamma interferon; block copolymer adjuvants, RIBI adjuvants (available from Ribi ImmunoChem Research, Inc., Hamilton, Mont.); and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark). Carriers include polymeric controlled release formulations, biodegradable implants, liposomes, oils, esters, and glycols.
Fungal compositions of the present invention can also include one or more pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient refers to a substance suitable for delivering a fungal composition to a site in vivo or ex vivo. Excipients can maintain a fungal composition in a form that is capable of eliciting an immune response at a target site. Examples of pharmaceutically acceptable excipients are saline, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols. Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity. Other auxiliary compounds include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer. Auxiliary substances can also include preservatives, such as thimerosal, m- or o-cresol, formalin and benzol alcohol.
The administration of fungal compositions can be performed ex vivo or in vivo. Ex vivo administration refers to performing a step of a method for administration outside of the subject, such as administering a composition of the present invention to a population of cells (e.g., peripheral blood lymphocytes) and returning the cells to the subject. Suitable dose sizes are doses capable of eliciting antifungal responses in a subject when administered one or more times over a suitable time period. A suitable single dose of a fungal composition can be a dose that is capable of effectively providing fungal antigens to a given cell type, tissue, or region of the subject body in an amount effective to elicit an antifungal immune response, e.g., when administered one or more times over a suitable time period.
The fungal compositions described herein can be administered to mammals including primates, rodents, livestock and domestic pets. Livestock include mammals to be consumed or that produce useful products (e.g., sheep for wool production). Mammals to protect include humans, dogs, cats, mice, rats, goats, sheep, cattle, horses and pigs.
Fungal infections which may be treated or inhibited by agents described herein include, without limitation: Aspergillosis, Blastomycosis, Candidiasis, Chromoblastomycosis, Coccidioidomycosis, Cryptococcosis, fungal eye infections, Histoplasmosis (capsulati and duboisii), Lobomycosis, Mycetoma, Otomycosis, Paracoccidiomycosis, Phaeohyphomycosis, Rhinosporidiosis, Sporotrichosis, Zygomycosis, Occulomycosis (including Mycotic keratitis), infection by Penicilliosis marneffei and various fungal hair, skin and nail infections (including Onychomycosis (Tinea unguium), Piedra, Pityriasis versicolor, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris, Tinea favosa, Tinea nigra, and Tinea pedis).
In various embodiments, the compositions described herein are administered to patients at risk for fungal infections. These include patients with impairment of neutrophil function due to decreased neutrophil production in the bone marrow, increased neutrophil destruction, or qualitative defects in neutrophil function. Factors that can cause a decrease in neutrophil production include, but are not limited to (1) administration of cytotoxic drugs, including alkylating agents such as cyclophosphamide, busulfan, and chlorambucil, and antimetabolites such as methotrexate, 6-mercaptopurine and 5-flurocytosine; (2) administration of other drugs known to inhibit neutrophil production including, but not limited to, certain antibiotics, phenothiazines, diuretics, anti-inflammatory agents, and antithyroid drugs; (3) bacterial sepsis infections, viral infections such as HTV, EBV or hepatitis; typhoid, malaria, brucellosis, and tularemia; (4) primary hematologic diseases resulting in bone marrow failure, as well as both hereditary syndromes and acquired defects; (5) bone marrow failure due to tumor invasion or myelofibrosis; and (6) nutritional deficiencies such as deficiency of either vitamin B12 or folate. Factors that can cause an increase in destruction of neutrophils, thereby rendering an individual susceptible to fungal infections, include, without limitation, the presence of antineutrophil antibodies, autoimmune disease (such as Felty's syndrome, rheumatoid arthritis, or systemic lupus erythematosis), or idiosyncratic reactions to drugs that, in an idiosyncratic way, act as haptens at the surface of neutrophils, initiating immune destruction of neutrophils.
Qualitative defects in neutrophil function that can lead to increased susceptibility to fungal infections include many disease states, for example, leukocyte adhesion deficiency syndromes, neutrophil chemotactic defects, and neutrophil phagocytic and killing defects. Neutrophil function is also compromised by administration of corticosteroids used in the treatment of a wide variety of diseases. Thus, patients treated with corticosteroids are at increased risk of fungal infections.
Additional factors increasing individual susceptibility to fungal infections include: (1) treatment with broad spectrum antibiotics, especially in the hospital setting and in Intensive Care settings in particular; (2) application of intravenous catheters, particularly central venous catheters;(3) surgical wounds, particularly those associated with intra-abdominal surgeries; (4) tissue, bone marrow or solid organ transplantation; (5) cancer chemotherapy; (6) Acquired Immune Deficiency Syndrome; (7) Intensive Care Unit stay; and (8) diabetes. In addition, neonates and aged patients are at increased risk. Immunosuppressed patients (e.g., patients with acquired immunosuppression, e.g., due to HIV infection or immunosuppressive medical treatments such as chemotherapy; or with an inherited immunosuppressive disorder) can exhibit increased susceptibility to fungal infections as well.
Fungal compositions can be administered to provide a beneficial effect (e.g., a prophylactic or therapeutic effect) specific to the strain administered, or which also is beneficial towards one or more additional strains (e.g., by inducing a cross-reactive response). Thus, one may administer compositions derived from one particular strain to induce a beneficial effect in a subject at risk for infection with a second strain.
Human and animal subjects at risk for (or exposed to) infection by strains of any of the following species may be administered compositions described herein including, without limitation: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Saccharomyces spp., Paracoccidioides spp., and Coccidioides spp.
Combination Therapies The fungal compositions described herein can be administered in combination
(e.g., coformulated with, and/or coadministered with), one or more additional therapeutic agents, e.g., anti-fungal agents. Among the agents that can be used in combination therapy are polyenes (e.g., Amphotericin B (including lipid or liposomal formulations thereof), Mepartricin, Nystatin (including liposomal formulations thereof), Pimaricin, SPA-S-843), candins (e.g., Anidulafungin (also called LY303366, VER-002, V-echinocandin) Caspofungin, Cancidas (caspofungin acetate), Micafungin (FK463), and Cilofungin), aminocandins, sordarins (e.g., Azasordarin, GM 222712, GM 237354), azoles (e.g., Azaconazole, Azoline, Albaconazole, bal 8557, Bispyrithione Magsulfex Butoconazole Nitrate, Bifonazole, Butoconazole, Clotrimazole, Croconazole, CS-758, Eberconazole, Econazole, Econazole Nitrate, Enilconazole, Fenticonazole, Fenticonazole nitrate, Fluconazole, Flutrimazole, Fosfluconazole, Isoconazole, Itraconazole, Ketoconazole, Ianoconazole, Immidazoles, Miconazole, Miconazole nitrate, Neticonazole, Orconazole Nitrate, Oxiconazole, Oxiconazole Nitrate, Parconazole Hydrochloride, Posaconazole, PR-2699, Propenidazole, Ravuconazole, Saperconazole, SCH-56592 (Schering Plough), Sertaconazole, SSY-726, Sulconazole, Sulconazole nitrate, Terconazole, Thiabendazole, Tioconazole,Zinoconazole Hydrochloride and Voriconazole), allylamines (e.g., Butenafine, Naftifme, Terbinafme), morpholines (e.g., amorolfϊne), pradimicins (e.g., BMS-181184), and other antifungals (e.g., 501 cream; Acrisorcin; Ambruticin; Azaserine; Basifungin; basiungin/ECB; bactericidal/permeability- increasing protein (BPI) described in U.S. Pat. Nos. 5,627,153; 5,858,974; 5,652,332; 5,763,567; and 5,733,872; BAY 38-9502; Biphenamine Hydrochloride; Calcium
Undecylenate; Candicidin; Carbol-Fuchsin; chitinase; Chlordantoin; Ciclopirox olamine; Disodium chrmoglycat; Echinocandins (including MK-0991 (Merck);
Ethonam Nitrate; Filipin; FK 463; Fungimycin; Gentian violet; Glutaraldehyde; Hamycin; Hydroxystilbamidine; Iodine; Kalafungin; Lomofungin; Lydimycin; MK
991; Monensin; Monensin Sodium; Naftifine Hydrochloride; Neomycin
Undecylenate; Nifuratel; Nifurmerone; Nitralamine Hydrochloride; Octanoic Acid;
Oxifungin Hydrochloride; Partricin; Potassium Iodide; Prednisone; Proclonol ;
Pyrithione Zinc ; Pyrrolnitrin; Resorcin; Rutamycin; Sanguinarium Chloride ; Scopafungin; Selenium Sulfide ; Sinefungin; Thiabendazole; Thiram; Ticlatone ;
Tolindate; Tolnaftate; Triacetin; Triafungin; UK 292; Viridofulvin; Zinc
Undecylenate; Alpha interferon; Amantanium bromide; aminopyridine; amphotech; α-MSH (melanocyte stimulating hormone) peptide; BAY-10-8888/PLD-l 18; β-(l,6)- glucan synthesis inhibitors; Ciclopirox; Cyclopiroxalamine; DB-289; ECO-02301; ECO-14401; Exalamide; Flucytosine (5-fluorocytosine); Fumagiline; Griseofulvin;
Haloprogin; Iseganan; Liranaftate; Natamycin; Nikkomycin; Siccanin; Tolciclate;
Undecylenate; Undecylenic Acid; Zadaxin; beta-amino acids, e.g., PLD-118 or derivatives thereof).
The antifungal agents that are administered in combination may act, for example, by blocking ergosterol synthesis (e.g., azoles or allylamines), by interfering with the cell wall (e.g., candins), by interfering with the cell membrane (polyenes) or by interfering with protein translation (e.g., sordarins).
Fungal compositions may also be administered in combination with an antibody (or antigen-binding portion thereof) that specifically binds to a fungal component (e.g., a fungal polypeptide or carbohydrate, e.g., a mannoprotein). The antibody (or antigen-binding portion thereof) can be a monoclonal antibody, e.g., a human or humanized monoclonal antibody. EXAMPLES
Example 1. Mice are protected from lethal infection with Candida albicans by pre- inoculated with a hypofilamentous mutant strain. Experiments
Experiment #1. Fifteen Balb/c mice (female, 6-7 weeks old) were inoculated in the tail vein with 2.O x IO6 cells of C. albicans strain MCl 91 (crvlA::ARG4/crvlA::HIS3 ade2:: URA3/ADE2 ura3Δ::imm434/ura3 Δ::imm434 hisl ::hisG/hisl::hisG arg4: :hisG/arg4: :hisG) or saline control. MC191 is a strain of C. albicans derived from BWP 17 in which both copies of the CRVl gene were deleted using a sequential PCR mediated disruption strategy and complemented with URA3 targeted to the ADE2 locus. Fourteen days post-inoculation, mice were challenged by inoculation with 2 x 106 cells of strain MC243, a virulent C. albicans strain. Survival was measured for 22 days, at which point the surviving animals were sacrificed. The results are depicted in FIG. IA. All of the mice that were pre- inoculated with saline died within 2 days, suggesting that the inoculum of MC243 was a particularly strong challenge and might obscure the magnitude of the significant difference observed. Therefore, the experiment was repeated with a lower inoculum of a different virulent C. albicans strain, CAF-2.
Experiment #2. Ten Balb/c mice (female, 6-8 weeks old) were inoculated in the tail vein with 1.9 x 106 cells of strain MC191 {crvl) or saline control (8 mice). Fourteen days post-inoculation, mice were challenged by inoculation with 4.4 x 10 cells of CAF-2, a virulent C. albicans strain. Survival was measured for 28 days, at which point the surviving animals were sacrificed. The results of this experiment are shown in FIG. IB.
Kidneys were removed from both control mice and crvl /crvl pre-inoculated mice at the time of sacrifice. Colony forming units (CFU) of bacteria were determined by homogenizing one kidney from each mouse and plating the homogenate on YPD media or serum-containing plates, crvl /crvl strains were readily identified on serum plates as round colonies of non-filamentous cells while CAF-2 clones grew as invasive colonies of filamentous cells. The remaining kidney was retained for histologic analysis. Results Pre-inoculation of a crvl/crvl strain was found to confer resistance to subsequent challenge with a wild type isolate of C. albicans, as shown in FIGS. IA and IB. Survival was significantly increased in mice previously inoculated with crvl/crvl cells - either for several days (FIG. IA) or indefinitely (FIG. IB). The two experiments differed in the apparent virulence and speed of death caused by infection with a virulent strain, hi experiment #1 , crvl/crvl pre-inoculated mice survived up to 8 days while mice pre-inoculated with a saline control died within 2 days (FIG. IA). More dramatically, in experiment #2, mice previously inoculated with crvl/crvl cells showed no outward signs of infection when challenged with a virulent C. albicans strain and 100% survival throughout the experiment (24 days post-CAF-2 infection) (FIG. IB). In contrast, all of the mice pre-inoculated with saline in experiment #2 died within 9 days.
Histologic examination of kidneys from infected mice revealed striking differences between saline and crvl/crvl -inoculated groups. Mice pre-inoculated with saline had large numbers of filamentous C. albicans cells in the kidneys (FIG. 2, upper panels). In contrast, mice pre-inoculated with the crvl/crvl strain were characterized by the presence of non-filamentous C. albicans in the tissue with few or no filamentous organisms (FIG. 2, lower panels). Phenotypic characterization of fungi growing on serum plates onto which kidney homogenate was plated revealed that essentially all of the C. albicans isolated from the crvl/crvl pre-inoculated mice were in fact avirulent crvl/crvl mutants with few or no virulent CAF-2 cells observed (<1%) (data not shown).
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. Table 1. Amino Acid Sequences of C. albicans Crvl
Figure imgf000031_0001
Table 2. DNA Sequences of C. albicans CRVl
Gene; DNA sequence IEQ
GenBank® :D
Accession TO:
No . ;
GenBank® GI
No .
CRVl; ATGAATCATAAACAAGTACTACCAGAAAATGAACCGATATCAACAACAACAGCA Acc. not ACTCCATCATCATCCAATACTATGGTTCCCAACACAACTAAACAGGTTTTAAAC available; TCGTTGATTTTGGATTTTTTGGTCAAACATCAATTTCAAGATACAGCAAAAGCA GI not TTTTCTAAAGAAAGTCCCAATTTGCCTTCTATTCCTCCTTTGΆTGGATTGTTCT available CΆAGGΆTTTTTATTGGAΆTGGTGGCAAGTTTTCTTTGATTTATTTCAAGTCAGA TATGGAGACGGTAACAGTAATAATAACCCTAACAACAAGCTTTATCATGATTAT CTCAGAGTCCAAGAAACTCAΆAAACATCTTTTCΆGTCAACTTCCTCTTATΆCAG CAGCAGCAACAACAACAACATCACTTTCAACAACAACAGCAACAACAAGGGCAA CAGGGACAGCCTTTCCTGCAGCAACAGCAAAGAGGAATCGGTGTTGCTAGTGGT ATGCAAAATCAACAACATCAATTTGCCCCACAGCATCAAGGCCAACCTCAAGGA CCAGGTCAAACACCTCAACCGCCAGGTTCTGCAACTAACGCTAATTTCCCTATC AATATGCCACCAAATCTGAATCCTCAACAACAAATGTTCCCCATTAATCAACAA TTTGCTCAGATGCCAAATGGTCAAAΆTCAGCCTTCAATGGAACΆΆCAΆCAAAGA ATGGCAATGATGATGAAACAACAAGCAATGGCTGCACAAAGACAACAAATCCCA ATGAATGGTTTAGATCCACAACAACAACAGCAAATGATGAATGCTGTAGGTGGT
GACCTGGTAATTTGAATTTGCAACAACAACTATTTTTACAΆCAACAACAGCAG CAGCAGCAΆCCCAAAACTACTTTCCAGCAACAAGCACAAΆATCAAATGAACAAT TTGCGTCAACAAGCTGCAATGGTTGCTCAGCAGCAGCAACAGCAACAGCAACAG CAACAACAACAGGGTCAGTTGCAAGGCAATTTGACATCAGCAATGGGTGATTCA TCTCTGAAGAATAACTCTCCTGTTGGTGCAAGATCAAATCAACAGCTGACTCCA CAACAAAATGCTGCACCAGCTTCACTGCCACATCCTTCTCAACAAGGTCAAGCA CAAGCTCAACATAACTTCCAGAGCCATCAACAACAACAACAGCAAATGACTAAG ATGGCTGGGTCTCAAGGAATGAAAAAGAATGGTCAGATGTCAAACGGCACTAGT AATAACAGTAGTGGCAGΆAACΆATAATGCTCTACGΆGATTATCAAΆATCAATTA ATGTTATTAGAAAGACAGAATAAAGAGAGATTAGAATTTGCTAGAAACACTGGT ΆΆTTCCGACTCCAΆCCCΆTTGAGTAATGGAATGATGTTTGCCGGTCAΆAATCAA TATTCAAΆTTCAAATCΆAAΆTCAAAATCAACTTCCTCCTAATCAACAACΆACCA ACTCCAGCAACTTTCCACCCACCACCTCCGCCAACAACTGCAAATGGTCCTCAG GGACAATTTAATCAAAAACCATCACCTGCAACGTCAAACAATTCACCTGCATTA GGCAATAAATCATCACCAGCAATGGGCAATAAGAAATCGAAGAAAGAATCCAAT AGTAAAAAGGGTAAAAAGGCGAATTCAAATGCTTCTACAACAGCAAACAACAAA ACATCTGGACAAACAACACCAAACATGTCACAACCTCCTAGTGCTGGCACGGAG CAAAAGCAGCCTCAACCAACAGAGCAΆATGCGTCAATTACAAGACAAGCAACAG CGTCCAGGTTCAAATACTCCAAGTATGGGAAAGAAGGATTTCCAGCCATTGACA CCTCGCTCTGAACCAATTAGCGGTGAAACTACGAAAAAGAAGCGTAAATCAGGT AAATTGAATGACAATAATGAAAATAGTAATGGCAATTCTCCAAAGAAGCΆAGCC AΆAACCAATGCAAACTCCAAAAACTTAGATCCTΆTAΆTAAAΆGAAGAAGAGAAT GGAGTATTATCTTTGAAGAAAGAATCTTCAACTTCGTTACAAGATCAAGATCTA
[ATTTAAACCCCCCATTGGCACCAACTCAAGCCACTGCTATGTCCAATACATTT AACGACGATCCATTTGATGTTCATTTATTAGATACACAACATCATCACCAACAA AATAGCAACAACAGCAATCATAATCGTGGGCAAAΆTCTTTCAAΆTGGAAGTAA1 AATCTCAGTGTAAGTGGCCCAGGAATGGGAATGAATAATCTGGTATTTGGTGAT TCGACTCATGCΆTTTGACATTAATTTCAACATTGATAGTCTTGATGATATATGG ACAACTACTGGACCAGGAGGTGATATTACTGGCACTGGTTCGGGTTCAGGAGG' GCTGGCGGTACCGATGATGATAACTTCATGGGAATGAATTGGGCTGCAGATCCJ ATTGAAAATGGAGAT IPF10214 ATGAATCATAAACAAGTACTACCAGAAAATGAACCGATATCAACAACAACAGCA
(Gen ACTCCATCATCATCCAATACTATGGTTCCCAACΆCAACTAAACAGGTTTTAAAC
Bank® TCGTTGATTTTGGATTTTTTGGTCAAΆCATCAATTTCAΆGATΆCAGCAAAAGCA
CRVl) ; TTTTCTAAΆGAAΆGTCCCAATTTGCCTTCTATTCCTCCTTTGATGGATTGTTCT
AF41411333; CAAGGATTTTTATTGGAATGGTGGCAAGTTTTCTTTGATTTATTTCAAGTCAGA
310062 TATGGAGACGGTAACAGTAATAATAACCCTAACAACAAGCTTTATCATGATTAT CTCAGAGTCCAAGAAACTCAΆAAACATCTTTTCAGTCAACTTCCTCTTATACAG CAGCAGCAACAACAACAACATCACTTTCAACAACAACAGCAACAACAAGGGCAA CAGGGACAGCCTTTCCTGCAGCAACAGCAAAGAGGAATCGGTGTTGCTAGTGGT ATGCAAAATCAACAACATCAATTTGCCCCACAGCATCAAGGCCAACCTCAAGGA CCAGGTCAAACACCTCAACCGCCAGGTTCTGCAACTAACGCTAATTTCCCTATC AATATGCCACCAAATCTGAATCCTCAACAACAAATGTTCCCCATTAATCAACAA TTTGCTCAGATGCCAAATGGTCAAAATCAGCCTTCAATGGAACAACAACAAAGA ΆTGGCAATGATGATGAAACAACAAGCAATGGCTGCACAAAGACAACAAATCCCA ATGAATGGTTTAGATCCACAACAΆCAACAGCAAATGATGAATGCTGTAGGTGGT
IGACCTGGTAATTTGAATTTGCAACAACAACTATTTTTACAACAACAACAGCAG CAGCAGCAGCAΆCCCAAAACTACTTTCCAGCAACAAGCACAAΆATCAAATGAAC AATTTGCGTCAACAAGCTGCAATGGTTGCTCAGCAGCAGCAACAGCAACAACAA CAGCAACAACAACAGGGTCAGTTGCAAGGCAATTTGGCATCAGCAATGGGTGΆT TCATCTCTGAAGAATAACTCTCCTGTTGGTGCAAGATCAAATCAACAGCTGACT CCACAΆCAAAATGCTGCACCAGCTCCACTGCCACΆTCCTTCTCAACAAGGTCAΆ
CACAAGCTCAACATAATTTCCAGAGCCAACAACAACAACAACAACAGCAAATG ACTAAGATGGCTGGGTCTCAAGGAATGAAAAAGAATGGTCAGATGTCAAACGGC ACTAGTAATAACAGTAGTGGCΆGΆAACAATΆATGCTCTACGΆGATTATCAAAAT CAATTAATGTTATTAGAAAGACAGAATAAAGAGAGATTAGAATTTGCTAGAAAC ACTGGTAΆTTCCGΆCTCCAACCCATTGΆGTAATGGAATGATGTTTGCCGGTCAA AATCΆΆTATTCAAATTCAΆATCAAAATCAAΆΆTCAACTTCCTCCTAATCAACAA CAACCAACTCCAGCAACTTTCCACCCACCACCTCCGCCAACAACTGCAAATGGT CCTCAGGGACAATTTAATCAAAAACCATCACCTGCAACGTCAAACAATTCACCT GCATTAGGCAATAAATCATCACCAGCAATGGGCAATAAGAAATCGAAGAAAGAA TCCAATAGTAAAAAGGGTAAAAAGGCGAATTCAAΆTGCTTCTACAACAGCΆAAC AACAAAACATCTGGACAAACAACACCAAACATGTCACAACCTCCTAGTGCTGGC ACGGAGCCAAAGCAGCCTCAACCAACAGAGCAAATGCGTCAATTACAAGACAAG
IAACAGCGTCCAGGTTCAAATACTCCAAGTATGGGAAAGAAGGATTTCCAGCCA TTGACACCTCGCTCTGAACCAATTAGTGGTGAAACTACGAAAAAGAAGCGTAΆA TCAGGTAAATTGAATGACAATAATGAAAATAGTAATGGCAATTCTCCAAAGAAG
IAAGCCAAAΆCCAATGCAAACTCCAAAAACTTAGATCCTATAATAAAAGAAGAA GAGAATGGAGTATTATCTTTGAAGAAAGAATCTTCAACTTCATTGCAAGATCAA
'.ATCTAGATTTAAACCCCCCATTGGCACCAACTCAAGCCACTGCTATGTCCAAT ACATTTAACGACGATCCATTTGATGTTCATTTATTAGATACACAACATCATCAC CAACAAAATAGCAACAACAGCAATCATAATCGTGGGCAAAATCTTTCAAATGGA AGTAATAATCTCAGTGTAAGTGGCCCAGGAATGGGAATGAATAATCTGGTATT'
GTGATTCGACTCATGCATTTGACATTAATTTCAACATTGATAGTCTTGATGA' ATATGGACAACTACTGGACCAGGAGGTGATATTACTGGCACTGGTTCGGGTTCJ GGAGGTGCTGGCGGTACCGATGATGATAATTTCATGGGAATGAATTGGGCTGCJ GATCCAATTGAAAATGGCGATTAG Table 3. Amino Acid Sequences of Crvl Homologs
Figure imgf000034_0001
EAK92553; TSRYGKSPSVSGKSTPKPGKSPATSGKSTPHFGKSPSVSGTTTPKARSS 46433099 TPVNDPKNKPKPDSKPKNKAVNEKLENASNTKPKPKIDKKTPTEKAENK
SKSKENNTSSPKEPKGQAPTKLGSKKSPEKDKTKESSSKTGKKPESAVK SDKKQKSNVPQSYSKTKSGSKAQQTANDNKKSGANLPSSKESSLVLPPY ITKFHPSEKPKLTYDSMNEYPKEISPNVFLEDQLNNESNIIDSSNFTIS WYEDLDKKNNQFQLHIPMRPEIIDKFLSQKLKKFKKNPFSVDQAIFLIL DDEIMWSGYIATVDEIASKKGRRVKKDVIELIIMLHPWSQΆLPRTVHVS NLKILPASQPVSRVLNAMKTINNASFTRMLLGKEPIKQIDFKNFLKFQG QNLNESQKKGVQSVLNNSITVLQGPPGTGKTSTIYEIILQLLDSLNTYP
ILWAASNIAIDNIAEKLMTKHGKDILRITAAEKΞRDYNRSHPLASICL HHKMYDAMPMKYQQVMDEMKRGMAPSIGTTAYKKYAQERFFLSNQIVTQ AKVVLATPVVAGGIKSLNNVRVVIIDEATQSSEPTTLIPLALPSVEKLV LVGDQKQLSCFSLIPNLSLSLFERVLLNGTYKTPHMLDTQYRMHPΞISE FPRTKFYGGLLKDGIDANARQSEGVISSPLYFWDTKGNARΞQSVRNFLR EDGGYTYTNRDEIGYIQQVLRTLIITKGVKPEQIGIITPYSGQRDLISA TLVKDDVINPSNΞQMKTEVDIDDLKNDSKPVTIHIVSGIMIASIDAFQG REKDYMIMSCVRSNTKGVIGFLRDERRLNVALTRAKYGLIMVGDKKCLQ NGDKLWKEYLQYLDSKKAIHDNDTFGE
Hypothetical MNYQQQFLNMDSNDGQGDPGPSSMAQQNQSRFRPPFPGQPGMNAQQLAM protein LQQMSQAAQAQAGQPNQGQGRPSLTPQQIQMAMASMQAQAQAQGFNMAN
CNBA6990; MNPQALIQAMRNQQLNQNQQQGMQAGSQMGQGQGSQAQLGQQNQQQGQQ
Cryptococcus PQAQNLVGSYQPGQPHPNPTQLAFQQQRIAQLMQAQGMQARSGGPGSPI neoformans; RPPQQFPQQQQPQQRAGSMPPPPVPGQQPQQQQQQNTPFPPQQPNQQPT
EAL22930; SQSMQLSLSPAQQQMLTQQRQNLLGNPQFQSMPPQQQHALLQQQQTQYL
50260271 RMIAMQQAANQQQGGQHQPQGQSQPSPQQPQQHSTQGRRGSSQGVPQSP VIHRQPTPQQLGGTSQQPPLSGLPQHMAPPRPGSAASQRPVTPQTGQVG PGSPAIMRTPPAGGMFQQPLQHMSHSANAPSPTLSTHSHHSQQHHTPQL QQGPIMASPMHPRMDGAGTPQPGQGQGSGMNGESQGFPTQQGQHGQQPM AGPSGQDPNNSGTPYRSFRLPGPLDVRALPTLPTNYTPEQQQQVASALT LMSQAVQGQGQGQGPNQVSEGQQQGQGQFSQPPQIQPSVRPGPGSVQAP GGPGPNANMPRLPPLPLNIDTSDFPFDPRILQYLPYFGDARWRTQIQAQ NPGLFAAVQHAAGLWQTIRPΞVMQRMQAALIAMKNAAFRGTQQGIPVQS
GQPGQGQQGQQPLGQQQGLVQQQQQQQQKLQQQQQQQQQQQQQQQQQQQ QQQQQQQQQQQQQQQHQQQHQQQQQQQQQQHQQQQQQQQQQQQQQQSGQ
APSTQLGPAQLAQQAWTQQQAAQAQAQMQAHAQAQAQAQARMQAQESPV
PGSNMSPLTRPPATPHVPPVPSSPVGGRPSSSSMKDIKRDRTPSGSGSA
GQSSMPPPNFIPSHNGKPVSASGGSLEQWSATPPSATMGAASLPATAA.
ISTHTAPAHAPTSTPAVAPAPRRQSASGPSLPIKEWATALHLDIPVTKI
SPLPVNTVDEAIDPTFDGQLPPLSDKEKANIKEWLDKDVAFVAREKARQ
PRVLGKMKRWAEΞDDKGTEWWMLRKGEKRVMPQTKLRVLWPSDKERMRA
QRTHKGRRQVKFSQADLKKMAEVEDHIVPVRLELEHEGQKLKDTFMWNC
SDTWTPELFAHILCDDFAVPHQHFASRIVSAIEERVREYKDQVLPLLE
RHPKEDCQGKLDPDGDDEARAMCEVFRKAREGSGIEEEIKTDPGEEDGM
DHIRIVTFDDQVNGIDLDDERPWTVEEAMTLVPKELPQDLRILIKVDII
IGTQNLTDSFEWDIHSSVTPEΞFAASYVTELGLSMEFATAIAHDIREQI
LIYQRSLFLVGHTDSSSVILDDΞVRGAFLPPVTTTLRKEDIAMASYTPI
FNELGPDQLALLΞSQREKEMKRKKRAGRARRGIVLPEREPVKTQRTLLN
NLGPNGVPILFQADNVPVRDSAPTSRRRGAALAAEANINLLAQDLPIPA
SASPAPHLPHISARGKRLGRPPKNRAISPVSIREGPLANGGTPTTGDIK
GHRKGYLDDSADEQSINGALSASGRKKPGHYNRIPDSPSEPSTPLSGKV
ENLPSSFHLDSQTDQTSILKKRKSHNDVDERPPKSAKPDEVGVPFPISK
PASDNKIEKKKRKSSDSSGIDSDSDSGSDSGSDDSDSTFGGRKDRKKMA
AGRTETPAARSSWPTGTPGLASAASPGSGRKAIEVPMWIQRALGNMRA
KYSRDSFLVIQKPRPADQPDAPPEWRAKCNDCPGRIYALGPGETLNNFE
VHLKNKGHIGNRLAREGKTQ unnamed MSHHSTPHLHNKKTPGGVGGDNGPSASTSTNRGPMDSNTSISDSQAANA 10
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
LQQQQQQQFMRTQGQVPPQPGQVQGQVNQNVQGAQVAAGQAGMAQRPAG QIPQGQMPAQQGQVPPGQΆGNQΆQMMRPNMRMRPGGPQAAAPNEHLNAL IRQLQNQNPALSLEAATKLΆHVQVQRPVQKQQRVARQAQGQTPPQGQMR PGQPQGQPSPQMRSGSSTPMNMQSPQLMNVQLQQQQQQRSASPGQSPAQ QHAMLMRMNQQQQQQQQQQQNQGQTQGQNQGQGPSE
Table4. DNASequencesofCRVlHomologs
Gene; DNA sequence SEQ Organism; ID
GenBank® NO: Accession No. ;
GenBank® GI No.
Hypothetical ATGAATCCTGGTGTCGGTGGTCCGGTTGGAGGTGTCCAGATGGTCAATA 29 protein ATGGTTCGATGGTACCCCGTAATGATGGCAGTATGAACAATTCCCCTGA
AN9087.2; AGTCΆTGATCGGCAACCTCAACACATΆTATTTATGΆCTACTTCCTGAAA
Aspergillus CGCGGTTACCATGACTGCGCACGAGCCCTCGTCAAGGATGAATCAATCA nidulans; AGCTCAΆCACTGAACCTCCTATCAAGACAAGTCCGGGTCAΆCGCAGGGA
XM_413224; GGGCGAAGTGAATGGTGTCGACGGCGACGCGGTGATGACAGACAGTAAA
49134393 GACGGTGACAAACTGAAGATTCCCGACGACTTGCCTCGTCCCAATCTCA
ACAGCGAAAGTCΆGTCGTCTTCGTTCCTCTTGGATTGGTTCAGCCTGTT
CTGGGAGTTTTTTTGGTCCCAGCGTAAGAAAGGGAACAGCGCCGATGTG
AGGCAATATCTCCAACACACTCAGAΆTATGATGCGCATTAGAGAGCAGC
AACAAAGTCAAATGTTCCGAAΆCCAGCAACAAATGΆTGCCGGGTCAGAT
GGGGCGGCTCAACAACATGCGTGGGAACGGAATGGTCCCTCCCAACTTA
CAGAAGGCCGTCCTGCAGAATAACACTGGTGGCTTCTCCCAGCAGCAAT
ATGCGCAACTACAACAAAAGAGTCAACAGATGCAGATGATGCAGATGCA
ACGCGAGCATTCTGATATGGATATGAACGGCCACCGACCGCCCTCTCCA
TCCTCCGCCGAGAACGCGCCATCCCCGTCGAAACGACCCCGCCTTGAAG
GTGGTCCCATGAATGGGCAACAACTGGCACCCAACGGACGTGGCCAGGG
TCAGGCGATGCCTGGCCAGCAGAACCCGATGTTGATCCAGAATGGACTT
ACGCCGCGCGCGATGAACCCTAACCAGTTTGGTGCTTTTCAGCAATCGG
GTCCGGCTGCACAGCCAAAACCAATCCAGGTATATGCTCAAAACTTGGC
TCTACATCACTCTCGCTCAGCAATGAATAACCAGGGCATGCCTAATGGT
TTAATGAATCCCGGCGTGATGCCGAATCAGGCTGATCTGGTTCCCATGT
CAGΆCGGCCAGGGTATGTΆTCAGATGΆACAACGGCGAGTTTTATCCGAA
TGGCCAAATGGCGCAGGTTAGGCCTGGGGCTCAAACTCCTGGTGGCCAG
CATGGTAACCATGCTCTCCAGGACTATCAAATGCAACTCATGCTCCTTG
AGCAGCAAAACAAACGCCGACTCATGATGGCTCGCCAAGAGCAGGACAG
CATGACTCGTGGCCCCGATGGTCAACCCTTGCCTGGGCAGCAGGGCCAA
CAGCAACCGGGTCAAATGCCTCCGGGTACTTCTCCCCAGGGCAGTAGGA
CTGGGGCGTCGCCAATCCCTAACGACCAAATGAAGCGCAACACTCCCAA
ATTGAATCAATCTGGTCTTCCGAATTCACCGAACGCTCCCGACGCAATG
ATGCAGGGCCGTGGTTCTCCTGCTTCAATGAACTTCACCGGGCAACTAC
CCCCCGAAATGGCAGGTCAATTCTACATCAAGACGATGCAGGAAGGTAT
GCAGGGCGCCAACGGTATGCGGCCACCGAGCTCCAACCCGGCATTTAGT
GGCCCGCAAATGGGCCAACCAGTCCAGGCTGGCACGGCGAATCGAATGC
CGAATGGAGGCTGGCAACAACAGCCAGGTGGTCAACCTGTTGTCCCACA
ACAATCTCCGATAATACAGCCCCCAACTACCGGAACACCCCAGAGTGTG
AATTCAATGCCACCTCCCCAΆCCTCCTACAGCCAATGCCGGCCGTCAGC
CTCCTCCGTCCCCCCAGACTGGAAATGCTGCTCCCCCGACTCCGCAACC
CGCATCTAAGGCCGCGCCGAAGAAGAAAGAGACTAAGGATAGAGCCAAG CGACCAAACAAGAAGACTGCAGCTGCAGCCGCAGCGGCGGCGGCTAACA ACACGACCGCTACACCATCATCAGAGGCAGAGCAGCCACCGACTCCTAC ACCAGCGΆCGCCAATCACTCCCCAGCATCATCAATCCTTTAACAAGTCT GGTGGGAATGCCACTGCGGGCGCTCCTCCTCAGCCCACATCCGCTCCCG CTCAACAGACTCTTGTGCAGCCTCCGCCGCCTGATCAAACCCAGTCATT CAACGATCTTACCATGCCCGATCCATCTGCATTTAGCCTCGATTTCAGC GCACTGGAGAACCCGGACATCCTCGAGAATTTTGACTTCGATACATTCC TCAACACCGATACGGATACAACAGGGTTCGGGTTCGACCCAAGCATATC ATACACCGΆCGGTGTTGAGACTGGCΆCCGAGAGTGGTCTCTGA
Hypothetical ATGTCTAAACCACCACCTCAACATCAACTGAAGAATGCTAATAATTCAT 30 protein TATCACTGCCGGTATCAGATAAACAATCTAATGATTCTCGACAATTATT
CaO19.6309; ATTAGCTCATTTATATAATTATTTCAAAACTAATGGATTAGAAGAAACT
Candida GCTCAAGCATTATTAATAGAATGCAATAATACCATTCCTAAGGCAACAA albicans; CAAATTCTAAAGGTTATTCΆTTAGATAATAGTGGTCCTGATCAAAAAGA
AACQ01000214; TACATTTTTAGATCAΆTGGTGGGGGTTATTATGGTCAATTCAATCATCA
46432362 ATTAΆTCCTAATTTAAATCAAATGACAAATCCTTCAGGAATΆTTAACTC
CTCAACATCAAΆTGΆTTGTACAACAAAGAATGCTTCAACAACAACAACA
ACAGGCTCAACAGCAGCAGCAΆCAGGCTCAACAACAACAGGCCCAACAA
CAGCAΆCAACAACAACAATTGTTGCAACAACAAAGACTACΆGCAACAAG
CAATGATCCAACAACAACATCAACAACAATTGATTAATAATTTGAGTGC
TCGTCAΆCAACAAGTTGGTCTATCTACAACTACTAΆTCAAΆTGGGACCA
CCTGGTΆGTAΆTAGTAATAΆTCTTCAΆTCAAATATGTCACCAAATAATG
AACAATTACAATCACAAGCAAGATTACAACAATTGΆAATTACAATTTCA
ACAACAACAACAGCAΆCAACTTCAACAΆCΆGCAGCAACΆATTGCAATTΆ
CAGCAACAGCAACAGCAACAACAACAGCAACAACAACAACAGCAACAAC
AACAACAACAACAACAACGTCAACAGCAACGTCAACGACAAAAGAAATT
CCAACGTCAATTACTGACTCTGTCTCAAAGACTGCCAGTTATTAATAAT
GGACAACCGCAACAACAACTCCAACAAGATCAACGTCCTGCACTGGCAC
CACAΆAATCAACCTACTCCAGGAAACAACAACAACAACAACAATACTAA
TGCTGTATCΆCCGGAATTACATAGACAATCTGTTGATGATTATCΆAATG
AACTTATTACAAATGGAAAΆTCAAAΆTAATTCACAAAGACAΆΆAATATT
TGAATAATCAACAAACACGTAACTCACAACAΆCAACAACAACAACAΆCA
ACTGCAACTGCAACTGCAΆCAACTGCTGCCATTTCAACCACCAGCTCAG
CAACCTAAAAATAGTACAACAACATCAACTAATACTACTACTAGTCGAG
CACAGAAGTCCTCGAGAAAACAΆCAACCAΆAGAATTCAAGACGTCAATC
TGTTCAACAACAACAACAACAACAACCCCAGCAACAACCCCAACAATCT
CAACAAATGTCGACTTCTTCACAATCTTTTACCGCTGCTAΆTAATTCAA
ATAATGTGAATAATACATTTGATATTTCACCACAAATTCAAGATCAAGG
AATGTTATCCACCAAAGAACAACAACAACAACCCCAGCAACCGCAACCA
CAACCGCAATCGCAATCGCAATCACAATCACAΆTCTCTACCTTCAAATA
ATAACAATAACAATAACAATAAACAAGATGTTGTTAATGTAGTATTTGA
TGATGCΆTTTTTCCTGGGTAATTTACTTTTAGATGATTTTΆATGAATTT
GCCAATAGTACAAGTAATAATGGTAATGGTAATGGTAATAATGATATGA
ATTCACAATTTAATAATACACAAΆCAGAAAGAATAATGTTTAGTATGCC
ΆCCTAATCAGAATCAAAATCAΆTTTCCTTCACAATCTGGTGATGGTGGA
GGAGGAGGTGGTGGAAGTATGCAACCTAATTTTTTCGAAGGTATTGAAT
TAGGTGATGGAAATAATAGTGGTAATGGAGATGATGATGΆTGCTCCTAT
ΆΆTTACTACTGATTGGTTAAGTCTGATGGGATCAGGTCCΆGGTTATGAA
TAA
Hypothetical ΆTGTCTAAACCACCACCTCAACATCAACTGAΆGAΆTGCTAATAΆTTCAT 31 protein TATCACTGCCGGTATCAGATAAACAATCTAΆTGATTCTCGACAATTATT
CaO19.13686; ATTAGCTCATTTATATΆΆTTATTTCAAAACTAATGGATTAGAAGAAACT
Candida GCTCAAGCATTATTAATAGAΆTGCAATAATACCATTCCTAAGGCAACAA albicans; CAAATTCTΆAAGGTTATTCATTAGATAATAGTGGTCCTGATCAΆAAAGA
AACQ01000213; TACATTTTTAGATCAATGGTGGGGGTTATTATGGTCAATTCAATCATCA
46432380 ATTAATCCTAATTTAAATCAAATGACAAΆTCCTTCAGGAATATTAACTC CTCAACATCAAATGATTGTΆCAACAAAGAATGCTTCAACAACAACAACA
ACAACAACAACAGGCTCAACAGCAGCAGCAACAGGCTCAACAACAACAG
GCCCAACAGCAACAACAACAACAACAATTGTTGCAACAACAAAGACTAC
AGCAΆCAAGCAATGΆTCCAACAΆCAACATCAACΆACAΆTTGATTAATAA
TTTGΆGTGCTCGTCAACAACAAGTTGGTCTATCTACAΆCTACTAATCAA
ATGGGACCACCTGGTAGTAATAGTAATAATCTTCAATCAAATATGTCAC
CAAATAΆTGAACAΆTTACAATCACAAGCAAGATTACAACAATTGAAATT
ACAATTTCAACAACAACAΆCAGCAACAΆCTTCAACAΆCAGCAGCAΆCAA
TTGCAATTACAGCAACAGCAACAGCAACAACAACAGCAACAACAACAAC
ΆGCAACAACAACAACAACAACAACAACGTCAACAGCAACGTCAACGACA
AAΆGAAATTCCAACGTCAATTACTGACTCTGTCTCAAAGACTGCCAGTT
ATTAATAATGGACAACCGCAACAACAACTCCAACAAGATCAACGTCCTG
CACTGGCACCACAAAATCAACCTACTCCAGGAAACAACAACAACAACAA
CAATACTAATGCTGTATCACCGGAATTACATAGΆCAATCTGTTGATGAT
TATCAAATGAACTTATTACAAATGGAAΆΆTCAAAATAATTCACAAAGAC
AAΆAATATTTGAATAATCΆACAAACACGTAACTCACAACAACAΆCAACA
ACAACAACAΆCTGCAΆCTGCAACTGCAACAACTGCTGCCATTTCAACCA
CCAGCTCAGCAACCTAAAAATAGTACAACAACATCAACTAATACTACTA
CTAGTCGAGCACAGAAGTCCTCGAGAAAΆCAACAACCAAAGAATTCAAG
ACGTCΆATCTGTTCAACAACAACAACAΆCAACAACCCCAGCAACAACCC
CAACAATCTCAACAAΆTGTCGACTTCTTCACAATCTTTTACCGCTGCTA
ATAATTCAAΆTΆATGTGAATAATACATTTGATΆTTTCACCACAAATTCA
AGATCAAGGAATGTTATCCACCAAAGAACAACAACAACAACCCCAGCAA
CCGCAACCACAACCGCAATCGCAATCGCAATCACAATCACAATCTCTAC
CTTCAAATAATAACAATAACAATAACAATAAACAAGATGTTGTTAATGT
AGTATTTGATGATGCATTTTTCCTGGGTAATTTACTTTTAGATGATTTT
AATGAATTTGCCAATAGTACAAGTAATAATGGTAATGGTAATGGTAATA
ATGATATGAATTCACAATTTAATAATACACAAACAGAAAGAATAATGTT
TAGTATGCCACCTAATCAGAATCAAAATCAATTTCCTTCACAΆTCTGGT
GATGGTGGAGGAGGAGGTGGTGGAAGTATGCAΆCCTAATTTTTTCGAAG
GTATTGAATTAGGTGATGGAAATAATAGTGGTAΆTGGAGATGATGATGA
TGCTCCTATAATTACTACTGATTGGTTAAGTCTGATGGGATCAGGTCCA
GGTTΆTGAATAA
Hypothetical ATGACTAGTGAAAAGTATACCTGTTTGACATGTTCTGAACAATTTTCAG 32 protein AAGCTGGCCAΆATTCAGAAACATCTCTCGACAACTCGACACAAGTCAGT
CaO19.702; GCGATTAGAAAGTTTGGATGAGACTTTAGAATGTGAAGAATGTTCCGAC
Candida AGTAATATTCATCAGTTGTCCATTGTTAGATATGGGTTTAACGATATGT albicans; CTTTATTGTGTCAAATTTGTCTTGAGAAAGATAATAAGAAAACAGGTGA
AACQ01000183; AACACCCAGTGCTAGTTACACGCTATCAAATGGGGCATTTTTCAATAAA
46433089 CTTCCGCAGTACTTGAAATTTAGGGACATTGAATGTATGGAATGTGGAG
ATGATACCCATTTGTCTGTTGCCAACACGTCTTCTGGGCAATTAGTGAT
TTGTCGTAΆΆTGTTTACCGAAATATGAAAGTGΆTAATGTGAAATTTATΆ
AGTGAΆGATAGCGATGATTTTCTTTCTGAGTTGTTGGGGATTAAGGAAG
TGATAATCAAGAAΆTCTTCAAGAAAGAGAAAΆTCCGGGAAGAATGGTGG
TGGCAAGAGAGGGGGGAAAGCAGGAAGACGAACAAGAAAGCCAGACCCT
GATGCAGAAGCTAGAAAAGCACATTATTTACAATCTAAGCAAACGGCAA
AAGATATTAAATCTGGTACTACTGTCAAAGCTATAGGGTCAAACGGTGC
TGCTAACAΆTAAAACATCAΆCAACAGGAACAAAAAACAACACAAAGCCA
ACATCAAGGTATGGTAAAAGCCCGAGTGTTAGTGGCAAATCAACTCCTA
AACCTGGTAAGAGTCCAGCAACCAGTGGCAAGTCAACTCCACATTTTGG
TAAGAGTCCATCTGTGAGTGGTACTACTΆCGCCAAΆGGCTAGATCGTCA
ACTCCTGTAAACGACCCCAAAAATAAACCAAAACCAGATAGTAAΆCCCA
AGAACAAAGCTGTTAATGAGAΆATTGGAAAATGCGTCAAATACTAΆGCC
AAAACCAAAAATTGATΆAAAAΆACTCCTACAGAAAAAGCΆGAGAATAΆG
TCTAAACTGAAAGAAAACAATACACTGTCTCCAAAΆGAACCAAAAGGAC
AGGCTCCTACTAAGCTAGGATCTAAGAAATCTCCTGAAAAAGATAAAAC AAAGGAAAGTTCATCAAAGACAGGCAAAAAACCAGAGTCAGCAGTAAAA
TCCGΆTAAAAAACAGAAATCTAATGTCCCACAACTGTATAGCAAGACAA
AATCTGGATCTAAAGCACAACAAACTGCTAATGACAACAAAAAATCAGG
AGCAΆATTTACCGTCTTCCAAAGAΆAGTTCACTTGTACTTCCTCCGTAT
ATCACAAAATTCCATCCATCAGAΆΆAACCAAAACTTACCTACGATTCAA
TGAATGAATATTTCAAAGAGATAΆGTTTTAATGTATTTTTAGAGGATCA
ATTAAACAATGAACTGAΆTATTATTGATTCCAGTAATTTCACTATTTCT
TGGTATGAAGATCTAGATAAAAAGAATAATCAATTTCAATTACATATTC
CTATGCGTCCAGAAATCATTGATΆΆATTTTTATCGCAAAAΆTTGAΆAAA
ATTTAAAAAGAATCCATTTCTGGTAGATCAΆGCAATTTTTTTAATTTTA
GATGATGAAATCATGTGGTCAGGTTATATAGCAACTGTTGATGAAATTG
CTAGTAAAAAGGGTAGAAGAGTTAAAAAAGATGTTATTGAACTAATTAT
TATGTTACΆTCCTTGGTCACAAGCATTACCAAGAACTGTCCΆTGTTTCT
AATTTGAAAATATTACCAGCTTCACAACCAGTTAGTCGAGTATTGAATG
CTATGΆAAACTATTAATAATGCAAGTTTTΆCAAGAATGTTATTGGGTAA
AGAACCAATCAAACAAΆTTGATTTCAAGAATTTTTTGAAATTCCAAGGA
CAAΆΆTTTGAATGAATCTCAGAAAΆAGGGGGTACAΆTCAGTTCTTAATA
ATTCTATTACTGTGTTACAΆGGGCCACCAGGTACTGGTAAAACATCTAC
AATTTATGAAATTATATTACAATTACTTGATTCATTAAACACTTATCCT
ATTCTTGTGGTTGCAGCATCTAACATTGCTATTGACAATATAGCTGAAA
AGTTAATGACAAAACATGGCAAAGATATTTTGAGAATTACTGCAGCAGA
AAAGGAACGTGACTATAATAGATCACATCCATTAGCGTCAATTTGTTTA
CATCATAAAATGTATGATGCTATGCCCATGAAATATCAACAΆGTTATGG
ATGΆΆATGΆAACGAGGCATGGCACCΆTCAATTGGAACTACTGCTTATAA
GAAATATGCTCAAGAAAGATTTTTTTTGTCGAATCAGATTGTTACTCAA
GCAAAAGTTGTATTGGCAACACCTGTAGTAGCAGGTGGAATCAAATCGT
TAAATAATGTCAGGGTAGTGATTATCGATGAAGCAACTCAATCATCTGA
ACCΆACAACTTTAATTCCATTAGCGTTACCATCΆGTAGAAΆAATTGGTA
TTAGTGGGAGATCAAAAACAATTAAGTTGTTTTTCATTGATTCCTAATT
TATCATTGTCCTTGTTTGAAAGAGTTTTATTAAATGGTACTTATAΆGAC
ACCACATATGTTGGATACACAATATCGTATGCATCCAGAGATCAGTGAG
TTCCCACGGACAAAATTCTATGGTGGGTTATTGAAAGATGGCATTGATG
CCAATGCAAGACAACTGGAAGGGGTTATTTCCAGTCCACTTTATTTTTG
GGATACCΆΆGGGGAATGCAAGAGΆΆCAATCTGTTAGAAACTTCCTTCGT
GAAGATGGAGGTTACACTTATACGAΆTCGTGATGAGATTGGTTATATTC
AACAGGTGTTACGAACATTAATTATAACAAAGGGGGTTAAACCAGAACA
AATAGGTATAATAACACCATATTCTGGACAACGTGATTTGATTTCAGCA
ACGTTGGTGAAAGΆTGATGTCATCΆATCCTAGTAATGAACAAATGAAAA
CCGAΆGTTGATATTGATGATTTGAAAAΆTGATTCCAAACCΆGTTACAAT
TCATATAGTTTCTGGTATTATGATTGCATCTATTGATGCCTTCCAAGGT
AGAGAAAAGGATTATATGATTATGTCATGTGTTAGATCGAATACTAAAG
GGGTGATTGGATTTTTAAGAGATGAAAGAAGATTGAATGTGGCACTTAC
TΆGAGCCAΆATATGGTTTAATAΆTGGTAGGAGATAAGAΆATGTTTGCAA
AATGGAGATAAATTATGGAAGGAATACTTGCAGTATTTGGATTCCAAAA
AAGCTATACATGATAATGATACTTTTGGCGAATAG
Hypothetical ATGAACTATCAACAGCAATTCCTCAACATGGACTCCAATGATGGACAGG 33 protein GCGACCCGGGACCATCTTCCATGGCTCAACAGAACCAGTCGCGCTTTCG
CNBA6990; TCCACCGTTTCCGGGCCAGCCCGGCATGAATGCTCAGCAACTAGCCATG
Cryptococcus CTCCAGCAAATGTCTCAAGCTGCTCAAGCTCAGGCCGGGCAACCGAATC neoformans; AAGGCCAGGGTCGGCCGTCΆCTCACACCTCAGCΆAATACAAΆTGGCGAT
AAEYOlOO0005; GGCTAGCATGCAGGCGCAAGCTCAGGCGCAAGGGTTCAACATGGCGAAT
50260213 ATGAATCCTCAGGCGTTGATACAAGCGATGAGAAATCAGCAGCTGAATC AGAACCAACΆGCAΆGGGATGCAAGCGGGATCGCAGATGGGACAGGGGCA GGGAAGCCAGGCGCAGCTGGGGCAGCAAAATCAGCAGCAAGGGCAACAA CCTCAAGCTCAΆAACTTAGTGGGGTCGTATCAACCCGGCCAACCGCATC CAAACCCTACACAACTGGCATTTCAGCAACAGCGGATAGCCCAGTTGAT GCAAGCGCAAGGGATGCAGGCTAGATCCGGTGGTCCAGGATCGCCAATA
CGGCCGCCTCAACAGTTTCCCCAGCΆGCAGCAACCTCAACAACGTGCAG
GTTCGATGCCTCCTCCGCCTGTTCCTGGGCAGCAGCCACAACAACAGCA
ACAGCAGAACACGCCATTTCCTCCTCAACAGCCTAATCAGCAGCCCACT
TCTCAATCGATGCAATTATCCCTCTCACCTGCACAGCAACAAATGCTCA
CCCAACAACGCCAAAACCTGCTGGGCAΆCCCTCAGTTTCAGTCAATGCC
GCCTCAGCΆGCAGCACGCGCTCCTTCAGCΆΆCAACAAACTCAGTATCTG
AGAATGATTGCGATGCAGCAGGCTGCCAACCAGCAGCAAGGTGGACAAC
ATCAACCCCAAGGTCAGTCTCAGCCATCCCCACAACAACCTCAGCAGCA
CTCCACCCAAGGCCGGCGCGGTTCATCTCAAGGTGTACCCCAGAGCCCT
GTCATCCACCGCCAACCTACCCCTCAACAGTTAGGGGGTACATCGCAAC
AGCCCCCTTTATCTGGTCTGCCTCAACATATGGCACCACCGAGACCAGG
GTCAGCAGCGTCCCAAAGACCTGTCACACCTCAGACTGGACAGGTTGGA
CCAGGGTCACCAGCTATAATGAGAACACCTCCAGCAGGTGGAATGTTCC
AACAACCACTTCAΆCATATGTCCCACAGTGCTAATGCGCCCTCTCCCAC
ATTATCTACACATTCACATCATAGTCAACAACACCATACACCCCAACTG
CAGCAGGGTCCGATAATGGCGTCACCCATGCACCCGAGGATGGACGGTG
CGGGTACGCCTCAGCCTGGTCAGGGACAAGGGTCAGGGATGAACGGCGA
GTCACAAGGCTTTCCAACCCAGCAGGGTCAACATGGTCAGCAΆCCCATG
GCCGGACCATCAGGTCAΆGACCCCAΆTAATAGTGGGACGCCATACAGAT
CGTTCAGGCTTCCGGGCCCGCTGGACGTTCGTGCTTTGCCGACATTGCC
GACGAATTATACGCCTGAGCAACAACAGCAGGTGGCTTCAGCCCTCACT
CTGATGAGTCAGGCGGTTCAAGGGCAAGGACAGGGGCAAGGGCCGAATC
AAGTGTCTGAAGGTCAGCAACAAGGACAAGGTCAATTTTCTCAACCGCC
TCAGATACAACCATCAGTTCGCCCCGGTCCTGGCTCGGTTCAAGCTCCG
GGAGGTCCAGGTCCAAATGCTAACATGCCCCGGCTTCCACCCCTTCCCC
TCAΆTATCGACACTTCTGATTTCCCTTTTGACCCACGTATCCTCCAATA
TCTTCCTTATTTTGGCGACGCTCGCTGGCGTACACAGATCCAGGCCCAG
AACCCGGGATTGTTTGCGGCGGTGCAGCATGCAGCAGGACTGTGGCAGA
CTATAAGGCCGGAGGTGATGCAGAGGATGCAGGCGGCGCTGATTGCTAT
GAAGAATGCTGCGTTTAGAGGGACACAACAΆGGGATTCCAGTACAGTCT
GGTCAACCAGGTCAGGGTCAGCAGGGTCAGCAACCGCTGGGACAGCAGC
AAGGATTGGTACAGCAGCAGCAGCAGCAGCAACAAAAATTGCAACAACA
ACAACAGCAACAACAGCAACAACAGCAACAGCAΆCAACAACAGCAACAG
CAACAGCAACAGCAACAACAGCAACAGCAACAGCAACAACAACAACATC
AACAACAACATCAACAACAACAACAGCAACAACAGCAGCAACACCAACA
ACAACAGCAACAACAACAACAACAACAGCAGCAGCAGCAGTCTGGACAA
GCACCAAGTACTCAGTTGGGACCGGCGCAGTTGGCCCAGCAGGCATGGA
CTCAACAACΆΆGCTGCTCAAGCTCAGGCTCAGΆTGCAΆGCCCATGCTCA
AGCACAGGCTCAAGCACAAGCCCGAATGCAAGCACAAGAGTCTCCAGTG
CCAGGAAGCAACATGTCCCCTCTCACTCGCCCTCCCGCCACACCCCATG
TACCGCCTGTGCCCAGCTCCCCTGTCGGCGGCCGACCGTCCAGTTCAAG
TATGAAGGATATTAAACGAGATCGCACGCCTTCAGGTAGTGGATCGGCT
GGTCAGTCTTCAATGCCGCCGCCCAΆCTTTATACCTTCΆCΆCAATGGAA
AGCCAGTGTCAGCATCGGGAGGATCACTGGAGCAAGTCGTCAGTGCTAC
TCCTCCCAGCGCTACTATGGGTGCTGCCTCACTCCCGGCAACAGCTGCT
ATCTCTACTCATACTGCTCCTGCTCACGCTCCTACCTCCACGCCCGCAG
TGGCGCCCGCACCCAGGCGGCAATCCGCGTCTGGTCCCAGTCTCCCCAT
CAAAGAATGGGCCACCGCCCTTCACCTCGATATCCCAGTTACCAAGATC
AGCCCTCTCCCTGTCAACACCGTTGATGAAGCTATCGACCCAACCTTTG
ACGGGCAACTGCCTCCGCTCTCAGATAAGGAGAAGGCCAACATCAAAGA
ATGGCTCGATAAGGATGTGGCATTTGTGGCCCGAGAΆAAGGCCAGGCAA
CCGAGGGTGCTGGGAAAGATGAAAAGGTGGGCGGAΆGAGGATGATAΆGG
GTACAGAATGGTGGATGTTGAGAAAGGGTGAGAAGAGAGTGATGCCGCA
GACAAAGTTGAGGGTCCTTTGGCCGAGCGATAAGGAGAGGATGAGAGCA
CAAAGAACGCATAAGGGAAGGAGGCAGGTCAAATTCTCCCAAGCGGACC TTAAAAAGATGGCAGAGGTCGAGGATCACATTGTGCCTGTCAGGCTGGΆ
GTTAGAGCACGAAGGGCAAAAGTTGAAGGACACTTTCATGTGGAACTGC
TCTGATACTGTTGTGACCCCTGAGCTTTTTGCCCATATCCTTTGCGACG
ACTTTGCCGTTCCCCATCAACATTTTGCGTCCCGTATCGTCTCCGCTAT
CGAAGAGCGTGTCCGCGAGTACAAAGATCAAGTCCTTCCTTTGCTTGAG
CGTCACCCCAAAGAAGATTGTCAAGGCAAGCTTGATCCCGATGGTGACG
ATGAAGCTCGTGCGATGTGTGAAGTCTTCCGCΆAAGCTCGGGAΆGGAAG
CGGCATTGAGGAGGAAATCAAGACCGATCCAGGAGAGGAGGATGGAATG
GACCACATCAGGΆTTGTTACCTTTGATGATCAAGTGΆΆTGGGATTGATT
TGGACGATGAGCGACCATGGACAGTGGAAGAAGCCATGACCTTGGTGCC
AAAGGAGCTGCCCCAGGATTTGAGGATATTGATCAAGGTAGACATCATT
ATTGGTACCCAGAACTTGACGGATAGCTTTGAGTGGGATATTCATTCTT
CGGTTACTCCAGAAGAGTTTGCGGCGTCTTATGTCACTGAGCTGGGCTT
GAGCATGGAATTTGCGACCGCTATCGCACACGATATTCGCGAACAGATC
CTCATCTΆTCAACGTTCCCTCTTCCTTGTCGGCCACACTGATAGCTCTT
CTGTTATTCTTGACGACGAAGTGCGCGGCGCCTTCCTGCCTCCTGTCAC
TACCACTCTTCGTAAAGAAGACATTGCCATGGCATCGTACACACCCATC
TTCAATGAGCTTGGTCCTGATCAGTTAGCATTGCTCGAGTCACAGCGAG
AGAAGGAGATGAAGCGCAAGAAGAGAGCTGGCCGTGCTAGACGCGGTAT
CGTACTTCCTGAAAGGGAGCCCGTTAAGACCCAACGCACTTTGCTCAAT
AACCTCGGTCCCAΆTGGAGTTCCGATTCTGTTCCAAGCCGATΆACGTCC
CTGTCCGAGACTCTGCTCCTACCAGTCGAAGGCGTGGTGCTGCTCTCGC
CGCAGAGGCAAACATTAATCTCCTGGCTCAAGACCTTCCTATTCCCGCA
TCCGCGTCTCCTGCTCCTCATTTΆCCTCATATCTCTGCCCGGGGCAAGC
GCCTTGGTAGGCCCCCTAAGAACAGAGCAATAAGCCCTGTTTCTATACG
AGAAGGGCCTCTTGCCAATGGCGGTACACCCACCACAGGCGATATCAAA
GGCCATAGGAAAGGATATCTGGΆCGACTCAGCGGATGAGCAGTCCATCA
ATGGAGCACTGAGCGCATCCGGGAGGAAGAAGCCCGGTCATTATAATAG
AATTCCCGATTCACCTTCTGAACCCTCTACTCCTCTCTCCGGCAAGGTG
GAAAATCTCCCGTCATCATTTCΆTCTAGACTCGCAAACCGATCAGACTT
CGATTCTCAAGAAACGCAAAAGTCATAATGACGTTGATGAACGACCACC
GAAGTCTGCCAAGCCTGATGAAGTCGGAGTGCCATTCCCGATTTCCAAA
CCCGCTTCTGACAATAAGATCGAAAAGAAGAAAAGGAAGAGTTCCGATT
CTTCTGGCATCGATAGTGATAGTGATAGTGGCAGCGACAGCGGGAGTGA
TGACTCAGACTCAACTTTTGGCGGAAGGΆAAGATAGGΆΆGAAΆATGGCG
GCGGGCAGGACTGAGACGCCTGCAGCAAGGTCCTCTGTGGTGCCAACTG
GAACTCCAGGCTTGGCGTCGGCTGCATCTCCTGGCTCGGGAAGGAAAGC
TATCGAAGTTCCGATGTGGATTCAGAGAGCTCTCGGTAATATGAGGGCA
AAATATTCTCGAGACTCGTTCTTGGTCATCCAAAAGCCCCGGCCGGCGG
ATCAACCAGATGCGCCTCCAGAGTGGAGAGCCAAATGTAATGACTGCCC
AGGTCGAATCTACGCTCTCGGTCCCGGTGAGΆCTCTCAΆCAATTTTGΆA
GTCCACCTCAAAAACAAGGGCCACATCGGCAATAGGTTGGCAAGGGAAG GGAAGACTCAGTAA unnamed ATGAGTCATCATAGTACTCCACACTTACATAATAAGAAAACGCCTGGGG 34 protein GTGTTGGAGGCGATAATGGGCCCAGCGCATCAACATCCACAAATAGAGG product; GCCGATGGACTCGAATACAAGTATCAGTGATTCACAGGCTGCGAATGCG
Debaryomyces AAGCAGCTCTTGAACGCTTACGTGTATGATTTTCTTATTAAGAGCAGAC hansenii; TCCCCCAAACAGCGAGAATTTTTGTCAACGAGGCAGAGGTTCCGTCGAT
CR382133; CCAAAACAGCTCGGCGAGCTCAAATAACAATTCGCCGCGTCAGGTGAGT
49651994 ACTGGTAATACAAAGGGTACTTCTAACGAGTCCACACCCCATACACCCA GTGGTGTTTCCCAACAGTTTCCGAΆGGAAAATAACTTGCCΆTGTTTGGC GTTGGCAATGGAAGCACCCCAGGGGTTTTTGTTCGAATGGTGGCTGATA TTCTGGGACGTGTTACAAGCGAAGAΆTAATAAAGGTGGATCCCΆGTTGG CGGCGCAATACTACCAGTCCCΆGATGTTAAAGCAAΆGΆCAGCAGCAGGA CCTTCAAGGGTTGΆATATGCAGCCTAATATGTTCGGACCCGCAAΆTGGG CAAATTCAACAGCAAATGCAACAGCAGCTAAAATCATCGATAGATCAAC
Figure imgf000048_0001
ACAACCACAGCAGCAGCAGCAGCAAACACΆACAACAAACACCACCACCA
CAACAAACACCACCACAACAACAAGCACCACCTACTCTACAAAAΆCCAA
AGCCACAGCAATCACAGCAGCAACAGCAACAACAATCATCACCATCACA
ACCACAACATCATCAGCAACCCCAAGCACTACCACCCGCGCCACTACCA
CAAGCΆCCAGAACCAGCACAGCAACATTCGCAACAACCTCAACCTCAAC
AACAACCCCAGGCGCAACAGGCAAAATCACCTTCGCAGCAGCATCATCA
ACAGCAAGCGCAAGCGCAAGCACAACAGCAGCAGGATTCACAACAGGAA
GCACCGCAAACACACACACAGATACAAGCACAAGCACAAGCACAAGCAC
ACGCACACGCACACGCACAAGCACAAGCACACGCACAAGCACAAGCACA
CGCACAAGCACAAGCACAAGCACAAGCACAAGCACAAGCACAAGCACAA
GCACAAGCACAAGCACACGCACAAGCACAAGCACAAGCACAAGCACAGT
CACAGTCACAGTCGCAGCCACAAGCACAAGTΆCAAGCACAATCTCAGGC
AGCACAAGCACAAGCACAAAATCAGGCGCAGCAGACCCAAGTACCCCCT
CCACAGCATGCGCAGCAACAGCTACAATCGCAGCCTCAGCΆATTGΆΆGA
AGΆATATTCAACTTCAGGAGATGCAGCAGCTACATGCCCAGCAGATGGT
ATACCAAATGCAAAGTCAACAACAGCGACAGGTATCTAATATCCAAAAG
CGCCCCCGCAGGCCAAAGCGGGAATCACCTCAAAGGATATTGGAATCGC
CCAAGAAGAAGGGCCATCTCTCGGTTCCGGCGATGCCGGCGATGGCTAG
CTTGACTGCGAGTACAGGCCCGGGCTCGAGTCAGCTGAAAAAAATGATG
CCAAACAACTTAGAGAAGATAGAAATTAAAGGCCAGAAAACCAACACTC
AGCAAGCCCAGCTCAACTGGACCAAGCTACAGCAACAACAGCTGCAACA
ACAGGTACAACAAAAACAGGAGCAACATCAGGATGAGCTTGAGCAACAG
CATCAACAACAACATCAAGAAAAAGAGCAAGAGCAGCATCAACAGCAGC
ATACACCAAATCATCAGTTGCAGCTGGACAAACAATCTCAAGATCAΆCT
GCAACAGAAGTCCAATATTGAGGGCGGGACGGAGGCACAGCCGCAACAA
CAAACCCCACAAAGCGCTACGCCTCAACCCCGCCAGCTCTCTCAGCACC
AGATACAAGCGCACCAACAACTATCGCATGATΆCCAAAGCAGAGGΆGCA
GTCTCTCACTGAGCATCAAAAGGCTGAAGAAGCTACTCCCAAAAGAGTG
CAGCAGGTCCAGTTTACGCAGGCGTCCCTGCATATTCAGCCTTCGGCCA
TGATCCGGGATGACCATATGGTACAGGAGTCCGAGAAGGAGCAGGAACC
TCAAAGTCAAAAGCATCATCTTCATCATCCGAACAATCAGCAGCAATTG
ACGGATCCCACGCCGGCTAGGGGTCAGCCGCCACCACAATTACATCCAG
AACAGCAGCAAAGASAGCAGGGGTCGCCCATCCGAACATCACAGCCGCA
GGGACAGGCATCGCATCTGAAGCAGCCATTACGGAAACCATCGCATCAG
TCACACAATCAGCCATCGTACCTCGCCCAGAACATGTCCCAGAGCCAGG
GCCTGCAGCAGCTGGATTTTATGAACCCAATGTCTATGATCCCACCGGT
TCGGGCTGCAACGGCGGGCAATATCTCCGTACAGCCCATCGCCGAATCG
TCATCAGCCGCTAGCCAGCACCACGTGATGTCAACTCCTTATGGGCCTG
CGGGTGTTAACCCAGAAGTCGATGGGCTCGATCCTCTTTTTTTCCAGCA
GCAGGTGCGCTTTCCAGGCTCCATCTTAGACCCTGCCATGTTCAAGACT
CCGGCATACGCACAGCTCTCGTCACAGGCAAGTAGGAAAAATCCACCGG
ATAACGTCTCCGATAAΆAAAGGTCGTAΆGCAGACAGGTGCGTCCTTTCA
GCCTGCGCAGGACGGTCTGCAGTCTGTTCAGGACATGAACACCATCTTG
CCTGACACTTCTTCGCAAGATCGAGCCGAGGACCAAAGCCTCAGTACGC
CTCTGAACATGGACATGGATTTGGACCACTTCGATATCACCGTCTTTAA
CAATGACTTTATGGGCTCGTGGAΆGTGA
AGL300Cp; ATGGTGGAGAACAAACAGCTACTGAATTCGTACATATACGATTTCCTAA 36 Eremothecium TAAAATCATCGCTCGAAGAAACGGCCGAGCTGTTCAAGCAGGAGGCGGG gossypii; CGTGCCGGATGGGCAGCCGGACATGGΆCGCGCCGCACGGGTTTCTGTAC AE016905; GAGTGGTGGCAGATCTTCTGGGACATCTTCAACGCTCGGACCCACCGGG 44985424 GGGGCTCGGACCTGGCGCAGCAATACTTCCAGATGCAGCTGTACAAACA GCGGCAGGAGCATGCGTACCGGGGGATCGCGATGCACGCGGCACGCGTG CAGCGGAAGGCGGAGCAGCGCGGAGAGTATGCGCAGGAGATGTTCGACC GGGTGCTGTTTTCGATGATGGCGATGAACTCACΆAΆGCGCGGGCCTGCG GGGCGGCAGCCAGCAGGCGGCGCACGCGGTGCGCAGCGCTCCATACGCC GCGCCTGGGCCGTACACGCCGCAGCAGGGCATGACGGCGCΆCTACGCGG GGGGGATGGCCAGCGCAGTCGGTCAGCCTTCTGGTAAGGTGCCCCCGGT
GGTGGCCGGCCCGGCGTCGTACTGCGTCCACGCAGCGCTCTCTCCGCTC
CAGATGATGGGGGGGCTTGCGCAAGTCCCAGGCGGTATGATTTCGCTAC
CGGAGCAGCTGGΆCGGGCAGCGACAGGTAGATCCGCAGCCAΆCTCCACC
GATGACCGTGTCGCCTAGTGGCACTATGGGCCAGGGTCAGGGTCAGCAT
CGCGGCCCGATATTCCΆGAATCΆGCCGGCTCTGTATCCATACΆACGTTG
CAGGCΆCCATGTATCCAATGCAGCAGCTΆTCGCCAATGGCGCAGCCTTT
TGTGCATTCCCAGGTGATGCCAATGTCGATGTCTTCTGGTGCGGCGACG
CCΆGTTGGCCGACCCGCCTCGGCCACCTCCGCCAACCCTCCCACACAGC
GTAGACGCAAGAGGTCGCAGCAGCAGGCTCAGCAGCAGGCTCAGCAGCA
GGCTCAGCAGCAGGCTCAGCAGCAGGCTCAGCAGCAGGCTCAGCAGCAG
GCTCAGCAGCAGGCTCAGCAGCAGGCTCAGCAGCAGGCTCAGCAGCAGG
CCCAGCAGCAGGCCCAGCAGCAGGCCCAGCAGCAAGCTCAACAGCAGGC
TCAACAGCAGGCTCAGCAGCAGGCTCAGCAGCACGCCCAACAGCACGCC
CAGCAGCACGCTCAACAGCAGGCTCAACAGCAGGCCCAGCAGCAGGCCC
AGCATCAAGCCCAGCAGCAGGCCCAGCGGCAAGCCCAGCATCAAGTCCA
GCATCAAGTCCAACAGCATGCCCAGCΆTGCCCAGCATCAAGCTCAACAG
CATGCCCAGCATCCAATGCAACCGCACGTCCAGCAGCAΆCACTCGCATT
TCCCCCAGCAACAACACCACCGCCACTCACAACAGCTACCAATGTCGCA
CCTTCAACΆTTCTCAGTCACAGTTACAGCAGCGATCACAAATACACCAT
GCACCTCCTCATCAACAGGTATCGTATCCACCGCAACCTTTAAAGCAGC
AGCGACATGCGTCCCTTCCACAGCTTCCCGΆGGCTCAGAACCTGTATGC
ACAGCACCATCCTATACAGCAGGATTCACAAGCGCAGGATAGACCGGAC
TCACGACATTCTAGTATGGACAAAGACTTTACCAΆCGCTGACGGCTTGC
ATAACTACCGCAGGCAGCTAATATTACTAGAGAGGGAAAACAAAAAGGC
AATTTCTGCTCCTCCGCGGGACGTCCAGTCTGCCTCGAGCACGCCGCTC
ACCAGCCCACAGGTGCTCCATCGCTTCAACCACAGCATGTTACCACCGT
CTTCCGTGATATCCCCACAGACCAGCGGTAGTCCCAACCCCGTAGCCAT
GCAAATGTCTGCGATGACGGGAAGTATCGGTATTGTGGGCGCACCAACA
GCAGCTACCCAGAGCTCCGCGGGAGCAACTGCTGTAAAGAAAAGAAAGT
TCACTAGGCGAAAGGTTGATAGCACGAAAAGGTCCCTATCGGAGCCTAA
TTCTCCTGCAACACCGATAACTCCCTTCACAAGCAGTACACTGACATTA
GCAΆGCACCTTAACCACCGTCACCGAGCATCCGCAGCACGAATTAAGCT
CTGCGTTGCTTGAGGAGGATGAGCGCAAGAAAAAGAGGCCTAGAAAGTC
ACTGTCAGTTCATCCCACTCCGCCGTTTTCCACCGATAGCCTGATGGAA
ACTGTCCCTTCGGGTAATGCTAACATAAAGAAGAACTCTCATGCATCTT
CCGTAACGGCTGCAGTTTCCGGTGCAGTTTCCGGTGCAGTTTCTATGAA
CAAACTAAGGATGAACGGAAAGAAAGCTATGGGTGTACCCTCCAACAAA
AAGGCACCAGCTCCATCTGGCACTGTGCAGTATGCGGCCCCCCCGGGCG
TCATCACTGCCGCAGCACCCTTTGCTGCTGTTCCCACGGCCGAGGATCT
GCTCAGCGGCAGCAGTGCAAGCACTGAATCCGTTGCACACATGCTGCCA
TTGGGGCCTAACAGCAGCGGACTCAGTCCCAGCCATGGTACCGGCCTGG
ACACTCTCCACGACGACCCTACCCTAAGCGGCGATGTGCCCTTCCAGTT
CGATCAGGAGGATGCCGACCTGCTCGCATCCGTTAAAAAΆCCCATCGAT
GTTGΆCGTCATCAACTCGGCCΆTCAGCACCGACACCGCCAACCCTGGGT
CCGCCGCGGGCTCGCTTGCGGCCAGCGTCACAAACCCGAAGGACCAAGA
CACTTTCAATCTCGACTTTTCCGATCCAAATTCCAATTATAATGACTTC
AACTTCTTCCAGTTCAGCTGGCGCTGA hypothetical ATGTCAAACACAAACGACGAGATTCAACCTCAGGCAACCTCAGCCGATG 37 protein CTGAGATGTCAAACΆGGGGTCAGTCATCTCGAGAGGAGGGAACAAGCTC
FGO1527.1; CAAAAAGGGTCGCGGCCTCCTCAAGGTTCCTTCGAGATCATCGTCACAG
Gibberella CGGAACCAATCGTCACCAACATCGΆCTGGGCTGAGTGGGGCTΆCAGTCA zeae; GCGATCCCCGAAACAGTATCGGAAGCCGATCGAAGGAGTCTAAAGGAAG
XM_381703; TCTCCGGGCGCGACGACGGAATGGAAGCACCTCAAGCAACAGGACAGGA
46109289 GGTGAAACCGAGCCTΆCAAACACTGCGGTAAACTCCCAGCAAAACTCCA CTGCCGCCCCCCCTCAAAAGAAGAAGCGTGGTGGTCTTTTCGCCTTTCT CGGATGCTGTGGTACGCCCGAAGGTCCAGCTGGCAACGAGGAAAACAAC
GAGAACGTGCACAAGCTCGACGTCCTACCTCAACGCCCGACATCCGCAA
GGTCGCGAACCAATACTCCCCAGGAACAACCCAGGCCAGTTACCGCGAG
AGAGTCTCAAGTCACCGTTCCCGCCCCGGAGCCCAAGGAAGAGGCTACC
TCATCAGGCCACGCCCACGACGAAATCACAACGACAGAGCGAGAAAACA
GGGAATCGAAACAATCGGTTCCCCCTTCAGTCACAGTGGATCCTCCCAA
GCCTACTCCCACAGAAGΆTGAGCCTCACGTGGCAGACAAGΆCGCCCAAC
AGCGGTGACGTGGATATGCGAGATGCTGCCACTGAGGAGCCTGAGGAAG
AGGCGGCTGTAGCCCCTGCAGTCGAAGCTCCAGCCCAAAGGACGATACC
ACCTCCCCCACCCCCGGCTGTCGTGGCACCCAGTCAATTCACGGATGCA
GGCCCCTCAGCGCCCGAGCCGCAGAAGTGGTTGTTGCCCCCGATTGCAC
CAGAGCACAAGGGTAGAAAΆTGTCTGGTCCTCGΆTTTGGATGAGACTCT
GGTTCACAGTTCCTTCAAGATCCTACACCAAGCCGACTTTACAATCCCT
GTCGAGATTGAGGGTAACTACCACAATGTGTATGTGATTAAGCGACCAG
GTGTCGACGAGTTCATGAAGCGAGTTGGCGAGCTCTATGAGGTCGTCGT
CTTTACAGCTTCTGTCTCCAΆGTATGGAGATCCGCTATTGGACCΆGCTC
GATATCCACAAGGTTGTCCACCATAGACTCTTCCGTGAGAGCTGCTACA
ACCACCAAGGAAATTACGTCAAGGACTTGTCCCAAGTTGGCCGAGACCT
GAAGGATACCATCATTATCGATAACTCGCCCACCTCGTACATCTTCCAC
CCACAGCACGCCGTGCCCATCAGCAGTTGGTTCTCTGATGCCCACGACA
ACGAGCTACTAGATCTCATACCCGTCCTCGAAGATTTGGCCGGACCTAA
TGTCGCCGACGTCAGCCTTGTTCTTGACGTCACACTCTGA
Hypothetical ATGTACTCCGCCGGCTACAACTTTGGCAACAATGCTGCTCCCTCTTTCA 38 protein ACAACCCTGCCCCACAGCAGCAATCTGGAGCTCAGCCAGCCGCTCAACA
FG09637.1; GATGATGTATAACCAGCAGCAGCAGTTCGCCGGTATGGCTCCGCAGGGA
Gibberella GGCTTTAATCCTGGCGCGAATCCTCAAATGATGGCTGGTGGTCCTGGAG zeae; GTATGATGCCCAACGCAGGCATGCAACATATGGCTGCCAATAGTCAAAT
AACM01000398; GGCAGGATTTCAGCAGCAATTCTCCGGTAACCCGTACGGCCAAGTCGTT
30475272 CCCTCCTCGGTCGCTCCTCAAAGCTTCΆCGCCAAACTATATGΆTGGGTG
GAGGCATGCAAGGCTTTCCGATGAACCAGGGCGGTATGCCCCAACAACC
CCATATGATGCAGCGAATGCAACAGCAACAGCAACAGCAACAGCAACAA
CAACAACAGCAACAGCAACAGCAACAGCAACAGGCACAAGCGCAGGCAC
AAGCGCAGGCACAAGCGCAGGCACAAGCGCAGGCACAGGCACAGGCACA
GGCACAGGCGCAACAGCAGCAGCAGCAGCΆGCAGCAGCΆGCAAGCTGCT
AACGCCGCTGGTATGGGCCAGGTCTCTACTCCGCAGAGACCCCCAAGCG
CAGCACAAGGGACACCAAACAATGCCTTGCCATCTCAACAGGGCCAATT
CCCGACTCCCCAGCAGCCACCGCAGAGTCAAΆCTCCCACAAACCACCAG
CAACAGCΆGCAACAACGACAΆCAGTCGCAACCTCCACAACTACAGCAGC
AACAGCCCCAGCAACCGCAGGGGCAAATGCAGGGACAGGTCCAGCAACA
ACAACCGCCTTCGGCTTTAACAACACCTCAGACTCCAACTTTCTCAAAC
CAGGGGCAAGCCGTGAATGGCAGCTCATCAGCCGCTGTACCACTAAGTC
CTGGAACAGAATCCCGCGACAAGGAACGTTTTGCTTTGTTATTGGACAT
CAACCATGAACTTCTGTACGAATCGATTCAΆΆTCCAGGAGACGCAAAAG
AAGTTGAAGAAAGAAAGCGCTGCGGCTGGAATTCCGGGAGACAACAAGC
CGTCAGAGGAGGAAGCGCAGCTACAGCATGATTATCTTCAATGTATGAG
GCGATTGCAGGCAAACTTATCTTATATGGCGGCACTTGCAGACCGAAAG
CCCGAGGTTAAAGTTCCACCTTGCCCAGCATATCTCAACGCACCACCCC
TAAATCTTTCTGCCAAACTCCGGCCTCCAGAAATTGAAGGCATAGAGAA
CAATATCGACCCAGTGGCAGACCGCGAAGAGCGAAACAATAGTATTAAG
GACCTCTACTCGAGATTACAAGCCGCCTTTCCCGGGTTCGATCCTAAGA
AAGAGCCCGTTTTCCGTGCGAACGCACAGGGTGGACAAΆAGCCTGGCAA
CATGATGGGAAGCCAGGCCAGTCCCACAGCTCAAAGGACACCAAAGATG
ACCAATATGGGGGCACCTCCAATGCCATAG unnamed ATGAAGCGAGAGATGTACTCTGGGCAGTCAGACGTTGCTGATACTGGAT 39 protein GGAGTGCTCCAAAGCCAGGTCATATGTCGCTAGAAAGGTCGAGGATGTT product; GCAGGCCGCGGCGGCCGCAGCCGCTGCTGGTGGTGGGAGTACTCCAAAC Kl uveromyces CATAATCAAAATTATAACAGACCTCCGAΆTATCAATACAAACAATAACA lactis; GCAGCAACAGCAACTCGTATGGTACTGGCAΆGCCGGGAAΆCGCACCTGG CR382125 ; ATTGGCAGGTACACCGGTGGGCATGGTTTCTGATCCTTCGCCTGTTCAG 49643087 GACΆCTATGGTGTTTAATGCAAGCGAGTACGACGATTTGCGAACCAAGA
AACTGCTCGATGCTTTCATCCATGACTTTCTAATAAAATCAAATTTGAA
CGAAACΆGCACAATCATTTGAΆCGAGΆΆGCGAAGCTTCTCGATGTTGAG
AAAAGGCTGGACCCCTCGCATGATGTCCCAGAGGGGTTTCTTTACGAAT
GGTGGCAGATTTTTTGGGACGTGTTTAACGCAΆGGACTCATAGΆGGCGG
ATCAGACGTCGCTAAGAAΆTATTTCGAΆCAGCAACTTCAACGGCAΆCGA
CAAGAACATACTTATAGAGGAGTTACCATGCATGTTGCTAGGGTTCAAC
AAACTGCTGAGCAGAAAGGATTTTACCAGCACGAAATGTTCGATCCAAT
GGAATTCGCGTCCATTGCTTCCATGGCTGCTAATAACCAATTTAATATG
TCCAATTCAGTAGCTCAGACGGCTCAGCCAAGTGTGCCTTCTTCGGCTT
CCTCGGCTAATTTCCCGGGGTATACACCTCAGTATAΆCTCCAΆCACTGC
TCCGATGGCTACTCATTCAGCAGCGTCGTCTCAACAGCAACAACAACAA
CAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAAC
AACCGCAACAGCCTATCAAACCTCAACCTCAGCGTCAACAAAATAATAC
TCACCCCTCTAGTGTACAGCAACΆTCAΆCAACAACAACATCATCTTCAA
ATGCAACATCATCTTCAAGGCTTCTATAATGGTGTACCAGGTGTTCCAA
ATGGAGGTTATTATACACCTTCTATGAATCCTTATAACAATACACAGCA
AGCTCAΆCAAGCTGCGTGTATGGGCTCTAATCCTGTTTCAAACTCTATA
CCGTTGGCAAGTAATΆGTGGACCAGCTGGTACTGGTACTGTTCCAACCA
ATTCTCATAACACTGCTAATAATGTAAGCAATAGTAGTGACAATGGTAA
CACTAATAACGGTAGTAATATCAATGTCAATGGAAATGAAGGCATCATA
AACAATGAACACATGACGCCCAATTCATCGTCATCCTATGCAATCAACA
TGGTAGCCCCCACTCAAATCCCAAGCTCAGGTCAGGGCCAGGCTCCTTA
TTCAAAACCATCTTCTTTATCCCAΆCAATTTGGATCCATTCCAACTTAC
ATCAATATGAACATTCCAAACTCTGCACCGGCGATGCCAAGTCAAAGAA
ATTCTCAAACCCAAATTCCTCACAACCAATCGGCTGCGTTAGTCCAAGG
CATGCTGTCCGCCCCTAGCTATTCTTCGCATCTGTCCAGTAACATTGGT
GTTAACAACATGCCAATGAATAGTATGAATACAATCCCTGGTTCAAACG
TAAATGGCATGCATCATAATACGAATCCTTCATTTGAAATGTCAAGTAT
GGATGGTCTATACAACTATCAGAAAGAGCTATTAATGCTAGAAAAGGΆA
AACAAAAAGGTTTTATCCATCGCAAAGGAAACATCCCTGTCTTCTGGAT
CTACGCCCCAGTTCTTGACTCTGTCTACATCTGGGAATGCTGGAAACAA
AAAGGGTTCAAACCCAATGCTCCCTCCTAATTCCTCACAGATTGCTACT
CCTCCTAACCAAAGTCCTTTAAATGTAGGAACTGCACCACCTGCTACCG
CTGCAGCTCCAAAGAAACGGAAGTATACCAAGAGGGTTAAGGATTTCAA
GAAATCTCAΆTCAGCACCAAACACGCCCAATACAACTGCATTGACTCCA
GGATCTGGAAATAGAAATAATATCCCATCTAATTTAAACCCCGTTTACG
AGCACTTATCTGCAAACAACTCGCCAAGAGATAAAACTCCGAAAGGTAA
CTTGGTTAATAATTCTCCGTTCACTTTGAACΆCAGΆGGCATCCACGGAA
AATGGAAAAGCCCCCGCTGGCAATAAACGAGCTCGTAAGAATAGCAGTA
CTAGGCAATTATCCGTTTCATCTACCACAACAACGAATAAACCAAAGAA
ΆGTGGCTGCAAAGAΆAACCCCAGTAGATATTACGACAACTCCACAGAAC
AACATCGAAGAAGAGGACTCCACCGGAGCTAGCAGCAAGGATCCTGGCA
GTAATAATAGCCTTGGATTGTTGCCGCATAATGCTTTGACCGATCCAAC
CCCACATACTGACTTCGATCCTATGAGTATAGATCCTGCTCTGAACGCC
TCTGCTGCATTTGATTATGCTGACAATGAGGATTCAΆTGTTGGGCACTT
TAGAAACTGCCTCTCTCGCGAAGAAAGGCGATACACAGGGCGATTCTAA
CGΆTGAATTTGCGAAAGACGAGAAGAΆCAGCGAGAAAΆTGΆAATTΆGAT
CAAAGCGGTTTCAATTTGGATTTCTTAGATCCGAATΆATAGCTATAATG
ATTTCAACTTCCTGAATTGGCAATGA unnamed ATGAAGCGAGAGATGTACTCTGGGCAGTCAGACGTTGCTGATACTGGAT 40 protein GGAGTGCTCCAAAGCCAGGTCATATGTCGCTAGAAAGGTCGAGGATGTT product; GCAGGCCGCGGCGGCCGCAGCCGCTGCTGGTGGTGGGAGTACTCCAAAC Kl uyveromyces CATAATCAAAATTATAACAGACCTCCGAATATCAATACAAACAATAACA lactis; GCAGCAACAGCAACTCGTATGGTACTGGCAKGCCGGGAAACGCACCTGG XM_454887 ; ATTGGCAGGTACACCGGTGGGCATGGTTTCTGATCCTTCGCCTGTTCAG 50309748 GACACTATGGTGTTTAATGCAAGCGAGTACGACGATTTGCGAACCAAGA
AACTGCTCGATGCTTTCATCCATGACTTTCTAATAAAΆTCAAATTTGAA
CGAAACAGCACAATCATTTGAACGAGAAGCGAAGCTTCTCGATGTTGAG
AAAAGGCTGGACCCCTCGCATGATGTCCCAGAGGGGTTTCTTTACGAAT
GGTGGCAGATTTTTTGGGACGTGTTTAACGCAAGGACTCATAGAGGCGG
ATCAGACGTCGCTAΆGAAATATTTCGAACAGCAACTTCAACGGCAACGA
CAAGAACATACTTATAGAGGAGTTACCΆTGCATGTTGCTAGGGTTCAAC
AAACTGCTGAGCAGAAAGGATTTTACCAGCACGAAATGTTCGATCCAAT
GGAATTCGCGTCCATTGCTTCCATGGCTGCTAATAACCAATTTAATATG
TCCAATTCAGTAGCTCAGACGGCTCAGCCAAGTGTGCCTTCTTCGGCTT
CCTCGGCTAATTTCCCGGGGTATACACCTCAGTATAACTCCAACACTGC
TCCGATGGCTACTCATTCAGCAGCGTCGTCTCAACAGCAACAACAACAA
CAACAACAACAACΆACAACAACAACAACAACAACAACAACAACAACAAC
AACCGCAACAGCCTATCAAACCTCAACCTCAGCGTCAACAAAATAATAC
TCACCCCTCTAGTGTACAGCAACATCAACAACAACAACATCATCTTCAA
ATGCAACATCATCTTCAAGGCTTCTATAATGGTGTACCAGGTGTTCCAA
ATGGAGGTTATTATACΆCCTTCTATGAATCCTTATAACAATACACAGCA
AGCTCAACAAGCTGCGTGTATGGGCTCTAATCCTGTTTCAAACTCTATA
CCGTTGGCAAGTAATAGTGGACCAGCTGGTACTGGTACTGTTCCAACCA
ATTCTCATAACACTGCTAATAATGTAAGCAATAGTAGTGACAATGGTAA
CACTAATAACGGTAGTAATATCAATGTCAATGGAAATGAAGGCATCATA
AACAATGAACACATGACGCCCAATTCATCGTCATCCTATGCAATCAACA
TGGTAGCCCCCACTCAAATCCCAAGCTCAGGTCAGGGCCAGGCTCCTTA
TTCAAAACCATCTTCTTTATCCCAACAATTTGGATCCATTCCAACTTAC
ATCAATATGAACATTCCAAACTCTGCACCGGCGATGCCAAGTCAAAGAA
ATTCTCAAACCCAAATTCCTCACAACCAATCGGCTGCGTTAGTCCAAGG
CATGCTGTCCGCCCCTAGCTATTCTTCGCATCTGTCCAGTAΆCATTGGT
GTTAACAACATGCCAATGAATAGTATGAATACAATCCCTGGTTCAAACG
TAAATGGCATGCATCATAATACGAATCCTTCATTTGAAATGTCAAGTAT
GGATGGTCTATACAACTATCAGAAAGAGCTATTAΆTGCTAGAΆAAGGAΆ
AACAAAAAGGTTTTATCCATCGCAAAGGAAACATCCCTGTCTTCTGGAT
CTACGCCCCAGTTCTTGACTCTGTCTACATCTGGGAATGCTGGAAACAA
AAAGGGTTCAAACCCAATGCTCCCTCCTAATTCCTCACAGATTGCTACT
CCTCCTAACCAAAGTCCTTTAAATGTAGGAACTGCACCACCTGCTACCG
CTGCAGCTCCAAAGAAACGGAAGTATACCAAGAGGGTTAAGGATTTCAA
GAAATCTCAATCAGCACCAAACACGCCCAATACAACTGCATTGACTCCA
GGATCTGGAAATAGAAATAATATCCCATCTAATTTAAACCCCGTTTACG
AGCACTTATCTGCAAACAACTCGCCAAGAGATAAAACTCCGAAΆGGTAA
CTTGGTTAATAATTCTCCGTTCACTTTGAACACAGAGGCATCCACGGAA
AATGGAAAAGCCCCCGCTGGCAATAAACGAGCTCGTAAGAATAGCAGTA
CTAGGCAATTATCCGTTTCATCTACCACAACAACGAATAAACCAAAGAA
AGTGGCTGCAAAGAAAACCCCAGTAGATATTACGACAACTCCACAGAAC
AACATCGAAGAAGAGGACTCCACCGGAGCTAGCAGCAAGGATCCTGGCA
GTAATAATAGCCTTGGATTGTTGCCGCATAATGCTTTGACCGATCCAAC
CCCACATACTGACTTCGATCCTATGAGTATAGATCCTGCTCTGAACGCC
TCTGCTGCATTTGATTΆTGCTGACAATGAGGATTCAATGTTGGGCACTT
TAGAAACTGCCTCTCTCGCGAAGAAAGGCGATACACAGGGCGATTCTAA
CGATGAATTTGCGAAAGACGAGAAGAACΆGCGAGAAAATGAAATTAGAT
CAAAGCGGTTTCAATTTGGATTTCTTAGATCCGAATAATAGCTATAATG
ATTTCAACTTCCTGAATTGGCAATGA
Frequency ATGTCGGACCTCAAAAGTAAACGCCGCAACGCGCCATCGCTGGCGCAGC 41 clock protein; ACACATACCCCCGGAGGGTGTCCCCCGAAAATTCGGTCACGCTCCGACA Leptosphaeria TCACCGGCTAGCACGCGATGCCAGCCTGCAAGCAAACTCCTCGAGATCT austra.lien.sis; CAGGCGGCGACGTCTTCACCGCGACGAAATTCTTCCGACGAGAGCCATG
U25851; ACACCGGCCAAAGCGACGCGAATAAGTGGTTCGACCAGTCGAACCTTAA
852503 CCCTACCGCCAACTATGACAGCAATGCCATGGACGTTGATCCTCCGTTT
TATCΆGAGAGAGTCAGAGTCGTCCAATGAAGGAGGCAAAΆTTCCCTACC
ATGGCGGATCCGTACCCATGCTCAAGCCCACCGTCACGCACAGCAGCAG
TGCCGATGACTATCGCTCCGTCATCGACGACTTGACGGTGGAGATCCAG
AGGCTGAAGGAAGAGTTGAAGCGATACAAGCAATTCGGATCCGACGTGA
TGAAGAACGAGAAGCTTTTCGAAATCAAGGTGCATGGGTTGCCGAAGAG
GAAAAAGAGGGAATTAGAGGCAACGCTGCGGGACTTCGCCGCGAGTCTG
GCCGGAΆCCTCGAGCACTGACATGGCGTCGTCTCACAAGAΆGAAGTCGT
CCCGGCACATGAATCGGATGCAGTCGTCTGCCTCCGGATCCATGTCAAA
GCACGCCTCGTCTTCGGCAGGGTCGCATTCGCGACCGGTCGATTCTGCC
TATGCTTCCATGTCGACAGGGCCGAACTCATCTGGAACATCGCTGAACC
GGCCATCAATGAGCGCGCGAGCGAGGACATCTGAGCAAAΆAGTTGAAAA
CTACCTCCGAGACATTCCCGAGGGGCTCTACCCGAGACACATGATCATG
ACTGAGAAGGAGCGAAAGAAGTTGATTGTTCGCCGCCTGGAGCAAATAT
TCACGGGAAAGATGGTCCGCGGAGCGAACACGTCAAACTCATACCAAGT
CAACTCGGGCCTAACGCCAGTCACGCATGACGGTCAGAGTGGGAAAGCA
GCGGGGTTGCACCAGCCCCCGAGTCTCAAGGCTCCGCCGATAAATGTGG
AAAACATCGΆGCCGGCAΆGGGAGGCAΆGGATCTTGCCGGCTGATAACΆT
GAAGAAGAGTCGGTCTCGAGACAATGAGTCCACGTCAAACTCGAATCAG
GACCAAACCGAGTCCGGAGGCAAAACTGCCAACAGCGGCTCAGGATCCA
ACACATCTCCACCTATTGCTCCGCCTCCCGAGCAGCGGCCCACGCGCCC
CTTGGATCTTGATCCTCATCGCACACAGGTTCCGTCCGAGAACATGGAA
TATCTCCGGCATCTTGGCCTGGTGCCTCCGGAACTGCTGCCCGACTCCA
ATGACCTAGAAGGAGACGTTGCACCAGACGCCGACGGGTGGATACATCT
CAACCTTCTTTGCAACCTCGCTCAGCTGCACATCCTTAACGTGACACCC
GACTTCATACGATCTGCTGTCAACGAGAAGAGTACCAAGTTTCAACTGT
CACGTGACGGCCGCAAGGTCCGTTGGCGCGGTGGCCTCGACGGGACGCG
ATTCAGCAGCGACAGCTCGGGCGACAACTCGCAAAGTCCTGTCGGCGAC
GAGACTGACAGCTCAAGCAAGAATGGCCAGCGCAAGAAGCGTAAGGTTG
TGACAGCCGACGGCCAGACAACCTCCGCTCCATCAAGTAAAGAGGCATC
GAAGTATGACCGCCAAATATCGCAGTCTTCGGACAGTTTCCACTATAAA
CCGCTGTTCGCTCACCACCCCTCATCGCACGAAACTTCTCTTGATACAG
GCTCCTCATATGGGCCGCCAGAGGAAAGTGCACAGGGTGACTCACGCTG
GGGGTTGAGTGGATCGGGGGGCACGTCGCAGCGTAAGAAACGCCGTGTA
GACGGGGCCATCGTATATTACAGCGGCGCGCCATTCTGCACCGACTTGT
CCGGCGATCCGGGTGACGCAGGCGTTGACAGCCAGACTGGTGGCATCTC
TCCGGCCACGTACATGCAGAATGCCGGGCAGGCCCAAGCCAAGGCAGAG
GCGAGGGCCGAAAAAGGGAAGGTGCCACCAΆAAGCGGTCCGAATGGTCC
CTATCAGAAGTCAGTCAGGATCCTTTCTACCTCACCGACCGCTCACCGC
CTTCTCTCCGTCTACCGAGGATGTCCCCATGTCAGATGTCGACGAAGCA
ATAGCGCTGGAGGATGACATAGAGATGGAGTTTCCCTGGTCAGACAGTC
AGCAATATCTCGAAGTTCGACCTCTCGAGCCTAGCGGTCTCGGCGGCGT
ACTTCCTGATGACAATTTCATGGTGGTTGTCACGACCAAGCGACCACAC
GGAATGGAGCCCGGAGAGAAGACCCCAGCTCTCGGGCGCACAAAGTCTG
ATGAGACAACGCGAACAACTGATTCCATCGTTAΆTCTTCTCGCCTCGAT
GAGTACGTCGGGTAATGAGAACATGCCCGCGGGGCGTCCAGTTCTACAT
AAGACTGGGAACATTGAGATCGAATACCTCTCAGGAAGAATCAAGCGTC
TGAACCCAGTTCCTCTTCCGCCTCCGGCCATTTTCTTCCCTCCGTTTAG
CTCGACATCGTCGTACAACTCGGAGTTAGATTTGGGCTCGGATGCTGAT
GACGΆTGΆGTCTTCGGAAGAGTTCATGAGTCGGCGCGCCAΆCCCCCACC
AGTCCGACAACGAATATCCCGACGATGTTGACATAACAAGCGGTGATGA
AGTCGGCGAGGAGCCAGACGATGAGCTGGCTCCCACAGATGATGATGAA
GAAATGGAGTCCGCCGGTGACGAAGGAGGCGCATCCAGGGGTΆGGGCCG
CCGGGCCACGAAGTGCGAGACCGAGCCTACCCAGCGGCAAGTCAGCAGG GCACAGAGCGGTGAGGCGGACTGGAAGTCTTGCAGCGACAGCAGGAGGA GAΆGAAΆGTGGTTACAGTAGTAGCGCGGAGGAGTCGTGA
Hypothetical ATGTACGATGCCGCTAGGGGCGTATTGAAAAGTGGCCAACCCATCAATG 42 protein TTGAACAAGATCGCGAGAATGGGCTCGGCGGCGACTCTATGGATACCGA
MG04708.4; CTCCAAAGACGATGTCAATAGCAAGAAGCCCGAAGACCTCCCCGCGCCC
Magnaporthe ATACTTGGTTCCGCGACACCCGACATCAGCTTCTTGTACGAGTGGTTCT grisea; CGATGTTTTGGGACTTGCTGAACGCCTCCAAGGGCAΆATACGCACCGGC
AACU01001152; CCAGGTCAGCCAATACATTACACATACGCAGAACCATACACGGATGAGA
38104369 CAGCAGACTCAACAΆGAGATGTTGCGGGGCΆTGCGΆCCCGACATGGCTG
CTCAGCAGCAGCAGTTTCTGATGATGAACAGGCCAAATGGAAACATGAA
CATGATGAACAAGAACCAGAGCTTACATCGTGGTGCCATCGCCAACACC
CAGAACCAAATGCAGATGCTCGCTCAACAAAAGCAΆGGCCAGATGCAAC
GCGATCCTTCGGACATGGACGGTAACCGCCAAAGACCCAGCTCCCCTAG
TTCAGCTGACAATGCTCCATCACCCTCGAAGCGGGTGCGTCTCGACGGC
GGCCCTGGGTTCAACCCGGGCCAACCCGGAATGATGCCGAATGGTCGTC
CTGGCGCACCAGGAΆTGCCCAATCAACAGACGTATGCGCAGAACCTACA
GCAGCACCACGGCAACCAAATGCCTAACAAGCCCATGCCTGGCCCCAAC
GCCCCCCAGGGTCAAGGCTCGCCGATGGTTGCCTCTGGCCCCGACGGCA
CACAGCTCAATGCATTCTACAATGCTCAAGAACCGATGGGTGCCGCACC
CAACGGCGGAATGCGTCCCGGCGTCCCAGCCACTCAGAACGGAAGCAAC
CATGCTCTTCAAGACTACCAGATGCAGCTCATGTTGCTAGAGCAACAGA
ACAAGAAGCGACTGATGATGGCCCGGCAAGAACAGGACGGCΆTTCAAGG
ACAAGGTATGGCTCGGGCCGATGGTCCTGGCGGTCCCGGTCCTGCCGGT
GGCCCCGGCGGTCCCGCAGGCGCACCGAACGGACCCCAGTTCCAAGGGG
CTTCTCCCCAGGGCGCGAGGCCCGGTGCTTCTCCGAACCCGAGCGAGCA
GATGAAGCGCGCCGCTGGGCAGATGAACAATGGTAGCATGGGATCACCT
CTTCCGGAAGGCGCTCAAAACCGCGAGTCCCCGAACAACCCGATGAACT
TCATGGGTACGAATATGGATCCCAACGGCGCACCGCACTTCTTCAAAGG
TATTAACAACGGCATGGATGCAAACATGGCAGCCGCGCAGATGAATGGA
GGCATGAΆCCGGCCCCCTAGCTCGCACCCGGGCCAΆCAGCCCTTCAGCC
AGATGAATCCTCAGCAGCAGGCCATGATGCGTCAACAGCAGATGCAACA
GCAGCAGCAGGGTGGTCCCAATGGCCAGCCCATGCCCGGGCAATGGCAA
GGTGGACCTAACGGTCAGATGCCCGGTGGTCCTCAGGGCGGCCCGCAAC
AGGGACCTGTCCACGGAACGCCCCAGCAAAGGGCGATGCCCCCGCCTTC
GGCACCCACGGCCGCAGCAAACAGCAACGCGAATCAGAGGAACACTACA
GCATCCCCGCAGGTTTCCAACGCCGCGCCGCCTACGCCATCACAAGCTA
ACAAGGCAGCCCCCAAGAAGAAGGATACCAAAGCTAAAGACAAGCGGGC
CGCCACGCAGAAGAAGTCCAATGCAAACCTGAATGCCGCCGGGGGTGCT
ACACCCGCGGCCGACGGAGGAAACGACGGCGAGGCTCCTACCCCGGCAA
CTCCCATGACGCCGATGGCTGCCTCACAGCAAAACTTCAACAAGCCTGG
GCCTGCCGCAGGGGGTGCTCCACCGCAGCAGATGCCTAATGGTCAACCT
CCCGCCGCTGCCCCTACAGCGGCACCAGTCGCTCCTCAGCAACACAΆCG
ACCCCAACCAGTTTAACATGGAGGGAGGCGGAATGGACTTCAACTTGGA
CTTCGCTAACCCATTGGCCTCGGGCGACGTACTTAACGATTTCGACTTT
GACTCTTTCCTGCACGATAACGTGGAAGACACCGGATTCGGCTTCGACG
GCCCCGGCCTCAΆCTTCGAGGGCACCAACGAAATTGGCGCCGACTAG
NcSOMl; ATGAACATGAACAACATGGGTAACATGGCGCAGATGAACGCCATGGGCG 43 Neurospora GTCCCGTCGGCGGCGCCCCTATGCCAATGATGAATAATGGCGCAATGCC crassa; CGTCCGTCCTCAGCAGCCCCCACAACCTCAACCGCAACAGCAACAACAA AF265233; CAGCAGCAGCAGCAGCAGCAΆATGCATTTTGGGGCTGGAGCTATCGATG 8453193 GCGGCCGTTCGTTGCTCGAGACCTACATCTACGACTATTTCATCCGCCA AGGCATGTACGACGTTGCCCGCACAATGCTACAAΆATAACCCTCAGATC AAGACGGACAAATCTGCGAGCCCTGGTCAAAACTTGAATGGCCTGGGTG ACGATCCCATGGATACCGACTCAAAGGACAΆCCTGGACCAAAAGCGTCC CGACGACCTACCCCCAGCTGCGATTCCGAATTCCTCGACAAGCAATAAC CCCTTTCTGCTCGACTGGTTCTCACTGTTCTGGGATATGTTCAΆCAGCC AAAAGAGCAAGGGCCCTGCTCTTGTGAACCAATATGTGCAACACAACCA
GAACCAGTCCCGCATGCGTCAGGAACAGATGCTGCGGCAAATGCGTCCT
GACTACGCCCACGTGCAATATCAGCAGCAAATGATGAGGAACATGAATG
GTATGGGCGGCATGATGAΆGCCCGGΆAACCAGCTGCCACGGGCAGCCAT
GGCGAACAGCCAAAATCCCCAAGCCATGCACATGCTTCAGGCACAGAAA
GCTGCTTCAATGCAGCGAGATCCCTCGGATATGGAAGGAAACCGAGTGA
GGGCGGCGTCGCCAGGATCGGCAGACAACGCGCCATCCCCATCCAAGCG
GCCACGTCTCGAGGGGGCCCCCTTCAACCCCAΆCGCGGGTGTCATGGTG
CCCAATGGCAGACAGATGCAAGGCATGCCAGGCCAGCAGCAGGTAGGAG
GTGGCCCCAΆTTCAGCACAAGCATTTTTCATCAACCAAATCCGCCCAAA
CTCATTAACTCTTGACCAACTCCAGGTCTTAATCAATGCCAATCCCAAT
CAGCTCAAAGCGTACGCCGCTAACCTCCAGCAGCACCACGGTAAACAGA
TGCCCACCAATCCGATGGCGAATGCTGGCGGTCCGCAAAACCAGGGCTC
TCCTATGCTGCCGCAGGGACCCGATGGCCAGAACATCAACCAGTTTTAC
AACCAGGAAATGGGCGCCGGAAACATGCGAGCTGGGCCTGGTAACGGCC
AGAACGGGTCAAGTAACCATGCCCTTCAGGACTACCAGATGCAGCTGAT
GCTCCTCGAGCAACAAAACAAGAAGCGTCTCATGATGGCTCGACAGGAG
CAGGATGGGATGCCACGACCTGAAGGCCCCAACGGTCCAGGCGGACCTG
GCGGCCCGGGAGGACCTCAGGGACCGAATCCTCAAGGCTTCCAAGGCAA
TTCGCCACCTGGGCAGCGCAATGGAGCATCACCTAACCCTTCGGAGCAG
ATGAAGCGTGCCAACCAGCAATTGAACAACCCCCAGAACATAGGTTCCC
CTCTTCCGGATAGCGCCCAGAACCGCAGTTCACCGAATCCAACGATCTT
TATGGGCGGCAACATGGATCCCAACGGAGGACAGCCCCATTACGGCATG
AACATGAACATGGGCAATCAGATGGGAGGCGGTATGCGTCCACCGAACG
CACACCCAGGACAGCCCTTCAATGGCCAAATGAACCCACAGATGATGGC
TGCCCAACAGCAGCGTCAAGCACAAΆTGCAACAGCAGGCTCAGCAGCAA
GCACAACAACAACAGCAACAAGCCCAACAAGCGCAGCAGCAACAAGCGG
CTCAACAGCAGCAAAACCAAGGGGGCCCTAATATGCAATGGCAGCAGCC
TGGACCCAATGGCCAGATGGTTGGTCAGCCTCCTCAAGCTCAGCAGGCT
CAGGGTCCAGCGCAGCAGAGAGCCATGCCGCCACCTTCTGCTCCCCCAA
CGGCAGCGGCGATGACCAACGCTGCCAACTCGAGGAACGCGACGTCATC
TCCTCAAGTCACCAACGCTGCTCCTCCAACCCCCAACCAGGGCAACAAG
CCGGCACCCAAGAAGAAGGAGACCAAGAATGCTAAGAACAAGAAGAAAT
CCAATCAGAACCTCAACGCAGGTGTTACACCTGCTGCAGATGCCGΆCCA
GCCGCAAGAACCTCCGGCGCCGGCCACTCCAATCACCCCAGTCAACCCA
GCTAGTTTCAACAAGAACCAΆGTΆGGCAACCAGGTTGTΆCAGAATGGAC
AGCCGGCTGCCCCGGTCCCGCCGCCCTCCGTGCCTCAGGTCGCCGCCCC
GCCACACCCGGACCCGACCCAGAACAACAATTTCGCCGAACCAATGATG
AACTTCGATGTTGAGTTTGCCAACCCACTCΆCGTCAAΆCGATGTTCTGA
ACGACTTTGATTTCGACTCCTTCTTGCACGATAATGACAATGGCGGAGA
GACTTTCGACTTCAATGCCGGCGTGTTTCTGGATGGCΆACGAGATCGGA
ACGACGGAGTAG
Hypothetical ATGAACATGAACAACATGGGTAACATGGCGCAGATGAACGCCATGGGCG 44 protein; GTCCCGTCGGCGGCGCCCCTATGCCAΆTGATGAATAATGGCGCAATGCC
Neurospora CGTCCGTCCTCAGCAGCCCCCACAACCTCAACCGCAACAGCAACAACAA crassa; CAGCAGCAGCAGCAGCAGCAAATGCATTTTGGGGCTGGAGCTATCGATG
XM_325645; GCGGCCGTTCGTTGCTCGAGACCTACATCTACGACTATTTCATCCGCCA
32410330 AGGCATGTACGACGTTGCCCGCACAΆTGCTACAAAATAACCCTCAGATC AAGACGGACAAATCTGCGAGCCCTGGTCAAAACTTGAATGGCCTGGGTG ACGATCCCATGGATACCGACTCAAAGGACAACCTGGACCAAAAGCGTCC CGACGACCTACCCCCAGCTGCGATTCCGAATTCCTCGACAAGCAATAAC CCCTTTCTGCTCGACTGGTTCTCACTGTTCTGGGATATGTTCAACAGCC AAAAGAGCAAGGGCCCTGCTCTTGTGAACCAATATGTGCAACACAACCA GAACCAGTCCCGCATGCGTCAGGAACAGATGCTGCGGCAAATGCGTCCT GACTACGCCCACGTGCAATATCAGCAGCAAATGATGAGGAACATGAATG GTATGGGCGGCATGΆTGAAGCCCGGAAACCAGCTGCCACGGGCAGCCAT GGCGAACAGCCAAAATCCCCAAGCCATGCACATGCTTCAGGCACAGAAA
GCTGCTTCAATGCAGCGAGATCCCTCGGATATGGAAGGAAACCGAGTGA
GGGCGGCGTCGCCAGGATCGGCAGACAACGCGCCATCCCCATCCAAGCG
GCCACGTCTCGAGGGGGCCCCCTTCAACCCCAΆCGCGGGTGTCATGGTG
CCCAATGGCAGACAGATGCAAGGCATGCCAGGCCAGCAGCAGGTAGGAG
GTGGCCCCAATTCAGCACAAGCATTTTTCATCAACCAAATCCGCCCAAA
CTCATTAACTCTTGACCAACTCCAGGTCTTAATCAATGCCAATCCCAAT
CAGCTCAAAGCGTACGCCGCTAACCTCCAGCAGCΆCCACGGTAAACAGA
TGCCCACCAATCCGATGGCGAATGCTGGCGGTCCGCAAAACCAGGGCTC
TCCTATGCTGCCGCAGGGACCCGATGGCCAGAACATCAACCAGTTTTAC
AACCAGGAAATGGGCGCCGGAAACATGCGAGCTGGGCCTGGTAACGGCC
AGAACGGGTCAAGTAACCATGCCCTTCAGGACTACCAGATGCAGCTGAT
GCTCCTCGAGCAACAAAACAAGAAGCGTCTCATGATGGCTCGACAGGAG
CAGGATGGGATGCCACGACCTGAAGGCCCCAACGGTCCAGGCGGACCTG
GCGGCCCGGGAGGACCTCAGGGACCGAATCCTCAAGGCTTCCAAGGCAA
TTCGCCACCTGGGCAGCGCAATGGAGCATCACCTAACCCTTCGGAGCAG
ATGAAGCGTGCCAACCAGCAATTGAACAACCCCCAGAACATAGGTTCCC
CTCTTCCGGATAGCGCCCAGAACCGCAGTTCACCGAATCCAACGATCTT
TATGGGCGGCAACATGGATCCCAACGGAGGACAGCCCCATTACGGCATG
AACATGAACATGGGCAATCAGATGGGAGGCGGTATGCGTCCACCGAΆCG
CACACCCAGGACAGCCCTTCAATGGCCAAATGAACCCACAGATGATGGC
TGCCCAACAGCAGCGTCAAGCACAAΆTGCAACAGCAGGCTCAGCAGCAA
GCACAACAACAACAGCAACAAGCCCAACAAGCGCAGCAGCAACAAGCGG
CTCAACAGCAGCAAAΆCCAAGGGGGCCCTAATATGCAΆTGGCAGCAGCC
TGGACCCAATGGCCAGATGGTTGGTCAGCCTCCTCAAGCTCAGCAGGCT
CAGGGTCCAGCGCAGCAGAGAGCCATGCCGCCACCTTCTGCTCCCCCAA
CGGCAGCGGCGATGACCΆACGCTGCCAΆCTCGAGGAΆCGCGACGTCATC
TCCTCAAGTCACCAACGCTGCTCCTCCAACCCCCAACCAGGGCAACAAG
CCGGCACCCAAGAAGAAGGAGACCAAGAATGCTAAGAACAAGGCTGCTA
CGCAGAAGAAATCCAATCAGAACCTCAACGCAGGTGTTACACCTGCTGC
AGATGCCGACCAGCCGCAAGAACCTCCGGCGCCGGCCACTCCAATCACC
CCAGTCAACCCAGCTAGTTTCAACAAGAACCAAGTAGGCAACCAGGTTG
TACAGAATGGACAGCCGGCTGCCCCGGTCCCGCCGCCCTCCGTGCCTCA
GGTCGCCGCCCCGCCACACCCGGACCCGACCCAGAACAACAATTTCGCC
GAACCAATGATGGTAAGTCCGGAACCTTTGTTCATTGCCCAGCGGAGGG
TGCTAACCAGCAAGCTGCAGAACTTCGATGTTGAGTTTGCCAACCCACT
CACGTCAAACGATGTTCTGAACGΆCTTTGATTTCGACTCCTTCTTGCAC
GATAATGACAATGGCGGAGAGACTTTCGACTTCAATGCCGGCGTGTTTC
TGGATGGCAACGAGATCGGAACGACGGAGTAG
Hypothetical ATGTCCGGCAATCAACAAGGCCAGTGGCCACCATTCGTCGGCTACCAAA 45 protein; TACCCAACATGTCTGGCAATCAACAAGGCGACTTACCGCAATTCGAAGT
Neurospora. CAATCAAGGGCCCΆTGATATCTGGTGCTCAGCCAGGCGAAGΆACCCAAG crassa; TTTGGCGAAGATGAGACGCCTACCGGTAACATCCTGTATGAACACTCGC
XM_327362; AAGCGGATTTACAGCAGTTCGACGTCAACCAGATGCCTACCGGTAGCAT
32413766 GCATAGAAGTCAGCAAAGCGAGTTACCGCAATTCGACCCTAACGAATTG CCTGGCCTGTTTGAAAATCAGCATGGAGAGTTACAGCACTTCGACGTCA ACCAAGCGCCCATGTTGTTTGGCGATCAACAAGGCGTGCTACTAGAGCA TTTTGACGACGTCAACCAGΆTGCCTACCGGTAGCATGTATGAAAGTCAG CAAGGCGAGTTACCGCAATTCGACGCCAACGAAATGCCTGGCATTTATG AAAATCTACAGCAGTTCAACGCCAACCAGATGCCCATGTTGTTTGACGA TCAACAAGGCGTGCTACTAGAGCATTTTGACGCCAΆCCAGATGCCTTCC GGTAGCATGTATGGAAGTCAGCAAGGCGAGTCATCTCTTTCCCCTTCCA ACCCGGTGCCCATGATGTTTGACAATCAACAΆGGCGAGTCGTCGCTGTC CCCTGCCAACCAGGTGCCCΆCGATGTCTAGCAATCAGCAAGGCGAGTTA CAGCAGTTCAACGCCACTCAAATGCCCACGATGTCTAGCAATCAGCAAG GCGAGTTACAGCAGTTCAACGCCACTCAAATGCCCACAATGTCTAGCAA
Figure imgf000058_0001
TCACCTTCCGCTTTAGCTTCTAAACAGCCCACAAAGGTAAGGAAAAATA
CAAAAAAGGCATCCACCTCAGCTTTTCCAGTAGAGTCTACGAATAAACT
CGGTGGCAACAGCGTGGTGACAGGTAAAAAGCGCAGTCCCCCTAACACT
AGAGTGTCGAGGAGGAAATCCACTCCTTCTGTTATTCTGAATGCTGATG
CCACTAAGGATGAGAATAATATGTTAΆGAACATTCTCGAATACTATTGC
TCCGAATATTCATTCCGCTCCGCCCACTAAAACTGCGAATTCTCTCCCT
TTTCCAGGTATAAATTTGGGAAGTTTCAACAAGCCGGCTGTATCCAGTC
CATTATCTTCAGTGACAGAGAGTTGCTTCGATCCAGAAAGTGGCAAGAT
TGCCGGAAΆGAATGGACCCAAGCGAGCAGTAAACTCAAAAGTTTCGGCA
TCATCCCCATTAAGCATAGCAACACCTCGGTCTGGTGACGCTCAGAAGC
AAAGAAGTTCTAΆGGTACCAGGAAACGTGGTTATAAAGCCGCCACATGG
GTTTTCAACCACCAATTTGAATATTACTTTAAAGAACTCTAAAATAATC
ACTTCACAGAATAATACAGTATCCCΆΆGAATTGCCGAΆTGGGGGAAACA
TACTGGAGGCGCAAGTAGGCAATGATTCAAGAAGTAGTAAAGGCAATCG
TAACACATTATCTACTCCAGAGGAAAAAΆAGCCGAGTAGTAATAATCAA
GGATATGATTTTGACGCCCTCAAAAATTCAAGTTCTTTGTTGTTTCCTA
ATCAAGCTTATGCTTCTAACAATAGAACACCAAACGAGAATTCAAATGT
TGCTGATGAAACCTCTGCATCTACAAATAGTGGCGATAATGATAACACA
TTAATTCAGCCCTCATCCAATGTGGGTACAACTTTGGGTCCTCAGCAAA
CCAGTACTAATGAAAATCAGAATGTACACTCTCAGAACTTGAAGTTTGG
GAATATTGGTATGGTTGAAGACCAAGGACCGGATTACGATCTCAATTTA
CTGGATACAAATGAAAATGATTTCAATTTTATTAATTGGGAAGGCTGA
MSSIl; ATGGATAACACGACCAATATTAATACAAATGAGCGCTCTAGTAACACGG 47
Saccharomyces ATTTTAGCTCAGCTCCCAATATCAAAGGTTTGAATAGCCATACTCAGTT cerevisiae; GCAGTTTGATGCGGATTCTCGAGTTTTCGTTTCGGATGTAATGGCTAAG
NC_001145.2; AACTCTAAGCAATTATTGTACGCCCATATTTATAACTATTTAATCAAAA
44829554 ACAATTACTGGAACTCTGCCGCAAAATTTTTAAGCGAAGCTGACCTTCC
TTTATCTAGAATAAACGGATCTGCTTCGGGTGGGAAAACTAGCTTGAAC
GCCAGCCTGAAGCAGGGATTAATGGATATTGCATCTAAGGGTGACATTG
TTAGTGAAGATGGGCTATTACCTTCGAAAATGCTGATGGACGCTAATGA
CACGTTTTTACTGGAATGGTGGGAAATTTTTCAATCATTGTTCAΆTGGA
GACCTAGAΆTCTGGGTACCAACAGGATCATAATCCTTTAAGΆGAGAGAA
TAATACCAATTTTGCCAGCTAATTCTAAATCTAΆTATGCCTTCCCATTT
CTCTAATCTCCCACCAAATGTGATTCCACCAACTCAAAATAGTTTTCCA
GTTTCAGAGGAGAGTTTTAGGCCCAATGGTGACGGAAGTAACTTTAATT
TAAACGATCCAACCAATCGAAACGTCTCCGAAAGATTTCTATCGAGAAC
TTCCGGTGTCTACGACAAACAGAATΆGCGCTAΆTTTTGCACCTGATACT
GCTATAAACAGTGATATTGCTGGGCAGCAGTACGCAACTATAAATCTAC
ATAAACACTTCAATGATTTGCAATCACCAGCACAGCCCCAGCAATCΆTC
TCAACAGCAGATCCAGCAGCCTCAGCATCAACCCCAGCATCAACCGCAA
CAGCAACAGCAACAGCAACAACAACAACAACAACAGCAACAGCAACAGC
AACAGCAACAGCAGCAACAGCAACAGCAACAGCAACAACATCAACAGCA
GCAACAGACACCGTATCCTATTGTCAACCCACAAATGGTCCCTCATATT
CCATCGGAAAATTCTCATTCAACCGGACTTATGCCTTCAGTGCCTCCTA
CAΆATCAACAATTTAATGCACAAACCCAATCTTCAΆTGTTTTCAGACCA
GCAGCGCTTCTTTCAATATCAATTACACCACCAAAATCAAGGACAGGCG
CCATCTTTTCAGCAAAGCCAATCTGGCAGGTTTGATGACATGAACGCTA
TGAAAATGTTTTTTCAGCAGCAAGCACTACAGCAAAATTCACTACAGCA
AAATCTTGGAAATCAAAATTATCAATCTAATACACGTAACAATACTGCG
GAΆGAAACTACGCCCACAAATGACΆATAACGCAAATGGCAΆTΆGTTTAT
TGCAAGAACACATACGAGCCCGCTTCAΆTAAGΆTGAAAACAATTCCTCA
ACAAΆTGAAAAATCAAΆGCACTGTCGCAAATCCGGTTGTTAGTGΆTATA
ΆCATCTCAACAGCAGTACATGCATATGATGΆTGCAAAGAATGGCGGCTA
ACCAGCAATTACAAAATAGTGCCTTTCCTCCAGACACTAATCGTATAGC
GCCAGCTAACAΆCACTATGCCATTACAΆCCΆGGAAATΆTGGGGTCTCCT
GTCATTGAAAATCCAGGTATGAGGCAGACTAΆTCCATCCGGACAAAACC CTATGATCAATATGCAGCCCTTATATCAAAATGTTTCTTCCGCAATGCA TGCGTTCGCTCCGCAACAACAATTTCATCTACCACAACATTATAAAACC AATACTTCAGTΆCCACAAAATGATTCTACCTCCGTCTTTCCTTTGCCTA ACAATAACAATAACAATAACAACAACAACAATAATAATAATAΆTAATAA TAGTAATAATAGTAATAΆTAATAATAATAATAATAATAATAATAATAAT AGTAΆTAATACACCCACAGTATCACAACCATCATCAAAATGTACTTCTA GCTCCAGCACAΆCTCCTAATATAACTACAACAATTCAACCCAAGCGGAA ACAGAGAGTGGGTAAAACAAAGACCAAGGAATCAAGAAAAGTTGCTGCA GCTCAGAAAGTTATGAAΆTCTAAGAAACTGGAACAAAATGGTGATTCAG CTGCTACAAACTTCATCAATGTCACTCCAAAGGACAGTGGCGGTAAGGG TACCGTAAAAGTTCΆAAACAGTAΆCTCGCAGCΆACΆACTAAATGGCTCT TTTTCTATGGATACAGAAACATTCGACATATTTAACATTGGTGΆCTTTT CTCCTGATCTAATGGATAGCTAA
SpSPCC70.01; ATGGCTGATTTCATGGACATAGAGCCATCCTCTCATTCTGCAAAAGCTT 48
Schizo- CTCAATACGAATCCTCGGCTCCTGCGTCTTCTTCACTGGGTAATTCGCA saccharomyces TCCAAACGAGTCTCTGGATTATTATATATACGACTATTTTGTTAAGCAC pombe; AACTTTGAGGAAGCCGCACAGGCTTTTTTACGAGAGTCAAAAATTCAAA
NC_003421; TTCCAAAATCTTCTTCATCTACTGCCTTTTCACCTTCCAACAATAACGC
19075172 ACCTTCACCTTTCCCCCCAAAGAATTCATCTTTAGCCTCTCCTAGCAAA
ATTTCTGAATCGΆTTTCTGGTGATCGACTTTACAACCACΆTGTCATCAG
CTCCGTCTCCCAACAAAAAGGAAGAAACCAATGTCGTACATGCTAACGA
GGACATTTCΆTTΆGΆTAAACGCCAGTCATTTGGATCATCATCCCTTCCC
CCTTCTGAAGTTTCTATAAATGTTCCCGAAGGTTTCTTGGTGGAGTGGT
TTAATATTTTTTGGGATGTATTTAGTGCGCGAGTAAGTCGTGTAAATAG
CACGCCTATTCAATTATATGATCCTTCTACTCAAAGACAΆATGGCCCGT
CCCATGTCTAACCTCCAAGCATCTCAACCTGTTCCTTCCTCCACTTTTT
CTCGTTCCGCTGTTGTCCCCAATCCTTCTCTTCCTTTAAATCCTTCTGT
TTTACAGGGACAAGTGATGAATAACCCAACCATACCAAΆGGGCACTCCT
TCTACATCCATTGAAGGTGCAAAGACTTCTATCCCACCTTCTCATGCTA
TGCAAAATCCGCΆTAΆCTCTTTCCCTGCATCAGCΆGATAGACTTCAAAA
GAACCACCCTGTTCAATCTTCCAACTTTAACCCGTACACACCTGCACCT
TCGATTACTGTCCCACCTAΆTTATATACCGAACACTGCAATGATGGGCC
CTTCTTATTCTTCTTTTGGTGΆTΆCTGATCCTCGTACTTATCCTGCAGG
AATGGGACCAAACCCTACTGCTGCTAGAAACGGCTTTTATCCTCCAACT
CCGGCCCAGATACATCAATTAAAGGCTCAACAACAGCATCTCCAACGAC
AAAGCAAACAAATGTCGGAGCCTGCTCCTATTAACATGAAATCGAACAA
AGATCAACAATTGCAGTACGTGGATTTTCGAGGTGTTGGTAGTGGCGCC
GATCTTCAAAAACAGCAATGGAACAAATCTACTTCTGCTGAAGGTCTCC
AGCCAAATGGATTGGTTATGAGGAATTTCGGGGACGTTCGCCATCAAAA
GCTTCCTACCTCTTCACCTCCTTCGCAACATCCACCTGTAGGGCAGATT
CCATCACAGTACCTTCCTTATCAGGCTGGGCTCAAAGTGCCAGGTAATA
CACCTATACCCGTTAAACAAGTAGGTGGTATGCCTTTACAATCACCATT
ACCTGTAAGTATGAAGCCTTCCGCAGATGACCATTCACGCGCTACTCCA
ACACGTTCTGTTGAAGCTCCCACTTTGCCGTCATACGCTCCTCGGCATC
CTACTCAΆGCAAATGGATC
SpI; ATGGCTGATCCAGGTTTAAGGTCCGGCGTCGGATTGCCAAGCCAGCAAG 49
Schizo- GACAGAAACATGATTTACAAAAAGATCAAAAACAACCGCACGTAAATAA saccharomyces TGCCGATAGGACCACACAATCCTTACTGAATTCGTACATATATGATTAT pombe; TTAΆTCAΆGAAGGATTATTGTGAGGCAGCCCGAGCTTTTGGCCGTGAAG
NC_003423; CACAAGTACAAACGCTCGTCAGAAGTCAAGAAGAAACCAATTCCTTAGC
19111836 TAAGCGTCACAAAAGAATGTCTCCTGTTGCTGTAAAGCATGAΆGGTATA ΆGTAATAATGAATCTTCGGΆTGAAAACATGAATGTAAATAACGGTAATT TAGATTCCTTTTCTTCTTCTTCTGCTCCGCCGCCACCTCCTATTTTGCC TATCGATTCAGCTGGTGGTTTTTTAATCGAGTGGTGGAATGTTTTTTGG GATATTTACAATGCTCGTCGGGGTCAAGGATCTGAGCCGGCAAAGGCGT ATATGTCTCATATTAGCAATCTTΆGGAAGAAATCTCGTTTAAATTTGCA AGAAATTCAAAAAAACTCTCTACΆCΆCTGGAAΆTACTTCTCACCCTTAT
GCAAACGCCTCATTTCCCCATGATCCTGCCAACGCAATGGGTCAGCAGA
TTGACTCATCTCAGTTTCATCAAGGGGCAGGTGGATTGAACGATAGAAA
TCAGCACTTAATGCGGCAAGCTATGCTAAATAATCAAAGCCGTGAAACG
TTTCCCCCGACCGCTGCTCAACTTCAACAATTAAΆACAATTACACTACA
GGCAGCTACAATCTGTGCAACAACAACAAAAGCAGCACCAGCAAAAGAA
AACTCCACAAAGTGGTTCTACCCCACAAATGCAAAΆCACGΆCTTCTCAA
CCTACAACTCACGATACACATCCACCTAAGCAGCAAGGTCCAATTTCCG
ATTTTCGATCCATCCCTTCTTCACCCAAAACAGAAGGTGCTCCATCTAA
TGCTCAATTTCGCCCTAGTTTACCGGCAΆCTCCTAATGGTTCCGTTCCC
CAGTCGAATCCGTTGTACGATACCACTGGTCTTAACGGAGGACAATACC
CTGTTGTTCAAAΆCTCTGCTCAACCATTGCTTCACGAGATAAATTTTGC
TTCAAACΆGAAATCCACATCTCAAACAAGGAGGAGCΆGTACCTTCTTCT
ACCCTTCCTCAACAACAGAAΆTCTTTAGACAAACCTAAACCTGCTCAAC
AGCCTTCAACTGGGCAATTTTCTGGAAATCAAATGAACCAATACGGATT
CTCTAATTCTCCTTACTCTCAAAATATGCTATATAATTTTAACGGAAAC
GCAAACCCCAGTCGTCTAAACCCAGCTCTCAΆGAΆTTATΆTGGAGGAGT
TAAAGCTACTAGAACAACAGAATAAAAAGAGGCTTCTGTTAGTTAGTCA
GGAAAAAGAAAGAAAAGGGTΆCACATCGGCATCGCCTGATAGACCGCTT
TCTCAGACTATTACTGAATCTAGTGTTGCAAAAACCAAAAGCACTACTC
CTAAATCTACTGACACTCCTACAGAAGCCACCACATCTCCTGTAAAGGT
CTCAACAAAAAATAGTAATACTACTGAAAATCTTAATGGCATCAATGAG
TCAAATΆTGCCTATGTTACAAAΆTGGTCTTCCTTTACGTACATCAGGTG
ΆTCATCCATCΆAACTATTCTAATCTGATTGAAAΆCTCATCTACCTCTGA
CACAAATAATGCGGACAATGGAATGGACGTTATGGGGAATTGGCAATTA
CAACAAACTCATTCATCGCGACCCACTCCAAATGCCΆGTTCTCCATTGG
ΆCGTTCGATCAAAACAAAAGCCTTCTTCTGCTΆΆTTCAAATGCTCCAAC
TCCAGCACCGACCGTCAACACTACCAΆCCCCGAATCATCAACAAATGAA
GCAACAAGTGTAGGTCCTGCTTTGGAACCATCGCAAGGAGCAAATGTTC
ACAAATCCGATTCTGAGTTGGATAΆTCAAAATCAGTCAGGAAAATCAAA
TCCTGATACTTCCGCGACTCCTTCTGCACCTACGGAGTCTACCACAGTT
GCCACTAAATCTTCAGACAATCAATTATTGGATGTTGGAAATTCAACAG
ACATCGATGCGGCTCTTCTAΆATGATTTTGACTTCGACAAATTTTTAAA
AGATACTAGTACTGGTGACGATTTATGGTTTGGATTGTTTAATTTGCCG
GATAATGAAGACTCGACTGCTGCTTAA
Hypothetical ATGTTTGGCAACAATTTCGCTGGCATGTTTGGCCAGCAACAACCCCAGC 50 protein CTAACCCTACTGGTGGCGCTACCGGCACCATGGACGCCAACAACATGAC
UM04381.1; CAGCATCAACCCCGCCATGTTTGGCGGCCTCGACCTCACCACCCTCCAG
Ustilago AACAATCCACAGCTAGCTGCTGCGCTGTTACAACAACAGCAGCAACAAC maydis; AACAACAACAACAACAACAACAGCAGCAGGCTTCGCAACCAAACACTCC
AACP01000154; TCAACAGCCGCGCTTTAACCCGGCCATGTTGAATTCTGCCATGATGGGC
33302112 CTGGATCAGAACAATCAGGCGTCTGGTGGTATCAACATGCAAGCTCTCC
AGCGCGCTGCTGCAGCTGGCGTCAATAATCCCACGGCCTCCTTCAATCC
GCAGATGCTTTTGCAACAACAACAACAACAACAACAACAACAACAACAA
CAACAGCAGCAGCAGCAGCAGCACCAGCAACGCCAAGGCACACCGCAGC
AGCAACAGCCAGGCCAAGTGTCGCGGTGGCCACAACAGCAACAGCAACA
GCAACAGCAACAACAACAACAACCGCAGCAACAGATGCAACAGAATCTG
CTCACACAGCTGCAGAACAACGGAGGTGCCATGTTCAACAACAACAΆCA
ACAACAACAACAACAACAACAACAACAACAACAACAGCAACAACAACAT
CTTTGGTCAGATGGGTGGTATGGGGCATCCACAACAGCAACAGCAACAA
CAACΆACAATCTCAACAGCAGCAGTTTGGTGCCAGCCAATTCAATCCCG
CTGCCTTTGGTCTCAATCCGCAGACTATGGCCTTTTTCCAGCAGAACCC
CATGCAGGCTATGCAAGCAATGCAGACGTTTGGTCAGCTCAATCCTGGT
GCTTTCCCCCCGGGTGCTTTCAACCAACTCATGATGCAACAGCTTCAGC
AGTCCCAAAACCTGTCCGGCGGCTCAAATCAGCCAACTCAAGTCCCCAA
CATGTTTCAGCAGGCTCAAAATGGCAACATGGCTGGCATGCTCGATCCA GCTGCCTTGATGGCGGGTGCATCCAACCCACAACAGCAGCTAGCTATGT
TTGGTGGCGCTGCTCCCGTTCCTGGCTCCTCGCCAGTCCGACCCAACTT
GGCGCTTCAACAACAGCAGCCGCCAAACAGTCTTCCCTCGTATCTGCAG
GCCAACAΆCCAGAACCTGAATCΆGCCCGGTCAATCTTCGCCCGTCGCAA
CACATCAGCAGCCCGGAACGCCTCAGAACAATTCCAGCAACGGTACCGT
TCCTTCCACCCCTACAGCCACCACCAAGCCCAAGCCGCCACGCAAGAAA
GCCGAAAAAAAGTCCACCGCCAAATCGCAGCAAAACCAAAACCAGACAC
CAGTCATGCAACACGCCAATGCTCCTGGTACCACCAGCATGCACCCCTC
TCCCAGCGCTTCATCCGTGACTGGTATGCCGGGTCCCTCACTCCCAGGC
AGCGCTTTCGAACGCTCACGCAGCCATACCCGCTCTCCCAGCGTCTCCT
TGGGCGGTCAAGGAACGCCATCACAGGTACATTCATTGCCTCCCGCCGT
CCAAGCCATGTCACAGCAΆCAACAGCATCAGCAACATCAGCAGCAGCAG
CAGCAGCAGCAGCAGCAGCCACCGCCGATACCGCAACAGCAGCAGGTGG
TCCCGCCTAATTGGATGCCGAGTCTCAATCCGCAACAGCAGCAAGCCGT
CTTGTCCCGAGCGCTGACTCTTGCAAAGGCGCAGGAAGGCTCTGGTTTA
ACACCCGTTCATACACTTATGCΆGATGGGCTACTTGTTCCTCAAGGCTT
CCAGCTTGCCAGGCGGCTCACATCCGTCCATGATGCCCAACGGTGGTAT
GGTGCTCACCATTAATGAGGCGCGCGGACTCAACCTCATCCCTCAGCAA
GGCTCTCAATCAGGACAAACAGGCGCCATGGCACAGCAACATCATCAGC
ATCAGCACCAGCACCAGCAACAGCCTCAGCCTCAGCGGCAGCCTTCCTT
CTCCGGTATGGCGAGCCAGCAACCACAGCAACCACTTGCACCATCACAG
CAGCCACTCGGCTTTGGAGCTCCTCCATTGACGCCGCAGCAGCAACAAC
AACAGCAAATCATGCTCGCCATGCAGCAACAGCAGCAGCACATGCACCC
ACAGTCTATGCACCAACCGCAGGCTCCTCTCGTCGCACCGCAGCTTGGC
CATCCCCACGGCCAGCGATCTACCACGCCAGCAGGTCAGCACGCTTCTC
CCTCGGCCATACATGCGCCTTCACCTATGGGCCCAGCAGGCGCCGTCTC
GAGCCCTGGTATGGCCAΆCAAGTCCCGTCCACGCCAGCCAAGTCTCGCC
CTCAGTACΆTCCAGCCGTCCAGACTCGCGTGGAGGGCTGGCGCCGCCTC
CTTTCCAGCAACAGCCΆCAGCAACAACAGCACCATCAGCCAΆCAGCAGG
CCCTCAAGGTCTGATGGCACCGCCGCCCGCTCCTGGCCACATGCCTCCA
GCTATGGCACCGGGTATGGGCGCCATGCCCCAGGGCATGGTTCCTCCAG
GTGTGCAGGGTGGCCAGCTGCCTCCGGGCTTTGGACCAGCTGGTGCGCC
TCAGATGGGTCCAGATGCGACACCGCCCATGCTCAAGCAGCAAGCACGA
CACCCATCTATGGCGCAGGATCCGTCGCTCGTTGCTACTCCGGAGCACC
CCCGGCCATCGTTGGCTGGCACGGCTGCTTCCAGCATGGACGGCGTTGC
TACCACGACACCGGATCCCATGATGTTGGCCGTAGCΆAGCGCTGCCGCT
GGTCAACCATCGGCTCAATCGCAGCTGATGGGCAGCTTTAGCAGCGCAA
CACCCACACGCAAAGCTCGCAAGGGCTCTCAGCCTGCTCCGACCGGTAC
GCCAGGTGCTGTGTGTACACCTGGCGATGGTGACACACCCGCGCTCTCC
GATGCAGCCGTAGACGCTACGACGGCGACTGGCAAGCCCACAACACTGG
CCGCCAACACTCCCGCTTTCATCCAAACCGTGCCTTCCAACTTGGCCAA
CATGCCCATGCTGCTTGGTGGACCAGCGCCGAAAGAGTCGGCGATCGGT
ACGTCTATTACTCACTTCAATACGCGTGTCACCAAGCTCGACGACGCGA
TGCGTCCTCAGCGTGCAGCCGAAGACGAGGGCGGTGCAGGTTCAAGCCA
AGTCGACAAGGAGGATGGCGATCAAGTGTGGACGCCACTCACGGCGGAA
CAΆGAGGCGGAGCTGGCCAGCATCATGAGGCGCGATCTCGAGTACGAAA
AGCTCTTCCGACAGCAGCAGCAAGAGATGGAAACGTCGCTCAGGCACCG
TATCGACAGCGTAAGGCCGCCACGAAGAΆAGGCGTCAGATGGCAGCATC
ACCAAGCCCAAACCTCTGGCGTGGTGGGAGCGTCCCGAGGAGGAGGATA
CGTCGGGTCTGTCGCGCGATGTGTTCAGACCTTTCGGCGTGCTCTTCCC
GAACCAGAAGCGAGCTGAGCTCGAACAGGGTCAGCGCGGTGCTCGTCCT
CACATTCCTCTGAAGCGCTCGCTCATGGAAATGGTCTCGCAGCAGGGTG
AAGATTTGGTCCCCATTCGCCTCGAGATTGACCACGAGCACTGGAAGTT
GCGCGACACTTTCACGTGGAACGCTCAAGACTCGCACATCAATGTCGAG
GCATTTGCCCAGTCGATTTGCGAGGACATCGGACTGCCTGCGTCCGTGT
TTGTGCCGCAGATCAAAGAGCAAATCACCGCACAGATCCTGGATCACCA GAGCACCAGCGCATTCAAAGCCAAGCCTACGTTTGATTTAAΆCATCGAC
ACCAΆGGAGGGCAAGGGATCGCTCGACGACCAGGACCTTCGCTGGTGGT
CCAAGTGGCGACGCAAAGTTGATCGTCTTCCTTTTGGCGCGGCTTCAGA
ACCACGCGCCAAAGGTGACGGTGACAATGCCGTGATGGAGGTGGACAAC
AGCAGCGAAGAGGACGAGGTGCGATCAGAACCGCCCGAGCTCGTCGACA
CGACTCCGGTCGAGGAACTGCGCATGATGATCAAACTCGATATCACCGT
AGGTGCCATGAATCTGATCGATCAGTTCGAATGGGATGCGAGCGAGTCG
GATCCCGCAGCTGCTGAΆAAGTTTGCCGAGGCCTTTGCCGCTGATCTGG
GCCTTTCGGGCGAGTTCAAAACGGCGATTGCCCATTCGATCCGCGAGCA
GGTCTCTGTACACGTCAAGTCGCTTGCCATGACCGGTCACACGTTTGAT
GGCCGAATGATTGCCGACGAAGAGCTGCGTGCCGCTTTCCTGGGACCTG
TCAGCAAGTCCAΆCTTGTCCAGAGGCGAGΆTCGAGTCGTATCACTTTAC
GCCTCGGCTGCTGCAGCTCACCGAGGCCGAGATCGAGCGACTGGATCGT
GAACGCGAGCGCGAAGCACGTCGAAAACGTCGACAGACGCGTGGTCGCC
GCGGTATCAATCTGCCGGACCGCGATCCTCAAAAGACGCAAAGAACGCC
AGCGGTGTACGGCATCCAGACGGCACAGACGGGTGCGGACAΆCGCTCTG
CAGAGTGTCAATGGTCTCAGCGACCGGTACGGAGGCATGTCAΆCACGGC
GTGCAGCAGCTGCAGCCGCCAACGCCTCAATTGCGCCCTCGCAGGCGGT
CGACATTAGCACGCCCACACCAGGCCCCGATGGACTTGGCCTGCCGGAT
CGCAΆGAAGCCAAAGATCAACCATCACGCGATCCACTTTGACTTTCCAG
GCGGTCTGGGTCGCAAATCGGATCCTGGTGGACCCAAGTTTGCGCCCGA
CTATATGGAAGAGGAGGCCAAGAAGCGTGCGCGTTCACCCGAGAACCAG
GCGACTGGCTCGCAGGTGGAAAAGCCTGCACCGAAGCTGGTCTCGCTGT
CGTATGCGCAGCGCAACAΆTGTGCGACCCGAAGATCTAGAGCGACAGCA
TCCCAACTTCCACGACGGCATGTGGCACTGCTCCAACTGCGGTATTCCA
GGAACGCTCGCGCCAGGTCGACGAAAGGGACCGTTGGGCGACAAGTCGC
TGTGTGGGCCTTGCGGTAAATACTACCACCGTCACCGCAAGGTCATCTT
TTTAGAGTACACGCGCGACCCGGTGGTGCACATGAAGCAGCAGCAGGCG
CTGAΆCCGCAAGATGGGCATTTCGAATCCGCTCATCGATACAGCGCTGC
TCAACGCGTTAGGAGAGCAGGAGGACTCGACCGAGCCTACAAGCGCTGC
GGATACGCCCAAGCCCGACGGCGGCGCTGGAGGCAATGACGATCCGACG
GGCACGGATGACAATGGGATGCGACGCAGAGGACGACCAGCGGCGTCAT
CGCGTGGAGCAΆGTCGTGGAAATGGTGGCGACGACGACGATCGCTCGGA
TGATGAGGATCTGCCGTTTGAGATGGTGGGCAGTCCGGACGATAGCGAC
TCTTCTTCGAGATCGAGCAGCGCTGAGCCCGCGCCTCGTTCGCGCAAGT
CGGCATCGCAGCCGTTGGCGAATGACGAAGGCTCGCAGATCGGGCGACG
CGCAGCCGCCGAGAGCGCACGCGACAAGGTGACGGCTTCATTTGCTGCT
GCTGAAGCTGCTGCGATCAAGACGGAGGCAGACACAGGAGTTGGAGCTA
GCGAAGCTGCCGATGCCAGCAAAGAGGCTGGCGATGCGGTTGCAGCAGC
GACTGCATCGACCGACGCTAACGCCTCTTGCACCAGCAGCACTGGCACT
GGCACTGGCACCAGCAACAGCAACAGCCACAGCGCAGTACCCGTCTCGA
TGACAGAAGTCACAGGCTCACCATCCACAAGTCGTGCAGCTGTCGTTAT
GCCCACGCTCTCCAATGCTTCGCCGCGCATGGCAGCCATCCCTGGCGCC
ACGCCGCCGGACTGGCTCACCGAATCAΆGCGCTGCACTGAAAGCGCGCT
ACCCGAACGACCGGTTCGAGATCCAGCAACGACCGCGTCCCGCTGGCGT
GCCGCCTCCACCACAGCCCGAGTGGCGAGTCCGATGTCTGGACTGTCCT
GGTAAGCTGTATACGCCCGGCCCAGGTGAGAGTCTGACCAACTTTGAGA
TCCACCTGCGCAACCGGTTGCACCGCGCCAACGTCAACAAGCGCGTGTA
TGGCAACAGTGCGCCACCGGCΆGTGGCTGCAGGTGGCGGATCTCCTGGT
GCTGCGGCTGGTTCGCCACACAAGAGTCCGAGCGTGGCTCATGCGCCTG
CGCCGTAG
UM05368; ATGAATCTGCCCCATCAGCCTCCGCGTGACGGCGGTGCTTCACAGCCAA 51 ϋstilago CAGCCTCAGAΆGTGACCCCATCGCCCTGGGAΆGGCGATCACATGCTGCA maydis; CATCTACGTCTGCGACTATCTGCGCAAACGCGGCTACGACCAGGCGGCG
XM_402983; CAGGCTCTCGGCTACGAAGCAGGCCTGGATCCGCAACGTCAΆGTCCCCA
49078465 TCGATGCACCTCAGAGTTTGCTCTTCGAATGGTGGCTCGTCTTTTGGGA AGTGTTTTCGTCCAGAACACGACAACTCGACACAGCTGCCTCGACCAGC
CTTTCCGCAGATGCTTACGCCTACTCGATCCAAAGACCTCCTGGTCTAG
CAGAGGCCAAAACTCCAGCCTCCTCCACTTCAGCCGTTCACAACGTGCC
ATCAGCTTTCACCACGGCCGCACCTCACACCCAAAGTCCTTTTTCGGCA
ACCGTCCAAAACACATCAGTCGCTΆCAAGAACTTCACCGACACGGCAAG
ACTGTTTGAACCAGCCAAATCATGCCTCAAACGCCTCGGCGCCTTTGCA
AGCTGGCGCATCTACACGCACΆTCGCCTCCGAGCCTGCACGTTCTACAA
CAGCAACAGCAACAACAGCAACAACAGCGAAGAGCTTCGTTGTCGACAA
TCCCGCAACTCGATCTCGAGGCAAGTCAGATGCTTGGTCTGACACGACC
CGCGAGCCGTGTTGTCATCCAGCAGTGCATGGACATGATGAACTTGGCT
CCCAAAGAGATCGACCAACTGACGGCGCAAGAGAAGCAAGCGCTTGCCA
AGCGTGTCACACGCCTGCAAAAGGCTCAGAACGATGCGCAGCTGCGGCT
CGCGCAGTTGCACGGTCTGCAGCCTCCAAΆGCCGCTCGTGCCTGCTTCG
CTTGCATCCATACAGACGCAGGCGCAATCACTGTCCGCGCAACTTCAGC
AGGACGGCGCATCGTCGGCCAGCGCACTTGCCAACCAGGCTCACGTCCG
ACGCAAGCGCAΆGGACCCCCCCAATCCAGACGCGGATCGCΆACAGGATA
GGCGCCACACCTGTAGCCACGCAGCCACACGATACCCGACAGATGCAGC
TACAGAAGGTTCGCTCGATGCGACGCGTCTCGTACCCTGCTCTTGCCGC
CGTACCCAGTGCGCCTTCCCCGCTCACGCCGACCAGCAGTGCGACACTT
GCTGGCATTCTGCCGTTCTCGCAAGCATCTCCTCACCCTATGGTGCAGC
ACAGTCCAGCATCGAGCGCTCCCACACCATCCACCCATCCGACCAACCT
GCATGTGCGTCATCCTTCGGTATTGGGTGCCGAACCAGCCGTATTGCAA
GCCCCCAGTCCGCAAAAAGTGTTTATGCACGCTTCTGGTCTCGCCTCGG
TCTCGCCATTTCCAGCGTCATCTGCCAGCCCTCTGGATGAGTGGCACTC
TTTCGACGCGCAGCAGCAACAACGCTTCGCGCCACCATTGCAGCAGCAG
CCACAACGTCCCGTCGTCATGGCGAGCAGTGTGGACCAGCCTACATTTC
AGCCTCAGCCTCAGCCTCAGCCTCAGCCTCAACCTCAACCTCAACCTCA
GCCCGTCATGCTGGATGCAACACGATATCCGCATTCCGGCTTTCCTCAA
GTGTTCTCTGGTCTGCCTTCAGTAGCAGCAAGTGCAAGACCGCCAACTC
ATGCTGTTGGACTCAAAGACACCGCAGCAGCACCGCTGTCGATGCGTCA
GCTCGGCCTGTCAGCGCAGCCCAAACCGTCCGTGTTCGCCAATATCGCC
ACGGGCGGCGATATCAACCCAGCAACAGCCGCTATGGCGTTCAACGGTA
TACCAATAATGCACCATTCAGATCCAGGTGCACCCCTGGCACCTTTCGC
AGACCTCGAGTACGATCTCAACGCCCTGCTGTCCAACACGACTTAG unnamed ATGATGGACCCGCGGCAAGAGACGTGCGGAGACATTGTGTCGACGCGTA 52 protein AΆCGTCGGCTTGAAGAGCTATACTACGTCTCCTTGCACCCTCGGTACCC product; CCAAGGTCTGGATGCCAAACAGAAACTGAAGCAGTTCCAGGACCAGTTC
Yarrowia GACCTGACACAAAACCGACTTTTCGACGAAAACAAATTACCAAAGGCGG lipolytica; TCGAAGAGCCCAAGCCAGTGCCGACCCTTCAAACCTCGACACCTGATGC
CR382130; AGGCTCTTCTCCAGAGTTGAAGCGACGACGTACGTCTAGTATTGCGCAA
49648093 CTGTCACCTACATTCTCACGCACATCACTCAAAACAAACGAGCAGCAAC
TGCAGGAAATGCTGCTGTTTCTGGTGCCCAGCAACATCCCCGAACCCAC
CACAGAAACCAAGTCGCTCGCTGAGCTATACTACACCACACAGACCCTA
CCACTGTCCAAGCTTATTCCGTCGGCGCACAAAACACTTACCACAGACT
CCTACCATCTGGCGTTGCTGGAGGGCAAGCTTGCAGTAGCACATGCTCG
TATAGAGGAGCTGAAGCGGGCAGGGAAATGGGGCCCCAGGCAGCCAAAG
CGGTTCCAGGACCCTATCCGACGGAAAACACACTGGGACCATGTGTTAG
ATGAAATGGAGTGGATGTCTACGGATTTCCGGGAGGAGAGAAAATTCAA
GCAGGCGATGGCTTGTGAAATTGCCTTTTCCGTGCTGGAGTACCACAAG
TACGGTAAGGΆAGCTTGTTGTGTGAAGACGAAGCCTATCAAGTTCCTAC
CAGAGGAAATTAΆCGAGTCTGAΆGATACAGAGAGCAAGATGGACATTGA
TACAAGCATGCCACCACCAAGTATCAACCCTGTTGAGGTGACAΆACATC
TCAGCAGCGGATTCTGTCACTGTTGTTGACTACGΆTACTCTCCTCTCAC
AACCCAGGACACTGTCATCGACTGAGGAGTCTGAAGACAAGCCGGAAGA
GCCTTCTACAGACAGTGAAGAGGTCGTCGGTGGGGAGGTGCCCAAGCGA
CCTGCTGCTCCTAAACTTCCTGAGAGCTCTCCGTTCAAGCTGTACGCCT CAGTGGACAAGCTGGACCCTCTATCCAAGGCTCTCTTTGACAACCTCCC TGTCACTACACCTCCTGGTTCTGCCGTTAATGCTCTACAGGTTCCCTAC
AGCGΆTCCTCTGGACAACTCAAAACTCGCACCTGTCACGCATCTTCTAG
CGGCTCCCCCGGAGCAΆGATGATTGGTGGTCGGTATGTCTTGAAGACTC
TCCTGCCGATGAGGACCCTCTCCCTCTACGΆTCTAACACTCGTTCTACA
CTGTTCAATTCGGAGACCATGCGCCGACATGTCGTCATTAAGGCGCCGC
AGCCTCCACAGACCAΆGTACCTCGACTTCCGAACGCCAACAATGTGGTT
ATTGGCTGATGATTCΆCAGCTTCTTCGACTGGTCAΆGGAGTATTCCTAC
AACTGGGACATTGTGTCTGCCCACΆTGCTGCCCCAAAAAACTTACGGCT
TCACAGCTAACATTGAGAGACGTACGTCATGGCAGTGCTTCGAGCGTTG
GTTCCAGCTCAATCCGACGTTTTCTCTGACGGATTTGCGTGGTCCCTAC
GCTCAGGCTGCCCAGCAATGGATGGCCGCTGCTGCCAAAGCCCAGGCTC
AGTCCAAGCGTCGCATCTCGCCTCTTGGTGTGTCGAATGAGTCTΆTCCA
GAGAGGTCACCGGAAGCTGCGATGGGCTTCCATGTTTGACGGTATTCGA
AAGAGCATGCGAAAACGAGAAACTACCCCCCGACCTAACCCTCAGCCGC
CTCGAAAGTCGCAGCTATCCGAGTCCAACAAGAΆAGATATTGCTTCGCC
TCTGGATCTGTGCAAGATGAAGTTTGAGCAGGATAAGAATCTCGCCAAG
GCTTACGCTCAGCAGCGGATGATGCCTGGTCAGATGCCTGGTCAGATGC
CCCCGGTACCTTCTAACATTCCTGCTAACCGTCAGTTCCCCGGTCAACG
ACCTCCTCCTCCTCAGACCGCGGCTCAAATTCAGGCACACACGCAGGCA
CAGGCTCGAGCTGCTGCTGCCGCCTCTGGACATATGCAGCAGCGTATGG
CTGGTGTGGGCATGAACAGAΆTGCCTGGCCAGATGAACGACCAGCACCA
GATGATGCAGTTTGATCGACAGCGGCAGCTCATGGAGCAGCAGAAGATG
CTGCAACAΆCAGCAGCAGCAGCAGTTTATGCGAACCCAGGGACAGGTGC
CTCCTCAGCCAGGCCAGGTGCAGGGACAGGTGAΆCCAGAACGTCCAGGG
CGCTCAGGTGGCTGCCGGTCAGGCTGGTATGGCTCAGAGACCGGCCGGC
CAGATACCTCAGGGCCAGATGCCTGCTCAACAGGGACAGGTTCCTCCTG
GCCAAGCTGGAAACCAGGCCCAGATGATGCGTCCCAΆCATGCGAATGCG
ACCCGGAGGTCCCCAGGCAGCTGCCCCCAACGAGCATCTGAATGCTCTA
ATTCGCCAGTTGCAGAACCAΆAACCCTGCTTTGTCTCTGGAGGCCGCCA
CCAAGCTGGCGCATGTGCAGGTGCAGCGGTTTGTCCAGAΆGCAGCAGCG
AGTAGCTCGTCAGGCTCAGGGACAGACTCCTCCTCAGGGACAGATGCGT
CCTGGACAGCCCCAGGGACAACCCTCTCCTCAGATGCGTTCGGGTTCTT
CGACTCCCATGAACATGCAATCGCCACAΆCTGATGAACGTACAGCTCCA
ACAGCAΆCAGCAGCAACGGTCTGCTTCACCAGGTCAGΆGCCCCGCCCAG
CAGCACGCCATGCTTATGCGAΆTGAACCAGCAGCAGCAGCAGCAGCAGC
AGCAGCAGCAGAACCAGGGACAGACCCAGGGACAAAACCAAGGACAAGG
TCCATCCGAGTAA
Table 5. Amino acid sequences of C. albicans gene products that regulate hyphal growth.
Figure imgf000065_0001
HYETPRSKQLIALKENASNPNRQSQLQKDQGQTSQQSNQDLKNASGVPN APMFQSTTGTAAAR
CDC24; MEHPPAALRTFSTQSTSSLNSVSTVSSSRIVSSGPVNINNFNKPSTPKD 54
AAO25556; HLFYRCESLKRKLQKIPGMEPFLNQAFNQAEQLSEQQALALAQERSNGN
28192690 GHSNGKRHQSLDGAMNRLSVGSDSSSIQGSLTRMATNASTSSLISGMPN NNTLFTFTAGVLPANISVDPATHLWKLFQQGAPFCVLINHILPDSQIPV VSSDDLRICKKSVYDFLIAVKTQLNFDDENMFTISNVFSDNAQDLIKII DVINKLLAΞYSDASDSGGGDEDVNMDVQITDERSKVFREIIETERKYVQ DLELMCKYRQDLIEAENLSSEQIHLLFPNLNEIIDFQRRFLNGLECNIN VPIRYQRIGSVFIHASLGPFNAYEPWTIGQLTAIDLINKEAANLKKSSS LLDPGFELQSYILKPIQRLCKYPLLLKELIKTSPEYSKQDPHGSSSSTS FNELLVAKTAMKELANQVNEAQRRAENIEHLΞKLKERVGNWRGFNLDAQ GELLFHGQVGVKDAENEKEYVAYLFEKIVFFFTEIDDNKKSDKQEKKSK
FSTRKRSTSSNLSSSTTNLLESINNSRKDNTLPLELKGRVYISEIYNIS APNTPGSTLIISWSGRKESGSFTLRYRSEEARNQWEKCLRDLKTNEMNK QIHKKLRDSDSSFNTDDSAIYDYTGISTSPVNQSTQQQYYDHRGSHSSR HHSSSSTLSMMKNNRVKSGDLSRISSTSTTLDSFSNNLNGSPNTTNPSL MSSDATKTIPTFDVAIKLLYKSTELSEPLIVNAQIEYNDLLQKIISQII TSNLVADDVNISRLRYKDDEGDFVNLNSDDDWGLVLDMLTSEDFYQTSS NEKRSVTVWVS
CHK2; MSMNFFNSSEPARDHKPDQEKETVMTTEHYEFΞRPDVKAIRNFKFFRSD 55 AAC39451; ETETKKGPNLHISDLSPLΞSQSVPPSALSLNHSIIPDQYERRQDTPDPI 29S1066 HTPEISLSDYLYDQTLSPQGFDNSRENFNIHKTIASLFEDNSSWSQES
TDDTKTTLSSETCDSFSLNNASYLTNINFVQNHLQYLSQNVLGNRTSNS
LPPSSSSQIDFDASNLTPDSIPGYILNKKLGSVHQSTDSVYNAIKIPQN
EEYNCCTKASASQNPTNLNSKVIVRLSPNIFQNLSLSRFLNEWYILSGK
HSSKEHQIWSNESLTNEYVQDKTIPTFDKESARFRPTLPINIPGILYPQ
EIINFCVNSHDYPLEHPSQSTDQKRFAMVYQDNDYKTFKELSMFTLHEL
QTRQGSYSSNESRRKSSSGFNIGVNATTTEAGSLESFSNLMQNHHLGAT
STNGDPFHSKLAKFEYGVSKSPMKLIEILTDIMRWETISVIHELGFVH
NGLTSSNLLKSEKNVRDIKITGWGFAFSFTENCSQGYRNKHLAQVQDLI
PYMAPEVLAITNSWDYRSDFYSLGVIMYELVLGILPFKNSNPQKLIRM
HTFENPIAPSALAPGWISEKLSGVIMKLLEKHPHNRYTDCHSLLHDLIE
VKNMYISKLLDSGETIPNSNLNLSDRQYYLTKENLLHPEKMGITPVLGL
KESFIGRRDFLQNVTΞVYNNSKNGIDLLFISGESGRGKTIILQDLRAAA
VLKQDFYYSWKFSFFGADTHVYRFLVEGVQKIITQILNSSEEIQNTWRD
VILTHIPIDLSILFYLIPELKVLLGKKYTSIYKHKIGMGMLKRSFKEDQ
TSRLEIKLRQILKEFFKLVAKQGLSIFLDDVQWCSEESWRLLCDVLDFD
SSGEVRESYNIKIWCYALNADHLENVNIEHKKISFCRYAKQSHLNLRE
FSIPHIPLEDAIEFLCEPYTRSHDHECNSKKSDVIANLNCTNEYPQNTC
KVIPSIIQELYQSSEGNVLLLIFLTRMTKLSGKVPFQRFSVKNSYLYDH
LSNSNYGTTRKEILTNYLNMGTNSDTRALLKVAΆLISNGSGFFFSDLIV
ATDLPMΆEAFQLLQICIHSRIIVPTSTYYKIPMDLIASDQTPFDLTDDN
IWKLATLCSYKFYHDSICTHIIKELNASGEFKELSRLCGLRFYNTITKE
RLLNIGGYLQMATHFRNSYEVAGPEENEKYVEVLVQAGRYAISTYNMKL
SQWFFNWGELVYNLDSKTQLKSVLTIAENHFNSREFEQCLSWENAQR
KFGFDRLIFSIQIVRCKIELGDYDEAHRIAIECLKELGVPLDDDDEYTS
ΞNSLETCLGKIPLSVADIRGILKIKRCKNSRTLLMYQLISELIVLFKLQ
GKDKVRRFLTAYAMSQIHTQGSSPYCAVILIDFAQSFVNETTTSGMLKA
KΞLSIVMLSLINRAPEISLSYVQSIYEYYFSCHAVFFESIEKMSDLIHP
GNASSHCTRSSYYSSFHLIVNVSKIFFSCMNGESFKMFSTFKCKSYLTG
DPQMPEMDNFLYDSΞMLLAGHSELNEFMRKYQSFNQTSVGKFCYYLIVL
LVMSREHRFDEAADLVLKVLEDLSEKLPVSFLHHQYYLICGKVFAYHQT
KTPESEEQVERILARQFERYELWASTNKPTLLPRYLLLSTYKQIRENHV
DKLEILDSFEEALQTAHKFHNVYDMCWINLECARWLISINQKRHRISRM
VKQGLKILRSLELNNHLRLAEFΞFDEYIEDΞDHRNKWAGLTNNPTLDTV
Figure imgf000067_0001
FETLKGLQHLHKKHIIHRDIKSDNVLLDAYGNVKITDFGFCAKLTDQRN KRATMVGTPYWMAPEWKQKEYDEKVDVWSLGIMTIEMIEGEPPYLNEE PLKALYL IATNGTPKLKKPELLSNS I KKFLS I CLCVDVRYRASTDELLE HSFIQHKSGKIEBLAPLLEWKKQQQKHQQHKQETSDTGFA
CRKl ; MSVIAGHHVPRSNDQRQYDTPSVPINIAPDSEGHIHEMSRLKDYEVIEK 58
AAD25159 ; LGQGTFGWQKAKSKKDGSLVAIKQLINHSAKEGFPITAMREITILKQL
4584846 NHKNILTIQDMIFEEPKMSNRTDIITMRGSFYTVTPYMSSDLVGLLENP
KIKLELGQIKCIMQQLLKGIQYVHNQKFLHRDIKAANILIGQDGVLKIA
DFGLARIYHGNVPRLGMGPGGGEKAYTGLWTRWYRPPEILLGERKYTT
AVDQRGIGCVFAELFTGKPILVGKSDSHQAQIVFELVGSPLTWTDAAKL
PNKNEYSCGLACKRSLEAKFASIMPTEAIDLLSGLLTLDPFKRLNALDA
LNHKFFSTDPLPLLPTQMPKFEESHEIDKERFKKLKDKEQAVSELKPPT
EIRYDNHSESRYNADHSTFGGGGVGGKETSFSSGKSDYIDHYΞPRARRD
HYEPRIRNDNKDSNDVRGEFESATRQEQRRRDIQNRLDAGGMDTYIPKT
TTGKLREHSGTESLSQKYDNYQPINVSRGSKSPSPSKLSSISQSKADLI
SKPSAPKVASRESSLERKQVSNGIRTTTDVEPPRARARRPTDMFGRPLT
SNSTQAQPTRNKSVERPKDLEKPTNGVTEDRNKKPVLEEKKEWKPNLA
IPKIKKSSSLVSLSSRSSTTPVISNPSKVTKRAASSVTPPVLPKKPKIS
KTSSESΞVSDLEEDSDFTGENATVFERFMALEQLQKSPVYKRIINEKMR
FEKLSGGHKSM
CYR1/CDC35; MSFLRRDKSKANFRDGSATGLEΞPVSPTTHFSPNVPPPLDGNHGDHYHD 59
CAB60230; PDSPRSSWSLPQLIHNSATHHLKENYRGFHANKRPKGIANVPPLAQPI
7009583 KPRFKKKSNSLLNKLIYSTKKEDDEAATSGKΞSRSSSIISDEKRKSASS
ASSGSSRQKFRFSSFDSNLSTSSSSPPKDKKVSVSDTVSDSSTVTASMS
NMPTISIDLNLDEMHDIIKSPETPTPTAGLPTQKAEKKASPTAIKNWQA
PESWDVKAPIKKEEPHAPKIEEVAENDVAIDNVLEKKRLPVLYGTHQVP
HVTNSKDIKSSHIIRVFKEDNTFTTILCPLETTTSELLAIVQKKFFLES
TTNFQLSVCIGNCVKVLEDFEKPLKIQMGLLLLSGYTEEDKLRMLGRED
LSFVCKFWENIFLRSLTHDEEVLLSRNYVDVNISSLNLKNVPIIFHQH
TYEIEKLNVANNPSIYLPLDFIQGCTSLAYVDFSHNGCSKFPNNLLEAP
QLTHLNLEMNFLDEIPQRISCLSNLTNLKLSSNQLYSLPHSFSTLTNLK
QLDLSSNYFDSYPEAVNKLTNLVELNFSYNDLSIIPΞSIANLINLQKLN
LCTNKLSGTLPGYLSQLKALKRLDIRYNYISNVDVLGIIPNLEVAYASK
NAISTFSDQMKCLRLLHFDRNPITELKFNTQMQMLSVLDLSRAKITAFP
AEFVEKVPNIEKLVLDKNHLVSLPNELCQLSKLVSLSVHANNLQSLPAN
IGDLRFLKYLDLHSNNLKSLPDQIWDLCHLTSLNVASNNLTSFPKAPYS
WKRLSSSLVDVHLESSQTLSLADSLLILILSDNRLSDDCFDEISFLIA
LKSLNVSYNDLIEIPQGTLSRLTRLNELYLSGNELTTLPADDLEVLKSL
KLLYMNNNKLVSLPAELSRIANLQHLDVSSNQLKYNISNWPYDWSWHWN
KNLKYLNFSGNKRFEIKQSHIKNPETGEDFDSLLVLKQLRVLGLIDVTL
TTTNVPEQAVDLRLRTTASΞFDNFGYGVSDSLGMRDHVSARDLFVQKFR
GKENEMLLCAFDGKHGATNQGHRISLVAKNMFVRNFTKELDEIKSDDEI
ENALRKAFLNFNKEINGILTAKKNKSFTPVPNMSKEALELNLVDDGNAG
CTVSVIYIKDKKLYSANIGDIEALLCRNNGDQFLLTEKHDPTNREEFER
IRASGGYVSGGGELDGQLSVSRGVGFFNFLPHTHCGPTIRRFKITNDDD
MIILGSKQLWDFISYESAVDIIRKDKNDPMVAAQKLRDFAICYGATDKI
CVIVLTFGNRQKQAANMYSNYGVDRRRRDKQQWGGDSNLRKLΞQEIEP
PIGPLALVFTDIKNSTLLWDSYPAPMRSAIKIHNTIMRRQLRITGGYEV
KTEGDAFMVAFPSPTAALLWCFQVQQNLVTADWPSEILETDQCCWSDS
ENNTIFRGLSVRMGIHWGSPVCEPDVITGRMDYFGPMVNRΆSRISAIAD
GGQIAVSSDFLDVLNSLTVKHNNIKNNVESLIDAYQGKFENAGMTIEREL
NALEDLGCNYFKIGERKLKGLETPEPITLVFTNRLKLRYDIFQKRLDAN
HSTRVAGTLPVEIIYGLRTVSLRLENLCSSINNGGNYCSEGFESSSGVI
SQKMNSSFKDSDLISLLNHVTTRIESCTTTLFLRQQLSQIKGNGGLIET
NNSPSLDVIMDEVADIMKTVNELK
EFGl; MSTYSIPYYNQMNGNYNNGMPQQTTAANQQAFPQQQQPTTTGNASQQQQ 60 CAA83640; QAAATAAAVQQPYNYMFYQQQGQPGQQTGQTAGQQQQQQQQQQQYDYNT 832907 YNRYQYPAΆTSQGNYYQQTIPNQLSQPQPQHYNGSNRNYTSΆPSGAPIP SNSTSGPSQQPPLPGQQAVPIPPHVSTMQQPTPVQDTLNASSTSTVGQF QPPGIRPRVTTTMWEDEKTLCYQVDANNVSVVRRADNNMINGTKLLNVA QMTRGRRDGILKSEKVRHWKIGSMHLKGVWIPFERALAMAQREQIVDM LYPLFVRDIKRVIQTGVTPNAAAATAAAAATATSASAPPPPPPPVAAAT TTAATAISKSSSGNGNSISATSGGSNVSGASGAGSTTSPVNTKAATAAG IPQGNYYQTYNQQQYPQQYGQYNAPGKNQNTPASQPGSTTNDQYLQQQQ QQQQQMYGYQSNYYQGGAANSSYYPNYYQQQQPNYASSYPYQQQQQKQQ QQQPNQQQQSDQQQTSTPSGGAGTRSVHQSPQVQSLTQGSVHPSPQQHQ ANQSASTVAKEEK
ERG24; MKSSKLNPVTTHKEFNGISGALGITIGLPTLTVLFYLLCNQTYSIHGIN 61
EAK91422; VDFAKIKSQLPITQDELWQLVFDKTCWSAYLAWFFILVILDYLLPGKSL
4S431903 NGVKLRDGTVLNYKINGLSMGSLLIVLLLARLFQSNSDSSLEYYLPELQ FIYDNQLQLIIICFLFSFMLAVFVYIISFIPLAKPNGIGTKΞRILSING NTGNPFYDWFIGRELNPRIGSWDIKLFCΞLRPGMLLWLLINLSCLHYQY HNLGYVTDSMIWNLLQAFYIFDGVLNEEGCLTMIDITTDGFGFMLSFG DLAWVPWTYSLQARYLSIKGNEVNLGWTLSLLIVGLQALGFYIFRSANK QKSDFRQGKLPHLKSIQTKTGSKLLVEGWWGLSQHINYLGDWLIGLSWC LPTGFQTPLTYFYVIYFASLLIHRQVRDEMKCRAKYGEDWEKYEKLVPY KIIPYVY
FAS2; MKPEIEQELSHTLLTELLAYQFASPVRWIETQDVFLKQHNTERIIEIGP 62
AAA34345; SPTLAGMΆNRTIKAKYESYDAALSLQRQVLCYSKDAKEIYYKPDPADLA
456443 PKETPKQEESTPSAPAAATPTPAAAAAPTPAPAPASAGPVESIPDEPVK
ANLLIHVLVAQKLKKPLDAVPMTKAIKDLVNGKSTVQNEILGDLGKEFG
STPΞKPEDTPLEELAEQFQDSFSGQLGKTSTSLIGRLMSSKMPGGFSIT
TARKYLESRFGLGAGRQDSVLLMALTNEPANRLGSEADAKTFFDGIAQK
YASSAGISLSSGAGSGAGAANSGGAWDSAALDALTAENKKLAKQQLEV
LARYLQSRLKQGSLKSFIKEKEASAVLQKELDLWEAEHGEFYAKGIQPT
FSALKSRTYDSYWNWARQDVLSMYFDIIFGKLTSVDRETINQCIQIMNR
ANPTLIKFMQYHIDHCPEYKGETYKLAKRLGQQLIDNCKQVLTEDPVYK
DVSRITGPKTKVSAKGNIEYEETQKDSVRKFEQYVYEMAQGGAMTKVSQ
PTIQEDLARVYKAISKQASKDSKLELQRVYEDLLKWESSKEIETEQLT
KDILQAATVPTTPTEEVDDPCTPSSDDEIASLPDKTSIIQPVSSTIPSQ
TIPFLHIQKKTKDGWEYNKKLSSLYLDGLESAAINGLTFKDKYVLVTGA
GAGSIGAEILQGLISGGAKVIVTTSRFSKKVTΞYYQNMYARYGAAGSTL
IWPFNQGSKQDVDALVQYIYDEPKKGGLGWDLDAIIPFAAIPENGNGL
DNIDSKSEFAHRIMLTNLLRLLGAVKSKKPTDTRPAQCILPLSPNHGTF
GFDGLYSΞSKISLETLFNRWYSEDWGSKLTVCGAVIGWTRGTGLMSANN
IIAEGIEKLGVRTFSQKEMAFNILGLLTPEIVQLCQEEPVMADLNGGLQ
FIDNLKDFTSKLRTDLLETADIRRAVSIESAIEQKWNGDNVDANYSKV
MVEPRANMKFDFPTLKSYDEIKQIAPELEGMLDLENWWTGFAEVGPW
GNSRTRWΞMEAYGEFSLEGAIEMAWIMGFIKYHNGNLQGKPYSGWVDAK
TQTPIDEKDIKSKYEEΞILEHSGIRLIEPELFNGYDPKKKQMIQEIWQ
HDLEPFECSKETAEQYKHEHGEKCEIFEIEESGEYTVRILKGATLYVPK
ALRFDRLVAGQIPTGWDARTYGIPΞDTISQVDPITLYVLVATVEALLSA
GITDPYEFYKYVHVSEVGNCSGSGMGGVSALRGMFKDRYADKPVQNDIL
QESFINTMSAWVNMLLLSSSGPIKTPVGACATAVESVDIGIETILSGKA
KWLVGGYDDFQEEGSYEFANMNATSNSIEEFKHGRTPKΞMSRPTTTTR
NGFMEAQGSGIQVIMTADLALKMGVPIHAVLAMTATATDKIGRSVPAPG
KGILTTAREHHGNLKYPSPLLNIKYRKRQLNKRLEQIKSWEETELSYLQ
EEAELAKΞEFGDEFSMHEFLKERTEEVYRESKRQVSDAKKQWGNSFYKS
DPRIAPLRGALAAFNLTIDDIGVASFHGTSTVANDKNESATINNMMKHL
GRSEGNPVFGVFQKYLTGHPKGAAGAWMLNGAIQILESGLVPGNRNADN
VDKLLEQYEYVLYPSRSIQTDGIKAVSVTSFGFGQKGAQAWVHPDYLF
AVLDRSTYEEYATKVSARNKKTYRYMHNAITRNTMFVAKDKAPYSDELE
Figure imgf000070_0001
Figure imgf000071_0001
PLDl; MSPTAEQPISPLDENPLDENVNNSKLKASSANDKEDGSYNLKAVQQDGT 69
BAA32278; IDDNDALRKSSDIDRIFRSVHSGPILPEHRSPSPNTRDDSSQVIGNPLS
3413518 FYYSNDDKESRYDEDRSQRQSLGKNKYPEDEQQLPNRFELVDDEDINKA
PPRKESSRPTHSRSATLSGFMQSRILGRSTSTNQEMPNTEPEPANLHDA
LHPREDSTKSGRFIKTLRRFNRRKTKDKRQSTMTAEFDELNDESΞNATI
ERAEKLLAGMSTGAPAINLMASCLLEDEHGITRAPLLLSVLGFKLSDVT
PKETSRNRRFRIDLEYGIDKHRMKWSIERNATDLAYLAYKLERTRIVSR
WGNKSQPLPRLPIPPIRKLDNKRSKKTKSVLSDSRARDDRMSVPDIND
NHSLSPVPSALSRVRSRLGSITSVGSLEKHPELLELRRKKNAQFMKDVE
SYLKELIEITELKTSANILFTFFELSPLSSLLSYESGYTGKQGPVHIGG
TAKAQGWRVGHFKVNDLKGIYERRVEKWMLVRNSYITYVSDINSTTPLD
VFLVDSDFKISARNLΞIANRDDDDSLFDNSSVAQQQMHENENKFFPHLK
ITLENRERKLVMSPKSQREHSLWIDSLRTMQNSTIWSQNKRFDSFAPVR
ENCFAQWFVDARDYFWAVSTALEMAKDTIMIHDWWLSPELYLRRPANGN
QQYRIDRLLQRKAKEGVKIFVIIYRNVGTTVATDSLYTKHSILSLDEEN
IHVIRSPNQLLQNTFFWAHHEKLCIIDHTYAFLGGIDLCYGRYDTPDHA
LTDDSGVDFSNIAQDDRITAENFANFQVFVGKDYSNPRVKDFSELEKPY
ESMYNRNIVPRMPWHDVHMYTCGQTARDLSRHFVQRWNYLIRQKRPSRL
TPLLLPPSDLTΞEEVLAHGLDGTCEVQLLRSSGNWSLGLKEHEQSIQNA
YLKLIETSEHFVYIΞNQFFVTACFIDGTEIKNRIGDALVDRIIRAHREG
TNWKAIIVIPLMPGFEAQVDEAEGSSVRVIMQCQYMSISRGETSIFAKL
RKKGIDPDQYIQFFSLRKWGRIGSNRTLVTEQLYIHAKTMIVDDRSVII
GSANINERSMRGLRDSEVAAWRDKEMVKSKMNGKPYMAAKFAHTLRMR
LMREHLGVNIDIVDWERRFKRFENFAASEEGKKFATNKFRNPENRTLS
AMVEIASRDILQQPΞGTRRWKEFIHVSKYDAEIAEVNFEEEDTSLPPPL
FLPISFNNRTGPFEANKGVRDSKKHSYDNRVQNSESHKKDVYGEGLDKY
RSKLAKRARVSSGKFLNELSLLAMETNPTGSFLPDFDSVRNFLESDDCH
MSGEMDDESEDIIAERNKERWMLLKKISYLQRLAAREKSMNDTENQKRA
KLGLPLLSKTGNAVNGNESQELPVSATLPISEGIDTDFSLDKEFPTVSL
SEPAARDIINNLTTPDAΆVSNFVDPYEFEDPIDPDFYEARWNEFARRNT
DIYRMVFHCQPDDWGRWSEYTHFTKLQSMFMKAQDTDTDQGQSAENYS
DEKVΈAGDNQEPRRANNSKLEKIDEASEDEYGLLGKAPPERGLENQNKS
EQETNLRΆKLSRRVSTFAGVTENRDKHFSDKAΆPKSEGELQGGEKTSTE
EEESEESGTPTDKPSATAGTVPASKTRKRARTYLARRKIQTGDWYDKN
SAERLLNAVQGHLVYFPAEWLSVELRNNNWFYNTDRLPPMEIYD
PMTl; MAKKPVTPASKVAAKQAAVRSRHQEDVFTLDPLIDPIFQKGELRSYLVT 70
AAC31119; EPSPSVLKKRSIHTKEYWMLSSLLLIAFYVRMYNLSNPNSWFDEVHFG
3411013 GFARKYILGTFFMDVHPPLAKMLFGΆVGAIGGFKGDFEFKSIGDKFPDS
TPYIFMRQFPALLGVGTVILCYLTLRQSGVRPIIAYITTFLLIIENSNV
TISRYILLDSPLIFFIAΆAIYAWKKFEIQIPFTFGWYRSLLATGIALGL
ALSSKWVGLFTVAWVGFLCIYQLWFLIGDLSVSTKKIWGHFFARGIILL
GVPIALYLGFFAIHFQLLNKEGDGGAFMSSAFRAGLQGNKIPRDITEQV
GLGSWTIRHVDTQGGYLHSHEHFYQTGSKQQQITLYPHLDSNNKWLIE
PYNGTIHNETFVPLINGMKIRLKHINTGRRLHSHDEKPPVSERDWQKEC
SCYGYDGFAGDANDDWWEIVNYRSQKGEAQTFVKAINTIFRLRHAMTG
HYLFSSEVKLPEWGFGQQEVTSASQGKRALTHWYIETNENSILPPSEAK
IINYPKLSLWQKWESHKRMWKINQGLTSHHHWQSSPSΞWPLLLRGINY
WNKEHKQVYLLGNAVTWWAATLSIITFGTYVLVTVFRWHLGTPLSTNKH
VFNFNVQTFSYVLGWALHYLPFFIMGRQLFLHHYLPALYFGILALGHFF
EIFTGYLTSRSKYFQQVAFVLVGLFSILSLVFYVNYSSLIYGTPWTKAS
CΞLTKPFSGWDYNCGTFFDTLGEYDIQEKSLASESEIPTETWVEAKQT
PKAEPKLAKQDDHIESPAAAEPVEΞKEVKEEVEQLAPPLAVDFEEETPK
VEDPQVADVDASSNDEKSVEEKQQQEQQQEQEQVEDESVHQVQQ
SLNl; MΞRDLTYNAPKIKFTDTEGQEEHFYFNRSNNSTNDLTSHDSSSTQLQDA 71
BAA19594; NSRRQAPPPPPHNPFSDNSHENSTESLYQSΞTRFHQPLLHNDSNNSNSS
1944426 IGMNRQRIPSQQHDTSSLYSASPISTSPLVSNFQSYSDNQDEMTRGKYN
Figure imgf000073_0001
KSYCFITYTTLRKNSNLILNLFQLMLDANIPDIQFDPSRVIEKVQEKFC LQMTEEEAILHFQNLINDSVNAFLPWIDRLHSLAQYWRA
Table 6. DNA sequences of C. albicans genes that regulate hyphal growth
Figure imgf000074_0001
CGATCCAAAGATTGTGTAAATACCCACTTTTGTTGAAAGAGTTAATCAAAACA
TCACCAGAATATTCAAAACAGGACCCCCATGGCAGCTCGTCATCGACATCATT
CAATGAATTATTGGTGGCTAAAACTGCAATGAAAGAATTGGCAAATCAAGTCA
ATGAGGCGCAAΆGACGAGCAGAΆAATATCGAACATTTGGAAAAACTAAAAGAA
AGAGTAGGTAATTGGCGTGGGTTTAATTTGGΆTGCTCAAGGAGAACTATTATT
CCACGGACAAGTTGGGGTTAAAGATGCTGAAAATGAAAAGGAATACGTTGCTT
ΆTCTTTTTGAAAAAATCGTATTTTTTTTCACAGAAATTGATGATAACAAAAΆA
TCTGATAAACAGGAAAAGAAGAGCΆAGTTTTCGACAAGAAAGAGATCAACTTC
ATCAAATCTTAGTTCATCGACTACTAΆTTTGTTGGAATCAATAAACAATTCCC
GAAAGGATAACACATTGCCATTGGAATTAAAGGGAAGAGTTTATATATCGGAG
ATTTATAACATTTCCGCACCAΆΆCACTCCTGGCTCAACTCTAATCATCTCATG
GTCAGGTAGAAAGGAAAGCGGCTCATTCACTTTGAGATATCGTAGTGAAGAAG
CCAGAAACCAATGGGAAAAGTGTTTACGTGATTTGAΆGACTAATGAAATGAΆT
AAACAAATTCATAAGAAGTTACGTGATTCCGACCTGTCATTTAATACTGATGA
CTCTGCCATATATGATTACACGGGTATTAGTACGTCACCAGTCAATCAATCAA
CTCAACAACAATACTATGATCATCGGGGCTCTCACAGTTCCCGCCATCACTCA
TCGTCATCCACTTTGAGTATGATGAAGAATAATAGAGTTAAATCTGGTGATTT
GAGTAGAATATCTTCAACTTCAACAACATTΆGATTCTTTCΆGTAACAACTTGA
ATGGGTCACCAAATACCACTAATCCATCTTTGATGTCTTCAGATGCCACCAAA
ACAATTCCAACATTTGACGTTGCAATTAAATTGCTTTACAAATCGACAGAATT
GTCAGAGCCATTGATTGTCAATGCACAAATTGAGTATAATGACCTTTTACAGA
AAATTATCTCCCAGATTATCACTTCGAACTTGGTGGCAGATGATGTCAATATT
AGTCGATTGAGΆTATAAΆGACGACGAAGGAGACTTTGTGAATTTGAATTCAGA
TGATGATTGGGGGTTAGTGCTTGATATGTTAACCAGTGAAGACTTTTACCAAA
CATCAAGCAATGAAAAACGACTGGTGACAGTGTGGGTTTCTTGA
CHK2; ATGTCTATGAACTTTTTTAATTCAAGCGAΆCCTGCAΆGGGACCACAAACCGGA 77 AFO13273; CCAGGAΆAAGGAAACAGTAATGACGACAGAACATTATGAATTTGAACGACCAG 2961065 ATGTCAAAGCTATACGAAATTTCAAΆTTCTTCAGGCTGGACGAAACAGAΆACC
AAAAAAGGACCAAACCTTCΆTATTTCGGATCTATCCCCTCTTGAATCACAATC
TGTGCCCCCTTCAGCCTTAΆGTTTAAATCATTCGATAATACCAGACCAATATG
AACGACGTCAGGATACACCGGATCCTATACACACTCCTGAAATTTCATTAAGT
GATTATTTATATGATCAGACATTGAGTCCCCAΆGGTTTTGACAATAGCCGTGA
AΆATTTCAΆCATCCACAAΆACAATCGCCAGTTTATTCGAAGATAACTCATCTG
TTGTATCACAAGAATCTACTGATGACACCAAGACAACATTATCACTGGAAACA
TGTGATAGCTTTTCATTGAATAACGCATCATATTTGACCAACATTAACTTTGT
GCAAAATCATTTACAATACCTTAGTCAAAATGTTTTGGGAAATCGCACTTCCA
ACAGCTTACCGCCATCATCATCATCACAGATAGACTTTGATGCCTCCAATTTG
ACACCCGATTCGATACCAGGGTACATTCTCAACAAGAAACTTGGCTCTGTTCA
TCAACTGACAGACCTGGTATACAACGCTATCAAGATTCCTCAAAACGAAGAAT
ACAΆCTGTTGCACTAAAGCTTCTGCTAGTCAAAATCCAACAAATTTGAATTCT
AAΆGTGATAGTGAGGCTATCACCTAATATTTTTCAAAACTTGTCACTTTCGCG
TTTTCTTAATGAGTGGTACATATTATCTGGGAAGCACAGTTCAAAAGAGCACC
AAATATGGTCCAATGAGTCTCTCACAAATGAATACGTACAAGACAAAACAATT
CCGACATTTGATAAAGAAAGTGCACGTTTTAGACCAACGTTGCCCATAAATAT
ACCAGGTATCTTGTACCCGCAAGAGATAATAAACTTTTGTGTGAACAGCCATG
ATTATCCACTTGAACACCCATCACAGTCCACTGATCAAAAAAGATTTGCCATG
GTGTACCAAGACAACGATTACAAGACATTCAAAGAACTCAGCATGTTCACTTT
GCACGAGCTACAAACTAGACAGGGGTCGTATTCGTCCAACGAGTCACGACGAA
AΆTCCAGCAGTGGCTTTAATATAGGTGTCAATGCAACCACCACTGAAGCTGGG
TCTTTGGAATCTTTTAGTAATCTAATGCAGAΆTCACCATCTTGGTGCAACTTC
AACCAACGGAGACCCATTTCACTCAAAACTAGCAAAGTTTGAGTATGGAGTTT
CCAAATCCCCTATGAAGCTTATAGAGATTTTGACTGATATAATGAGAGTTGTC
GΆGACAATAAGTGTTATTCATGAACTAGGATTTGTTCACAATGGCCTAACTAG
CAGCAATTTATTGAAGTCAGAGAΆAAATGTCAGAGATATAAAAATAACAGGAT
GGGGGTTTGCATTCAGTTTTACTGAAAATTGCAGCCAGGGTTACAGAAATAAA
CACTTGGCACAAGTCCAAGATTTAATACCTTACATGGCACCAGAGGTGTTGGC TATTACAAATTCGGTTGTGGATTATCGGTCGGACTTTTACTCGTTAGGGGTAA
TAATGTATGAGTTAGTTTTGGGTATTTTGCCATTCAAAAATAGCAACCCCCAG
AAATTGATCAGAATGCATACTTTTGAAAACCCΆATAGCTCCCAGTGCTCTAGC
ACCAGGTTGGATTTCAGAGAAATTGAGTGGCGTTATTATGAAATTGTTAGAGA
AGCACCCACATAACAGATACACCGACTGCCACTCATTGCTCCACGATTTAATT
GAAGTTAAAAATATGTACATTAGCAAATTATTGGATTCAGGGGAAACAATCCC
CAATΆGTAACCTAAATTTAAGTGATCGCCAGTΆCTATTTGACTAAAGAAAATT
TACTTCATCCCGAGAAAATGGGAATTACTCCTGTΆCTTGGGTTGAAΆGAAΆGT
TTTATTGGAAGAAGAGATTTCTTGCAAAATGTTACTGAAGTTTACAATAACAG
CAΆAAATGGGATTGATTTACTTTTTATATCCGGTGAAΆGCGGAAGAGGTAAAA
CGATAATΆTTACAΆGATCTTCGAGCAGCAGCAGTTTTGAAACAAGACTTTTAT
TACTCATGGAAGTTTAGTTTTTTTGGAGCAGATACACATGTGTACCGGTTTCT
TGTTGAAGGTGTTCAAAΆGATTATTACCCAGATTCTAAATTCTTCAGAAGAAA
TTCAAAATACATGGAGAGATGTGATTTTGACACACATTCCTATAGATCTAAGC
ATATTATTTTATTTGATTCCTGAGCTAAAAGTACTATTGGGGAAAAAATACAC
TTCCATTTACAAACATAAAATTGGAATGGGGATGCTAAAGAGAAGTTTCAAAG
AAGACCAAACACTGAGACTAGAGATTAAATTGAGACAAATACTAΆAAGAATTT
TTCAAACTTGTAGCGAAACAAGGCTTGTCTATTTTTTTAGATGATGTACAGTG
GTGTTCAGAAGAGTCCTGGAGGTTATTATGTGATGTATTAGATTTTGATTCAT
CTGGAGAGGTGCGAGAGAGCTATAACATCAAAATAGTTGTGTGCTATGCTTTG
AATGCAGACCATTTAGAGAATGTTAΆTATCGΆGCATΆAΆAAGATTTCTTTTTG
CCGATATGCCAAACAAAGCCACTTAAATTTGCGTGAGTTTAGTATACCTCATA
TCCCACTTGAAGACGCTATTGAATTTTTGTGTGAACCTTACACGΆGACTGCAC
GATCATGAATGTAACAGTAAAAAGTCTGATGTAATTGCCAATTTAAACTGCAC
AAATGAATATCCTCAGAACACTTGCAAAGTCATCCCCAGTATAΆTCCAAGAGT
TGTATCAATCATCAGAΆGGGAΆTGTTTTGCTTTTGATATTCCTAACAAGAATG
ACAAAGCTATCTGGCAAΆGTTCCCTTTCAACGATTTTCGGTCAAAAATTCΆTA
TCTATATGATCACCTACTGAATAGTAACTATGGAACTACAAGAAAAGAGATTC
TTACAAATTATTTGAATATGGGAACTAΆCTCAGACACAAGAGCCTTGCTTAAA
GTTGCAGCGTTAATCTCCAATGGATCGGGATTCTTTTTTTCAGATTTAATTGT
AGCCACCGACTTGCCCATGGCTGAAGCGTTTCAGTTGTTACAAATATGTATTC
ATTCCAGAATAATTGTTCCTACTAGCACATATTATAAAATACCTATGGATTTA
ATAGCCTCTGACCAGACTCCATTTGATTTAΆCAGATGATAATATTTGGAAACT
AGCCACTTTATGCAGCTACAAGTTCTATCATGATTCTATTTGTACTCATATAA
TCAAAGAATTAAACGCCAGTGGCGAATTCAAAGAACTTTCTCGGTTATGTGGG
TTGAGATTTTACAATACAATTACAAAAGAACGTTTATTAAATATTGGTGGCTA
TCTTCAAATGGCTACTCACTTTAGAAACTCATACGAGGTGGCAGGTCCCGAAG
AAAATGAAAAGTATGTTGAAGTTTTGGTCCAGGCAGGACGATATGCCATATCG
ACATATAATATGAAGTTGTCTCAATGGTTTTTCAATGTTGTTGGCGAATTGGT
ATATAΆTCTTGATTCGAAAACTCAGTTAAAΆTCCGTGTTAΆCAATAGCCGAGA
ATCATTTTAATTCTCGTGAATTTGAACAATGCCTΆAGTGTGGTTGAAAATGCA
CAGAGGAAATTTGGTTTTGACAGGTTGATATTTTCCATTCAAATAGTCCGTTG
CAAAATTGAATTAGGTGATTATGACGAAGCACATCGAATTGCAATTGAATGTC
TTAAGGAATTAGGTGTTCCATTAGATGACGATGACGAATATACAAGTGAAAAC
CTGCTTGAGACGTGTTTGGGAAAAATTCCGCTCTCTGTTGCTGACATTAGAGG
TATTTTGAAGATTAAAAGATGCAAGAATTCAAGAACATTGCTAATGTATCAGT
TAATTTCAGAGCTAATTGTACTATTCAΆGCTTCAAGGTAAAGACAAΆGTGAGA
AGGTTTCTCACAGCTTATGCGATGAGTCAΆATTCATACTCAAGGGTCTTCTCC
TTATTGTGCAGTAATTCTTATAGACTTTGCACAATCATTTGTCAACGAAACCA
CAACTTCAGGAATGCTTAAAGCAAAAGAACTCAGTΆTTGTCATGTTGTCATTG
ATTAATAGAGCACCAGAAATATCTTTATCATATGTTCAGTCTATTTATGAATA
TTATTTCAGTTGTCATGCTGTATTTTTTGAATCAATTGAΆAAΆATGCTGGATC
TTATACATCCAGGTAACGCTAGTTCCCATTGCΆCAAGΆCTGTCTTATTATTCA
TCTTTTCATTTGATAGTTAATGTTTCCAΆGATTTTCTTTTCATGTATGΆΆTGG
AGAAAGTTTCAAAATGTTCTCAACATTCAAGTGTAAATCCTATTTAACAGGGG
ATCCCCAAATGCCTGAAATGGACAΆTTTTTTATACGΆTAGTGΆAATGTTACTT GCTGGACATTCAGAATTGAATGAATTTATGAGAAAATATCAGTCATTCAACCA
AΆCTTCCGTTGGTAAATTTTGCTACTΆTTTAΆTTGTACTACTTGTAATGTCAC
GTGAACACAGATTTGACGAGGCTGCCGATTTGGTTTTGAAAGTTTTGGAAGAC
TTACTGGAAAAATTGCCTGTATCTTTTTTGCATCATCAATATTACTTAATATG
TGGTAAAGTGTTTGCTTATCACCAGACCAAAΆCCCCAGAAAGTGAGGAACAAG
TGGAACGTATTTTGGCTCGTCAATTTGAAAGATATGAATTGTGGGCACTGACG
AATAAGCCGACCCTTCTACCACGGTACTTGTTGTTGAGTACCTACAAACAGAT
TAGAGAAAACCATGTTGACAAGTTAGAAATACTAGATTCATTTGAGGAGGCGT
TACAGACGGCCCATAAATTTCATAATGTATATGATATGTGCTGGATCAATTTG
GAATGTGCAAGATGGTTAATTAGCATAAACCAAAAAAGGCACAGAATCTCAAG
AATGGTTAAACAAGGTCTTAAAATTTTGAGAAGCTTGGAATTAAATAATCATT
TAAGATTAGCTGAATTTGAATTTGATGAATACATTGAGGACGAAGATCACAGA
AATAAATGGGCAGGGTTAACTAATAΆTCCΆACATTGGATACTGTTACTACCTG
GCAACAACAGAACATGCCCGATAAGGTATCTCCATGCAATGACAAGCAGTTGG
TCCΆCGGAAAACAATTTGGCAAAAAAGAGTTTGATAGCCATTTGCTCAGATTG
CACTTTGATGGCCAATATACAGGCCTAGATTTGAATTCAGCTATTCGTGAATG
TCTAGCAATATCCGAAGCTTTAGACGAAAATTCCATTCTCACAAAGTTGATGG
CATCTGCCATCAAGTATTCAGGTGCCACATATGGGGTAATTGTCACGAAGAAA
AACCΆGGAGACACCTTTTCTTAGAACΆATTGGCTCGCAGCACAATATTCACAC
ATTAAACAACATGCCAATTTCCGACGACATTTGTCCTGCTCAGTTGATTCGTC
ATGTATTGCATACAGGAGAAACGGTGAACAAAGCTCATGATCACATAGGATTT
GCTAACΆAGTTTGAGAΆTGAATACTTTCAΆACAΆCAGATAAAAAGTATTCAGT
TGTGTGTTTGCCATTAAAGAGTCTGCTTGGATTATTTGGTGCACTTTATCTAG
AΆGGTAGTGATGGTGΆTTTTGGACATGAAGATTTGTTCAATGAAAGGAAATGT
GATTTGTTACAACTTTTTTGCACACAAGCAGCTGTGGCTTTGGGTAΆGGAGCG
TTTGCTTTTGCAAATGGAACTΆGCAAAAATGGCAGCAGAAGACGCCACTGATG
AAAΆAGCCAGTTTTTTGGCAAACATGTCACATGAAATACGAΆCCCCATTCAAT
TCGTTATTGTCATTTGCTATTTTTTTGTTAGATACCAAATTGGATTCTACTCA
AAGAGAATATGTCGAGGCAATTCAGAGCTCCGCAATGATAACGTTGAATATTA
TTGATGGGATACTTGCGTTTTCCAAAATTGAGCATGGATCCTTTACATTAGAA
AATGCCCCCTTTTCTTTGAATGATTGTATCGAGACTGCTATTCAAGTAAGTGG
GGAAACAATTTTGAATGACCAGATTGAGTTGGTGTTTTGTAACAATTGTCCAG
AGATTGAATTTGTGGTTGGTGATCTAΆCGAGGTTCAGACAAATTGTGATCAAT
TTGGTGGGTAATGCTATTAAGTTTACAACCAAAGGTCΆTGTTTTGATTTCTTG
TGATAGCCGAAAAATTACGGACGACAGATTTGAGATCAATGTGTCAGTTGAGG
ATTCAGGAATTGGAATTTCCAAAAAATCTCAAAATAAΆGTGTTTGGAGCΆTTT
TCTCAAGTAGATGGTTCCGCAAGACGΆGAΆTATGGTGGCTCTGGATTΆGGTTT
AGCTATATCAAAGAAATTGACTGAACTAATGGGTGGCACAATTAGATTTGAAA
GTGAGGAAGGGATTGGCACAACGTTTTATGTTAGCGTCATTATGGACGCAAAA
GAATACTCATCCCCGCCATTTAGTTTAAATAAAAAATGTTTGATTTACAGCCA
GCATTGTCTTACTGCCAAGTCAATTTCAAATATGCTTAATTATTTTGGATCAA
CAGTTAAAGTCACTAATCAGAAGTCTGAGTTTTCAACTTCCGTGCAAGCCAΆC
GACATCATTTTTGTTGATCGCGGAATGGAACCTGATGTTAGTTGCAAAACCAA
AATCATTCCCATCGACCCAAAΆCCTTTCAAΆΆGAAACAAACTCATTAGTATTC
TCAAAGAACAACCAAGTTTGCCCACCAAAGTGTTTGGAAACAACAAATCTAAT
TTATCAAAACAATACCCTCTAAGAATATTATTAGCAGAAGACAATCTTTTGAA
CTATAAAGTATGTTTGAΆGCATTTGGATAAATTGGGGTACAAGGCAGATCATG
CCAAAGATGGAGTAGTAGTTTTGGATAAATGTAAAGAACTACTAGAAAAAGAC
GAAAAATATGΆTGTCATATTGATGGATATTCAAATGCCTCGTAAGGACGGTAT
TACAGCTACAAGGGATTTGAAAACATTGTTTCACACACAAAAAAAGGAAAGTT
GGTTACCCGTGATCGTAGCATTGACAGCTAATGTTGCTGGAGACGACAAAAAG
AGGTGTCTAGAAGAGGGAATGTTTGATTTTATAACCAAACCCATTTTACCAGA
TGAACTTAGACGTATTTTAACAAAAGTAGGGGAAACAGTGAATATGTAA
CHS3; ATGTCTAATTTTAGAGATAGTTCTAGTCCTCGAAGAGGCTATTCAGAATTTGA 78
D13454; TCCTGAATCTGGTGAAGGTTTAGGAAGAAAGAAATCATTAATTAGACCAGAAA
218361 GATCAAGAATGGATGAAAGCCATCCACGATTCCATTATACTCAAGTTGCAAAT CAΆGAATCTAATCATATTAAAGTACAGCCATCTTCAΆCTGGTGTTGATCCTCG
TAAATCAΆATGAATTATCAACATCAAGATCACATTTGAGTAATTACGCTACTC
CACCACATCAAGAGGAAGAAGAAGACGAAGGGATCCCTTTAATGGATATΆCAC
AATGCTTCACCCAATGTTAGCAGTGACCAAAATAATGATCTAAAAGGTGGACG
TGAAGTTTATGGΆTTAAATGATGAAATCAACGATTATGGTΆGTTCACCCAAGA
AAAACCAAGTCATTTCATCTTCAAGACCAATGAACAACGAAAAACCAGCTAAA
CCTAAΆCATGATΆTATATTTCTGGAAAGTTTATTGTTATGCTATTACATTTTG
GGCACCAGCTCCATTATTGAAΆTTATTTGGATTACCAACΆΆAAGΆTCGTCAAT
TCGCTTGGAGAGAAΆAAATAGGGTTGATTTCTTGTATTCTTTACGTTGGGGCA
TTTGTTGCTTATTTGACTTTTGGTTTCACTAAΆΆCTGTTTGTTCGAGTCAAGT
GGTCAGΆACCCΆΆATTAATCATGTCAACGGAGGTTATTTGATTATCAATGGTA
GAGCTTATGATTTGACTTCGTCACAACATCCTAAAGCAGCTGGTATACAAGCA
GGTTCTAATGTTTTATATCCTCCCATGAΆTGCCGGTGGTAAAGACGCATCATT
TCTTTTCCAAAATGTTAATGGTAACTGTAAGGGTTTGATTAAΆCCAAGAGATA
ATTGTTCTATTCCCTACGATGGTGATGAATTGGCTTGGTATATGCCATGTCGT
CTTTTCAACCAΆGATGGTTCAACCAAACCAAATAACACATTTGCTTATTATAA
AGGTTGGGCATGTCATACTAGTGAGACCGCTCGTGATGCCTACTACAΆATTGA
AAGTCAATGGTGATGTTTATTTCACTTGGGATGATGTCAAGAΆTTCTTCAAGA
AACTTGGTAGTGTATTCTGGGAATGTGTTAGATTTGGATTTGATAAATTGGAT
TGAAACCGATGATGTTACTTATCCGGAATTATTTGACAAATTAAGAGATGATG
AAACTTATCGTGGATTGGATATATCTTTGGTTTTGACAAATTCTGAAGAACGA
CAΆGCAGCTAGATGTTTAΆCCGAAATCATCAAAGTTGGTTCTATTGATACAGA
TACTATTGGTTGTATTGCCTCTAAAGTTGTGTTGTATATGTCCTTGGTGTTTA
TTTTATCGGTTGTTGTCGTCAAATTTATTATGGCTTGTTGGTTTΆΆΆTGGGTC
ACTTCAAGAAAACAGGGGGCAACAATGTATGATTCCAAGGCTTGGGCCAAAAG
AAATAGAGAAATTGAAGACTGGGTCGATCATGATCACGGTATTGGTGCTGAAG
TTAAGACAGTGCCTGTGAΆAGCTΆGAGCCAATTATAAAGCAGCTAΆΆACTAAT
AGACAATCTGTTTTCCACAGAGCTCAAAAATTGTCATTGGGACCAAATGCCGA
TTTATCACAATATTATGATAATCCAAATGCTCTTTCCAAGACTTTTAAATATA
CCACTATGTCTACCCAAGCGGCATTGTTAGGACGTAΆCGGATATGGTAAACGT
GGTAATAATGCCAATAAAAGTGTTAGTGGAGGGTTTAATGGTAGACAATCCAA
TCTTTATTTAACTGATCAAGGTTCTTCCACTGATTTATTGAACCGTCCAGTGT
CTTCTTATAATCCATTTGATTCCATGGGTGATGATTCTATTGTCATTAATGGG
TTATCTCCAGATATTATTCACCCAGATGTTGTTCCTCAACCACCAGTCGAATA
CCAACCATTTGGATACCCATTAGCTCATACAATTAATTTGGTCACTTGTTATT
CTGAAGATGAAGAAGGTATTCGTATCACTTTAGATTCTATTGCCACCACCGAT
TACCCTAΆTTCTCATAAATTAATTCTTGTTATTTGTGATGGTATTATTAAAGG
TTCAGGTAATGATGAAACCACTCCTGATATTGTGTTGGATATGATGTCGGACT
TGACTGTGCCAAGAGATGAAGTTGAAGCTTATTCCTATGTTGCTGTTGCCCAA
GGTAGTAAACGTCATAATATGGCCAAAGTTTATGCTGGGTTTTATAAATATAA
CGATGAAACTGTGCCACCAGAAAAGCAΆCAACGTATTCCGATGATTACTATTG
TCAAATGTGGTACCCCTGAΆGAΆGCCAGTGCACCAΆAACCAGGTAATAGAGGT
AAGCGTGATTCACAAATCATTTTAATGTCATTTTTACAAAAAGTTGTTTTCGA
TGAAAGAATGACTAGTTTAGAATATGAAATGTTACAAAGTATTTGGAGAATCA
CGGGATTAATGGCAGΆATTCTATGAGATTGTATTGATGGTGGΆTGCTGATACA
AΆAGTTTTCCCTGATTCTTTAACTCATATGGTTGCTGAAATGGTGAAAGATCC
AACTATTATGGGATTATGTGGAGAAACAAAAATTTCTAACAAGGCGCAAACCT
GGGTTACAGCAATCCAAGTTTTTGAATATTATATTTCACATCATCAAGCCAΆG
GCGTTTGAATCGATTTTCGGTGGGGTTACTTGTTTACCTGGTTGTTTCTGTAT
GTATAGAATCAAGGCACCAAAGGGGTCCGATGGATATTGGGTGCCTATTTTGG
CAAATCCTGATATCGTGGAAAGATATTCTGATAATGTGGTTGATACTTTACAT
CGTAAGAATTTGTTATTATTGGGTGAAGATCGTTATCTTTCGTCATTGATGTT
GAGAACTTTCCCTACGAGAAAACAAGTGTTTGTTCCTAAAGCTGCTTGTAAGA
CTGTTGTCCCCGATAΆATTTAAΆGTGTTATTATCGCAΆCGTCGTCGTTGGATC
AΆTTCTΆCTGTGCACAATTTGTTTGAΆTTAGTTTTAGTTAΆAGATTTGTGTGG
TACTTTCTGTTTTTCTATGCAΆTTTGTTATTTTCATTGAATTGATTGGTACTT TGGTGTTACCAGCAGCCATTACATTTACTATTTATGTGATTATTGTTGCTATT
GTATCTAAACCAACTCCAGTTATGTCCTTGGTTTTΆTTAGCAGTTATTTTCGG
GTTACCTGGTTGTTTAATTGTCATTACTGTGTCATCCTTATCTTATCTTGTTT
ATTTTGTTATTTATCTTTTCGCATTACCAATTTGGAATTTTGTGTTΆCCAΆGT TATGCCTATTGGAAATTTGATGATTTCAGTTGGGGTGAAACAAGAΆCAGTTGC TGGTGGTGATAAAGGAGATCATAGTGCTGTTGAAGGTAAATTTGATTCATCAA AGATTGCCATGAAAAGATGGAGAGAATGGGAAΆGAGAΆCGTAGAAGTACTGAA AATAGAAAACΆGCAACAACAGCAACAATTGΆCAAACAATTCTAGTAΆTAATTT GGCTGTTCCTGGTGCTGCTTGGGATCCATCTAATΆCTGGAGGAAATTTGATTG ATGATTTAAGTCAΆGGATCTTCTTCAGGGTCCAGTTGA
CLA4; ATGACAAGTATTTATACATCAGATTTGAAAAACCATAGACGTGCGCCACCTCC 79
U87996; ACCAAATGGGGCAGCTGGCTCTGGCTCAGGTTCTGGCTCAGGTTCTGGTTCTG
2351701 GTTCTGGCAGTTTGGCTAΆTATTGTTACCAGTTCTAATAGTCTTGGCGTAACA
GCAAATCAAACCAAACCTATTCAΆTTAAATATAAATTCTAGCAAACGTCAATC
AGGTTGGGTTCATGTTAAAGATGATGGTATTTTCΆCATCATTTAGATGGAΆCΆ
AACGGTTTATGGTTATTAATGATAAAACTTTAAACTTTTATAAACAAGAACCA
TATTCTAGTGATGGTAΆTTCCAATTCTAATΆCCCCTGATTTATCATTCCCACT
ATATTTAATTAATAATATTAATTTGAAACCAAACTCCGGGTATAGCAΆAACTT
CΆCAATCATTTGΆAATTGTTCCCAAAAACAATAATAΆATCAATTTTGATTTCT
GTTAAAACCAATAATGATTATTTGGATTGGCTAGATGCATTCACCACAAAATG
TCCTTTAGTACAAATTGGTGAAAATAATAGTGGTGTATCAAGTAGTCACCCTC
ATTTACAAATTCAACATTTAACCAATGGTTCCTTGAACGGCAACTCATCTTCA
TCACCAACATCTGGATTATTΆTCTTCTTCΆGTGCTAACTGGAGGTAΆTTCTGG
CGTTTCTGGTCCTATTAATTTCACTCATAAAGTACACGTGGGATTTGΆTCCTG
CCAGTGGTAATTTTACTGGATTACCAGACACTTGGAAAAGTTTATTACAACAT
TCGAAAATCACTAATGAGGATTGGAAAAAAGATCCTGTTGCTGTTATTGAAGT
TTTAGAATTTTATTCCGATATAAATGGΆGGTAΆTTCAGCTGCTGGAACTCCAA
TTGGATCACCCATGATCAATTCCAAAACCAACAATAATAATAATGACCCTAAC
AATTACTCATCΆACCAAAAACAATGTCCAAGAGGCAAATTTACAAGAATGGGT
AAAACCTCCAGCΆAAATCTACTGTCTCACAΆTTCAAACCTAGTCGAGCTGCΆC
CAAAACCACCAACTCCATATCATTTGACACAACTAAATGGCTCTTCCCACCAA
CATACATCATCATCAGGCTCATTACCTAGTTCTGGTAATAATAATAATAATAA
CAGCACTAACAATAATAATACTAAAAACGTTTCACCATTGAATAATTTGATGA
ATAAATCTGAACTTATTCCTGCTAGAAGAGCTCCACCACCTCCAACAAGTGGC
ACATCTTCAGATACATATTCTAATAAGAATCATCAAGATAGΆTCTGGATATGA
ACAACAACGTCAACAACGTACTGACTCATCACAACAACAACAACAACAAAAGC
AACATCAATATCAACAGAAATCCCAACAACAACAACAACAACCACAΆCAΆCCA
TTATCTCTGCATCAAGGTGGGACTTCGCATATTCCGAAACAAGTACCTCCTAC
ATTACCATCATCTGGACCACCCACTCAGGCTGCTTCAGGAAAATCAATGCCAT
CTAAAATTCATCCTGATCTTAAGATTCAACAAGGCACAAATAATTATATTAAG
AGTAGCGGTACTGATGCTAATCAAGTCGATGGTGATGCTAAACAATTTATTAA
ACCATTTAATTTACAACTGAΆAAAGAGTCAGCAACAATTGGCATCAAAACAΆC
CGTCACCACCTTCATCTCAACAACAGCAACAAAAACCTATGACATCACATGGA
TTAATGGGTACATCACATTCAGTTACTAAACCATTGAATCCAGTCAATGATCC
AATCAAACCATTAAATTTGAAATCATCTAAATCCAAAGAAGCATTAAATGAAA
CTCTGGGGGTGCTGAAAACACCATCACCTACAGATAAATCAAATAAACCAACT
GCACCTGCTAGTGGTCCTGCAGTGACCAAAACAGCTAAACAACTCAAGAAGGA
ACGAGAAAGATTGAATGATTTACAAATCATTGCTAAATTGAAAACAGTGGTTA
ATAATCAAGATCCTAAACCATTATTTAGAATTGTTGAAAAAGCTGGTCAAGGT
GCTAGTGGGAATGTTTATTTGGCGGAAATGATCAAAGATAATAATCGAAAGAT
TGCGATTAAACAAATGGATCTTGATGCTCAACCCCGTAAΆGAGTTAATAΆTAA
ATGAAATCTTGGTTATGAAAGATAGTCAACATAAAAATATTGTTAATTTTTTG
GATTCTTATTTAATTGGTGATAATGAATTATGGGTAATTATGGAATATATGCA
AGGTGGTTCATTAACGGAAATCATTGAAΆATAATGATTTTAAATTGAATGAAA
AACAAATTGCCACTATATGTTTTGAAACCTTAAAGGGGTTACAACATTTACAT
AAAAAACATATTATTCATCGTGATATTAAATCCGATAΆTGTTTTATTAGATGC ATATGGTAATGTTAAAATCACTGATTTTGGATTTTGTGCTAAATTAACTGATC AAAGAAATAAΆCGTGCCACAATGGTGGGGACACCATATTGGΆTGGCACCTGAA GTGGTTAAACAAAAGGAATATGATGAAAAAGTTGATGTTTGGTCATTGGGGAT TATGACTATTGAAATGATTGAAGGAGΆACCACCTTATTTGAATGAAGAACCAT TAAAAGCTTTATATCTTATAGCTACTAATGGTACACCAAAΆTTGAΆAAAACCC GAATTATTATCGAATTCAATTAAAAΆΆTTCTTATCAATTTGTCTTTGTGTTGA TGTTAGATATCGTGCTAGTACTGATGAATTATTAGAACATTCATTTATTCAAC ATAAATCAGGGAAAATTGAΆGAATTGGCACCATTATTAGAATGGAAAΆAACAA CAACAAAAGCATCAACAGCATAAACAAGAAΆCACTGGATACAGGATTTGCATA
G
CRKl; ATGTCTGTTATTGCTGGCCATCATGTGCCGAGGTCAAATGATCAAAGGCAATA 80 U92261; CGATACACCGAGCGTACCAATAAATATCGCTCCGGATTCAGAAGGTCATATTC
4584845 ATGAAATGTCTCGATTGAAΆGATTATGAAGTGATAGAGAΆACTAGGTCAAGGA
ACATTTGGAGTTGTTCAAAAAGCAAAATCCAAAAAAGATGGCCTGTTAGTTGC
AATTAAACAATTGATTAACCATTCTGCAAAGGAAGGATTCCCAATCACTGCCA
TGCGAGAAATTACCATTTTGAAACAATTAAATCATAAAAATATTTTAACCATA
CAGGATATGATATTTGAAGAΆCCCAAAATGAGCAATCGAΆCAGATATTATTAC
TATGAGGGGTTCTTTTTATACTGTAACCCCATACATGTCGAGTGATCTTGTTG
GATTACTAGAGAACCCGAAAATTAAACTTGAACTTGGACAAATAAAΆTGTATC
ATGCAACAATTATTGAAAGGTATTCAATATGTACACAACCAAAAGTTTTTGCA
TCGAGACATTAAAGCAGCTAACATTTTAATCGGTCAAGATGGTGTTTTGAAAA
TTGCAGATTTCGGTTTAGCAAGAΆTATATCATGGTAACGTACCGAGATTGGGG
ATGGGTCCTGGTGGAGGAGAAAAAGCATATACTGGATTGGTTGTAACTAGATG
GTATCGACCACCAGAAATATTACTAGGAGAAAGAAAATATACTΆCTGCAGTTG
ATCAAAGGGGGATTGGATGTGTATTTGCCGAATTATTCACTGGGAAACCAATT
TTGGTAGGGAAATCAGATTCTCATCAAGCACAAATTGTATTTGAGTTGGTTGG
ATCACCTTTGACATGGACTGATGCTGCAAAACTACCCAATAAAAATGAGTATA
GTTGTGGCTTGGCTTGTAAACGAAGTCTTGAAGCAAAGTTTGCTAGTATCATG
CCTACTGAAGCTATTGACTTGTTAAGTGGATTGTTAACATTAGATCCTTTCAA
GAGACTTAATGCCTTGGATGCTTTGAATCACAAGTTTTTCAGTACTGATCCAT
TACCATTATTACCAACCCAAATGCCTAAATTTGAAGAAAGTCACGAAATTGAT
AAAGAACGATTTAAAAAATTGAAAGATAAAGAACAAGCTGTTAGTGAGTTGAA
GCCTCCAACTGAAATACGTTACGACAATCATTCGGAATCGAGGTATAATGCAG
ACCATTCTACTTTTGGTGGTGGTGGTGTTGGCGGTAAAGAAACAAGTTTTAGT
TCCGGGAAATCAGACTATATCGACCATTATGAACCAAGAGCACGTΆGGGACCA
TTATGAACCGAGAATACGAAATGATAATAAAGATTCCAACGATGTTAGAGGAG
AGTTTGAACTGGCTACAAGACAAGAACAAAGACGGAGGGATATTCAAAATAGG
CTTGATGCAGGTGGAATGGATACTTACATTCCAAAAACTACCACAGGAAAACT
TCGGGAACACAGTGGTACAGAGTCTTTGCTGCAAAAGTATGATAACTATCAAC
CAATAAACGTCTCCAGAGGATCAAAATCTCCATCTCCGTCAAAACTCCTGTCT
ATTTCACAATCAAAGGCAGATCTCATTAGTAAACCATCGGCTCCAAAGGTTGC
ATCTAGAGAΆAGTTCGCTCGΆGAGGAAGCAAGTTTCAAATGGTΆTCCGTACTA
CTACCGATGTGGAACCACCAAGAGCAAGGGCTCGTCGACCAACTGACATGTTT
GGAAGACCGTTGACTTCAAATAGTACTCAGGCACAACCAACAAGAAACAAATC
GGTGGAGCGACCAAAAGATCTTGAGAAACCTACAAATGGTGTGACTGAGGATA
GGAATAAGAAACCAGTTTTGGAAGAGAAGAAAGAAGTTGTCAAΆCCAAΆTTTG
GCAATTCCAAAΆATCAAAAAGAGCAGTTCTCTAGTGCTGTTGCTGTCTAGATC
GTCCACAACACCAGTTATTTCTAATCCGTCGAAGGTCACAAAAAGAGCAGCAA
GTAGTGTGACACCACCAGTGCTACCAAAGAAACCAAAAATATCCAAAACTAGT
TCAGAAAGTGAAGTAAGTGATTTGGAAGAAGACAGTGATTTTACAGGTGAGAA
TGCAACTGTATTTGAAAGGTTTATGGCACTTGAACAATTACAAAAATCGCCAG
TTTATAAAAGAATTATAAATGAGAAAATGAGGTTTGAAAAGTTATCGGGAGGA
CACAAATCTATGTAA
CYRl/ ATGAGTTTTTTAAGGAGAGATAAATCTAAAGCCAACTTTAGAGATGGTTCAGC 81
CDC35; TACTGGATTAGAGGAACCAGTTTCCCCCACCACTCATTTTTCACCCAATGTTC
AJ250877; CACCTCCACTCGATGGCAATCATGGGGATCATTATCATGATCCAGACTCCCCA AGATCTTCTGTTGTGTCATTACCGCAACTAATTCATAACTCAGCTACCCACCA
TTTGAAAGAAAATTATCGCGGGTTCCATGCCAACAAACGACCAAAAGGTATTG
CCAATGTTCCTCCATTGGCTCAACCTATAAAGCCACGATTTAΆAAAGAAGAGC
AATTCATTATTGAATAAGCTAATATATTCCΆCAAAGAAAGAAGACGATGAAGC
AGCCACAAGTGGGAAAGAGTCTCGATCGAGCTCTATCATATCGGATGAAAAAC
GCAAAAGTGCTAGCCTGGCATCGTCTGGCAGTTCAAGACAAAΆGTTTAGATTC
TCTTCATTTGATAGCAATTTGTCTACATCCTCTAGTTCTCCTCCTAAAGATAA
AAΆAGTACTGGTTTCCGACACCGTGTCGGATTCATCAACGGTTACTGCATCCA
TGTCAAΆTATGCCAACGATATCGATTGΆTCTTAATCTCGACGAAATGCACGAC
ATTATCAAGTCACCTGAAACCCCAACCCCGACTGCTGGCTTACCAACCCAGAA
AGCAGAGAAAAAGGCTTCACCAACAGCCATCAAΆAACTGGCAGGCCCCTGAAA
GTTGGGATGTGAAGGCTCCTATTAAAAAGGAAGAACCTCATGCACCTAAGATT
GAAGAAGTTGCAGAGAATGATGTAGCAATAGATAATGTTTTGGAAAAGAAACG
ATTGCCGGTACTATATGGTACTCΆCCAAGTGCCGCATGTTACAAATTCGAAAG
ACATAAAGTCAAGTCACATTATTCGAGTATTCAAAGAAGATAACACTTTCACG
ACAATCTTATGTCCCTTGGAAACAACCACCAGTGAGCTTTTAGCTATTGTGCA
AAAGAAATTCTTTCTTGAGTCAACAACCAATTTCCAACTATCGGTGTGTATTG
GGAACTGTGTTAΆGGTATTGGAAGATTTTGAAAAGCCTCTCAΆGATTCAAATG
GGGTTGCTTTTACTCAGTGGTTATACAGAAGAGGATAAGTTGAGAATGTTAGG
AAGAGAAGACTTGTCATTTGTATGCAAATTTGTTGTTGAAAACATATTTTTGA
GGAGTTTGACTCATGATGAAGAAGTTTTATTGTCACGGAATTACGTCGATGTC
AATATATCTTCACTAAATTTGAAAAATGTCCCTATTATATTCCATCAACATAC
TTATGAGATTGAAAAATTAAATGTGGCCAATAATCCCTCCATATACTTGCCAT
TGGATTTCATTCAGGGATGTACTAGTTTGGCGTATGTGGACTTTTCCCACAAT
GGGTGTTCTAAATTCCCCAATAATTTATTAGAAGCACCCCAATTGACTCATTT
GAACTTGGAAATGAACTTTTTGGATGAAATACCCCAAAGAATAAGTTGTTTGT
CAAATTTΆACTAACTTGAAATTGAGTTCGAΆTCAACTTTATTCGCTTCCACAT
TCATTTAGTACCTTAACTAATTTGAAACAGCTTGATTTGTCATCAAATTATTT
TGATAGCTACCCGGAAGCAGTCAACAAATTGACCAATTTAGTGGAATTGAATT
TTTCATACAATGATTTATCGATAATTCCTGAATCTATTGCGΆATTTGATTAAC
TTGCAAAAATTAAATTTATGTACTAATAAGTTGTCAGGGACATTACCTGGTTA
TTTGTCCCAATTAAAAGCGTTAAAGCGTTTGGATATCCGATATAATTATATTT
CCAACGTTGACGTATTGGGAATAATACCTAATTTGGAGGTTGCCTATGCATCC
AAAAATGCAATCTCAACATTTAGTGATCAAATGAAGTGCTTGAGACTCTTACA
TTTTGATAGGAATCCAATAACCGAACTTAAGTTTAATACTCAGATGCAAATGT
TGTCCGTTTTAGATTTGTCAAGAGCAAAAATTACGGCATTCCCGGCAGAATTT
GTTGAAAAGGTTCCAAATATTGAAAAATTAGTGCTTGACAAAAATCATTTAGT
GTCTCTCCCTAATGAACTTTGTCAATTGTCAAAΆTTAGTATCATTATCTGTAC
ATGCCAATAATTTGCAGTCTTTACCAGCAAACATTGGAGATTTAAGATTTTTG
AAATATTTGGATTTGCACAGTAACAATTTGAAΆTCΆTTGCCTGATCAAATTTG
GGATCTTTGTCATTTGACACTGTTAAATGTTGCATCCAATAACTTGACTTCAT
TCCCCAAGGCTCCTTATTCTGTCGTGAAAAGGTTATCTTCGTCTCTTGTTGAT
GTACATCTCGAΆTCTTCGCAAΆCTTTATCTTTAGCTGACAGTTTGTTGATTTT
AATATTGTCTGATAATCGATTAAGTGACGATTGCTTTGATGAGATTTCATTTT
TGATAGCCTTAAAGTCGTTGAATGTGTCATACAATGATTTAATAGAGATTCCA
CAGGGGACATTAAGTCGTTTGACTAGGCTCAATGAGTTGTACTTGTCAGGAAA
TGAATTGACAACTTTACCAGCTGATGACTTGGAAGTGCTAAAGTCATTAAAAT
TGTTATACATGAATAATAACAAACTTGTTTCACTCCCAGCAGAGTTGAGCCGA
ATCGCCAATTTGCAACATTTGGACGTTAGTTCTAATCAATTGAAATATAATAT
TTCCAATTGGCCATACGATTGGAGTTGGCACTGGAATAAAAATTTAAAATATT
TGAATTTTTCCGGTAATAAACGGTTTGAAATAAAACAAAGTCATATTAAGAAT
CCCGAΆACAGGAGAGGATTTCGATAGTTTATTGGTATTGAAGCAATTGAGAGT
GTTGGGATTGATCGACGTTACGTTGACGACAACAAACGTGCCAGAACAAGCTG
TTGACTTGAGATTGAGAACTACTGCTTCTGAATTTGATAATTTTGGGTATGGG
GTCAGTGATTCTTTAGGTATGAGGGACCATGTTTCAGCACGTGATTTATTTGT
CCAAAAGTTTAGAGGTAAAGAAAACGAGATGTTGCTTTGTGCATTTGATGGTA AGCATGGGGCAΆCTAATCAAGGTCACAGGATCTCCTTGGTTGCGAΆAAACATG
TTTGTGAGAAATTTCACAAAAGAATTGGATGAAATAAAGAGTGATGATGAAAT
AGAAAΆTGCCCTTAGAAAAGCTTTTTTGAATTTCAATAΆAGAAATCAΆTGGTA
TTTTGACCGCTAAAAAGAACAAGTCATTTACACCTGTGCCTAACATGTCAAAA
GAAGCTCTTGAATTGΆΆTTTGGTAGACGATGGTAACGCTGGTTGTACCGTGTC
TGTGATTTATATTAAAGATAAGAAACTTTATTCTGCAAACATTGGTGΆCATTG
AGGCGCTACTTTGCAGGAACAATGGTGATCAATTTTTACTTACTGAAAAACAT
GATCCAACCAΆTCGTGAAGAGTTTGAAAGAATTAGAGCCTCTGGCGGATATGT
TTCAGGTGGGGGAGAGTTAGATGGGCAATTATCAGTGTCACGAGGGGTAGGAT
TTTTCAACTTTTTGCCTCATACACATTGTGGGCCTACTATTCGCCGGTTTAAA
ATAACTAΆTGACGATGATATGATTATTTTGGGAAGTAAACAGTTGTGGGATTT
CΆTCTCTTATGAATCAGCTGTTGACATTATCCGTAΆAGATAAGAATGATCCTA
TGGTGGCCGCACAAAAGTTGCGAGATTTTGCTATATGTTATGGTGCAACCGAT
AAΆATTTGCGTCATTGTCTTAACTTTTGGTAATAGGCAGAAACAAGCTGCCAA
TATGTATTCAAATTATGGTGTTGATAGAAGACGTCGAGATAAGCAACAAGTTG
TTGGTGGAGACTCTAATCTCCGTAAATTAGAACAAGAGATTGAGCCACCAATA
GGACCATTAGCTTTGGTTTTCACTGATATCAAAΆACTCAACTTTATTATGGGA
TTCGTACCCGGCACCTATGAGATCAGCAATCAAAATTCATAΆTACAATAATGC
GTCGACAATTGCGAATTACTGGTGGATATGAAGTGAAGACTGAΆGGTGATGCG
TTCATGGTTGCCTTCCCTTCGCCAACCGCGGCTTTGTTGTGGTGTTTCCAΆGT
GCAACAAAACTTGGTGACTGCAGACTGGCCATCAGAAATACTTGAAACTGATC
AGTGTTGTGTAGTATCGGATTCAGAAAΆCAATACCATTTTCAGGGGGTTGTCG
GTTCGTATGGGTATACATTGGGGTTCTCCTGTATGTGAACCAGATGTTATAAC
TGGCAGAATGGATTATTTTGGACCAATGGTCAATAGAGCGTCGCGTATCAGTG
CTATTGCTGATGGTGGACAAATTGCTGTCAGTTCTGATTTCTTGGATGTGTTG
AATAGTTTAACTGTTAAACATAATAATATCAAAAACAATGTTGAGTCTTTGAT
TGATGCCTATCAGGGCAATGAAAATGCCGGAATGACAATTGAACGAGAATTGA
ATGCATTGGAGGATCTTGGGTGTAACTATTTTAAAΆTTGGTGAGCGTAAATTG
AAGGGGTTGGAAACACCAGAΆCCTATCACTTTGGTGTTTACCAATAGATTGAA
ATTGAGATATGATATATTTCAΆAAGAGACTTGATGCAAATCATAGTACTCGΆG
TGGCTGGAACATTACCAGTGGAGATCATATATGGCTTAAGAACAGTATCGTTA
AGGTTGGAGAATCTCTGTTCTTCGATCAATAATGGTGGTAATTATTGCAGTGA
AGGATTTGAATCTTCΆTCAGGGGTTATTTCACAAAAGATGAATTCATCGTTCA
AAGATCTGGATTTGATCTCATTGCTCAATCACGTTACAACTAGAATTGAAAGT
TGTACCACAΆCATTGTTTTTGCGTCAACAATTAΆGTCAAATTAAΆGGAAATGG
CGGGTTGATAGAGACTAACAATTCTCCATCATTGGATGTTATTATGGATGAAG
TAGCAGACATCATGAAAACAGTTAATGAACTTAAATAGA
EFGl; ATGTCAACGTATTCTATACCCTATTACAATCAAATGAACGGAAATTACAATAA 82
Z32687; CGGTATGCCCCAGCAAΆCAACTGCAGCCAATCAACAGGCTTTTCCTCAGCAAC
6468469 AACAACCAACAACAACAGGCAATGCTAGCCAΆCAGCAΆCAGCAAGCAGCTGCT ACGGCAGCTGCAGTCCAACAGCCTTATAACTACATGTTCTATCAACAACAAGG ACAACCAGGTCAΆCAGACTGGACAGACAGCAGGACAACAΆCAACAACAGCAGC AGCAGCAGCAACAATATGATTACAATACCTACAACAGATATCAGTATCCTGCC GCAACATCTCAAGGAAACTATTACCAGCAAACAΆTTCCTAATCAATTGTCACA GCCACAACCTCAGCATTACAATGGATCTAATCGTAATTACACAAGTGCTCCTA GTGGTGCCCCCATACCTTCCAATTCTACCAGTGGACCTTCACAACAGCCACCA CTACCAGGTCAACAΆGCAGTACCTATCCCACCACATGTATCGACAATGCAACA ACCAACTCCTGTTCAGGATACGTTGAACGCCTCGAGCACTTCCACTGTGGGGC AATTCCAACCACCAGGAATCAGACCACGAGTAACAACTACCATGTGGGAAGAT GAAAAAACTTTGTGCTATCAAGTTGATGCCAATAATGTGTCGGTTGTCAGAAG AGCAGATAATΆATATGATCAACGGAACCAAΆTTGCTCAATGTGGCCCAAATGA CACGTGGTAGAAGAGATGGGATTTTGAAATCAGAAAAGGTGAGACACGTTGTG AAAATCGGATCAATGCATTTGAΆAGGAGTCTGGATTCCATTTGAAAGAGCATT GGCCATGGCTCAΆCGTGAΆCAAATTGTGGATATGTTGTATCCTTTGTTTGTCA GΆGATATTAAACGAGTGATTCAAACCGGAGTAACTCCTAATGCAGCTGCTGCA ACGGCCGCCGCCGCTGCCACTGCCACTTCTGCTTCGGCTCCTCCACCTCCACC
Figure imgf000083_0001
TCTCCTTGTCATCAGGAGCAGGCTCCGGTGCAGGCGCCGCAAATAGTGGTGGT
GCTGTTGTTGATAGTGCTGCCTTAGATGCTTTAACAGCTGΆAAACAΆGAAATT
AGCCAAACAGCAATTAGAAGTTTTAGCAΆGATACTTGCAAΆGTCGACTTAAAC
AAGGGAGCCTTAAATCTTTTATCAAGGAAAAGGAΆGCTTCTGCTGTTTTACAA
AAAGAGTTAGATTTGTGGGAAGCAGAΆCACGGAGAATTCTATGCTAAGGGTAT
CCAACCAACTTTCTCCGCATTAAAGTCTAGAACTTATGACTCCTΆTTGGAATT
GGGCCCGTCAAGACGTTTTATCAATGTATTTCGACATTATTTTTGGCAAGTTA
ACTTCTGTTGATAGAGAAACCATCAACCAATGTATTCAAATCATGAACAGAGC
CAATCCAACTTTAATCAΆGTTTATGCAΆTATCATATCGACCATTGTCCAGAAT
ATAAAGGTGAAACTTATAAATTGGCCAAGAGATTGGGTCAACAATTGATTGAC
AACTGTAAACAAGTTTTGACTGAΆGATCCAGTTTACAAΆGATGTTTCCAGAAT
TACTGGTCCAAAGACTAAAGTCAGTGCTAAGGGTAACATTGAATATGAGGAAA
CTCAAAAGGATTCAGTTAGAAAATTTGAACAΆTATGTGTATGAAΆTGGCCCAA
GGTGGTGCTATGACCAAAGTTAGTCAACCAACTATTCAAGAAGATTTAGCTAG
AGTTTACAAGGCTATTTCCAAACAAGCTTCCAAAGATAGCAAATTGGAATTGC
AAAGAGTTTACGAAGATTTATTGAAGGTGGTTGAAAGTTCCAAGGAAATCGAA
ACCGAACAATTGACTAAAGΆTATTTTACΆAGCTGCTACAGTTCCAACAACCCC
AACAGAGGAAGTAGACGATCCTTGTACTCCTTCTTCGGATGATGAAATTGCTT
CTTTACCAGATAΆGACTTCTATCATTCAACCTGTCTCGTCTACTATTCCATCT
CAAACTATTCCATTTTTGCACATTCAGAAAAAGACCAAAGACGGTTGGGAATA
CAATAAGAAATTATCTTCTCTTTACTTGGATGGATTGGAATCAGCTGCCATTA
ATGGTTTAACTTTCAAAGACAAGTATGTCTTAGTTACTGGTGCTGGTGCTGGC
TCTATTGGTGCCGAAATTTTGCAΆGGTTTAΆTCΆGTGGTGGTGCCAAAGTTAT
TGTCACAACCTCTAGATTTTCCAAGAAAGTTACCGAGTATTATCAAAACATGT ,
ATGCCAGATATGGTGCTGCTGGGTCTACTTTAATTGTTGTTCCGTTCAACCAA
GGTTCTAAACAAGATGTTGATGCATTGGTTCAATACATTTATGATGAGCCAAA
GAAAGGTGGTTTGGGTTGGGATTTGGATGCAATCATTCCATTTGCTGCTATTC
CAGAAAATGGTAATGGTCTCGACAACATTGATTCTAAATCTGAATTTGCCCAC
AGΆATCATGTTGΆCCAACCTTTTAAGATTGTTAGGTGCTGTTAAΆTCCAAAAA
GCCCACTGACACTAGACCTGCTCAATGTATTTTGCCATTATCTCCAAATCACG
GAACTTTTGGTTTTGACGGGTTGTACTCTGAATCTAAAATCTCATTGGAAACC
TTATTCAACAGATGGTATTCTGAAGATTGGGGATCCAAGTTGACTGTTTGTGG
TGCCGTAATTGGGTGGACTAGAGGTACAGGTTTGATGAGTGCCAΆTAACATTA
TTGCTGAAGGTATTGAAAAATTGGGTGTCAGAACTTTCTCCCAAΆAGGAAATG
GCTTTCAATATTTTAGGTTTATTGACACCAGAAΆTTGTACAATTATGTCAAGA
AGAACCAGTTATGGCTGACTTGAATGGTGGTTTGCAΆTTCATTGACAACTTGA
AGGATTTCACATCTAAATTAAGAACCGACTTGTTGGAAACTGCAGACATTAGA
AGAGCTGTTTCTATTGAATCAGCTATCGAGCAAAAAGTTGTCAATGGTGACAA
TGTCGATGCAAACTACTCAΆΆGGTTATGGTTGAACCTAGAGCCAACATGAAAT
TTGATTTCCCAACTTTGAAATCTTATGATGAAΆTCAAACAAATTGCTCCAGAA
TTGGAAGGTATGTTGGATTTGGAAAATGTTGTCGTTGTGACAGGTTTTGCTGA
AGTTGGTCCATGGGGTAACTCTAGAACCAGATGGGAΆATGGAAGCTTATGGTG
AGTTCTCATTGGAAGGTGCCATTGAAATGGCTTGGATTATGGGTTTCATCAAG
TATCATAATGGTAATTTGCAAGGGAAΆCCATACTCTGGATGGGTTGATGCCAA
GACTCAAACTCCAATTGACGAAAAGGATATCAAATCCAΆATATGAAGAAGAAA
TTTTAGAACATTCCGGTATTAGATTGATTGAGCCAGAATTGTTCAATGGCTAT
GATCCAAAGAAAAAACAAATGATTCAAGAAATTGTTGTTCAACACGATTTAGA
ACCATTTGAATGTTCTAAAGAAACAGCTGAGCAATACAAACACGAACACGGAG
AAAAΆTGTGAAΆTTTTTGAAATTGAAGAAAGTGGTGAATACACAGTTAGAATC
TTGAAAGGTGCAACATTGTACGTTCCGAAAGCTTTGAGATTTGATAGATTAGT
TGCTGGTCAAΆTTCCAACTGGTTGGGACGCTCGTACCTATGGTATCCCAGAAG
ΆCACTATTAGTCAAGTTGATCCAATCACTTTGTACGTGTTGGTTGCCACTGTT
GAAGCCTTGTTGTCTGCTGGTATTACTGATCCATATGAATTCTACAAATACGT
TCATGTGTCTGAAGTTGGTAACTGTTCTGGTTCCGGTATGGGAGGTGTCTCTG
CTTTGAGAGGAATGTTCAAAGATAGATATGCTGACAAACCAGTTCAAAATGAC
ATTTTGCAAGAATCATTTATCAACACTATGTCTGCTTGGGTCAATATGTTGTT GTTGTCTTCCTCTGGTCCAATCAAGACACCAGTCGGTGCTTGTGCCACTGCTG
TTGAATCGGTTGACATTGGTATTGAAACAATTTTGTCTGGTAAAGCTAAAGTA
GTTTTGGTAGGTGGTTACGATGACTTCCAAGAAGAAGGGTCTTATGAATTCGC
CAATATGAATGCTACTTCTAATTCTATTGAAGAGTTCAAACACGGAAGAACAC
CAAΆGGAAATGTCAAGACCAACTACTACTACCAGAAATGGTTTCATGGAAGCT
CAAGGTTCTGGTATTCAAGTTATCATGACTGCTGATTTGGCTCTCAAGATGGG
TGTTCCAATCCACGCTGTATTGGCCATGACTGCTACTGCCACTGATAAGATTG
GTAGATCTGTTCCAGCACCAGGTAAAGGTATTTTGACCACTGCCAGAGAACAT
CATGGCAACTTGAAGTACCCATCTCCACTTTTGAACATCAAGTACAGGAAGAG
ACAATTGAACAAAAGATTGGAACAAATCAAATCTTGGGAΆGAAACAGΆΆCTTT
CTTACTTGCAAGAAGAAGCCGAGTTGGCCAAAGAAGAATTTGGTGACGAATTT
TCTΆTGCATGAGTTCTTGAAΆGΆGAGAACTGAAGAΆGTGTACCGTGAATCAAA
GAGACAAGTTTCTGATGCTAAGAAΆCAATGGGGTAATTCATTCTACAAGTCTG
ATCCAAGAATTGCTCCATTGAGAGGAGCΆTTGGCTGCCTTCAACTTΆACCATC
GATGATATTGGTGTTGCATCCTTCCATGGTACTTCCACCGTTGCTAACGATAA
GAATGAATCTGCCACAATCAACAATATGATGAAΆCACTTGGGTAGATCCGAAG
GTAACCCAGTATTTGGTGTTTTCCAAAAATACTTGACAGGTCATCCAAAAGGT
GCΆGCTGGTGCTTGGATGTTGAATGGTGCCATTCAAATTCTTGAGTCTGGTCT
TGTTCCAGGTAACAGAAATGCGGΆTAATGTTGATAΆGCTTTTAGAACAATACG
AATATGTATTGTACCCATCAAGATCAATTCAAACCGATGGTΆTTAAAGCCGTT
TCTGTTACATCATTTGGTTTCGGTCΆAAAAGGTGCACAAGCCGTTGTTGTTCA
TCCAGATTACTTATTTGCTGTTTTGGATAGATCCACTTATGAAGAATATGCTA
CTAAGGTCTCTGCTAGAAATAAAAAGACCTACCGTTACATGCACAATGCAATC
ACCAGAAACACTATGTTTGTTGCCAΆAGACAΆAGCTCCATATAGTGACGAATT
GGAACAACCΆGTTTACTTGGATCCATTGGCTCGTGTTGAAGAAAACAAGAAAA
AGTTGGTATTCAGTGACAAAACAATTCAATCGAACCAATCTTATGTTGGAGAA
GTTGCTCAAAAAACTGCTAAGGCATTGTCTACTTTAAACAAATCATCAAAGGG
AGTTGGTGTAGATGTTGAATTGTTGTCAGCAATCAATATCGACAATGAAACCT
TTATTGAAAGAAACTTTACTGGTAATGAAGTTGAATACTGTTTGAATACTGCT
CACCCACAAGCTTCATTCACTGGAACTTGGTCAGCAAAGGAAGCTGTTTTCAA
AGCCTTGGGTGTTGAATCAAAΆGGTGCTGGΆGCAAGCTTGATTGATATTGAAA
TCACTCGTGACGTTAATGGTGCTCCTAAAGTAATTTTGCATGGTGAGGCCAAA
AAAGCTGCTGCTAAAGCTGGTGTTAAAAATGTCAATATTTCAATTTCTCATGA
TGATTTCCAAGCTACTGCTGTTGCTTTΆΆGTGAATTTTAΆ
HOGl; ATGTCTGCAGATGGAGAATTTACAAGAACCCAGATATTTGGGACTGTTTTTGA 85
X90586; AATCACCΆATAGATACACTGΆGCTAAATCCCGTGGGAATGGGAGCATTTGGTT
1616582 TGGTGTGCTCΆGCCGTTGATAGATTAACTGGTCAAAATGTTGCAGTGAAAΆAA
GTCATGAAACCTTTTCTGACCTCAGTATTGGCAAAAAGAACCTACAGAGAATT
AAAGTTATTGAAACATTTGAΆACATGΆGAATTTGATTACCTTGGΆTGATATTT
TCATATCTCCTTTGGAGGATATTTACTTTGTCAATGAATTGCAAGGTACTGAT
TTGCATAGGTTATTGAACTCAAGACCTTTGGAGAAACAATTTATTCAATATTT
CACATACCAAATAATGAGAGGTTTAAAATACATTCATTCTGCCGGTGTTΆTTC
ATCGTGATTTGAAACCATCCAACATCTTGATCAATGAAAACTGTGACTTGAAA
ATCTGTGΆCTTTGGTCTTGCAAGACTTCAAGΆTCCACAAATGACGGGTTACGT
GTCAACCAGATATTATCGAGCACCAGAAATCATGTTAACTTGGCAAAAATACG
ACACTGAAGTCGACTTGTGGTCTGTGGGTTGTATCTTAGCCGAAATGATTGAA
GGGAAACCACTATTCCCCGGGAAAGATCACGTGCATCAATTCTCCΆTTATAAC
AGAATTATTGGGCTCACCTCCTGCTGATGTGATCGATACTATTTGTTCCGAAA
ACACTTTAAGATTTGTCCAATCATTACCACATAGAGACCCTATCCCATTTAGT
GAAAGATTTGCTTCCTGTACTCACGTTGAACCGGAGGCTATTGATTTATTGGC
TAAATTGTTGGTTTTTGACCCTAAGAAAAGAATCAGTGCTGTTCAAGGTTTGA
CCCATCCTTATATGGAGGCATACCATGATCCAACCGATGAGCCTGTTTGTGAG
AGTAAATTCGATTGGAGTTTTAATGΆCGCAGACTTGCCAGTGGATACTTGGAG
AGTTATGATGTACAGTGAAATTTTAGACTTTCATCAAACTGTTGGTGTGGCAA
ATGAAACTGAGGGTTCCGAACAACCAGACCTGCAAGTGGAGCAAAACAACTTG
GATTCCGCCAACGGAGCTTAA HWPl; ATGAGATTATCAACTGCTCAACTTATTGCTATCGCTTATTACATGTTATCAAT 86 U64206 ; TGGGGCCACTGTCCCACAGGTAGACGGTCAAGGTGAAACAGAGGAAGCTCTTA 4028879 TTCAAAAGAGATCTTATGATTACTATCAΆGAACCATGTGATGATTACCCACAA
CAACAACAACAACAAGAGCCTTGTGATTACCCACAACAACAACAGCAGGAAGA
ACCTTGTGATTACCCACAΆCAACAACCACAΆGAGCCATGTGACTATCCACAAC
AGCCACAAGAACCTTGTGACTACCCACAACAACCACAAGAACCTTGTGACTAC
CCACAACAACCACAAGAACCTTGCGACAATCCACCTCAACCTGATGTTCCTTG
TGACAATCCTCCTCAACCTGATGTTCCTTGTGACAATCCTCCTCAACCTGATA
TTCCTTGTGACAATCCTCCTCAACCTGATATTCCTTGTGACAATCCTCCTCAA
CCTGATCAGCCTGATGACAATCCTCCTATTCCAAACATTCCAACCGATTGGAT
TCCAAATATTCCAACTGATTGGATCCCAGATATTCCAGAAAAGCCAACAACTC
CAGCTACTACTCCAΆACATTCCTGCTACAACTACTACTTCTGΆATCATCATCT
TCTTCTTCTTCTTCATCATCATCTACTACTCCAAAAACTTCTGCTTCAACTAC
ACCTGAATCTTCTGTTCCAGCTACCACTCCAAACACTTCTGTTCCAACAACTT
CTTCAGAATCAACTACTCCAGCTACTAGCCCAGAAAGTTCTGTTCCAGTTACT
TCTGGΆTCATCTATTTTAGCTACCACTTCAGAATCATCATCTGCTCCAGCTAC
TACTCCAAATACATCTGTTCCAACCACTACTACTGAAACCAAATCATCAAGTA
CTCCATTAACTACTACTACTGAΆCATGATACAACTGTTGTCACTGTTACTTCA
TGTTCTAACAGTGTTTGTACCGAAAGTGAAGTTACTACTGGTGTTATTGTCAT
CACATCTAAAGATACTATTTACACCACTTACTGTCCΆTTGACTGΆAACTACTC
CAGTTTCTACTGCTCCAGCCACTGAAACACCAACTGGTACAGTATCCACTTCT
ACTGAACAATCAACTACTGTTATTACTGTTACTTCATGTTCTGAAAGCTCTTG
TACCGAATCTGAAGTTACTACTGGTGTTGTTGTTGTTACTTCTGAGGAAACTG
TCTACACTACATTCTGTCCATTGACTGAAAACACTCCAGGTACTGATTCAACT
CCAGAAGCTTCCATTCCACCTATGGAAACAATTCCTGCTGGTTCAGAATCATC
CATGCCTGCCGGTGAAACCTCTCCAGCTGTTCCAAΆATCAGATGTTCCAGCTA
CTGAATCAGCTCCAGTTCCTGAAATGACTCCAGCTGGTTCACAACCATCTATT
CCTGCCGGTGAAACCTCTCCAGCTGTTCCAAAATCAGATGTTCCAGCTACTGA
ATCTGCTCCTGCTCCTGAAATGACTCCAGCTGGTACTGAAACTAAACCAGCTG
CTCCAAAATCATCAGCTCCTGCCACTGAACCTTCCCCAGTTGCTCCAGGTACT
GAATCCGCACCAGCTGGTCCAGGTGCTTCTTCTTCTCCAAAATCTTCTGTTTT
GGCTAGTGAAACCTCACCAATTGCTCCAGGTGCTGAAACCGCTCCAGCTGGCT
CAAGTGGTGCTATTACTATTCCGGAATCTAGTGCTGTCGTCTCTACGACTGAA
GGTGCTATTCCAACTACATTAGAATCAGTTCCACTCATGCAACCATCTGCCAA
TTACTCAAGTGTCGCTCCTATTTCTACATTTGAAGGTGCTGGTΆACAACATGA
GATTGACTTTCGGTGCTGCTATTATTGGTATTGCTGCATTCTTGATCTAA
INTl; ATGAACTCAACTCCAAGTAAATTATTACCGATAGATAAACATTCTCATTTACA 87
U35070; ATTACAGCCTCAATCGTCCTCGGCATCAATATTTAATTCCCCAACAAAACCAT
1144530 TGAATTTCCCCAGAACAAATTCCAAGCCGAGTTTAGATCCAAATTCAAGCTCT GATACCTACACTAGCGAACAAGATCAAGAGAAAGGGAAAGAAGAGAAAAAGGA CACAGCCTTTCAAACATCTTTTGATAGAAATTTTGATCTTGATAATTCAATCG ATATACAACAAACAATTCAACATCAGCAACAACAGCCACAACAACAACAACAA CTCTCACAAACCGACAATAATTTAATTGATGAATTTTCTTTTCAAΆCACCGAT GACTTCGACTTTAGACCTAACCAAGCAAAATCCAACTGTGGACAAAGTGAATG AAAATCATGCACCAACTTATATAAΆTACCTCCCCCAACAAATCAATAATGAAA AAGGCAACTCCTAAAGCGTCACCTAAAAAAGTTGCATTTACTGTAACTAATCC CGAAATTCATCATTATCCΆGATAATAGAGTCGAGGAAGAAGATCAAΆGTCAAC AΆAΆAGAAGATTCAGTTGΆGCCACCCTTAATACAACATCAATGGAAAGΆTCCT TCTCAATTCAΆTTATTCTGATGAAGΆTΆCAAATGCTTCAGTTCCACCAACACC ACCACTTCATACGACGAAACCTACTTTTGCGCAATTATTGAACAAAAACAACG AAGTCAATCTGGAACCAGAGGCATTGACAGATATGAAATTAAAGCGCGAAAAT TTCAGCAATTTATCATTAGATGAAAAAGTCAATTTATATCTTAGTCCCACTAA TAATAACAATAGTAΆGAATGTGTCAGATATGGATCTGCATTTACAAAACTTGC AAGACGCTTCGAAAAACAAAACTAATGAAAATATTCACAATTTGTCATTTGCT TTAAAAGCACCAAAGAATGATATTGAAAACCCΆTTAAACTCATTGACTAACGC AGATATTCTGTTAΆGATCATCTGGATCATCACAATCGTCATTACAATCTTTGA GGAATGΆCAATCGTGTCTTGGAATCAGTGCCTGGGTCACCTAΆGAAGGTTAAT
CCTGGΆTTGTCTTTGAΆTGACGGCATΆAAGGGGTTCTCTGATGAGGTTGTTGA
ATCATTACTTCCTCGTGACTTATCTCGAGACAAATTAGAGACTACAAAAGAAC
ATGATGCACCAGAΆCACAΆCAATGAGAATTTTATTGATGCTAAATCGACTAAT
ACCAATAAGGGACAACTCTTAGTATCATCTGATGATCATTTGGACTCTTTTGA
TAGATCCTATΆACCACACTGAACAATCAATTTTGAATCTTTTGAATAGTGCAT
CACAATCTCAAΆTTTCGTTAAATGCATTGGAAΆAACAAAGGCAΆACACAGGAA
CAAGAACAAACACAAGCGGCAGAGCCTGAAGAAGAAACTTCGTTTAGTGATAA
TATCAAAGTTAAACAAGAGCCAAAGAGCAATTTGGAGTTTGTCAAGGTTACCA
TCAAGAΆAGAACCAGTTCTGGCCACGGAAATAAΆΆGCTCCAAAΆAGAGAATTT
TCAAGTCGAATATTAAGAATAAAAAATGAAGATGAAATTGCCGAACCAGCTGA
TATTCATCCTAAAAAΆGAAAATGAAGCAAACAGTCATGTCGAAGATACTGATG
CATTGTTGAAGAAΆGCACTTAATGATGATGAGGAATCTGACACGACCCAAAAC
TCAACGAAAATGTCAATTCGTTTTCATATTGATAGTGATTGGAAATTGGAAGA
CAGTAATGATGGCGATAGAGAAGATAATGATGATATTTCTCGTTTTGAGAAAT
CAGATATTTTGAΆCGACGTATCACAGACTTCTGATATTΆTTGGTGACAAATAT
GGAAACTCATCAAGTGAAΆTAΆCCACCAAAACATTAGCACCCCCAAGATCGGA
CAACAATGACAAGGAGAATTCTAAATCTTTGGAAGATCCAGCTAATAATGAAT
CATTGCAACAACAATTGGAGGTACCGCATACAAAAGAAGATGATAGCATTTTA
GCCAACTCGTCCAATATTGCTCCACCTGAAGΆATTGACTTTGCCCGTAGTGGA
AGCAAATGATTATTCATCTTTTAATGACGTGACCAAAACTTTTGATGCATACT
CAΆGCTTTGAAGAGTCATTATCTAGAGAGCACGAAACTGATTCAAΆACCAATT
AATTTCATATCAATTTGGCATAAΆCAAGAAAAGCAGAAGAAACATCAAATTCA
TAAAGTTCCAΆCTAAACAGATCATTGCTAGTTATCAACAΆTACAAAAACGAAC
AAGAATCTCGTGTTACTAGTGATAAAGTGAAAATCCCAΆATGCCATACAATTC
AAGAAATTCAAAGAGGTAAATGTCATGTCAAGAAGAGTTGTTAGTCCAGACAT
GGATGATTTGAATGTATCTCAATTTTTACCAGAATTATCTGAAGACTCTGGAT
TTAAAGATTTGAATTTTGCCAACTACTCCAATAACACCAACAGACCΆΆGAAGT
TTTACTCCATTGAGCACTAAAAATGTCTTGTCGAATATTGATAACGATCCTAA
TGTTGTTGAACCTCCTGAACCGAAATCATATGCTGAAATTAGAAATGCTAGAC
GGTTATCAGCTAATAAGGCAGCGCCAAATCAGGCACCACCATTGCCACCACAA
CGACAACCATCTTCAACTCGTTCCAATTCAAΆTAAACGAGTGTCCAGATTTAG
AGTGCCCACATTTGAAATTAGAAGAACTTCTTCAGCATTAGCACCTTGTGACA
TGTATAΆTGATΆTTTTTGATGΆTTTCGGTGCGGGTTCTAΆACCAACTATAAAG
GCAGAAGGAATGAAAACATTGCCAAGTATGGATAAAGATGATGTCAAGAGGAT
TTTGAATGCAAAGAAΆGGTGTGΆCTCAAGATGAATΆTATΆAATGCCAΆACTTG
TTGATCAAAAACCTAAAAAGAATTCAATTGTCACCGATCCCGAAGACCGATAT
GAAGAATTACAACAAACTGCCTCTATACACAATGCCΆCCATTGATTCAAGTAT
TTATGGCCGACCAGACTCCATTTCTACCGACATGTTGCCTTATCTTAGTGATG
AATTGAAAAAACCACCTACGGCTTTATTATCTGCTGATCGTTTGTTTATGGAA
CAAGAAGTACATCCGTTAAGATCAAACTCTGTTTTGGTTCACCCAGGGGCAGG
AGCAGCAΆCTAATTCTTCAATGTTACCAGAGCCAGATTTTGAATTAATCAATT
CACCTGCTΆGAAATGTGCTGAACAΆCAGTGΆTAATGTCGCCATCAGTGGTAAT
GCTAGTACTATTAGTTTTAΆCCΆATTGGATΆTGAATTTTGATGΆCCAΆGCTAC
AATTGGTCAAAAAATCCAAGAGCAACCTGCTTCAAAATCCGCCAATACTGTTC
GTGGTGATGATGATGGATTGGCCAGTGCACCTGAAΆCACCAAGAACTCCTACC
AAAAAGGAGTCCATATCAAGCAAGCCTGCCAAGCTTTCTTCTGCCTCCCCTAG
AAAΆTCACCAATTAAGATTGGTTCACCAGTTCGAGTTATTAAGAAAAATGGAT
CAATTGCTGGCATTGAACCAATCCCAAAAGCCACTCACAAACCGAAGAAATCA
TTCCAAGGAAACGAGATTTCAAACCATAAΆGTACGAGATGGTGGAATTTCACC
AAGCTCCGGATCAGAGCATCAACAGCATAATCCTAGTATGGTTTCTGTTCCTT
CACAGTATACTGATGCTACTTCAACGGTTCCAGATGAAAACAAAGATGTTCAA
CACAAGCCTCGTGAAAAGCAAAAGCAAAAGCATCACCATCGCCATCATCATCA
TCATCATAAACAAAAAACTGATATTCCGGGTGTTGTTGATGATGAAATTCCTG
ATGTAGGATTACAAGAACGAGGCAAATTATTCTTTAGAGTTTTAGGAATTAAG
AATATCAATTTACCCGATATTAATACTCACAAAGGAAGATTCACTTTAACGTT GGATAATGGAGTGCATTGTGTTACTACACCAGAATACAΆCATGGACGACCATA
ATGTTGCCATAGGTAAAGAATTTGΆGTTGACAGTTGCTGATTCATTAGAGTTT
ATTTTAACTTTGAAGGCATCATATGAAAAACCTCGTGGTACATTAGTAGAAGT
GACTGAAAAGAAAGTTGTCAAATCAΆGAAATAGATTGAGTCGATTATTTGGAT
CGAAAGATATTATCACCACGACAAAGTTTGTGCCCACTGAAGTCAAAGATACC
TGGGCTAATAAGTTTGCTCCTGATGGTTCATTTGCTAGATGTTACATTGATTT
ACAACAATTTGAAGACCAAATCACCGGTAAAGCATCACAGTTTGATCTCAΆTT
GTTTTAATGAATGGGAAACTATGAGTAATGGCAATCAACCAATGAAAAGAGGC
AAACCTTATAAGATTGCTCAATTGGAAGTTAAAATGTTGTATGTTCCACGATC
AGATCCAΆGAGAΆATATTACCAACCAGCATTAGATCCGCATATGAAAGCΆTCA
ATGAATTAAACAATGAACAGAATAATTACTTTGAAGGTTATTTACATCAAGAA
GGAGGTGATTGTCCAATTTTTAAGAAACGTTTTTTCAAATTAATGGGCACTTC
TTTATTGGCTCATAGTGAΆATATCTCATAAAACTAGAGCCAAΆATTAΆTTTAT
CAAAAGTTGTTGATTTGATTTATGTTGATAAAGAAAACATTGATCGTTCCAAT
CATCGAAATTTCAGTGATGTGTTATTGTTGGATCATGCATTCAAAATCAAATT
TGCTAATGGTGAGTTGATTGATTTTTGTGCTCCTAATAAACATGAAATGAAAA
TATGGATTCAAAATTTACAAGAAATTATCTATAGAAATCGGTTCAGACGTCAA
CCATGGGTAΆATTTGATGCTTCAACΆACAACAACAACAACAACAACAACAAAG
CTCCCAACAGTAA
KEX2; ATGTTGCCAATAAAATTACTAATATTTATATTGGGATATTTATTATCACCAAC 88
AF022372; TTTACAACAATATCAACAAATTCCTCCTCGAGATTATGAAAATAAΆAATTATT
2511731 TTTTAGTTGAATTAAΆTACTACTAΆTTCTCAAAAACCTTTAATTGATTTCATA
TCCCATTATAGGGGTCATTATAATTTTGAACATCAATTATCATCATTAGATAA
TCATTATGTTTTCAGTATTGATAAATCTCATCCTCATAATTCGTTTTTAGGTA
ATCATAATTCAAΆTGAATATAATTTAATGAAACGΆCAATTAGGTCΆTGAACAA
GATTATGATGAATTGATTTCTCATGTTGAATCTATTCATTTATTACCCATGAA
AAAACTTTCTAAAAGAATACCTGTCCCTATTGAAΆTGGAΆGATGTGGTGTTTG
ATAATCGTGATGATACTGGTTCTGATAATCATGAGGCAACAGATGAAGCTCAT
CAAAAATTGATAGAΆATTGCTAAGAΆATTAGATATTCATGATCCAGAATTCAC
TACTCAATGGCATTTAATCAATTTAAAATATCCTGGTCΆTGATGTTAATGTCA
CTGGTCTTTGGTTAGAAGATATTTTAGGTCAAGGTATAGTCACAGCATTAGTT
GATGACGGAGTTGATGCAGAAAGTGATGATATTAAACAAAATTTTAACTCTGA
AGGGTCATGGGATTTTAΆTAATAAΆGGCAAATCTCCTTTACCTCGACTTTTCG
ATGATTATCATGGTACTAGATGTGCTGGAGAAΆTAGCTGCTGTGAAAAATGAT
GTTTGTGGTATTGGTGTAGCATGGAAATCGCAAGTTAGTGGGATTAGAATATT
ATCTGGCCCTATTACTTCATCTGATGAAGCTGAAGCTATGGTATATGGATTAG
ATACTAATGATATTTATTCATGTTCTTGGGGCCCTACTGATAATGGTAAAGTC
TTATCAGAACCAGACGTAATAGTGAAAAAAGCCATGATTAAΆGGAATTCΆAGA
AGGTCGTGATAAAAAGGGAGCAATCTATGTTTTCGCTTCTGGAAATGGTGGTA
GATTTGGTGATTCTTGTAATTTCGΆTGGTTΆTACTAATTCTATTTATTCAATT
ACTGTTGGTGCCATTGATTATAAAGGATTACATCCACAATATTCTGAAGCTTG
TTCTGCTGTTATGGTGGTTACTTATTCTTCTGGATCAGGTGAACATATTCATA
CCACTGATATCAAGAAAAAATGTTCGGCAACTCATGGTGGTACTTCTGCTGCT
GCACCTTTAGCTAGTGGGATTTATTCATTAATATTATCAGCTAATCCTAATTT
AACTTGGAGAGACGTTCΆATATATTTCTGTATTAAGTGCTACTCCTATAAATG
AAGAAGATGGTAATTATCAAΆCTACAGCTTTGAACAGAAAATATTCTCATAAA
TACGGTTATGGTAAAACTGATGCTTATAAAATGGTTCATTTCGCTAAAACTTG
GGTAAATGTTAAACCTCAAGCTTGGTATTATAGTGATATCATTGAAGTTAATC
AAACTATTACTACTΆCCCCAGΆACAGAAAGCTCCAAGTAAGCGTGATTCTCCT
CAGAAAATCΆTTCATTCATCAGTTAATGTTAGTGAGAAAGATTTAAAAATTAT
GAATGTTGΆAΆGAGTTGAACATATTACTGTTAAΆGTAAATATTGATTCTACTT
ATAGAGGTAGAGTTGGTATGAGAATTATTTCTCCCACGGGGGTTATTAGTGAT
TTAGCAACTTTCCGAGTTAATGATGCTTCAACTAGAGGATTTCAAΆATTGGAC
ATTTATGTCAGTAGCTCATTGGGGTGAAACTGGTATTGGAGAATGGAAAGTTG
AAGTTTTTGTTGATGATTCAAAAGGTGATCAAGTTGAAATTAATTTCAAAGΆT
TGGCAATTTAGAATATTTGGTGAATCTATTGATGGTGATAAGGCAGAAGTTTA
Figure imgf000089_0001
AAΆGTTGCTAGΆGΆTGTTGGTGTGCTTGGTATATTAGGAGGACAAGCGTTGAT TGAAAATGTTGAAGGTATTTGGGAAGAGTTGACTGATAATGTCAATGCCATGG CTCTTAΆTTTGACTACACAAGTGAGAAATATTGCCAATGTCACCACTGCCGTT
GCCAAGGGGGATTTGTCGAAAAAAGTCACTGCTGATTGTAAGGGAGAAATTCT
TGATTTGAAΆCTTACTATTAATCAAATGGTGGΆCCGATTACAGAATTTTGCTC
TTGCGGTGACGACATTGTCGAGAGAGGTTGGTACTTTGGGTATTTTGGGTGGA
CAAGCTAACGTACAGGATGTTGAAGGTGCTTGGAAACAGGTTACAGAAAATGT
CAΆCCTAATGGCTACTAΆTTTAACTAACCAAGTGΆGATCTATTGCTACAGTTA
CTACTGCΆGTTGCGCATGGTGATTTGTCGCAAAAGATTGATGTTCATGCCCAG
GGAGAGATTTTACAATTGAAAAATACAATCAACAAGATGGTGGACTCTTTGCA
GTTGTTTGCATCAGAAGTGTCGAAAGTGGCΆCAAGATGTTGGTATTAATGGAA
AATTAGGTATTCAAGCACAAGTTAGTGATGTTGATGGATTATGGAAGGAGATT
ΆCGTCTAΆTGTAΆΆTACCATGGCTTCAAATTTAACTTCGCAAGTGAGAGCTTT
TGCACAGATTACTGCTGCTGCTACTGΆTGGGGATTTCACTAGATTTATTACTG
TTGAAGCACTGGGAGAGATGGATGCGTTGAAAACAAAGATTAATCAAATGGTG
TTTAACTTAAGGGAATCGCTTCAAAGGAATACTGCGGCTAGAGAAGCTGCTGA
GTTGGCCAATAGTGCGAAATCCGAGTTTTTAGCAAACATGTCGCATGAGATTA
GAACACCATTGAATGGGATTATTGGTATGACTCAGTTGTCGCTTGATACAGAG
TTGACACAGTACCAACGAGAGATGTTGTCGATTGTGCATAΆCTTGGCAAATTC
CTTGTTGACCATTATAGACGΆTATATTGGATATTTCTAAGATTGAGGCGAATΆ
GAATGACGGTGGAACAGATTGATTTTTCATTAAGAGGGACAGTGTTTGGTGCA
TTGAAAACGTTAGCCGTCAAAGCTATTGAAAAAAACCTAGACTTGACCTATCA
ATGTGATTCATCGTTTCCAGATAATCTTATTGGAGATAGTTTTAGATTACGAC
AAGTTATTCTTAACTTGGCTGGTAATGCTATTAAGTTTACTAAAGAGGGGAAA
GTTAGTGTTAGTGTGAAAAAGTCTGATAAAATGGTGTTAGATΆGTAΆGTTGTT
GTTAGAGGTTTGTGTTAGCGACACGGGAATAGGTATAGAGAAAGACAAATTGG
GATTGATTTTCGATACCTTCTGTCAΆGCTGATGGTTCTACTACAAGAAΆGTTT
GGTGGTACAGGTTTAGGGTTGTCAATTTCCAAACAGTTGATACATTTAATGGG
TGGAGAGATATGGGTTACTTCGGAGTATGGATCCGGATCAAACTTTTATTTTA
CGGTGTGCGTGTCGCCATCTAATATTAGATATACTCGACAAACCGAACAATTG
TTACCATTTAGTTCCCATTATGTGTTATTTGTATCGACTGAGCATACTCAAGA
AGAACTTGATGTGTTGAGAGATGGAATTATAGAACTTGGATTGATACCTATAA
TAGTGAGAAATATTGAAGATGCAACΆTTGΆCTGAGCCGGTGAAΆTATGATATA
ATTATGATTGATTCGATAGAGATTGCCAAAAAGTTGAGGTTGTTATCGGAGGT
TAAATATATTCCGTTGGTTTTGGTCCATCATTCTATTCCACAGTTGAATATGA
GAGTATGTATTGATTTGGGGATATCTTCCTATGCAAATACGCCATGTTCGATC
ACGGACTTGGCCAGTGCGATTATACCAGCGTTGGAGTCGAGATCTATATCACA
GAACTCAGACGAGTCGGTGAGGTACAAAATATTACTAGCAGAGGACAACCTCG
TCAATCAGAAACTTGCAGTTAGGATATTAGAAAAGCAAGGGCATCTGGTGGAA
GTAGTTGAGAACGGACTCGAGGCGTACGAAGCGΆTTAAGΆGGAATAΆATΆTGA
TGTGGTGTTGATGGATGTGCAAATGCCTGTAATGGGTGGGTTTGAAGCTACGG
AGAAGATTCGΆCAATGGGAGAAAAAGTCTAACCCAATTGACTCGTTGACGTTT
AGGACTCCAATTATTGCCCTCACTGCACACGCCATGTTAGGTGATAGAGAAAA
GTCATTGGCCAAGGGGATGGACGATTATGTGAGTAAGCCATTGAAGCCGAAAT
TGTTAATGCAGACGATAAACAAGTGTATTCATAATATTAACCAGTTGAAAGAA
TTGTCGAGAAATAGTAGGGGTAGCGATTTTGCAAAGAAGATGACCCGAAACAC ACCCGGAAGCACGACCCGTCAGGGGAGTGATGAGGGGAGTGTAGAGGACATGA TTGGGGACACTCCCCGTCAAGGGAGTGTTGAGGGAGGGGGTACAAGTΆGTAGA CCAGTACAGAGAAGGTCTGCCACAGAGGGGTCGATCACTACAATTAGTGΆACA AATCGACCGTTAG
PLDl; ATGCTGCCAACAGCCGAACAACCCATTTCACCATTAGATGAGAACCCATTGGA 91
AB010810; TGAAAATGTTAATAATCTGAAACTAAAAGCTTCTTCTGCCAΆTGACAAAGAGG
3413517 ATGGTAGTTACAATTTGAAAGCAGTACAGCAAGATGGAACCATTGACGATAAC GATGCTTTACGAAAACTGCTGGATATAGACAGAATTTTTCGATCTGTCCATAG TGGACCAATTCTCCCAGAACATAGGTCTCCTTCCCCAAATACTCGTGACGACT CATCACAAGTAATTGGTAATCCTCTTTCATTTTATTATTCCAATGACGATAAG GAGTCCCGATATGATGAGGATAGATCACAGAGACAACTGCTTGGAΆΆGAACAA
GTATCCAGAAGACGAACAACAACTTCCCAACCGCTTTGAACTTGTGGATGΆTG
AAGATATAAACAAAGCTCCACCGAGAAAGGAGTCGTCAAGACCTACACATTCT
CGTTCGGCAACTTTGAGTGGTTTTATGCAGTCAAGAATTTTAGGGAGATCAAC
GTCCACTAATCAAGAAATGCCAAΆTACTGAGCCCGAATTTGCΆAATTTACATG
ATGCCTTGCACCCTAGAGAAGACAGCACTAAGAGTGGCAGATTTATAAAGACA
TTGCGTCGTTTCAATAGAAGAAAGACTAAAGATAAGCGACAAAGCACCATGAC
TGCCGAGTTTGΆTGAGCTTΆATGACGAGTCTGAAAATGCCACTATCGAAAGGG
CAGAAAAGTTACTAGCAGGTATGTCCACTGGTGCTCCTGCAATCAATTTAATG
GCCTCGTGTCTATTAGAAGATGAACATGGTATAACCAGAGCCCCGTTATTGTT
GTCAGTGCTTGGGTTCAAGTTGAGCGACGTTACTCCAAAAGAGACAAGCAGAA
ACAGGAGATTTAGAATTGATTTAGAATACGGAATTGACAAGCACAGAATGAAA
TGGAGTATTGAGAGAAACGCCACTGACTTGGCTTATTTAGCTTACAΆACTCGA
GAGAACAAGΆATTGTAAGTAGAGTTGTGGGAAΆCAAATCTCAACCATTACCCA
GACTTCCAATTCCACCAATTCGAAAATTGGATAACAAAAGAAGCAAAAAGACT
AAAAGTGTTTTATCTGATCTGCGTGCAAGAGACGACCGCATGTCAGTACCAGA
TATTAACGATAACCACTCGCTTTCACCAGTACCATCAGCTTTGTCTAGAGTGA
GACTGCGTTTGGGAΆGTATAACATCAGTGGGCTCACTTGAAAAGCATCCAGAG
TTGCTTGAGCTCAGACGGAAAAAGAATGCACAATTTATGAAAGATGTTGAGAG
TTATTTGAΆGGΆATTGATTGAAΆTTACAGAGTTAAAAACCCTGGCAΆATATTT
TGTTTACTTTCTTTGAGTTGTCACCGCTCTCGTCATTATTGAGTTATGAATCT
GGCTATACTGGTAAGCAGGGTCCAGTCCATΆTTGGGGGAACTGCTAAAGCACA
AGGTTGGAGAGTTGGCCATTTCAAAGTAAACGATTTGAAAGGAATCTACGAGA
GAAGAGTTGAAAΆGTGGATGCTTGTGAGAAACAGTTACATCACATATGTCTCG
GATATTAΆCTCGACTACACCGTTAGATGTATTTTTGGTAGATAGTGATTTCAA
GATCAGTGCCAGΆΆACTTGGAGATTGCAAACAGAGATGATGATGATTCATTGT
TTGACAACTCTTCCGTTGCCCAGCAΆCAAATGCATGAAAATGAAAACAAGTTT
TTCCCACATTTGAAAATCACTTTGGAAAATAGAGAAAGAAΆATTAGTGATGCT
GCCAAAATCTCAAAGAGAGCATTCTCTTTGGATTGACTCTCTTAGAACTATGC
AAAATCTGACAATATGGTCCCAAAATΆΆGAGATTTGATTCTTTTGCCCCAGTT
AGAGAAAATTGTTTTGCTCAGTGGTTTGTTGACGCTAGAGACTACTTTTGGGC
TGTCTCCACTGCTTTGGAAATGGCCAAGGATACCATTATGATACACGATTGGT
GGCTTTCTCCGGAATTΆTATCTTCGAAGACCAGCAΆATGGTAΆCCAΆCAATAC
AGAATTGATAGATTGTTGCAAAGAAAAGCTAAGGAAGGTGTTAAGATTTTTGT
GATTATTTATAGAAACGTTGGTACAACGGTTGCAACTGACTCATTATACACAA
AACATTCCATATTGTCTCTTGATGAAGAGAATATTCATGTTATTAGGTCACCA
AATCAGCTTCTTCAAAATACATTCTTTTGGGCTCATCACGAAAAATTGTGTAT
AATCGACCACACATATGCTTTCTTGGGTGGTATAGATTTATGTTATGGAAGAT
ACGACACGCCAGATCACGCATTAACAGACGATTCAGGTGTTGATTTTTCCAAT
ATCGCACAGGΆCGATΆGAATCACAGCAGAAAACTTTGCGAΆTTTCCAAGTTTT
CGTGGGTAAAGACTATTCCAATCCTAGAGTTAΆAGATTTCCTGGAACTCGAAΆ
AGCCATATGAATCCATGTACAACAGAAATATTGTCCCTCGTATGCCTTGGCAT
GATGTTCATATGTATACATGTGGGCAGACCGCAAGAGATTTGTCCAGACATTT
TGTTCAGAGATGGAACTATTTAATCAGACAAAAGCGGCCAAGTAGACTCACTC
CACTTTTGTTGCCTCCATCTGATTTGACTGAAGAAGAGGTATTAGCTCATGGA
TTGGATGGTACATGTGAGGTGCAGTTGTTAΆGATCATCCGGAAATTGGTCACT
TGGTTTGAAAGAACACGAGCAAAGTATTCAAAATGCGTATCTTAAATTAATAG
AAACTTCCGAGCATTTTGTCTATATTGΆGAATCAATTCTTCGTAACAGCTTGT
TTCATCGACGGTACAGAAATTAΆGAATAGAATTGGTGATGCGTTGGTCGACAG
AATCATTCGAGCACATAGAGAAGGTACTAATTGGAAGGCTATTATTGTCATAC
CTTTGATGCCTGGTTTTGAAGCTCAAGTTGATGAAGCAGAAGGGTCTTCTGTT
CGTGTGATCATGCAATGTCAATΆTATGTCAATTTCCAGΆGGTGΆAACGTCTAT
TTTTGCAAAATTGAGGAAAAAGGGAATTGATCCAGACCAATACATTCAATTTT
TCTCCTTGCGGAAATGGGGTAGAΆTAGGATCAAACAGAACTTTAGTTACCGAG
CAGTTGTATATTCATGCAΆΆGACGATGATTGTCGATGACAGATCGGTTATCAT
TGGGAGTGCCAACATCAACGAGAGGTCTATGCGTGGTTTGCGTGATTCCGAAG TTGCTGCAGTTGTTCGTGACAAGGAAATGGTAΆAGAGTAAAATGAATGGTAAG
CCATATATGGCAGCTAAGTTTGCTCACACATTGAGAATGAGGTTGATGAGAGA
GCATCTTGGAGTTAACATTGATATTGTTGATGTGGTTGAΆAGAAGGTTTAAGA
GATTTGAAAATTTTGCTGCTTCAGAGGAAGGTAAAAAATTCGCCACCAACAAG
TTTAGAAACCCCGAGAACCGTACATTGTCTGCTATGGTAGAGATTGCATCGAG
AGATATCTTGCAACAACCAGAGGGAACCAGAAGATGGAAGGAGTTTATCCATG
TGTCGAAATΆTGATGCTGAAATTGCCGAGGTTAΆCTTTGΆGGAAGAGGACACA
TCGTTACCTCCACCTCTTTTCTTACCAATTTCATTCAACAACCGAACAGGGCC
ATTTGAΆGCCAATAAAGGTGTCCGTGACAGCAAGAAGCATTCATACGATAACA
GAGTTCAAAATAGCGAGTCACATAΆAAAGGATGTTTACGGTGAAGGGTTGGΆT
AAATACAGGTCGAAGTTAGCCAAGAGAGCAAGGGTTAGCAGTGGTAAATTTTT
GAATGAGCTTTCCCTCCTTGCCATGGAAACTAATCCTACAGGGTCGTTTTTGC
CTGATTTCGATAGTGTTAGGAACTTTTTGGAGTCAGATGATTGTCATATGAGT
GGAGAAATGGATGACGAΆTCCGAAGATATCATTGCAGAAAGAAATAAGGAAAG
ATGGATGTTGCTCAAGAAAATCTCTTATTTACAAAGACTTGCCGCCAGAGAAA
AGAGCATGAATGATACAGAGAACCAAAAAAGGGCAAAATTGGGATTACCGCTC
TTGTCTAAAACTGGAAΆTGCTGTTAATGGTAACGAATCΆCAAGAATTGCCTGT
CAGTGCCACATTACCTATTTCCGAGGGAATTGACACGGATTTCAGTTTGGATA
AAGAGTTCCCTACTGTATCTTTGAGTGAACCCGCTGCTAGΆGATATCΆTCAAC
AATTTGACAACCCCTGATGCTGCTGTAAGTAATTTTGTTGATCCATATGAATT
TGAAGATCCAATTGATCCTGΆTTTCTATGAAGCACGATGGAATGAATTTGCAA
GAAGAAACACTGATATATACCGTATGGTGTTCCATTGTCAACCTGATGATGTG
GTGGGTAGATGGTCAGAGTACACACACTTTACAAAATTACAGAGTΆTGTTTAT
GAAAGCTCAGGATACAGACACCGACCAAGGTCAACTGGCAGAAAACTACTCCG
ATGAAAAAGTCGAAGCTGGTGATAΆCCAAGAACCACGACGTGCAAACAATTCC
AAACTAGAAAAAATTGΆCGΆΆGCGAGTGΆΆGACGAGTΆTGGTTTGTTAGGTAΆ
GGCACCACCAGAGAGAGGTCTTGAGAATCAAAATAAACTGGAACAAGAGACCA
ACTTGAGGGCTAAACTTAGTCGTCGTGTTAGCACATTTGCTGGTGTGACAGAA
AACCGGGATAAACATTTTAGTGACAAAGCAGCGCCTAAATCCGAGGGTGAACT
TCAΆGGTGGGGAΆAAGACAAGTACAGAAGAAGAAGAATCAGAGGAATCGGGAA
CACCTACTGATAAACCTTCTGCTACTGCTGGAACAGTACCAGCATCCAAAACC
AGGAAAAGGGCACGTACTTATTTAGCTAGAAGAAAΆATTCAAACCGGTGATGT
TGTATATGATAAGAATTCAGCTGAGAGATTATTGAATGCGGTGCAGGGACACT
TGGTGTACTTTCCAGCGGAATGGTTAAGCGTTGAATTGCGAAACAATAATTGG
TTCTACAACACCGATAGACTTCCACCTATGGAAATTTACGATTGA
PMTl; ATGGCAAAGAAACCGGTCACACCCGCTTCTAAAGTTGCTGCAAAACAGGCTGC 92
AF000232; TGTTAGAAGCAGACACCAAGAAGATGTATTCACACTTGATCCATTGATAGATC
3411012 CAATATTTCAΆAAGGGAGAATTGCGTTCGTATTTGGTAACCGΆΆCCTTCTCCT
AGTGTTCTTAAAAAAAGACTGATTCACACCAAAGAATACTGGATGCTTTCAAG
TTTATTATTAATTGCTTTCTACGTTAGGATGTATAATTTATCCAATCCAAACT
CAGTAGTTTTCGATGAAGTCCATTTTGGTGGGTTTGCCAGAAAATATATTTTG
GGTACTTTTTTCATGGATGTACACCCTCCATTGGCTAAAATGCTTTTTGGAGC
TGTTGGAGCCATTGGTGGATTCAAAGGTGATTTTGAATTTAAATCAATTGGTG
ATAAATTTCCTGATTCTACACCTTATATATTTATGΆGACAATTCCCΆGCΆTTG
TTGGGTGTTGGAACTGTTATCTTGTGCTATTTGACTTTGAGACAATCAGGTGT
TAGACCAATTATTGCTTATATAACTACCTTTTTATTGATTATTGAAAΆCTCCA
ATGTCACTATTTCAAGATATATTTTGTTAGATTCCCCCTTGATTTTCTTTATT
GCTGCTGCTATTTATGCTTGGAAGAAATTTGAAATTCAAATTCCATTCACCTT
TGGCTGGTATAGAAGTTTATTGGCAACTGGTATTGCTCTTGGTTTAGCATTGA
GTTCCAAATGGGTTGGTTTGTTTACCGTTGCCTGGGTTGGTTTCTTATGTATC
TACCAATTGTGGTTCCTTATTGGTGATTTATCAGTAAGTACCAAAAAAATTTG
GGGCCATTTTTTCGCAΆGAGGAATTATCTTGTTGGGTGTACCAATTGCCTTAT
ATCTTGGATTTTTTGCCATTCATTTCCAATTATTAAATAΆAGAAGGTGATGGA
GGTGCCTTTATGAGTAGTGCCTTTAGAGCCGGATTGCAAGGTAATAAAATTCC
AAGAGATATTACCGAACAAGTTGGATTAGGATCAGTTGTTACTATTCGTCACG
TTGATACTCAAGGTGGATATTTGCATTCACATGAACATTTCTATCAAACAGGT
Figure imgf000093_0001
TATACTTATGATTCATGTGATGCTGGTATTACACCTAATCAATCTTCTCCAGA TGGGATTTCTTATTTACCAGGTCAAAGATTAAATAAATGTACTTGTCCAGGTG AAGCTCATCCTAΆTCGTGGTGTTGGTAGΆGGTGCCCCTGAAATTGATGCATTG GAAGGGGAAATTCATGGTGTTATAGGTAGAGTTTCTCAATCΆTTACAAGTTGC TCCTTATGATATTTGGTATATGCCCAATTATGATTTTCTTGAAATTCATAATA GTTCAATAACATTAATGAATACTTATGCTGGTGGACCTTTCCAACAAGCTATT TCGGGTGTAACAATGTTAAATGTTACATGGTATGAATATGGTGΆTCATCAACA TAΆTTTCCAΆAAATATGGTTATGAΆTATTTAAATGATGATGAΆTCAGGTTATT TACGTTGGTTTGTTGGTGACAATCCAACTTTTACAATCTATTCTCAAGCTTTA CATCCAAATGGTAΆTGTTGGTTGGAGAAAGTTACCTAAΆGAACCTTTAAGTTT GΆTTTTAΆΆTTTTGGTATATCTAATAATTGGGCTTATATCGATTGGCCAAGTT TAGTTTTCCCTTCAACTATGAGAGTCGATTATGTAAGAGTTTATCAACCTAAA GATCAAATTAATGTTGGTTGTGATCCAACCGATTTCCCAACTTATGΆTTATAT TCAACAACATTTAAATGTTTATCAΆAATGTTAATTTAACAAAΆTTTGAAGATG GTGGTTATACTTTCCCCAAACATAAATTAATTGGATGTTAA
SSKl; ATGAATTTTCTCTATAACAATTCAGATTATAGTAGCACATCACATACTATGAA 94
AF084608; GTCΆCCACTGGCATΆTAATCΆGTTTCCTAAACTACAGGCAAGCAATTCGACAG
5915906 CTGGTAACAATAATACAGCCACAACAGCAACGGCAGCAGCGGCAGCAGCATCA
GCATCAGCATCAGCATCAGTTACΆCCACAΆTTGATATCACCAACAΆCGTTGAC
CACACCACAGAACAAGTATAAACGTGGAGGATTGGATAATACGCTTCCCAAAA
TAGAAACTACTΆGAAAGAACAGΆCCGGATGATGGCAATTCAATCACGCCCAGC
AATTCGATCAATAGTGGTACAACAAAGTTAACCTTACCACCACGACGAGTTTG
GGTTAAGAAACCGCAAΆCAAACAACCCAACCACGGTACTTTGTTATGTGAATG
ATATAATTGΆTGATTTAAAAGTAGCAGTGGTGAACAAΆTATCCAAATACCATT
GGCAGGTACGAGGATGCTGCCGATTTGCTTGTTAAGATAGATTTGAACAACAT
CΆGAGTGCCAGTTTCCCCCAGTGTTΆATCGAGTGTCGCΆΆAGAΆCTCCATTTG
ATAATTGTΆTAATTTTGGAACCAGATCAGAACGTTTGGCAAATΆCTAGACAAT
TATTTTCCTAATGGAATGGCCATGCACGATGCCTTGATAATTGAGACACCAAC
ATTCAAACCAGACCATCAAATGCTAACACCAATAACAGCCAATATGAACAATA
ATAGTAACACTTTTATACCTTTTCAAGAACGTCAATCGAGTΆTCGGGAACAAC
AACAACAACAACAGTAATGTAAACAACAACAATAAAGCACAAGCAGTCAAACA
CCCGCAACCAATGCAACCAAACAATACTCGTGTAGGTTTACACAAGTCTTATG
CCATGAATAGGTCGAGTTTCCTGACCAATAACAACCCTGTCCCATCTATCATC
AAGGATAGATCGGTGTCACCATCAAΆCTTGGGAGTTTCAAGAAΆCTCTCCTGT
TTCCCATAAAAGATCATATTCAAATCCAGTTTCTTCACCAAATTCTGTTGCTA
CACAAGCTAATAATCCGCTGGCAGTTTTACTATTACCCAGGAATTTCTCATTA
GCTAATAΆTAATAGTAATCAAGCACTGCAAAGTAGTGGTGGAACACCTGCCAA
AAAAGTTTTATCCGAGGACGGAAGTAAΆTCGGTCAΆTGACAAGACAGAAGAAG
TTGTATCATCCAAATTGAAACCAAACGATAACAATAAAAGCTATCAAGCTAAA
CAGCAAGAACAACAAACTGCCGAACAGTCTGAAAATGGCTTTAGTGAAACTTC
AGCATCGCCTGAAGCGGTTCATAATTCTAAAGCAGCACCATTACCGTTGACCA
AATCATCAACAACTGCTACCACAACCTCTTCCAACTCCATTAGTAATAΆCAAT
AATACTAGCAGCAAAGGAAAGCCAAGTCAATCCAAATTAAAAGCAGCTAATGA
TCCAACGCCGACGGATATAGTGTTACCGTCTATTTCTGTATTGGTΆGTTGAAG
ATAATGCCATCAATCAAGCTATTTTGGGAGCATTTTTACGTAAACGTAAAATT
CATTATCAAATTGCAAAAAATGGCCAAGAΆGCAATAGATAAATGGAAAAAGGG
AGGGTTTCACTTGGTATTGATGGΆTATTCAATTGCCAGTGAAATCAGGGATTG
AAGCAACTAAAGAAATCAGACACTTGGAGAAATTGAACAGGATTGGTGTATTT
CATGAAAACGAAATTGGGAAAAATGTΆATAATTAATGAAGAAGATAGATTGAC
TTCCAATACGTTTΆGATCTCCGGTGATTATAGTTGCTTTAACCGCCAGTTCAA
ATTCTTCTGTGGATAAGACTAATGCTTTAACAGCAGGCTGTAATGATTATTTA
ACCAAACCAGTCAATTTAGTTTGGTTACAGAATAAAATCACAGAGTGGGGGTG
CATGCAAGCATTGATTGATTTTGACGGΆTGGAAΆGATAAGAATCGAAGATTAA
ACAAAGCTTGA
TPSl; ATGGTTCAAGGAAAAGTCTTGGTGGTTTCAAATAGAATACCTGTTACAATCAA 95 Y07918; AAGATTGGATAATGGTTCATACGΆTTATTCCΆTGTCCTCCGGTGGACTCGTTA
Figure imgf000095_0001
CCATTGGCTGATTTCTTAATTGAAAGAGCAGTAGAAAATGAAAAATTGGGTAA
TTTCTTTTACTGGTATGTTAAAGTTGAAAATGAAGATCAACTCAATAATCCTC
ATATCGATGGCCCAΆTCAAAATCTACATGGATATTCTTAATCGCTATATTGAA
TTGCTAAAAGCACATTGTCATGΆΆAATAGACTTCCTTACTATAΆGCATTTAAA
ACATCAAATATGGTTCATCAAGAΆATTAACTTCTTTGGTAGAGTTATTACGTG
CTTCATTTAAGAΆAAACGAGGCAACAGCAAAGAΆAGTTGAΆTATTTGCGGGAG
TATCTΆGCAAATTCTGGGAATGAATTGTTAAAATTCCCTGΆACCTTTCCCATT
ACCACTTGATCCATCAGTTATGATATGTGGATGTTATCCTGAGGAATCATCAG
TTTTCAAATCTTCATTGGCACCATTAAAAATTACTTTAAAAACCATTGAAAAG
AAGAAACACGGACATGCCACTTCGCAATTATTTGGAAAACGATCTAGATATGG
GAAATACCCGTTAATGTTTAAAATAGGTGATGATTTAAGACAGGATCAATTGG
TAATTCAAATCATAGACTTGATGGATCAACTTTTAAAGAATGAAAATCTTGAT
TTGAAACTTACACCATATAAAATATTGGCTACTAGTCCAATTTCCGGGTTGAT
TCAATTTGTTCCAAATGAΆACTTTGGACTCTATTTTGTCCAΆGACATATCCAA
CATCGGTCACATATTCTGGTGGTGGTGAAACTTCTGATGGACCACCGTCAGTA
TCAAACAATGGTATTTTAAATTATCTTCGTCTTCATAGTCAAGAACAACAATC
CGAGGΆACCTATATCCAAAAGTATTTTAAGTACAAATΆCCAGTCAGTCCAATA
CCGAGATACCAGTTTTACCACGTCAACCTAAACCAACAATAACTTCAGATTTG
GGTGTATCACCGATTCTTATGGATAATTΆCGTCAAGTCATGTGCTGGTTATTG
TGTAATTACCTATATTTTGGGTGTTGGAGATAGACACTTGGACAATTTATTAC
TTTCACCCAATGGGAAGTTTTGGCATGCCGACTTTGGATATATACTCGGCCGT
GACCCTAAACCTTTCCCTCCATTAATGAAATTGCCTATACAΆGTAATCGATGG
GATGGGAGGGTTACΆTCACGAGAATTATAATGTTTTCAAGAGCTATTGTTTTA
TCACATACACAACATTGCGTAAAAATAGTAACTTGATTTTGAACTTGTTCCAA
TTGATGTTGGATGCCAATATCCCAGATATTCAATTTGATCCACTGAGAGTGAT
TGAAAAGGTACAAGAAAAGTTTTGTTTACAAATGACTGAAGAAGAAGCAATTT
TACATTTCCAAAATTTGATTAATGATAGTGTGAATGCGTTTTTGCCTGTTGTT
ATAGATΆGATTΆCATAGTTTAGCACAGTATTGGAGAGCTTAA
Table7. AminoacidsequencesofC.albicanspredictedgeneproductsthat inhibithyphalgrowth
Figure imgf000096_0001
Figure imgf000097_0001
Table 8. DNA sequences of C. albicans genes that encode polypeptides that inhibit hyphal growth
Figure imgf000098_0001
Figure imgf000099_0001
GCTGCAATTGAAGCTAGTGCAGCAGCAGCTGTTGCGTCTCAAGGATCACCTAATG TCACTGCAGCTGCTGTAGCCGCATTACAACACACACAGGGTAATGAGCACGATGC TCAACAACAACAAGATCGTGGTGGTAΆTAACGGTGGTGCTATTGATTCAAATGTC GATCCAAGTCTTGACCCAAACGTTGACCCTAATGTTCAAGCTCATGATCATTCTC ATGGATTAAGAAATTCGTATGGGAAAAGAAGTGGGTTTTTGTAA
RFGl; ATGTCTACTGCTATCTACTATTCAACTCATAATAACATGCACACAAATGATGATA 106
AF330198; TAACTAATGGTAGTGGTTCTACTACATCTGGTAATCCAGGTGCCAACCCATCAAA
13183713 TCCTAACCACACTAATGCTGGTGCAACTATCAACAACAACAGTAATATTGGTTTA
AATTCAGCTAATAAGAACCATACCACTTTATTACCTTCTTTGGCACACΆTTATGC
CTAGCAATAGCAATAACACTACTAATAGTGGATCTTCTATTGATATAAGCTCCAC
ACTTATCAATCCATATTCAAGTGGGGCTGCCGCTGCCGCTGCTGCAGTTGGTGGT
GGTAATGGTGGATATTATCATCCTCCACCACCACATTCTCAACAACAACAACAAC
AACAATTTGATACTTCTTATTCGAATCAAACTACTCCAACTTCAGCTTATACCAA
TTTCAATAATGATTCTACACATTCACCTACΆGATATTCTGATGCAACAGAATATG
AATAATTTAGCATCTTCATCAGGAAATATGTCTATTGGTGGTGGTATTGATGGTA
ACTTTTCCCACAATAATAATAATAΆTAATAACAACAACAACAATAACAATAATAA
ATGTATTTGTAAΆTCAAAAGTCAATAAAATTCCTCGACCAAGAAATGCATTTATT
TTATTCCGACAAAAATATCATCAAATGGTATTAGATGAAGGTACTGTTATTAGAA
CCAACCCTGAAGTTTCCCGAGAATTGGGTAGACGATGGAGAGGATTATCACCTCA
AGAAAAGGAACATTGGΆATAATCTTGCTGAAGAAGAAAAGAAGAATCATGCCAAA
AAATATCCTGGGTATAGATATACTCCAAGAAGAAATGGTAGAAACAAAAATTGTC
CTGTTTGTAAAAATAAACCCCTTCCTAATAATAAATCTAATTCTATTAGTGGAAT
GAGTGGTAGTGGTGGTGGTGGTGGTAGTATATCAGGTGCTAGTAGTCTCAGTGGT
GGATTAACTTCTCGTGATAATTCAATTACTAATGCAAATGCTATTGATTATCAAC
AACAACAACTACAACAACAACAGCAACAGCAGCAACAACAAGCTATACAATTTCA
ATCATTACCACCAGATCAATATCAACAATTAATTAAGCAACAACAGCAACAATTA
CAATTGCAAGCTCAACTTAATGGAGGTGGAGGTGGAGGTGGTATAACTAGCAACC
CACAAACTATACCACAATACATTACTAATGGGAATTATCCATCATACATAATTTC
TCCAAATCCTTACTCCACTACTAGTACAACTGCTCCTACAACAACAACTACTACA
ACCACCAΆTGCATCATCAATAGGTTTATCAGTACCACCCACAGCTACAACTACΆT
CAACATCATCACAACCTACATCAGCAAΆTTCCCAATTACATTTCTATGAAGCTGA
GAAATTATCTCCAGTATCATCAACTCATCATCAAAGTAGTATAAGTGAGATAGCA
GCTCAACAGCAACAACAACAACAACAACAACAATTTATGTATAATACTAATTATA
GTACTATACCACCTAΆTAATACTACTACGATGCAΆCAACATTCCGCAGGTACAGG
AAATGATTATAGTCTCAATGGTAATAATAGTGGAAACACTGGTTATGATAATAGA
TATGGTTATGGTCAACCTATGATAATTACTGGTCAATCACAACAAGGTTTACAAG
TTCAACAACAAGGTCAACATTATAATAGTGGTTTACATGCTGCTCAACATTATCA
ACAACAACAACAACAACAACATCATCAACAACAACCTCCACAΆTAA
TUPl; ATGTCCATGTATCCCCAACGCACCCAGCACCAACAACGTTTGACAGAGTTGTTGG 107
AF005741; ATGCAATCAAAACTGAATTCGACTACGCCTCAAACGAAGCAAGCAGTTTCAAAAA
2245633 GGTCCAAGAAGATTATGACTCAAAGTACCAACAACAAGCTGCCGAAATGCAACAA
ATCCGCCAAACAGTGTATGACTTGGAGTTGGCCCATAGAAAAATCAAAGAGGCAT
ACGAGGAAGAGATATTGAGGTTAAAGAACGAGTTGGACACTAGAGACAGGCAAAT
GAAGAATGGCTTCCAACAACAACAGCAACAGCAACAACAGCAACAACAACAGCAA
CAGCAGCAACAACAACAGATTGTGGCACCACCTGCCGCCCCACCTGCTCCACCAA
CCCCGGTCACATCATTATCGGTTATCGACAAGTCACAATACATTGTCAACCCCAC
CCAAAGAGCTAACCACGTCAAGGAAATCCCACCATTCTTGCAAGATTTAGACATT
GCCAAAGCCAACCCCGAGTTCAAGAAACAGCACCTCGAΆTACTATGTGTTGTACA
ACCCAGCGTTCTCCAAAGACTTGGATATTGACATGGTCCACTCCTTAGACCACTC
GTCAGTTGTTTGCTGCGTGAGATTTTCCAGAGACGGCAAGTTCATCGCCACCGGT
TGCAACAAAACCACCCAAGTGTTCAATGTCACCACCGGAGAGTTGGTCGCCAAAT
TGATTGACGAGTCCTCCAACGAAAACAAAGACGACAACACCACCGCCTCAGGCGA
CTTGTACATCAGATCTGTGTGTTTCTCCCCTGACGGAAAACTCTTGGCGACAGGT
GCAGAAGACAAGTTGATTAGAATCTGGGATTTGAGCACAAAGAGAATTATCAAAA
TCTTGAGGGGCCACGAACAAGACATTTACTCGTTAGACTTTTTCCCTGATGGCGA
TAGGTTGGTTTCAGGCTCCGGCGATAGGTCAGTCAGAATCTGGGACTTGAGAΆCC
Figure imgf000101_0001
Table 9. Amino acid sequences of fungal cell wall proteins
Figure imgf000101_0002
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
EAL02119; VHAVTKPLPTDYIACTAFLHDLLVDKSNVWVPLSYIKILKEMPSΞDIRISKK 46442833 FNNIHENSEIPTIRDTELARQEAVDGTILNEFIKKSVPPRPTKRDHSRDTLLD
EIKYSLELLNAHIFAVYSKSEFRLFEKLTSIYYSLYEIRTKLNHHLLTSEEAQ
VARETATFLLNRIPKILASRASRLGKDVIELDYSDTDVSGYKSILSRDAETGE
VLSLKTALPPRIALNNELGALVPNYPINIHDNFHNYSLKPSAMKKFYHDPPSH
ILVDFKSVTGSSAYQPPGFAGMVAYMYIRNSKKRLTEAFΆVHTNSVEDFVHVE
KISAALFRNLPASEIENNRVYLVAVLTEEVDLNIKGTGHTPTIKRVKKGVAAG
VADITRIFPRAEGSLQSGΞAHNFSIKLFGSYLSKKGHKNMVEDLRGLSNNGWG
ΞLVDRIIAGSSQGVAVNPRAEKLVITVKEFKHQFQGNVANQLSSSAPISRIKP
IFFDPLAENYERIYLKMGKVTLLGSNAREDLLTFEVSTPNNELITFAKΆSNQQ
EKRYWQFISVFPGESIGEIVKVNGVALKNSSKKLPKDDYILLSLYVNGVLAGE
GRLLYKSGNRLVEFNKKKTHTIE11SATHNVPMAHIELSTEYVGKVYNSDVSI
DNIFQYERFFQNGQKGIDELSNSLVAFTRLDIAQWKYFPELLSSLYGIIGFS
SHHSGPSIEILEDNTFKAVIHLLDTVFGKQDQYLYLLDNFIAKYKSSNQIGIF
LLTKVEQIFNRAGSSWNSVSRSVCRVLSIILRISILSMNAPNEQDLYLQTLNN
LFKSIAYLLTLDSTNMIDDQVLVMDIIDYIFAFDVNFKGSELVQIMINCIDSI
GLKGVGVDELSMESTPAGSRSIKDHKIIIGKLLLILRLLNSDLVKEESSRCIL
IPKAITWAVDVFLAPTDIEATRLACSVLNAACTALWNDGVIGKYQGDMEICYS
LAKFLPAISRTFIKYNKFTRGNGSFKKKRVFTQLFPSTYPFIEFSIDPWNDE
SMVEVLVELAITFSFVARVGKEAAGNEGYITILDSRIENDFFIPEKYLASDFH
GEDILTLLSGIRYMRLGKYFPETKWYSTYSVIIEGCLCAIELVRPLVIINQLP
ALDDSESFDRTLWGNYLRSLFKLAVLPPVAVEHLSDVPKSACAKITNDVRKRA
AFLINEAWDSLAWDATDEDMLRFNLKKFGGYQVEFINDEFGILPDLMLLGLQR
DSECQSVAIKILWSIMISEYILSDTLQDVΞRQCLLGLHEIYHNNSYKPTSLDQ
ENFIERMKMTVRLDREDEAFD11YNFIQNLSSFFGTLNYYISVPFGPEYEEDR
IFHEIKLKAQIKNAGKPELFNSYIHQMYEKYLSQNDYVQAALSLELLASTYSW DHHIIVPASFRPKFPEQSSFERKEILLKMIANNFVKGNSLEKAADTYNELLDS YNEHTYDLKSFAYVHNKLAQLYLDMESSDKLTPTYFKVEAIGGGFPTYLTQIS QIFQGLPFEHITSIHERFLKVFPGAKIISDDAEAIRLKΞKATNGRYLYIKTVE PVYEFSDKLINTSLGVRQYARNKDLRFFTSLKKFPGATSVFDLWTEETTYETW LSFPTLMNRSFIKDSKTVKLSPLDNAVRTIAAKNDDLIQLΞAFINAALKEKTD YSHYFNDLSRQLAGTVDSPVNGGVGQYRAFFSDSKYQINEESIAKTELLRNAF NDLAIILYRCVNLHGSLIGLSMKSSHQALVELFRKNFQEEIVALRLGEEATIT APSSSRVSIFHNKRANGLMTERANSISNMSGAGSTYSGSRLARSPTNASSVSS NNSSITRSGRASNTSGYPASVIQPGYTGLKGSSLKNGNGSVTSKSINGSGKTN
AINTKW
YMR029C; MPPFKLRSRSNSSSSSNPQTQWYNNKNQNQPSMSEPTYTLPGVINYLTSEFTK 167
EAK97460; LEQFKIVNNLERSEMKFKIKΞLΞGEIKSLTFTNKLQKKTIERLQTENKKLRSR
46438124 LNEEEVEEVIMTPSPEELAKMSKIDLQTIKRTRERLANSMKEIVTLLKPPTLE PSISLAKTSKNTNDLESLLDKPEINKADDFNFNVKPYSFESKDYESPVRNPSS LISQYFNSNTDLKEISKΞKKKAEMENDSIVDDDEILDAELEDVLEKAISETSD SATIVLISTDDDDPLADLNDDDFSLDDSPQERSQINNNNNNNNDDDDLDFEDKLS SFPSLVSPSLVLPSLVPPPLKSPQLQPPQLEPPVLEPQVSSSISSSSKKNKEE EGGYDHLDVYYHDPNTIYLRSMKDTTKKEVKLDMLLDGKLASTQKFEMETSAQ DIADILPIDVPDTLLIVKKNGDVKSMVFELGNGKEHTIMSVKSDFKDIESCGL TEFTVKMDDTYKYYGLCISGKSSSNRKFLSKIYΞLSYDLSNRΆVTSKEIGSYN KKFLTKGKPADEVHFAGWINNAKVDSLVDILEADKDPKSSISGDDLTLLPYEV LYDVDGKTIKLNIVSKQVLEILA
YPR098C; MLCQVGLNVKVPFHFLFYSLTFGGSAFYSFIVSPLVFKKLPREEFSNLQNKVF 168
EAL03384; PTYFTGQTLAPIILGLAQPFAYCPFTLGLLALSSVGGALNYLWLLPVCQKIKE
46444107 DRNKLIADKKDVGADGQPTEELKALNKQFGKYHGISTLVNITSILSLGVYGW LAKGLSKIKF Table 10. DNA sequences encoding fungal cell wall proteins
Figure imgf000114_0001
CCGAGTATTGGTCTCAΆTCCTTTGCTACTACTACTACAGTTACTGCTCCTCCA
GGTGGTACTGACTCAGTAATTATCAGAGAACCTCCAAACCCAACTGTCACCΆC
CACTGAATATTGGTCCCAATCTTACGCAACCACAACTACTGTGACTGCTCCTC
CAGGAGGCACTGACTCAGTAATTATCAGAGAACCACCAAACCACACTGTCACT
ACTACTGAATACTGGTCACAATCATATGCCACCACTACCACTGTAACTGCACC
ACCAGGTGGTACTGACACTGTTATCATTAGAGAGCCACCAAACCACACTGTCA
CTACTACTGAGTATTGGTCTCAATCGTTTGCTACTACCACAACTGTAACTGGT
CCACCAAGTGGCACTGATACTGTTATCATTAGGGAACCACCAAACCCAACTGT
CACCACTACTGAATACTGGTCTCAATCATATGCAACCACTACTACCATTACCG
CTCCACCTGGTGAAACTGATACCGTTCTTATCAGAGAGCCACCAAACCATACT
GTCACTACTACTGAATACTGGTCTCAATCATATGCTACAACCACCACTGTTAC
TGCACCACCTGGTGAAACCGATΆCCGTTCTTATCAGΆGAGCCACCAAACCATA
CTGTCACTACTACTGAATACTGGTCTCAATCATATGCTACAACCACCACTGTT
ACTGCACCACCAGGTGGTACCGATACTGTTATCATTAGAGAGCCACCAAATCC
AACAGTTACTACTACTGAATATTGGTCACAATCATTTGCCACAACCACCACAG
TTACTGCTCCTCCAGGTGGTACTGACACTGTGATTATCTATGAAAGCATGTCA
AGTTCAAAGATTTCTACATCCTCCAATGATATAACCAGTATCATTCCATCATT
TTCCCGTCCTCATTATGTCAACAGCACAACCTCCGATTTGTCAACATTTGAAT
CTTCATCCATGAATACTCCTACTTCTATCAGTAGTGATGGTATGTTGTTGTCT
TCTACAACTTTGGTTACTGAATCAGAAACAACTACAGAACTGATTTGCAGTGA
TGGTAAAGAGTGTTCTAGATTGTCCAGTTCTTCTGGTATTGTCACAAATCCAG
ATAGCAATGAATCCTCAATCGTAACTAGTACTGTTCCTACTGCAAGTACAATG
TCTGATTCACTTTCTTCAΆCTGΆTGGTATTAGTGCTACATCTTCTGATAATGT
TTCAAAATCAGGAGTATCAGTTACAACCGAAACTTCTGTTACAACTATTCAAA
CTACTCCAAACCCATTΆTCATCTTCAGTGACATCATTGACTCΆGTTGTCTTCA
ATTCCAAGTGTTTCAGAAAGTGAAAGTAAAGTTACATTTACAAGCAATGGAGA
CAACCAAAGTGGTACTCATGATTCACAATCTACTTCCACTGAAATTGAAATTG
TAACAΆCCAGTTCTACTAAAGTTTTACCACCTGTCGTTTCTTCTAATACTGAT
TTGACTAGTGAACCAACAAATACCAGAGAACAACCAACTACATTATCAACTAC
TTCAAACTCCATCACTGAAGATATCACCACATCTCAACCTACAGGTGATAATG
GAGACAATACTTCATCAACCAATCCAGTTCCAACTGTGGCAACAAGTACTTTA
GCATCTGCAΆGTGAAGΆAGΆCAACAAAAGCGGTTCTCATGAATCAGCATCCAC
AAGTTTGAAACCAAGTATGGGTGAAAATTCTGGATTAACTACTTCTACTGAAA
TTGAΆGCTACAACAΆCCAGTCCTACAGΆAGCTCCATCACCTGCTGTTTCTTCT
GGTACTGATGTAACTACTGAACCAACTGATACTAGAGAACAACCTACTACATT
ATCAACTACTTCAAAAACAAACΆGTGAACTGGTTGCTACTACΆCAAGCTACTA
ATGAAAATGGTGGTAAATCTCCATCAACTGATTTAACATCAAGCTTGACAACA
GGCACCTCAGCATCTΆCAAGTGCTAATAGCGAACTTGTTACTAGTGGATCTGT
TACTGGTGGAGCTGTTGCCAGTGCTTCAAATGATCAATCACATTCTACTTCTG
TTACCAACAGCAACAGCATTGTATCTAATACCCCACAAACTACATTGAGTCAA
CAAGTTACCTCATCCTCACCTTCAACCAACACATTCATTGCTTCTACATACGA
TGGCTCTGGTTCTATTATCCAACATTCTACTTGGTTGTACGGTTTGATCACAT
TATTGTCCTTGTTCATTTAG
CaO19.9891; ATGCTTTTACAATTTTTGTTGCTAAGCCTCTGTGTATCAGTTGCTACTGCAAA 171
AACQ01000149; AGTTATTACGGGTGTTTTCAATAGTTTTGATTCGTTGACATGGACAAGAGCTG
46434072 GTAATTATGCTTATAAGGGCCCAAATAGACCAACTTGGAATGCTGTTTTGGGC TGGTCTTTAGATGGTACTΆGTGCAAACCCAGGAGACΆCATTCACATTGAATAT GCCATGTGTTTTTAAATTTATTACCGATCAAACATCTGTTGATTTGACTGCTG ACGGTGTTAAATATGCTACATGTCAGTTTTATTCAGGTGAAGAATTTACAACA TTTTCTTCATTAAAATGTΆCTGTGΆGCAATACTTTAACATCATCTATTAAGGC TTTGGGTACGGTTACTTTACCAATTTCATTTAATGTTGGTGGAACAGGTTCAT TGGTTGATTTGGAAAGTTCTAAATGTTTTAAGGCTGGCACCAACACAGTTACT TTTAATGATGGTGATAAAAAAATCTCAATTGACGTTGATTTTGAGAΆAACAAA CGAAGATGCAAGTGGATATTTCATAGCGTCAAGACTTATTCCAAGTATTAACA AAGCTTCAATCACTTATGTGGCACCACAATGTGCAAATGGCTACACATCTGGT GCAATGGGGTTCACAATTGGCAGTGGTGACACTACTATTGACTGTTCAAATGT TCATGTTGGTATTACAAAGGGATTAAATGATTGGAATTTTCCGGTATCGTCTG
ATTCATTAAGTTACAΆTAAAACTTGTTCATCTACAGGTATTTCTATCACΆTAT GAΆAATGTCCCCGCTGGTTATCGTCCATTTTTTGACGTATATACTCTGGTGTC
AGACCAGAACAGACAATTAAAATATACTAATGATTATGCCTGTGTTGGTAGTT
CCTTACAAAGTAΆGCCGTTCAATTTAAGATTGAGAGGATACAATAATAGTGΆA
GCTAATTCTAACGGTTTTGTCATTGTTGCTACAΆCCCGAΆCAGTTACTGACAG
TACTACTGCTGTCΆCTACTTTACCTTTTAATCCAAGTATTGACAAΆΆCCAAAA
CAΆTCGAAATTTTGCAACCTATTCCΆACAACCACTATCACAACTTCATATGTT
GGTGTGACTACTTCCTACCTGACTAAAACTGCACCAATTGGTGAAACΆGCTAC
TGTTATTGTTGATGTGCCATATCATACTACCACAACTGTTACCAGTGAATGGA
CAGGAACAATCACTACCACTACAACTCGTACCAATCCAΆCTGATTCTATAGΆT
ACTGTCGTTGTGCAAGTTCCACTGCCΆAATCCAΆCTGTTAGTACAΆCCGAGTA
TTGGTCTCAGTCATATGCAACCACTACTACCATTACCGCTCCTCCAGGTGGTA
CCGATACTGTGATTATTAGAGAGCCΆCCAAACCACΆCTGTCACTACTACTGAA
TACTGGTCTCAATCATATGCTACΆACCACCACTGTTACTGCTCCTCCAGGTGG
TACTGACTCAGTAATTATCAGAGAACCACCAAATCCAACTGTCACTACAACCG
AGTATTGGTCCCAGTCΆTATGCAACCACTACTACCATTACCGCTCCTCCAGGT
GGTACCGATACTGTGATTATTAGAGAGCCACCAAACCACACTGTCACTACTAC
TGΆATATTGGTCTCAGTCATATGCTACTACTACTACTGTTACTGCTCCTCCAG
GTGGTACTGACTCAGTAATTATCAGAGAACCTCCAAACCCAACTGTCACCACC
ACTGAATATTGGTCCCAΆTCTTACACAACCACAΆCTACTGTGACTGCTCCTCC
AGGTGGTACTGACTCAGTGATTATCAGAGAGCCACCAAACCCAACTGTAACAA
CCACCGAGTΆTTGGTCACAGTCGTACGCAACTACAACTACTGTAACTGCCACT
CCAGGTGGTACTGACACTGTGATTATTAGAGAGCCACCTAATTATACTGTCAC
CACAACTGAATATTGGTCTCAATCGTACGCTACCACCACCACTGTTACTGCCC
CTCCAGGTGGCACTGATACTGTTATTATTAGGGAGCCACCAAATTACACGGTT
ACCACΆACTGAATACTGGTCTCAGTCGTACGCAACTACAACTACTGTAACTGC
TCCTCCAGGTGGTACTGATACCGTTATCATTAGGGAGCCACCAAACTATACTG
TGACAACTACTGAATACTGGTCACAGTCGTACGCAACTACCTCΆACTATCΆCA
GCCCCACCGGGAGGCACTGACACTGTGATTATTAGΆGAGCCACCAAATTACAC
GGTTACTACAACTGΆATATTGGTCCCAΆTCTTATGCTACGACCACCACTGTTA
CTGGTCCACCGGGAGGCACTGACACTGTGATTATTAGAGAACCTCCAAGTCCA
ACAGTTACAACAACCGAGTACTGGTCACAATCTTACGCAACCACAACTACCGT
GACTGCTCCTCCAGGAGGTACCGCTACTGTGATCATAAAAGAGCCΆCCAAATT
ACACGGTCACTACTΆCTGAATACTGGTCACΆATCATATGCTACAACCACTACA
GTCACTGGTCCACCAGGAGGTACCGATACTGTTATTATTAGGGAGCCACCAAA
TCCAACTGTAACCACTACTGAATACTGGTCTCAATCCTTTGCTACTACTACTA
CAGTTACTGCTCCTCCAGGTGGTACTGACTCAGTAATTATCAGAGAACCTCCA
AACCCAACTGTCACCACCACTGAATΆTTGGTCCCAATCTTACGCAACCACAAC
TACTGTGACTGCTCCTCCAGGTGGTACTGACTCAGTGATTATCAGAGAACCTC
CAAACCCAΆCTGTCACCΆCCACTGAATATTGGTCCCAATCTTACACAACCACA
ACTΆCTGTGACTGCTCCTCCAGGTGGTACTGACTCAGTGATTΆTCAGAGAGCC
ACCAAACCCAACTGTAACAACCACCGAGTATTGGTCACAGTCGTACGCAACTA
CAACTACTGTAACTGCCACTCCAGGTGGTACTGACΆCTGTGATTATTAGAGAG
CCACCTAATTATACTGTCACCACAACTGAATATTGGTCTCAATCGTACGCTAC
CACCACCACTGTTACTGCCCCTCCAGGTGGCACTGATACTGTTATTATTAGGG
AGCCACCAAATTACACGGTTΆCCACAACTGAATACTGGTCTCΆGTCGTACGCA
ACTACAACTACTGTAACTGCTCCTCCAGGTGGTACTGATACCGTTATCATTAG
GGAGCCACCAAACCATACTGTGACAACTACTGAATACTGGTCACAGTCGTACA
CTACAACCACCΆCTGTTATTGCCCCACCAGGTGGCACTGATTCGGTTATCATT
AGAGAACCTCCAAATCCAACTGTCACAACCACTGAGTACTGGTCTCAATCTTA
CGCAACTACCACTACCATTACCGCTCCTCCAGGTGAAACCGATACTGTCCTTA
TTAGGGAACCΆCCAAATCACACTGTCACTACTACTGAATACTGGTCACΆATCA
TTTGCTACAACCACΆΆCTGTAACTGCACCACCAGGTGGTACTGACACTGTTAT
CATTAGAGAACCACCAAACCACACTGTCACTACTACTGAGTATTGGTCTCAAT
CTTACGCAACCACTACTACCATTACCGCTCCACCTGGTGAGACCGATACTGTC CTTATTAGAGAACCACCAAACCATACTGTCACTACAACTGAGTATTGGTCTCA
ATCCTATGCAACTACTACCACTATCATCGCACCΆCCAGGTGAAΆCTGATACTG
TTTTAATCAGAGAGCCACCAAACCCAACTGTTACCACCACCGAATACTGGTCT
CAATCCTATACCACTGCTACTACCGTTACTGCACCACCAGGTGGAACTGATAC
TGTGATTATTTΆTGACACCATGTCAAGTTCAGAAATTTCTTCATTTTCTCGTC
CTCATTACACCAACCATACAACTTTGTGGTCTACAACTTGGGTTATTGAAACA
AAAACAATTACAGAAACTAGCTGTGAAGGTGATAAAGGTTGTTCTTGGGTTTC
TGTTTCTACTCGTATTGTCACAATTCCTAATAATATCGAAACTCCTATGGTTA
CTAATACTGTTGATACTACAACCACAGΆATCCACTTTACAATCCCCATCTGGT
ATTTTTTCAGAGTCAGGAGTATCTGTTGAAACAGAATCTTCTACTTTTACTAC
TGCTCAAACAAATCCAAGTGTTCCAACAACTGAAAGTGAGGTTGTATTTACTA
CTAAAGGAAACAACGGAAATGGTCCTTATGAATCACCATCTACTAATGTGAAA
TCAAGTATGGATGAAAATTCTGAΆTTTACTACTTCCACAGCTGCTTCCACTTC
TACTGATATTGAAAATGAAACCATAGCAACAACCGGTTCCGTGGAAGCTTCAT
CGCCTATCATTTCTTCTAGTGCTGATGAAACTACTACTGTTACTACTACTGCT
GAATCAACCAGTGTCATTGAACAACAAACCAATAATAATGGTGGTGGTAATGC
TCCATCTGCAACTTCAACTTCAACTTCATCTCCATCTACAACTACAΆCTGCTA
ATAATGACTCTGTTATTACTAGTACAACATCAATCAACCAATCTCAATCGCAA
TCCAATTCTGATACCCAACAAACTACATTGAGTCAACAAATGACTTCATCTTT
GGTTAGTTTACATATGCTTACTACATTTGATGGATCTGGTTCTGTTATTCAAC
ATTCTACTTGGTTATGTGGTTTGATCACATTATTATCCTTATTTATTTAA
ALS3-3; ATGCTTTTACAATTTTTGTTGCTAAGCCTCTGTGTATCAGTTGCTACTGCAAA 172 not avail; AGTTATTACGGGTGTTTTCAATAGTTTTGATTCGTTGACATGGACAAGAGCTG not avail GTAATTATGCTTATAAGGGCCCAAATAGACCAACTTGGAATGCTGTTTTGGGC
TGGTCTTTAGATGGTACTAGTGCAAACCCAGGAGACACATTCACATTGAATAT
GCCATGTGTTTTTAAATTTATTACCGATCAAACATCTGTTGATTTGACTGCTG
ACGGTGTTAAATATGCTACATGTCAGTTTTATTCAGGTGAAGAATTTACAACA
TTTTCTTCATTAAAATGTACTGTGAGCAATACTTTAΆCATCATCTATTAΆGGC
TTTGGGTACGGTTACTTTACCAATTTCATTTAATGTTGGTGGAACAGGTTCAT
TGGTTGATTTGGAAAGTTCTAAATGTTTTAAGGCTGGCACCAACACAGTTACT
TTTAATGATGGTGATAAAAAAATCTCAATTGACGTTGATTTTGAGAAAACAAA
CGAAGATGCAAGTGGATATTTCATAGCGTCAAGACTTATTCCAAGTATTAACA
AΆGCTTCAATCACTTATGTGGCACCACAATGTGCAAATGGCTACACATCTGGT
GCAATGGGGTTCACAATTGGCAGTGGTGACACTACTATTGACTGTTCAAATGT
TCATGTTGGTATTACAAAGGGATTAAATGATTGGAATTTTCCGGTATCGTCTG
ATTCATTAAGTTACAATAAAACTTGTTCATCTACAGGTATTTCTATCACATAT
GAAAATGTCCCCGCTGGTTATCGTCCATTTTTTGACGTATATACTCTGGTGTC
AGACCAGAACAGACAATTAAAATATACTAATGATTATGCCTGTGTTGGTAGTT
CCTTACAAAGTAAGCCGTTCAATTTAAGATTGAGAGGATACAATAATAGTGAA
GCTAATTCTAACGGTTTTGTCATTGTTGCTACAACCCGAACΆGTTACTGACAG
TACTACTGCTGTCACTACTTTACCTTTTAATCCAAGTATTGACAAAACCAAAA
CAATCGAAATTTTGCAACCTATTCCAACAACCACTATCACAACTTCATATGTT
GGTGTGACTACTTCCTACCTGACTAAAACTGCACCAATTGGTGAAACAGCTAC
TGTTATTGTTGATGTGCCATATCATACTACCACAACTGTTACCAGTGAATGGA
CAGGAACAATCΆCTACCACTACAACTCGTACCAATCCAΆCTGATTCTATAGAT
ACTGTCGTTGTGCAAGTTCCACTGCCAAATCCAΆCTGTTAGTACAACCGAGTA
TTGGTCTCAGTCATATGCAACCACTACTACCATTACCGCTCCTCCAGGTGGTA
CCGATACTGTGATTATTAGAGAGCCACCAAACCACACTGTCACTACTACTGAA
TACTGGTCTCAATCΆTATGCTACAACCACCACTGTTACTGCTCCTCCAGGTGG
TACTGACTCAGTAATTATCAGAGAΆCCACCAAATCCAACTGTCACTACAACCG
AGTATTGGTCCCAGTCATATGCAACCACTACTACCATTACCGCTCCTCCAGGT
GGTACCGATACTGTGATTATTAGAGAGCCACCAΆACCΆCACTGTCACTACTAC
TGAΆTATTGGTCTCAGTCATATGCTACTACTACTACTGTTACTGCTCCTCCAG
GTGGTACTGACTCAGTAΆTTATCAGΆGAACCTCCAAACCCAACTGTCACCACC
ACTGAATATTGGTCCCAATCTTACACAACCACAACTACTGTGACTGCTCCTCC
AGGTGGTACTGACTCAGTGATTATCAGAGAGCCACCAAACCCAACTGTAACAA CCACCGAGTATTGGTCACAGTCGTACGCAACTACAACTΆCTGTAACTGCCACT
CCAGGTGGTACTGACACTGTGATTATTAGAGAGCCACCTAATTATACTGTCAC
CACAACTGAATATTGGTCTCAATCGTACGCTΆCCACCACCACTGTTACTGCCC
CTCCAGGTGGCACTGATACTGTTΆTTATTAGGGΆGCCACCΆAATTACACGGTT
ACCACAACTGAATACTGGTCTCAGTCGTACGCAACTACAACTACTGTAACTGC
TCCTCCAGGTGGTACTGATACCGTTATCATTAGGGAGCCACCAAACTATACTG
TGACAACTACTGAATACTGGTCACAGTCGTACGCAACTACCTCAΆCTATCACA
GCCCCACCGGGAGGCACTGACACTGTGATTATTAGAGAGCCACCAAATTACAC
GGTTACTACAACTGAATATTGGTCCCAATCTTATGCTACGACCACCACTGTTA
CTGGTCCACCGGGAGGCACTGACACTGTGATTATTAGAGAACCTCCAAGTCCA
ACAGTTACAACAACCGAGTACTGGTCACAATCTTACGCAΆCCACAΆCTACCGT
GACTGCTCCTCCAGGAGGTACCGCTACTGTGATCATAAAAGAGCCACCAAATT
ACACGGTCACTACTACTGAATACTGGTCACAATCATATGCTACAACCACTACA
GTCACTGGTCCACCAGGAGGTACCGATACTGTTATTATTAGGGAGCCACCAAA
TCCAACTGTAACCACTACTGAΆTACTGGTCTCAATCCTTTGCTACTACTACTA
CAGTTACTGCTCCTCCAGGTGGTACTGACTCAGTAATTATCAGAGAΆCCTCCA
AACCCAACTGTCACCACCACTGAATATTGGTCCCAATCTTACGCAACCACAAC
TACTGTGACTGCTCCTCCAGGTGGTACTGACTCAGTGATTATCAGAGAACCTC
CAAACCCAACTGTCACCACCACTGAATATTGGTCCCAATCTTACACAACCACA
ACTACTGTGACTGCTCCTCCAGGTGGTACTGACTCAGTGATTATCAGAGAGCC
ACCAAACCCAΆCTGTAACAACCACCGAGTATTGGTCACAGTCGTACGCAACTA
CAACTACTGTAACTGCCACTCCAGGTGGTACTGACACTGTGATTATTAGAGAG
CCACCTAATTATACTGTCACCACAACTGAATATTGGTCTCAATCGTACGCTAC
CACCACCACTGTTACTGCCCCTCCAGGTGGCACTGATACTGTTATTATTAGGG
AGCCΆCCAAΆTTACACGGTTACCACAACTGAATACTGGTCTCAGTCGTACGCA
ACTACAACTACTGTAACTGCTCCTCCAGGTGGTACTGATACCGTTATCATTAG
GGAGCCACCAAACCATACTGTGACAACTACTGAATACTGGTCACAGTCGTACA
CTACΆACCACCΆCTGTTATTGCCCCACCAGGTGGCACTGΆTTCGGTTATCATT
AGAGAACCTCCAAATCCAACTGTCACAACCACTGAGTACTGGTCTCAATCTTA
CGCAACTACCACTACCATTACCGCTCCTCCAGGTGAAACCGATACTGTCCTTA
TTAGGGAACCACCAAATCACACTGTCACTACTACTGAATACTGGTCACAATCA
TTTGCTACAACCACAACTGTAACTGCACCACCAGGTGGTACTGACACTGTTAT
CATTAGAGAΆCCΆCCAAΆCCACACTGTCACTACTACTGAGTATTGGTCTCAAT
CTTACGCAACCACTACTACCATTACCGCTCCACCTGGTGAGACCGATACTGTC
CTTATTAGAGAACCACCAAACCATACTGTCACTACAACTGAGTATTGGTCTCA
ATCCTATGCAACTACTACCACTATCATCGCACCACCAGGTGAAACTGATACTG
TTTTAATCAGAGAGCCACCAAACCCAACTGTTACCACCACCGAATACTGGTCT
CAATCCTATΆCCACTGCTACTACCGTTACTGCACCACCAGGTGGΆACTGATAC
TGTGATTATTTATGACACCATGTCAAGTTCAGAAATTTCTTCATTTTCTCGTC
CTCATTACACCAACCATACAACTTTGTGGTCTACAACTTGGGTTATTGAAACA
AAAACAATTACAGAAΆCTAGCTGTGAAGGTGATAAAGGTTGTTCTTGGGTTTC
TGTTTCTACTCGTATTGTCACAATTCCTAATAATATCGAAACTCCTATGGTTA
CTAΆTACTGTTGATACTACAACCACAGAATCCACTTTACΆATCCCCATCTGGT
ATTTTTTCAGAGTCAGGAGTATCTGTTGAAACAGAATCTTCTACTTTTACTAC
TGCTCAAACAAATCCAAGTGTTCCAACAACTGAAAGTGAGGTTGTATTTACTA
CTAAAGGAAACAACGGAAATGGTCCTTATGAATCACCATCTACTAATGTGAAA
TCAAGTATGGATGAAAATTCTGAATTTACTACTTCCACAGCTGCTTCCACTTC
TACTGATATTGAAAATGAAACCATAGCAACAACCGGTTCCGTGGAAGCTTCΆT
CGCCTATCATTTCTTCTAGTGCTGATGAAACTACTACTGTTACTACTACTGCT
GAATCAACCAGTGTCATTGAACAACAAACCAATAATAATGGTGGTGGTAATGC
TCCATCTGCAACTTCAACTTCATCTCCATCTACAACTACAACTGCTAATAGTG
ACTCTGTTATTACTΆGTACAΆCATCAACCAACCAATCTCAATCGCAATCCAAT
TCTGATACCCAACAAACTACATTGAGTCAACAAATGACTTCATCTTTAGTTAG
TTTACATATGCTTACTACATTTGACGGATCTGGTTCTGTTATTCAACATTCTA
CTTGGTTATGTGGTTTGATCACATTATTATCCTTATTTATTTAA
ALS8; ATGCTACAACAATATACATTGTTACTCATATATTTGTCGGTTGCGACTGCAAA 173 AACQ01000270 ; GACAATCACTGGTGTTTTCAACAGTTTTAATTCATTGACTTGGTCTAATGCTG 46431624 CTACGTATAATTATAAGGGACCAGGAACCCCAACTTGGAATGCTGTTTTGGGT
TGGTCTTTAGATGGTACTAGTGCAΆGTCCGGGΆGATACATTCACATTGAATAT
GCCATGTGTGTTTAAATTTACTACTTCTCAAACATCTGTTGATTTGACTGCTC
ATGGTGTTAAATATGCTACATGTCAATTTCAGGCAGGTGAAGAATTTATGACC
TTTTCTΆCATTAACATGTACTGTGAGCAATACTTTGACTCCATCTATTAAGGC
TTTGGGTACTGTCACTTTACCACTTGCATTCAATGTAGGTGGAACTGGTTCTT
CTGTTGATTTGGAAGATTCTAAATGTTTTACTGCTGGTACTAACACAGTTACA
TTTAATGATGGTGGCAAGAAAATCTCAATTAATGTTGATTTTGAAAGGTCAAA
TGTCGATCCAAAAGGGTACTTAACTGATTCCAGAGTTATACCAAGTCTCAACA
AAGTGTCAACTCTTTTTGTTGCACCACAATGTGCAAATGGTTACACATCTGGT
ACAATGGGATTCGCTAACACTTATGGTGATGTTCAAATTGACTGTTCAAATAT
TCATGTTGGTATTACAAAΆGGATTGAATGATTGGAATTATCCGGTTTCATCTG
AATCATTTAGTTACΆCCAAAACTTGTTCATCTAATGGTATCTTTATCACATAT
AAAAACGTTCCTGCCGGTTATCGTCCATTTGTTGACGCTTATATTTCTGCTAC
AGATGTTAATTCGTACACCTTGTCGTATGCTAΆTGΆATATACTTGTGCTGGTG
GTTATTGGCAΆCGTGCACCTTTCACATTAAGATGGACTGGATACAGAAATAGT
GATGCTGGATCTAACGGTATTGTTATTGTGGCTΆCTACCAGΆACAGTTACAGA
CAGTACTACCGCCGTGACCACCTTACCATTCGATCCTAACCGCGACAAAACTA
AGACAATTGAAATTTTGAAACCTATTCCAACAACTACAATCACAACATCATAT
GTTGGTGTGACTACTTCCTACCTGACCAAΆACTGCACCAATTGGGGAAACTGC
TACTGTTATTGTTGATATTCCATATCACACTACCACTACTGTTACCAGTAAAT
GGACAGGAACAATTACTTCCACCACAACACATACTAATCCAACTGACTCAATA
GACACTGTCATTGTACAAGTTCCACTGCCAAACCCAACTGTTACTACCACTGA
ATATTGGTCTCAATCATTTGCTACCACCACCACCATTACTGGACCACCAGGAA
ACACTGATACTGTTTTAATCAGAGAGCCACCAAACCATACTGTCACTACAACC
GAGTATTGGTCAGAΆTCTTACACTACTACTAGTACTTTCACTGCTCCTCCAGG
TGGAACTGATTCAGTTATTATCAAGGAACCTCCAAATCCAACTGTTACAACTA
CCGAGTACTGGTCΆGAATCTTACACTACCACTACTΆCTGTCACCGCTCCACCA
GGAGGTACTGATACCGTGATTATCAGAGAACCACCAAACCATACTGTAACCAC
AACTGAATACTGGTCΆCΆΆTCTTACACTACAACCACCΆCTGTTATTGCCCCAC
CAGGTGGCACTGATTCGGTTATCATTAGAGAACCTCCAAΆTCCAACTGTCACA
ACCACTGAGTACTGGTCTCAATCTTACGCAACTACCACTACCATTACCGCTCC
TCCAGGTGAAACCGΆTACTGTCCTTATTΆGGGΆACCACCAAATCACACTGTCA
CTACTACTGAATACTGGTCTCAATCTTACGCAACTACCACTACCATTACCGCT
CCTCCAGGTGAAΆCCGATACTGTCCTTATTAGGGAACCΆCCAAATCACACTGT
CACCACTACTGAATACTGGTCACAATCTTACACTACAACCACCACTGTTATTG
CCCCACCAGGTGGCACTGATTCAGTTATCATCAΆGGAACCACCAΆACCCAACT
GTCACTACAACTGAATATTGGTCTCAATCTTACGCAACTACCACTACCATTAC
CGCTCCTCCAGGTGAGACCGATACTGTCCTTATTAGAGAACCACCAAACCATA
CTGTAACCACAACTGAGTATTGGTCTCAATCCTATGCAACTACTACTACAATC
ACTGCTCCTCCAGGTGAAACCGATACCGTTCTTATTAGGGAACCACCAAATCA
CACAGTTACTACTACTGAΆTACTGGTCACAATCATTTGCTACAACCACAACTG
TAΆCTGCACCACCAGGTGGTACTGACACTGTTATCATTAGAGAACCACCAAAT
CACACTGTCACTACTACTGAATACTGGTCACAATCATTTGCTACAACCACAAC
TGTAACTGCACCACCAGGTGGTACTGACACTGTTTTAATCAGAGAGCCACCAA
ACCCAACTGTTACCACCACCGAATACTGGTCTCAACCTTACACAACCACCACT
ACAGTTATTGCACCACCAGGTGGAACTGATACTGTGATTATTTATGACACCAT
GTCAAGTTCAGAAATTTCTTCATTTTCTCGTCCTCATTACACCAACCATAC
ALS3; ATGCTACAACAATATACATTGTTACTCATATATTTGTCGGTTGCGACTGCAAA 174
AY223552; GACAATCACTGGTGTTTTCAACAGTTTTAATTCATTGACTTGGTCTAATGCTG
29373982 CTACGTATAATTATAAGGGACCAGGAACCCCAACTTGGAATGCTGTTTTGGGT TGGTCTTTAGATGGTACTAGTGCAAGTCCGGGAGATACATTCACATTGAATAT GCCATGTGTGTTTAAATTTACTACTTCTCAAACATCTGTTGATTTGACTGCTC ATGGTGTTAAATATGCTACATGTCAΆTTTCAGGCAGGTGAΆGAATTTATGACC TTTTCTACATTAACATGTACTGTGAGCAATACTTTGACTCCATCTATTAAGGC TTTGGGTACTGTCACTTTACCACTTGCATTCAATGTAGGTGGAACTGGTTCTT
CTGTTGATTTGGAAGATTCTAAATGTTTTACTGCTGGTACTAACACAGTTACA TTTAATGATGGTGGCAAGAAAATCTCAATTAATGTTGATTTTGAΆΆGGTCAAA
TGTCGATCCAAAAGGGTACTTAACTGATTCCAGAGTTATACCAAGTCTCAACA
AAGTGTCAΆCTCTTTTTGTTGCACCACAATGTGCAAATGGTTACΆCATCTGGT
ACAATGGGATTCGCTAΆCACTTATGGTGATGTTCAAATTGACTGTTCAAΆTAT
TCATGTTGGTATTACAΆAAGGATTGAΆTGATTGGAATTΆTCCGGTTTCATCTG
AATCATTTAGTTACACCAAAACTTGTTCATCTAATGGTATCTTTATCACATAT
AAAAACGTTCCTGCCGGTTATCGTCCATTTGTTGACGCTTATATTTCTGCTAC
AGATGTTAATTCGTΆCACCTTGTCGTATGCTAATGAATATACTTGTGCTGGTG
GTTATTGGCAACGTGCACCTTTCACATTAAGATGGACTGGATACAGAAATAGT
GATGCTGGATCTAΆCGGTATTGTTATTGTGGCTΆCTACCAGAACΆGTTACAGA
CAGTACTACCGCCGTGACCACCTTACCATTCGATCCTAACCGCGACAAAACTA
AGACAATTGAAATTTTGAAACCTATTCCAACAACTACAATCACAACATCATAT
GTTGGTGTGACTACTTCCTACCTGACCAAAACTGCACCAATTGGGGAAACTGC
TACTGTTATTGTTGATΆTTCCATATCACACTACCACTACTGTTACCAGTAAAT
GGACAGGAACAATTACTTCCACCACAACACATACTAATCCAACTGACTCAATA
GACACTGTCATTGTACAAGTTCCACTGCCAAACCCAACTGTTACTACCACTGA
ATATTGGTCTCAATCATTTGCTACCACCACCACCATTACTGGΆCCACCAGGΆA
ACACTGATACTGTTTTAATCAGAGAGCCACCAAACCATACTGTCACTACAACC
GAGTATTGGTCAGAATCTTACACTACTACTAGTACTTTCACTGCTCCTCCAGG
TGGAACTGATTCAGTTATTATCAAGGAACCTCCAAATCCAACTGTTACAACTA
CCGAGTACTGGTCAGAΆTCTTACACTACCΆCTACTACTGTCACCGCTCCACCA
GGAGGTACTGATACCGTGATTATCAGAGAACCACCAAACCATACTGTAACCAC
AACTGAATACTGGTCACAATCTTACACTACAACCACCACTGTTATTGCCCCAC
CAGGTGGCACTGATTCGGTTATCATTAGAGAACCTCCAAΆTCCAACTGTCACA
ACCACTGAGTACTGGTCTCAATCTTACGCAACTACCACTACCATTACCGCTCC
TCCAGGTGAAACCGATACTGTCCTTATTAGGGAACCACCAAATCACACTGTCA
CTACTACTGAATACTGGTCTCAATCTTACGCAACTACCACTACCATTACCGCT
CCTCCAGGTGAAACCGATACTGTCCTTATTAGGGAACCACCAAATCACACTGT
CACCACTACTGAATACTGGTCACAATCTTACACTACAACCACCACTGTTATTG
CCCCACCAGGTGAAACTGATTCAGTTATCATCAAGGAACCACCAAACCCAACT
GTCACTACAACTGAATATTGGTCTCAATCTTACGCAACTACCACTACCATTAC
CGCTCCTCCAGGTGAGACCGATACTGTCCTTATTAGAGAACCACCAAACCATA
CTGTAACCACAACTGAGTATTGGTCTCAATCCTATGCAACTACTACTACAATC
ACTGCTCCTCCAGGTGAAACCGATACCGTTCTTATTAGGGAACCACCAAATCA
CACAGTTACTACTACTGAATACTGGTCACAATCATTTGCTACAACCACAACTG
TAACTGCACCACCAGGTGGTACTGACACTGTTATCATTAGAGAACCACCAAAT
CACACTGTCACTACTACTGAATACTGGTCACAATCATTTGCTACAACCACAAC
TGTAACTGCACCACCAGGTGGTACTGACACTGTTTTAATCAGAGAGCCACCAA
ACCCAACTGTTACCACCACCGAATACTGGTCTCAACCTTACACAACCACCACT
ACAGTTATTGCACCACCAGGTGGAACTGATACTGTGATTATTTATGACACCAT
GTCAAGTTCAGAAATTTCTTCATTTTCTCGTCCTCATTACACCAACCATACAA
CTTTGTGGTCTACAACTTGGGTTATTGAAACAAAAACAATTACAGAAACTAGC
TGTGAAGGTGATAAAGGTTGTTCTTGGGTTTCTGTTTCTACTCGTATTGTCAC
AATTCCTAATAATATCGAAACTCCTATGGTTACTAATACTGTTGATTCTACAA
CCACAGAATCCACTTCACAATCCCCATCTGGTATTTTTTCAGΆGTCAGGAGTA
TCTGTTGAAACAGAATCTTCTACTGTTACTACTGCTCAAACAAΆTCCAAGTGT
TCCAACAACTGAAAGTGAGGTTGTATTTACTACTAAAGGAAACAΆCGGAAATG
GTCCTTATGAATCACCATCTACTAATGTGAAATCAAGTATGGATGAAAATTCT
GAATTTACTACTTCCACAGCTGCTTCCACTTCTACTGATATTGAAAATGAAAC
CATAGCAΆCAACCGGTTCCGTGGAAGCTTCATCGCCTATCATTTCTTCTAGTG
CTGATGAAΆCTACTACTGTTACTACTACTGCTGAATCAACCΆGTGTCATTGAA
CAACCAACAAATAATAATGGTGGTGGTAATGCTCCATCTGCAACTTCAACTTC
ATCTCCATCTACAACTACAACTGCTAATAGTGACTCTGTTATTACTAGTACAA
CATCAACCAACCAATCTCAATCGCAATCCAATTCTGATACCCAACAAACTACA
Figure imgf000121_0001
TATTTTGTGACTATATCCTCCTTTTCGGTAATAGTACGAGAGCTCAGTGGCAA ACTTTTCGTCGTGGTTTCTTCTTCAAGTTCATATTCACTATCTGAGTCAGAAG AAGTATTGAGATGTΆTATCTTCTACTCCTTGCΆAAATTTCTTCTGAAGACATT ATTGATΆTTCTGTCCGTTAGATTCCTGATGAGGTTGCCAAAΆTTTTTTTTTTA
A
ECEl; ATGAAATTCTCCAAAATTGCCTGTGCTACTGTTTTTGCTTTATCTTCTCAAGC 179
L17087; TGCCATCATCCACCATGCTCCAGAATTCAACATGAAGAGAGATGTTGCTCCAG
311084 CTGCCCCΆGCTGCTCCAGCTGACCAAGCACCTACTGTTCCTGCACCTCAAGAA
TTCAATACTGCTΆTTACCAΆAAGAAGTATTATTGGΆATTATTATGGGTATTCT
TGGCAACATTCCACAAGTAATCCAAATCATCATGAGTATTGTCAAAGCTTTCA
AΆGGTAACAΆGAGAGAAGATATTGATTCTGTTGTTGCTGGTATCATTGCTGAT
ATGCCATTTGTTGTCAGAGCTGTTGACACAGCCATGACTTCTGTTGCTTCTAC
CAAGAGAGATGGΆGCTAATGATGACGTTGCTAΆTGCCGTCGTCAGATTGCCAG
AAATTGTTGCTCGTGTTGCCACTGGTGTTCAACAATCCATCGAAAΆTGCCAAG
AGAGATGGCGTTCCAGATGTTGGCCTTAATCTTGTTGCTAATGCTCCAAGACT
TATCTCTAACGTTTTTGATGGCGTCCTGGAAACTGTTCAACAAGCTAAGAGAG
ATGGTCTTGAAGATTTTCTTGATGAACTTCTTCAAAGACTCCCACAACTCATT
ACTAGATCAGCTGAATCTGCTTTGAAAGACAGTCAACCAGTTAAAAGAGATGC
CGGCTCAGTAGCACTTAGCAATTTAATCAAAAAGAGCATTGAAACTGTCGGTA
TTGAAAATGCTGCTCAAATTGTTTCAGAAAGAGATATTTCTTCTTTGATTGAA
GAΆTATTTCGGAAAAGCTTAA
ECM17; ATGACGATGACGACACATTTCTTATACGACAGAATACGCGGATGTTTCCTTTC 180
AACQOIOOOIIO; AAGTCTTGTAGTTGGGCATGTAACTTTCTTCGTTTGGTTTCCTGGTCAACCAA
46435633 CTCGGTTTTCATTCGACCAACTTCAAACTGTAACCGATGCATTCAAATTGGAT
TCTTCCAATTTAAGAAAGCAGTTATCAGACTTTTTAGAAAGAGAAAACAAATT
GACTTTGTTGGCATCTAAGGACCCATTGTTGTCTAGAAACTTGACTGCTAATG
CTAACACCGAGGCAAAAACCAAACAATCTAAGATTGCAGACGAATCATTCGCC
CAATTGTTACAAGGGTTATCCGGTCCACCTTTGACTGTTGCATTTGCTTCTGA
TGGGGGAAATGCAGAAGCCGTTGCTAAAAΆAGTTAATAGACAAGCTTTGGGTA
GΆGGTTTGAAGTCTGTTGTTTTACAAATGGATGΆCTTGTCAGTTGAAGACTTG
CCTACTGAAACTAATGTTGTTTTTATAΆCTTCAACATCGGGACAAGGGGAΆTT
TCCTACTAATGGTAAACAATTCTGGGACGGTGTTAAAAACACCACAGATTTGG
ATTTATCTGGTATCAGGTTTTCTGTTTTTGGTTTAGGTGACTCCCAGTACTGG
CCAAGAAAAGAAGACAAACATTACTATAACAAACCTGCCAAGGACTTGTTTGC
CΆAGTTAAAACTTTATGGTGGTGTTGAATTGGCAGATATTGGATTAGGTGACG
ACCAAGATGCAGATGGGTTTTCTACTGGTTTCAACGAATGGATTCCAAAGATC
TGGGCCGCATTAGGTGTTGACAATGTTGAAGGTGTTGAAGAACCAAAACCAAT
TACAAATGAAGATATGAAGATTGGTTCAGATTATCTTAGAGGTACGATTGTTG
AAGGATTAAACGATCAATCCACTGGTGCCATTTCTGCGGTTGATCAACAGTTG
ΆCAAAATTCCATGGTATCTATATGCAAGATGATCGTGATATTAGAGATGAGCG
TAAAGCTCAAGGTCTCGAACCAGCTTACACTTTTATGGTGCGTGTTCGTTTAC
CAGGTGGTATTGCTACTCCAGACCAATACTTGAAAATGGACGAGTTGGCTGAT
GAAAGAGGTAATGGTACGTTGAAATTGACCACCAGGGCTACTTTCCAATTGCA
TGGTGTGGTCAAGCACGACTTGAAACCAGCAATCAGAGGCATGAACTCAGCAT
TGATGGATΆCATTGGCTGCTTGTGGGGATGTTAACAGAAATGTTATGGTTTCA
GCTTTACCACΆTAATGCTAAGGTTCATGGTCAAGTTTCTCAAATCGGGGCTTT
GATTTCTGAATTTTTGTTACCAAΆGACAACAGCATATCATGAAATTTGGTTAC
AΆGGTGATGATGCTGGTGATAAΆCCTGGCTACΆGAGAΆGCTTGGGAAAACCGT
AΆAGAAGGACCAACTAΆAAAGAAAACCTTGGTTGCTGGTAATGTCTTGGCTGA
TGTGGAACCACAATATGGAGTCACATATTTACCTAGAAAGTTCAAGATTGTTA
TAACAGTTCCACCATACAATGATGTTGATGTTTATGCCCATGATGTGGGTTTG
ATAGCTATTGTTGAAGACAATGAAGTGGTTGGTTTTAΆCGTTTTΆGCTGGTGG
TGGTATGGGTTCTACACATAATAATAΆAAAGACATATCCTAGAACTGGGTCTA
TGTTGGGTTATGTATCCAAAGACCAAGTTCACATTGCTTGTGAAAAGATCATG
TTGGTGCAGAGAGACTTTGGTGATAGAACAAATAGAΆAGCATGCTAGATTGAA
GTATACCATTGATGACCTTGGTGTTGATGTCTTTAAAGCAAAAGTTGAGGAAT TGTTGGGCTATAAATTTGACGAGCCAAGACCATTCAAGATTGAATCAAACATT GACTATTTTGGCTGGTGCAAGGATGAATTAGGATACAΆCCATTTCACTGCATT CATCGAAAATGGTAGAATTGAAAATACCCCAGAATTGCCGCAGAAAACTGGTT TGCGTAAGATCGCTGAATTCTTGAΆGTCAGGAAΆTAGΆTCAGGAGAATTCAGA TTGACTGGTAACCAGCATATTCTTATATCCAATGTTTCTGATCAAGATTTGGA TGAAGTGAΆAAAATTGTTAGCTCAGTΆTAAATTGGACAATACTGACTTTTCTG CTTTAAGAAAATCTTCTGCAGCATGTGTTGCCTTCCCAACATGTGGTTTAGCT ATGGCCGΆATCTGAAAGATACTTGCCGGTTTTGATTACCAΆGTTGGAAGAAGC TTTAGAAGAATATGGTTTGAGACATGACTCGATAGTGATGAGAATGACTGGTT GTCCAAΆTGGTTGTGCTAGGCCTTGGGTTGCTGAAGTTGCATTGGTTGGTAAA GCATATGGGGCATACAATTTAATGTTGGGAGGTGGTCATCATGGTCAΆAGATT GAATAAGATTTATAGATATTCCATCAAAGAAGATGAGATTTTGGACATTTTGA AΆCCTTTATTCΆAAAGATGGAGCTTGGAAΆGAAACGAAAACGAGCCATTTGGT GACTGGTGTATTAGAGCAGGAATCATTGCAGAAACTΆCAGAAGGGAΆATATTT CCATGATGACATTCCTGAAGACGCATAA
FET31; ATGCGAACATTTCTATCATCATTCATTATTTTGACTACATTTTTAGCTTCATT 181
Y09329; GATAGCTGCTGAAACTCACACATGGTATTTCAAAACTGGTTGGGTAGACGCAA
1684655 ATCCTGATGGGGTTTATCCCCGTAAAATGATTGGGTTCAATGATTCTTGGCCA
TTACCCACTTTGAGAGTTAAAAAGGGCGACAGAGTTCAATTGTATTTGATTAA
TGGATTTGATAACTTAAATACTACTTTACATTTTCATGGATTATTTGTTCGTG
GTGCTAACCAAATGGATGGGCCAGAGATGGTTACCCΆGTGTCCTATCCCACCT
GGTGAAACATΆCTTGTACAACTTCACTGTTACTGATCAAGTGGGAACTTATTG
GTATCATAGCCATACAGGGGGTCAGTATGGAGACGGTATGAGAGGTGTCTTTA
TTATTGAAGATGATGATTTCCCGTATCACTACGATGΆAGAΆGTTGTTTTAACT
TTAAGTGACCATTACCACAAATATTCAGGTGACATAGGGCCTGCCTTTTTAAC
CAGATTTAATCCGACAGGAGCAGAΆCCGATCCCTCAGAACTTTTTGTTCAATG
AAACAAGAAATGCCACTTGGAAGGTCGAACCTGGAAΆAACTTACTTTGTTAGG
ATTCTTAATGTTGGTGGTTTTGTATCACAGTACTTGTGGATGGAAGATCATGA
ATTTACTATTGTTGAGATCGATGGCGTTTACGTTGAAAAAAACACCACTGATT
TGATTTATATCACAGTTGCTCAAAGATΆTGGGGTTTTAATAACCACAAAAAΆT
TCAACCGATAAGAACTATGTATTCATGAATGGTGTTGATACTACCATGTTGGA
TTCAGTTCCTGCTGATTTGCAΆGTCAATGGGACCAATTATATTGTTTATAATG
AAΆGCTCCGCCTTACCGGΆTGCTTACGATATCGATTCGTATGATGΆTGCCTTG
GATGATTTCTACTTGAAACCCTTGAGTAAACAAAAGTTGATGGATGATGCTGA
TTACACTATTACCGTTGATGTTCAAATGAATGTCTTGAATGATGGGATCAΆTT
ATGCTTTTTTCAACAATATTAGTTACAAΆGCACCAAAAGTTCCAACCTTACTA
ACTGTTTTAAGTGCTGGCGAAGCTGCAACAAACGAΆTTGATTTATGGTACCAA
TACCAATAGTTTTGTATTACAAGGTGGAGATATTGTTGATATTGTGCTAAATA
ATTTTGATACTGGTAAACATCCATTCCATTTACACGGTCACGTTTTCCAGTTG
ATTGAGAGACACGAAGCTATAGGTAGCΆAΆGΆAAGTGCΆGTTACATTCAATGT
CΆGCGΆTCATGCTGAATGGCCCGAGTATCCAΆTGATTCGTGACACCGTTTACG
TTAAACCTCATTCTTATΆTGGTTTTAAGATTCAAAGCTGACAΆCCCCGTGGTT
TGGTTTTTCCATTGTCACGTCGACTGGCATTTAGAACAAGGTTTGGCTGTTGT
TTTGATCGAAGATCCTCAAGCCATTCAAAAGAATGAAAAAATTACTGAGAATC
ATAAACGTATCTGTGAAAAAGTTGGTGTTCCATGGGAAGGTAATGCTGCTGCC
AACAGCAΆTGATTATTTGGACTTGAAGGGTGAAAATGTTCAAGTAAAGAGATT
ACCAACAGGATTTACCACCAAAGGAATCGTAGCATTAGTGTTTTCATGTGTTG
CTGCGTTCTTAGGCTTATTCTCATTTTCTTTCTATGGTATGAATGACATTGCT
CΆTGTTGAAGACΆAAGTAGCCAGAGATTTGGATATTGACTTGGAAGCAGAGAA
TGAGGACGAAGAAGAAGCAGTTGTTTTGAACCAGAATTCATCTTCTTCAGACA
GCAACTCTAAGCCACATTAA
FRE5; ATGGCTATTCCATTTGATCAΆCAGTTTTTTGTGGAAAΆGGATAGAAΆTAΆTAA 182
AACQ01000129; ATATGAGTGGTTGATATTTGTATTGACGTTCATTGTGTTAGCTGGACATGGGA
46434795 TACTTTTTTATTGGATTCCACGATACTTGCGAGTCAATAACAAACGCAACAAC TATTTTAGACTACTTAΆAGTGTGGGATGCATGGACGAGTTGTGTTCΆTGTATG GGGCGATTTCTACTTTCAGCCCAGTTTGGTGTTGTTGGGAΆTΆTTGTTTGTTG
Figure imgf000124_0001
Figure imgf000125_0001
AAAAGAGATTGGACATTATTTATCAGAGCAAAAGATATTGACCTTGATACTGG TAGAATCAATGTTGATTTAGATTTGTTACAACAAGAAATAGCTGAAGAAAAAG CTCAATTAGCTGAAAAACCATTCTATATTAGAATTTATAGATTTTGGTGCTAA
GAP1-4; ATGAGTAGGAAGTCTTCTATTGATATGCCTAAAGAGGCATCTAGCCCCGAGTG 186
AACQ01000199; CTACACAACATCGACATCCAGTAATGAAATAAGTGAAAAACCAGGCATGTGGC
46432706 GAAACTTCAAAGΆTTCATTCAAACCTCCTGTGCCCATCGATGATATTGAGAAT
GGATCGATATCTTCAACTCAATTAΆAAGGTGGACAGAATGTTCCATTACAACA
AAGTTTGAAAAAAAGACAACTACAGATGATTGCATTAGGTGGATGTGTGGGAT
CAGGGTTATTAGTGGCGTCCGGAGCTGCTTTGCGTAACGGTCCAGCAAGTTTG
TTAATTGCTTGGTTCATCGTTTCTACATTTTTGTATTGTACGATGCAATGTTT
AGCCGAATTATCGAGTACTTTCCCTGTGTCGGGATCCTTTGCAGTCTATTCTA
TAΆAGTTTATTGATCCAAGTTGGGGTACTGCCATGGGTTATAATTATGCATTA
TTTTGGGTTGTTGTCATGCCATTGGAGTTGGTTGCAAGTTCAATGACTATAAA
GTTCTGGCCATCAAATATAAATACATCTGTTTGGGTGGCAGTCTTCTATGTTT
TGATTATTGGTACAAATTTGTTTGGAGGAACAΆGAGCTTTTGGTGAGACAGAG
TTTGTTGCATCTGTTATAAAGTTGTTAGGAΆTTGTTGGTTTCAACATTTTGGC
AATTGTTTTGATTTGTGGTGGTGGTGACCAAGGCTATATTGGAGGTAAAAACT
GGCATCCTCCATTCΆCCACTGGTGTCAAAGGTGTGATATCCGTTTTATTGACA
GCAACGTATTCTTTAGCTGGTACAGAGTTGGTGGGGTTGACATCTGCTGAAGC
CGCTGGTGATGCTCGAAAAGTTTTACCAAAGGCAATCAAACAAGTATTGTGGA
GAATTTTGATTTTTTACTTGTTGACTTTGACATTAGTTGGGTTTTTAGTTCCG
GCCTCAGACCCACAATTAATTGGTGGTGGTAGCGGGGCATCTGCTTCTCCATT
TGTTATTGCAATTAGAGAAGGTGGAATCAAAGGGTTGCCTTCTGTATTTAATG
TTGTCGTCTTGGTAGCTTTATTGGCTATTGCTAACTCTGCGGTTTACGGATTT
TCAAGAACCATTTTGGCTTTGGCTGAACAAGGTGTTGCCCCTAGTATATTTAA
ATACGTTGACAGACAGGGAAGACCACTTGCTGGTATAGCCACTTCTGCCATTG
TTGGGTTGTTGTCTTTTGTTTCTGCCTCCAAACAGCAΆGAACAAGTTTTCGAC
TGGTTAGTCGCTTTGTCTGGTTTGTCTACCTTCTTCACCTGGGGAAGTATTAA
TGCTGCACATATTAGATTCAGAATTGCAATGAAAGTTCAAGGAAGATCATTAG
ATGAATTGCCATACAAGGCAAACACAGGTGTATTGGGAGCTTACTACGGTTTA
ATCATGAACGTTGCTGTATTGGCATTACAATTTTGGCTCGCAGTGTGGCCAAT
TGGAGGTAAACCAGATGCCACATACTTTTTTAAACAATATTTGGCTGCTGTCT
TGGTGCTTGCCGTTTACGTAΆTTCACAAAGTTGCTACCAGAAACTGGAAATTT
ATGGTCGATTACAAGGATATGGATCTTGACTCCGGAAGAAGTGATATAGATAT
TGATATACTTAAACAAGAGCTCGAΆGAAGAAAGAGAΆGCTTATAAGAGACAGC
CATGGTATTACAAGTTTTATCAATTCTGGTGTTAA
GAT2; ATGTCCAGTTCATCATCTTTATCTTCATCTACTACTACTACTGCAACAACAAC 187
AACQ01000243; CAGTGCACGTATTCGTTTACCATCAATAAGTGAATTGACTTCACGATCAACCA
46431962 TTAGTGGAGGTAGTAATAATGGTAATGGTTCTGCTTTGAAATCACAGATATCG
CCAAGATTGTCTGATACATCAAGΆATATTACCAAGTATACTTAAGΆATACTAG
TGGATCATCTACACCTACTTCTTCATCTACACCCTTTAAATGTCCACCAATAA
AGTCTACCATTGGCGGTACTTTATCAAGTGGAAACACTCAΆTCAAATTATGTT
TTGGGTAATACTAAAATAAATAATTTACCAAGACTTTCTTCACCTACATTGCC
CGCCAAAGTGCAACCTCAACAACAACCACATTTACCTCCTGCATCGTCACTTA
GCCCAGTGACAAGAGTAATCAATACCCCACCACAACAACCACAATCAGTTTCT
GCTTCTΆCATCACCAAATACCCAΆTACCAATACTATCAATACCAACAACAATC
TTCACCAATTCAACAGCAACAACAACAACAACAAGCCACCCCAGCTGCAACAC
CAACTGTCATGCAAATGGCACAAAATCAACCATCACACCCTGCCCCATTACAA
TACGCCACTCAACAGTACTATCCACAACCAGTATACTATCAAAGCCCAGCTGG
TGTGCCACCTCCACCACCATCTGTAACACATCAAGGTCATATAATAGCAGTGC
ATCAACATCCAGGCCATTTACCACAAGTTGGCGTTAATGGTATGCCACCTAAT
GTGGGTTACACTATAGTGCAGCCGGAAATCGTCAACAAATCAACTAACAGATG
TCACAGGTGTGGTACTACAGAGACACCTGAATGGAGAAGAGGTCCAAAGGGTG
TGAGAACATTGTGTAATGCATGTGGGTTATTCCACGCTAAATTGGTAAAGAGA
AAΆGGGGCAGCATTGGCAGCAGAAGAGGTATTGAATAATAAAGTGΆCAAAAGG
GAAGAACGGTCGAAGAATAAGTATGAAGAAACATCTTTTGAATGAGAGTTTAA
Figure imgf000127_0001
TTGATAGCTAΆAΆCAGTAGCATTAGTTTTTGCTATTGCACTGGGTATGTCATT
AGGAAAAGAAGGACCTTATGTTCATTTGGCAACTTGTGTCGGGAATATAACTT
CGAGATTTTTCCCCTTTATTTATGAAAATGATTTTTTTGAAAAACΆGATTTTA
TCTGCTAGTGCATCTGCCGGGGTAGCTTTGGCATTTGGATCTCCCTTGGGTGG
GGTTTTATTTATTCTTGAAGAAATTAATAATTACCTACCATCTAATCAATTGT
TCCΆAATTTTCTTTTGTGCAATAATTTCAACATTGTTCTTAAAATTCTTGAAC
CCTTΆTGGAΆCTGGGAAAACAGTATTTTTTGAATTGGAATATTTTTCAGATTG
GAGTCCTATGGAATTGATTTTTTTCGTTGTTATTGGAATCATGGGTGGAGTCT
TTGGTGCCAGTTTTATCAΆGTTTTCTCAATGGTGGGCCAAAAAATTTAGATCA
AATAAACACATCAAAACCCATCCTATTTTTGΆAGTTTTCCTTGTTGCAGCAGT
AACTGGTATAATTTCATTTTGGAACCCTTATACGAAGCΆAGCCTCGGCAGAAT
TGGTATTAGACTTAGCAACACCATGTAGTGGAGGAGAATTAGATCGGTCATTG
TGTCCACAGACAGAAAAACΆATTGTTAΆACGAGTTGGCGTCACTTTTATTTGC
ATTTGTTGTTAAAGTATTTTTAACATTTATAACATTTGGGTTGAAATTACCTT
GTGGGATTTATGTTCCTTCAATGGTTTGTGGAGCATTATTTGGTAGAATTTTT
GCATTGTTTATTAGATGGTTAGAGTTTTTATCCAGGAAATCATCGTCATCGTC
CTCCGCTTTCTCCACACTTTCACTTCCAGCCCCACCATTGGAATTTGGCCTTT
TATGTTCATCTGCAGGTCCTCATTGTGTTGATATGGGCATTTATGCTATGATT
TCTGCAGGTGCGTTTATGGCAGGTGTTACCAGAATGAATATAACATTGGTAAC
AATTTTGTTTGAΆTTAACTTCATCTTATACTTATGTTTTACCAATTTCAATAG
CTATAGCTGTGGCAAATTGGTCAGGTGGATTATTGGAGAAAAACTCACTTTAT
GAATCATTATTAATTAGTAΆTGATTATCCATTTATGGCACCAGAAACTGAACC
CATAGATCCΆTATGTATCAGCTGGTGATATAATTAATCAAGATTCTGTTCCCA
CAACACGGATTTCACGACATATACCTCCAGATAGACAATTATATATTGATGTT
AGTGΆTTCCGGTTATGTTCCTGTTTCTACATTAGAGTCTAAACTTCΆAATGTT
GGCΆGATAGATGTTTΆCTTGATGGATGTATTGCCTTGATCAAΆAATCAATTAT
GTGTTGGATTACTTTTCTTTCTGGAATTGGAAATATGTCTAGATCAAATTAGA
GCATTTACATTGAAΆCACGΆTGTGΆAAGAAGΆACTTTATTGTAACTTGTTTGA
TGATGATGATGGTGATGGCGGTGGTGTAGATAATAAAAGTCTTTCTAΆΆTCCC
GTGCTATGCΆTAΆTGACAAAGTGGTTAAAAATATTTTGAATCAAΆGTTTAGAT
TΆTTTCAATTATGGGGCAATTAATGAΆGATGAATATTTAGΆAATGAAATCTTC
CATTGΆTGTGTTAACAAATTTAΆCAAATTTTGTTGATCGTGTACCAATGTTTA
TCAATTATGATACCGAATTATGTTTTGCTCATTTGATTTTCGATAGAATCGGG
AATAGAGTGATTGTTTTGATCAΆAGATGGCAAATATTATGGTGTCTTACATAA
AAAΆGTACTTATTGΆCTACCTTAGΆAGAACTGAATAA
GITl-3; ATGGCTTCTAGAGATTTACCTCATTCACTCAATGATCTTGCCTTTGGATGGGC 190
AACQ01000081; TAAΆCACCTTAAAGAAGAAATCATTATTAΆTAAAAATTCCCAΆCAATTAGTCG
46437325 ATGAAGATTTCCAACCTGATGAAGATGTCACTAAAGAAACCAΆAGTCAAATTA
AATAATTTATGGCCGGCATTTGCCTCCGGAGCTGGGTTATTTGCCGATGGGTA
TGTCAATAATTCTATTGGTATTGTTATGGCATGTTTAAAAATTCTTTATGGTG
ATGAATTCACAAAATCAAATGCCATTAGTAATATTGGATCAATTGGATTTGTT
GGTACTGTTGTTGGACAATTGAGTTTTGGATATATTTCTGATCGAGTAGCTAG
AAAAGGTGGGATGATGACAGCTAATATCATGTTGATTGCTTTCACTTTATTAT
GTGCTGTGGGATCTTGGGGTACTACTATTCAAGGATTTTTTGCATGTCTTACT
GTTTGGAGATTTTGTTTAGGTGTGGCTΆTTGGGGCCGAGTATCCAACGTCTTC
TGTCATTGCCTCGGAATTTGCTAATCAATTGCCTGCTGGTAAAAGAAATAGAT
ATTTCΆTTTGGTTCACAGGGTTTΆTGATTGATTTTGGATTTGTTGTTTCTGCG
TTTGTCCCATTTGTGTTATTGTGGATTTTCACTGAAΆAACATTTAAGAGCATT
ATGGAGAGTTTCGATTGGATTAGGTGCCATTCTTCCAACTGCCTTGTTTTTTA
TTAGATTGAAAATGAΆAGATTCAACTTCATTTGAAAAATTΆCATATGAAAAAT
GTCAGΆTACAGAGATTATCCATGGTGGTTAATTGTTAAATTTTΆTTGGTTTAG
ATTΆACTATTGTGTCTATGATTTGGTTCATTTATAΆCTTTTCAGTTTATTCAT
TTGGTACATTTAATGCCΆTTATTTTGGGCCAAATTATCCCTGATGCTCCATTA
TGGCAACAATGGGGATGGTCTGTTGTGTTCAΆCTTGTTCTATATTCCAGGTTC
TTTCCTTGGTGCCTTTTCTGCTGATTATCTCGGTCCAAGATTGACATTGGCCA
TTGGGGTTGGATTGCAAGGAATTATTGGGTTTATTATGTCAGCTTGTTTGAAC
Figure imgf000129_0001
TTTCGCTΆTTGCCATGTATACCCCATCTGGTTTCAΆGAATATTAGTTGGAAAA CATATATCATTTATGGTGTATTCTGTTTGGCCATGGGTACCCATGTCTACTTT GGATTCCCAGAAACCAAGGGTAAAAGATTGGAAGAAATTGGTCAAATGTGGGA AGAAAATGTTCCTGCTTGGAGATCAAGATCTTGGCAACCAACCATTCCTATTG CCTCCGATGCCGAATTGGCAΆGΆAAGATGGAAGTTGAACATCAAGAAGATAAA TTGATGAATGATGATTCTAACTCAGAATCAAAAGAAAACCAAGTCTAA orf6.3044; ATGTCGTCCAAGATCGAAAGAATCTTTTCTGGACCTGCTTTAAAAATCAATAC 193
Y16834; TTATTTGGACAAGCTTCCAAAAATTTACAATGTTTTCTTCATCGCTAGTATAT
3336838 CCACCATTGCTGGTATGATGTTTGGTTTTGATATTTCTTCAATGTCTGCCTTT
ATTGGTGCTGAACATTATATGAGGTATTTCAATTCCCCAGGΆTCGGΆTATCCA
AGGGTTCATTACTTCATCCATGGCTTTGGGTTCTTTCTTTGGTTCTATTGCCT
CCTCATTTGTTTCTGAACCCTTTGGTAGAAGATTATCATTATTGACTTGTGCT
TTCTTCTGGATGGTCGGTGCTGCTATTCAATCATCAGTTCAAAATCGTGCTCA
ATTGΆTTATTGGTAGAATCATTTCTGGTATTGGTGTTGGTTTCGGTTCTGCTG
TTGCTCCAGTTTATGGTGCTGAATTGGCTCCAAGAAAAATTAGAGGTCTTATC
GGTGGTATGTTCCAATTCTTTGTCACCTTGGGTATCATGATCATGTTTTACTT
ATCCTTCGGATTGGGCCACATTAATGGTGTTGCTTCATTCAGAATTGCTTGGG
GACTTCAAATTGTCCCTGGTCTTTGTTTGTTCTTGGGTTGTTTCTTTATTCCA
GAATCTCCTCGTTGGTTGGCTAAACAAGGTCAATGGGAAGCTGCTGAAGAAAT
TGTTGCCAAGATCCAAGCTCATGGTGATCGTGAAAATCCTGATGTTTTGATTG
AAATTTCTGAAATCAAAGATCAATTATTATTGGAGGAGTCCAGTAAACAAΆTT
GGATATGCTACTTTATTCACCAAAAAATΆCATTCAAAGAACCTTCACTGCTAT
TTTCGCTCAAATTTGGCAACAATTGACTGGTATGAACGTTATGATGTACTATA
TCGTTTATATTTTCCAAATGGCTGGTTATTCTGGTAACAGTAACTTGGTTGCT
TCATCCATTCAATATGTTATCAACACTTGTGTCΆCCGTGCCTGCATTATATTT
TATTGATAAAGTAGGTAGAAGACCATTATTGATTGGTGGTGCCACTATGATGA
TGGCTTTCCAATTCGGTCTTGCTGGTATTTTGGGTCAATACTCΆATTCCTTGG
CCAGATΆGTGGTAACGACTCAGTCAACATTAGAATTCCAGAAGACAATAAGTC
TGCCTCCAAAGGTGCCATTGCTTGTTGCTACTTGTTCGTTGCTTCCTTTGCCT
TTACTTGGGGGGTCGGTATTTGGGTCTACTGTGCTGAAATATGGGGTGATAAC
AGAGTTGCTCAACGTGGTAATGCCATCTCCACTTCTGCCAATTGGATTTTGAA
TTTCGCTATTGCCATGTATACCCCAACTGGTTTCAAGAATATTAGCTGGAAAA
CATATATCATTTATGGTGTCTTCTGTTTCGCTATGGCTACCCATGTCTACTTT
GGATTCCCAGAAACCAAGGGTAAAAGATTGGAAGAAATTGGTCAAATGTGGGA
AGAACGTGTTCCTGCTTGGAGATCAΆGATCTTGGCAACCAACCGTTCCTATTG
CTTCCGATGCCGAATTGGCAAGAAAGATGGAAGTTGAACACGAAGAAGATAAA
TTGATGAATGAAGACTCTAΆCTCCGAATCCAGAGAAAΆTCAAGCCTAA orfβ.4884; ATGATTACTATCAAGAACCATGTGATGATTACCCACAACAACAACAACAACAA 194 AACQO1000139; GAGCCTTGTGATTACCCACAACAACAACAGCAGGAAGAACCTTGTGATTACCC 46434401 ACAACAACAACCACAAGAGCCATGTGACTATCCACAACAGCCACAAGAACCTT GTGACTACCCACAACAACCACAAGAACCTTGTGACTACCCACAACAACCACAA GAACCTTGCGACAATCCACCTCAACCTGATGTTCCTTGTGACAATCCTCCTCA ACCTGΆTGTTCCTTGTGACAATCCTCCTCAACCTGATATTCCTTGTGACAATC CTCCTCAACCTGATATTCCTTGTGΆCAATCCTCCTCAACCTGΆTCAGCCTGAT GACAATCCTCCTATTCCAAACATTCCAACCGΆTTGGATTCCAAATATTCCAAC TGATTGGATCCCAGATATTCCAGAAAAGCCAACAACTCCAGCTACTΆCTCCAA ACATTCCTGCTACAACTACTACTTCTGAATCATCATCTTCTTCTTCTTCTTCA TCΆTCATCTACTACTCCAΆAAACTTCTGCTTCAACTACACCTGAATCTTCTGT TCCAGCTACCACTCCAAACACTTCTGTTCCAACAACTTCTTCAGAATCAACTA CTCCAGCTACTAGCCCAGAAAGTTCTGTTCCAGTTACTTCTGGATCATCTATT
TTAG
HWPl; ΆTGAGΆTTATCAACTGCTCAACTTATTGCTATCGCTTATTACATGTTATCAAT 195 AFO01978; TGGGGCCACTGTCCCACAGGTAGACGGTCAAGGTGAAACAGAGGAAGCTCTTA 2275335 TTCAAAAGAGATCTTATGATTACTATCAAGAACCATGTGATGATTACCCACAA CΆACAΆCAACAACAAGAGCCTTGTGATTACCCACAACAACAACAGCAGGAAGA ACCTTGTGATTACCCACAACAACAACCACAAGAGCCATGTGACTATCCACAAC AGCCACAAGAACCTTGTGACTACCCACAΆCAACCΆCAAGAACCTTGTGACTAC
CCACAACAACCACAAGAACCTTGCGACAATCCΆCCTCAACCTGATGTTCCTTG
TGACAATCCTCCTCΆACCTGATGTTCCTTGTGACAATCCTCCTCAACCTGATA
TTCCTTGTGACAATCCTCCTCAACCTGATATTCCTTGTGACAATCCTCCTCAA
CCTGATCAGCCTGATGACAATCCTCCTATTCCAAACATTCCAACCGATTGGAT
TCCAAATATTCCAACTGATTGGATCCCAGATATCCCAGAAAAGCCAACAACTC
CAGCTACTACTCCAAACATTCCTGCTACAΆCTACTACTTCTGAΆTCATCATCT
TCTTCTTCTTCTTCATCATCATCTACTACTCCAAAAACTTCTGCTTCAACTAC
ACCTGΆATCTTCTGTTCCAGCTACCACTCCAAACACTTCTGTTCCAACAACTT
CTTCAGAATCAACTACTCCAGCTACTAGCCCAGAΆAGTTCTGTTCCAGTTACT
TCTGGATCATCTATTTTAGCTACCACTTCAGAATCATCATCTGCTCCAGCTAC
TACTCCAAATACATCTGTTCCAΆCCACTACTACTGAAGCCAAATCATCAAGTA
CTCCATTAACTACTACTACTGAΆCATGATACAACTGTTGTCACTGTTACTTCA
TGTTCTAACAGTGTTTGTACCGAAAGTGAΆGTTACTACTGGTGTTATTGTCAT
CACATCTAAAGATACTATTTACACCACTTACTGTCCATTGACTGAAACTACTC
CAGTTTCTACTGCTCCAGCCACTGAAACACCAACTGGTACAGTATCCACTTCT
ACTGAACAATCAACTACTGTTATTACTGTTACTTCΆTGTTCTGAAAGCTCTTG
TACCGΆATCTGAAGTTACTACTGGTGTTGTTGTTGTTACTTCTGAGGAAACTG
TCTACACTACATTCTGTCCATTGACTGΆAAACACTCCAGGTACTGATTCAACT
CCAGAΆGCTTCCATTCCACCTATGGAAACAATTCCTGCTGGTTCAGAACCATC
CATGCCTGCCGGTGAAACCTCTCCAGCTGTTCCAAAATCAGATGTTCCAGCTA
CTGAATCAGCTCCAGTTCCTGAAATGACTCCAGCTGGTTCACAACCATCTATT
CCTGCCGGTGAAACCTCTCCAGCTGTTCCAAAATCAGATGTTTCAGCTACTGA
ATCTGCTCCTGCTCCTGAAATGACTCCAGCTGGTACTGAAACTAAACCAGCTG
CTCCAAAATCATCAGCTCCTGCCACTGAACCTTCCCCAGTTGCTCCAGGTACT
GAATCTGCACCAGCTGGTCCAGGTGCTTCTTCTTCTCCAAAATCTTCTGTTTT
GGCTAGTGAAACCTCACCAATTGCTCCAGGTGCTGAAACTGCTCCAGCTGGCT
CAAGTGGTGCTATTACTATTCCGGAATCTAGTGCTGTCGTCTCTACGACTGAA
GGTGCTATTCCAACTACATTAGAATCAGTTCCACTCATGCAACCATCTGCCAA
TTACTCAAGTGTCGCTCCTATTTCTACATTTGAAGGTGCTGGTAACAΆCATGA
GATTGACTTTCGGTGCTGCTATTATTGGTATTGCTGCATTCTTGATCTAA
IPTl; ATGATAACAACAACATCTATATCGTCGGTGATATTGACGATCCTCAAACCCCT 196
AACQOIOOOOOI; TGTATTTATATATCAATTCATTTATCGAGTTTATTGGTCAGGATTAAATCAAC
46445439 GTAATATATTACAATTGATTCTAAATTTTTGTATTAATTTCAGTCCAGTTTTC ATTTGGTTATTAATATTTAAAΆATGCTGGATTGATCCCTCATGAAATACGTCC TΆΆAATTCATGTCAAATTAGCΆTATCΆTTTGGΆTCAATACATTTTTGAAACTA TAATTGGTGGCATAGTTAATATTTTGGGATTAGCATCTCTGGGTTGGTTATTA TATCGTTTTGTTTATCAACTGAΆATCGAGTAATAΆCAATAGCAACAGAAACAA CCATCACCAAAGTCAAATTTCTGGTGAGTACCCTCCTAGCAATGCCAATGACA TTTATTCATTGTACAAGATACCACAAAATTATGAΆTTGGATATCGACAΆCGAT AGTAGTAGTAGTAATAGCAGCAATAATAGTGATATTGAATTAGAATCATTTCC TAAAGAATTGTTGAAACCTTCTTATAΆTCAATTACCACCAATAAATTTCCAAG ACAATGACGATCAAATACAAGACTCACAACTAGATAACAATAGGGTCCATGAT GGCAΆTTCAGAGAATACTCGATTTGCGCCAATGGTATTTATCCCACAATTATC TCTGGTTCAAGTTGGTCAAATGGCACAΆTCAATCAATAATAAΆATTCTTAATC ATATCCATCCAAAAAATTCAAATTCTGGGTTCAATGATAATTATTCCCCCATC ATTCATGGGATTTTTGTCCATCATTATTATTAG
SKNl; ATGACTCGAGGTAAGTATAACCAGAATACAAATCGGTCAAGTTCAAATTATAT 197
AACQ01000066; TCAACACAGTCCAACATCAGCAGGGTACGATAGATATCCGCTTAAAACTCAΆT
4S438258 CCΆGTATTGGTGGATCAATGCTGAGAΆTTGGTTTATCATCATCATCGCCATCΆ CAACAACAACAACAACACATGTATGATAACAATTCATCTAATCGATCTCTGTA TTCACCTGATTCCGCCACTGATTTAATGGTTTATGAAAATGGAGAATTTAGTC CATTTGGAGGATATCCAGCAAGTTTATTCCCCTTAAGTATTGATGAAAAAGAA CCCGATGATTATTTACATAATCCTGATCCTGTTCAAGATGCCGAATATGATAΆ AΆATCGGTTTTTATATGACTTAAAAACCATGGATAAGAAATCTATGAATGGAT TAATTGCATTTATTGTAΆTGTTTTTAΆTTGCTΆTTGCTATATTTATAATTTTA
Figure imgf000132_0001
CATCATACCTGGGGCATTTATTGATACGATGAATTCTTTCCGTACAACGTCAG
CAGCATATTCAATTTTTTTTGTTCAAATCGCATCACATTGGTGTGGCAAATGG
CTAGCTAGAATTCTTCCTAAAAAGCAAGTTGGTTTTGGAAGATTGTCGTTCAA
TTTAAACCCGGGGCCCTGGTCTATCAAGGAAACGGCTTTGATTACAATCACCG
CAAATAGTGGTGCAACGGGGAGCATGGGTACCAATCCTTTGGCGTTGGCAGAA
CTTTTCTATGGTGAΆΆCTGTCAACCCTGCTGTTGCCATTTTCTTCATGTGGAT
GATTGTGTTTATTGGTTACTCATTTGCTGGTATTGCCΆGAAATTTCTTATTGT
ATGACCCTCAATTCACATGGCCACAAGCTTTGATGCAAACAΆCΆTTATTTCAA
ACCCAAAGTAAAAGTGACAAAGATGCCAAGCAAGCATCAAAGCAAATGAAAGT
GTTTTTCTTTGTCTTGATTGGTTTATGTATATGGCAGTTTTTCCCGGAATATA
TATTCCCCATGACTTCTTCGTTGGCTTTTCTTTGTTGGGTTGCGCCAGAAAAC
TATACAGCCAATTTCATTGGATCTGGTCTTGGTGGAATGGGGTTTCTTAATCT
TTCCCTTGATTGGTCAAATATCACCTCGAGTATTATGTTGTATCCGTACTGGG
TGCAAGTAGTACAATTCGCTGCGTTTGTTCTTGGGGCATGGATATTGATCCCA
GCTGCCAAATGGGGGGATCTTTCAAGTTATCCTTACGGGTTAATGTCAAACAG
TTTGTTTTTAGGTAACGGTACCAAGTACCCAACTACCGAGTTGCTCACGCCAA
ATTTAAGATTGΆACGAAACCCGATACGAAGAACTTGGGCCAGTGCATCTTGGT
GCCCAACGTGCTTGGAATATGTTTTTCGATTATGCTGCCTATGTTAGTGGATT
CATGTGGGTTGTTGCTTTTGGTTATAAAAGCTTGTCAGGGTCGCTCAAAAGAT
TGGTGAAGTCAΆGAAΆACAAAAGGGGTCCATAAΆTTTGCAATACACTGATAGG
TTGAATAAACTTCAAGCAGCCTATGAAGAAGTTCCATTGTATTGGTACGCTAT
TCTTTTCTTATGTGCATTTGTCACTCTTTTAGTGATATTTGCAΆCGΆACTCGT
TATTCATGCCGTGGTGGTGTCTTCTTGTTGGAGTTGCCTTTGGTGCTGTGATT
GTTACTCCTTTAGTTTGGTTGTATGCTCTATCCAΆCTTCCAGTTGCCCATTGG
TACCTTCAATGAATTATTATATGGTTATATGATTCAGAACAAAACGTCAAGAC
ATCCAGCTGGAGCTΆTGGTGTATGGTGCAGTTGGTGGGGATTTGTTTTACAGΆ
GCCCAGTATATTCTTAATGATCAAAAGATTGCCCATTACATGCACATTTCTCA
AAGAGCAGTATTTTTCTCGCAGATATTTGGAGAATTAATTGGTGTACCCATCA
ACTATGCCGCCTTAAGGTGGGTGATCCTGTCCAAAAGAGATTTCTTGGATGGC
ACAAAAGTCGACAAGCTTCACCAATGGACTGGCCAGACCATTGTCAGTTACAA
CACTAATGCTGTGCAGTATGTGATTTTGGGACCAGATAGATTATTCAAAAACT
ATCCAGTATTGCCATATGGATTCTTGCTTGGTGCTGGTGCTCCACTAGTATTA
TATCTTCTTCACCGATTGTTTCCCAAATCGAAATTGAAGTTCCATTTGTGGAΆ
CACCACTGTATTCTTTTCTACTATGAGTACCTTCTATGGTAACCTTTCAACGG
GΆTATTTTTCCAGATTCATTGGAGGGACCATAACAATGTTTTGGGCATTCAGA
TACAAGCACAGTTTATGGAAAAAGTATAATTATTTGTTGGCAGCTGCTTTGGA
CACTGGCCTTAATTTGAGTΆTCTTACTTATTTTCTTGTTCTTCTCGGCTGGTA
AAΆCAGTCAATTTCCCCGAATGGTGGGGCAACAATGGCAAGAGTGTGGAGAGA
TGTTTTGCCATGAGTTGA orf6.2773; ATGCCCAACACACCTTTACTTCTGATCAGATCTCCTAGATTTGACAGACTCTC 200
AACQ01000139; CCCTAGAATCACAACAACAACAGCCACAACAACTGATCCCAATGGTATTGTTG
46434401 ATATTATCAACCAACAGGAAATACAΆAATTATAAΆCTTGGTATAΆTTCTTCTT GTGATTGCATTGGCTACTTGGATTATTGGATTAGAATTGGTCAΆTGCGGTATT AAAAGGAGATGATTATGAAAAACCTTGGTTATTTGCAGTGATCACTGGTTCAT GTTTCTCAATAAATTTATTΆCCGGATATAATTCTACTTAAACΆCTGGGAAGTT TTCGGTCAAACTCAAATTGAAGAAGACTTACCATTACTTCAΆΆCGAAATCAAA AGAAAΆGAATGAAGATGTTTCAGAATTAACTCCCAΆGGAAGTGTTTATTTTGG CTTTTCAAATCGCAGTTATTTATTATTCATATAATGTCCTTGGGATGTCTGCG TTAAΆGTTCACATCAGCTCTGAATCAAΆCAGTCATGGGTTCAACAACATCΆAT GTTTACTTTGATTATAGGAGTAATACTCAAAACCGAAACTTTTACAATTAAAA AGGCACTΆTGTGTAATTGGTAGTTGTTTGGGTGTCTTTATGGTΆAGTTTTAGT AATACTTCAGCGGGGCAAGGCAAATTCCAACCGAAΆΆATCCCGTTCTTGGAAA TACATTGGCATTGGGTGCAGCATTAATGTATGGTTTTTATTTACTTΆTTATGA AATTTAAATGTGGTACTGGGGATAAΆACAΆCTAATGAΆAGAΆGACTTTTCGGA TACGTGGGATTAΆTAACTTTTGTAATTGGTGTGCCTGTGTTATACGTGGTTGA TTTATTAGAAATTGAAAAGTTTCAATTCCCTCCACCAAATAATACTATTTTAG
Figure imgf000134_0001
ATTTCTATTATACAATTTTTATCAACTTTACCAAATTGTTTAAATACTGTACC TCAAGAAGTTΆTTGAAGATAATAΆTAATAATAATAATAATAATAACAAAATGC ATGGΆATCACΆAATTATAATTTTCAAΆTCAAACAAAAAAGTAGTACCCCTTCT TCAΆGTTCATCAATTTCTGTGACGGTCTTAGΆTTCAGAAGΆTCATTTAATTGA TGATTCACAΆATGACTTATTTATATCGAΆTTAATAATGAATTATTAAATGATT ΆTAAATTATTATTTTTCCATTATCCATTΆCCTCAATTTCGTCCAΆAAGGGAΆA TTTAAAATTGTTGGATCATATAATGAAAAACATGAATTAGATCGTAAAACAAA ATTAAAΆTTTCATGATGATATAATAAGTTGTGGTTΆTAATGTCATATCTGTTG GTCATGAACATGAAAATGATGCTTGTTTATTΆTCATCGTCATCGTCATCGTCC AACTCCGATAAATCAATTTGGTTΆTGTTATAATΆGTATCACGGGTGATTCAGG TATAΆCTAAATTAGATAAACAATACGTTAGAAAATTACGATTATTTGAAATTG
ATTTTGAAAAAAATCGAATTTTAAGTTGGAAACGTAAAGAAATTGATAATCAA CCATTTGATTATCAACTGATATATGAAAAACCTCAAAAAAAGGAAAAAGAAAA GTAA orf6.3214; ATGGATCAAACATATTTGGACCAΆCAACΆATTGGATGCΆAATGTGAATCACCA 203
AACQ01000055; ACAATTATCCCAAGATACTAATCTGATTCCACAACAACAATTGCAACAGCAAC
46439033 AACAGCCGTTGCAACAATTACAGCAGTACCAACAACAACCACTAAGCAATGCA
AACTTTTCTGGTGACAACAGATTTCAGCAATATCAACCACGAGTAACTCCTTC
GGTTTCTTCTTCCCAACAATCAATACATACTACCACCGGATATGTAACAATGC
ATAGTGGTAATTACACCCCTAATCAACAATATGGTGTGCCAAATCAATACACT
GTACTCCAACAACAACCACCACGACAACAATCATATGAAGAGAATATTAATCC
TCTCAGTTATAATAGTAATGATAGAACATTGAGTGCCCCTATCCCACCATTAC
ATATTCAACATCAATTGGCTTCCAAACAAAATCAGGACCAAAACCAATCACAA
AACCGTTACGAGCAATCTTCAATGACAAGCATACΆTACAΆATGACAACAGCTC
ATCAGTTAACAΆTTCTCCAAACACGATGATGATCAAGCAΆGAGCATTCCACTT
TTCAACCACΆACATAGTAΆTGAAGGTAGTAGTGCATATCATCCAGTTGATCAA
CAAΆΆTCATCAΆCAGCAACAACAGCCTCAGCAACAGCAACAGCCTCAGCAACA
GCAACAGCCTCAGCAACAGCAACAGCCTCAGCAACCAATGACTAGATCCATTT
GTACCAGGTGTAAAAAAGGATTTGACCAACCAATAATTTATCCAAAATCAAGC
AΆTTCTACCAATGGTAACΆACAGCAATGGACAAAATTCGTCATCAATACCTCC
GCCTGAGCCAAGAACTTTCAAACTATGTGATCATTGTCGTAAATTACAACGTC
AACGGTCGAGAAGATGGCAGAAAAAAACTAAGGATAGAGAAGGAGTATGTCGC
AGATGTGGGTCAGAΆΆTACCATTGGCAGAAAGAAGATTTGTTTTGTGTCCTAG
TTGTCGGGAAAATTTACGTTTGCGAAAAGCTAGTCGGGCAGCCCAAGGGAGAT
GTGTTCATTGTTCGGGGCCΆTTGGATGCATCTΆTTTTATCCAAAGAAAACGAA
GGTAACAATAATGGTGATGAGCAGAATAATAΆGTCAAACGAAGATCAAAATAA
CGAGCTGAGAAGAGGAAGCCAAGAAGAAAAGCCTGCACGAGGTGCCAGTCACA
AAGTTTGTCAAAGATGTCGAGAAAATGATAAAATCCGAAGAGCAAATTTGGAA
AAAATGGGTAACTGTAATCGATGTGCTAAGGCATTAGATCCCAATGAATATGG
TAGAAATAAAGTTTGTTTTAATTGTCGAACTAAAAAGAAAAGATCACCTCCTG
AAAATGTCACAAATACTGATGAAGTGAGAACTTCGCCAATTCAAAACCAATAT
GGAATGAΆCΆTGTCGCATCAATACATTCAACCΆCCTCCACCGCCTCCACCACC
TTTAATGACAGGTCATCACCAGTTTCAACCTCAACCACATATGATGGGTCATG
AACAAATGAATACGTTCACAACAATGTCΆAACTCTGGTGTAGCTGGTATTCAA
CAACCAAACAATGGTATGGTAGTAGGTGATCAACAGCAACAACAACAACAACA
TAATGGCTCAATGCAATTACAACCTACGTACTATCAATCATATGTCCAAATGC
CACCTCCACTACAΆCTTCAGCAΆCAACAGCAACAGCAGCAGCAGCATTATTCA
CTCGACGGAATTCCCCAGCAGCCACATTCTGCGCCTACAAGTTCATTTCCACC
TCCACCGCCTCCACCATTGCAGTTGAATCAGCATCAGGGGCTTCAACAATATA
GTCATGCTCAACAACAACAGCAGCAGCAGCACCAACAGCAACAACCATACCAC
CAAGAGTATCCAAACAATTAA orf 6 . 4504 ; ATGCATTTCATATTCTACTTGATTCTTTTAGTATCTGCTGCTGATTACGGTAA 204
AACQ01000129; CTTTGGTACATACCCAAAΆGTCCCTAAAACTGCTTCCATTAATGGGTTCGCAG
4S434795 ATCCAΆTCTACGATTTATTACCAGACTGTGCAΆAGGAATGTGTCAAATTCAGT ACAAGTAACACCCCTTGTCCATATTGGGATACAGGATGTTTCTGCGTGATGCC ACAATGGGCTGGTTTAGTTGGTCAATGTGTTGCTCAAAAGTGTAAGGGTGAAG ATGTTGCTAGTGCCAGATTCTTGGCTACTTCGTTGTGTTCAGTTGTTGGTGCT AΆTACTTGGATGATGCCTGCTTCTATTTCCTCGATGCTTTCCACTGCCGCTGG ΆGATGCTAAGGΆAGTTACTACAATTGAAGGGAΆAACTGCTAAATCATGGGTTA CTGCTCCAGGAAGTGCTGCTGGGΆGCGTTGTTTCCGAAACTGGTAGTGCAAGT GAAACCGGCAGTTCCGAATCGGCTCAATCAACAACTACAGGCTCGTCATCTAC AGGCTCATCATCCACAGACTCCTCCTCTTCTTCTTCCTCATCTCCTTCATCTT CTGCTAATTTTGCTGTTTTGCAGACAGGAGGAATCGGATCGGTAATTCTTGGA TTCATGATGTACCTTCTTGTATAA orfS.4507; ATGTTCTTACACCCAGCAACTTTTGCAGGCACACCCAACATCATTGCTGTAGA 205
AACQ01000129; GGGCAACACTGCTGTTCCGCCTGGAACATACAACCCAACATTCTCAATCGGCT
46434795 TAGCAAATCTAGAACAATATACGCCGGGACTGGTTTCTACTGTCATAACTTTT TCTTTTGGTAATTGTGCAGCATGGAACTTTTCGATATTTTGCATGGACAAGTC AATGGCAGCCTTCATTTCTTCTGAAATATCCATCAAATCAGCCGGGAACGGAG CTTGTAAAACAGGAGCATCAAGTTTTACACCATCAAACTTGGAAGTCAACTCA ATAAGTGCTTTGTCTCCATCAGACTTGACTTTTTCAATAATAGGAAGCACGAG TTTCATAATGTCTGCAGTCTTTTGTACAGGTCTTGTCATTGCACGCTCAACAG CAGCAGCATCGTCAΆCACTAACAATCTCTΆGCTTGTAA orf6 . 6077 ; ATGTCATTTTGGGACAACAACAAGGATTCATTCAAGTCAGCTGGTAAATCGAC 206
AACQ01000151; TTTCAAGGGTATTACTAGTGGTACCAAAGCTGTGGGACAGGCAGGTTACAGAA
46434012 CCTATAAAAAGAATGAAGCCAAAAGAAAGGGTGTTGAATATCATGACCCGATT
AAAAATGAATCGAAAAGCGGAGAGACAAATGTCCCTTATAACCCAAGTCCATT
GCCTTCAAAAGACAAATTGAGTTCATACCAACCTCCACCTAAAAGAAATGTGG
GCACTTTTGGTGTTCCCCAAAGGGGAGAAGCTTCTCACTATTCTGCTCCTGCG
CCTACTTCGGGTCAAAGTACATATCCTGCAAATCAACAACAATATCAACATCC
GAATGAAATTCAAACCAGCAGTGGCTATCAAGAACCACCTCCGGAGTATCTGG
TAGΆTTCTAATAGTGACΆTGCAGGGATTTTCTGCGGGAAGTGAGTATCAGAGA
ACAGCACATCCAGCTCCGGCCAGTACTACTTTTACACCAGCTAATCAAACTAG
TTTTATTGCACTGCCTCAGCCAACTTCAATAGCTACGGACAATGCAATTCAGA
ATATACAACAGCAGTATAATAGTGTGCTGAAΆCAGCCATCACCAGCACCAGGG
TTACCACCATTACAGCACCAACCAGGGAACTTGGTTAATCCACCATTGCCCCC
ACAAGTGCCCCAGAAAAGTAATGTTCCTCCATCACTTCCTTCAAGAACATCAG
TTGCCAGTGTAGCAAGCTCCACATCTCAGCAAAGTGTTGGGCAAGGGAGTTTT
GTGAATGCACAGGAACAACCCAAACCTAAGCCAGCTTTGCCCGACCCTGGATC
ATTTGCACCACCACCAAGAAGACGTGACCAACAACCAATTAAACCCAAAATTT
TAACCAATAACTCAACCATGGGAAATGAGAAAATGCTGAGTCCATTAGTGCAA
GGGCAGAGCTCAAGTCTGAΆTATTGGATTACATCCACTGAAGTCTATTAGCGA
AAGAGAACATCAATCAGATTACAGTGACGCTCTGCTGAAACCACCATCGTTAC
CAAGTAGAACGAGCTCTTCTCACTCCAACTTACCTTTGAAACAAAAGCCACCG
AAACCAAAGAAACTTCAAGGTGATTCATCAATTACGACTTCACACACACCAGG
CTATAACTCAAATTACACTCATAATGTTTTTTCAGCTCGAAGCGAAGAAGAAT
ATGCAACGCCTCCAAAACCACCACGTCCAGTTGAAGACGAGGAATATACAAAT
CCACCTAAACCACCCAGACCAGTAGAAGATGAAGAATACACGAATCCTCCTAA
ACCGCCTAGACCAGTTGAAGATGACGAGTACACAAATCCACCAAAACCTCCTC
GTCCAGAGACCCAAAATTCTTCTGTGGTGACACCAAGAGCTATACCTGATGCC
ACTGAGCTATCTAACAAAAAGCCTCCACCACCTAAACCTTTGAAAAAACCTTC
AACATTAGATGGATCAACAAGTTCCCCTCCTTTATATTCCGAGCTTGATAACC
TGTTTAGCAAACCGAAGCAAATAATCTCGGAATCTACAAACTCGCAAAGTGCA
GTCCTGAGTGAGTTGAACAGTATTTTTCAAAAAATGAATATTAATAAAACTGA
AAGTGAGGCACCTGCTAGTAGTCCTGAAGTTAAACCGAAGCCCAAACCGAAGC
CGGTACCAAAACCGAAACCCGAGATGATTACTAAGAAGCΆAGAACTGCCGGAA
ACCAGTATACGAATAGCAACGACAACTAAACCGCCACCACCCGTGCGTCGTCT
TTCCACACCCCATAAGTCACCTTCTCCACCACCAGTTCCTCCAGCGAGAAATT
ATAGCAGGGCTCCTGCTCCACCACCTCCAAAACAATCTGGCCCTCCAAATTTG
GATTTAGAATTATCGAGTGGTTGGTATGCCAAAACCAATGGACCATTGCAGTT
ΆCCCAAAGTATTTCATGGAATCAATCACAAGTTTTCGTACACGACATCATCAG
GCTCTTATGGGAAGGGTACCACAACTTTAACTGTGAGΆCTTAAAGACTTATCC
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
GTCACCACTGGTGTTGTTGTTGTTACATCTGAAGATACTGTTTACACTACATT CTGTCCATTAACTGAAACTACTCCAGCTACTGAATCAGCCCCAGAATCATCTG CACCAGCCACTGAATCAGTTCCAGCTACTGAAAGTGCTCCAGTTGCTCCAGAA TCATCTGCACCAGGTACTGAAACCGCACCAGCTACCGAATCAGCTCCTGCCAC TGAACCTTCCCCAGTTGCTCCAGGTACTGAATCTGCACCAGCTGGTCCAGGTG CTTCTTCTTCTCCΆΆΆATCTTCTGTTTTGGCTAGTGAAACCTCACCAATTGCT CCAGGTGCTGAAACTGCTCCAGCTGGCTCAAGTGGTGCTATTACTATTCCGGA ATCTAGTGCTGTCGTCTCTACGACTGAAGGTGCTATTCCAACTACATTAGAAT CAGTTCCACTCATGCAACCATCTGCCAATTACTCAΆGTGTCGCTCCTATTTCT ACATTTGAAGGTGCTGGTAACAACATGAGATTGACTTTCGGTGCTGCTATTAT TGGTATTGCTGCATTCTTGATCTAA
RBT5; ATGCTCGCCTTATCCTTATTGTCAATCGTTTCCATTGCTTCAGCTGCTGGTGT 220
AF254145; CACTGCTATCCCAGAAGGTGATAATCCATACACTΆTTTTCCCAAGTGTTGCTA
9963987 AAACCGCTTCCATCAACGGTTTCGCTGACAGAATCTACGACCAATTGCCAGAA TGTGCCAAAGAATGTGTTAAGCAAAGTACTAGTAGTACCCCATGTCCATACTG GGATACCGGTTGTTTGTGTGTTATGCCTCAATTTGCTGGTGCCGTTGGTAACT GTGTTGCTAAAAACTGTAAAGGAAAAGAAGTTGGTTCTGTTGAATCTTTGGCC ACTTCCATTTGTTCATCTGCTGGTGTTTGGGAACCATACTGGATGATCCCATC AAGTGTTTCTGACGCTTTGGCTAAGGCTGCTGATGCCGCTGCTGAAACCACTG CCGAATCCACCACTGCCGAATCTACTGCCGCTGAAACCACCAAGGCTGAAGAA ACTTCTGCTAAAGAΆACCACTGCTGCTGΆΆΆCTTCCAAGGCTGCTGAAAGTTC TGCACCAGCTGAAACTTCTAAAGCTGAAGAAACTTCAAAGGCTGCTGAAACCA CCAAAGCTGAAGAATCTTCTGTTGCTCAATCTTCTTCTTCTGCTGCAGACGTT GCTTCTGTTTCCGTTGAAGCTGCTAACGCCGGTAACΆTGCCΆGCTGTTGCTAT TGGTGGTGTCATTGCCGCTGTTGCTGCCTTATTCTAΆ
RFX1-2; ATGTCCAATAACCCACATAGAACACATAAACGACAGAAATCGTCAGTGCTGAA 221
AACQ01000006; CCCTGGATATTATTTCACACCTGAGACCΆΆGCTGGAGATACΆGCAΆCAACAAC
46444619 CACAACAGCAAGAAAGTCAACAΆCAACAACAACAGCAGCAGCAACAGCATTCC
CAAACACACAATATCTACGATAATGACAACTACATGAATTACAATTTTCCACC
CACTAGCAATAGΆCCTAGAGCTTCGACΆACAACAGGΆACAΆCATCTACCACAC
ATCCAGGAAGCGAATTΆTCTCATGAAAGCCATTCCGTGCATACTTCGCCTTTG
AAACGAACAGCATCATCAGAGCTAGATCAACCTATTCCAGCCATGGCACCATC
TTCTCCCCTAGTAAGCTCAGCCCCATATTATTACCAACAΆCCATCTCAACAGC
AAAACCTTTCGTATCATGATCACCACCACCAACAGCAACAGCAGCAATCTACT
CCTCΆΆGGTCAGCAATTATCTCAGCAGACΆCAΆCTGAΆCCTGCAGΆGCGGAGT
ACCGCCACCACTATACGGTACTΆGCTCAAGTATTCCTCCTGGATCAACAATGC
AACCCAGCACTTCGTTTGCATTTCACACTTCGCATTCAACATATAATCCTTCA
TTTGACTCCTCCAATTTATATAΆTCTGGCTTTCAGGTTGCCAGAATΆCCCGAC
TACTAGCTCCAGCTCATTATTGTCTACCACGGGTGGTAAACAGTTTCAACAAT
CTTCTGCATTATTACCATCTGGTACATTGCCTCCTTCGATTTTΆGGCΆCATCA
TCATCACTGCATGTTTCTGCTTTACGACAACATCAGAAAAACAACTTGTCCAT
TTCTTCCCATTTAACGTTATTTAGTCTAAGTGGGΆACAΆCTCTTCACAΆTTGC
AGTCGCAAGGATCTTCGTTTCAACAATCTGAAACTGGCGTGGATGATACCAAA
CGATCTTCAAΆAGAATCAACAACCATCTTCAATGATTTATTGTTTCATTTAAC
TTCTGTTGATGGTTCAAATATTAATACΆTTCTTGCTATCTATATTGAGGAAGA
TCAATTCGCCTTTCACTTTGGATGACTTTTACAATTTATTGTACAATGATAGA
CAACGTACATTGTTGGATAATTCGAATTATCAGAACCGCATTGACAAGACAAT
TGTTAGTCCAAGTGACACAGΆTATGACGGTTTCCATAATCAATCAATTGTTGA
ΆTTTTTTCAAΆACTCCTAGCATGTTGGTTGACTATTTCCCAAACATGGAAGAC
AAAGATAACAAATTGGCAAATATAAACTACCATGAATTACTTCGTACATTCCT
TGCTATCAAGATTTTGCATGACATTTTAATTCAATTGCCAATCAGTGAGGATG
ATGATCCTCAAAACTACΆCCATTCCTΆGATTATCAΆTCTATAAAACCTACTAT
ATCATCTGTCAGAAATTAATAGCAAGCTACCCAAGTGCATCCAATACCAGAAA
CGAACAACAAΆAGTTAATTCTTGGTCAATCAAAGCTTGGTAAΆTTGATCAAGC
TΆGTGTATCCCAATCTATTAATCAΆACGATTAGGTAGCAGAGGTGAATCAAAA
TACAACTΆTCTTGGTGTAΆTGTGGAATGCAΆATATTGTTCAΆGAGGAAATTAA
Figure imgf000143_0001
Figure imgf000144_0001
CTTTGAGTGTGAΆGCAAΆAAATTGCTATTGAAAATGAATTGTCΆAATTTTTAT
GAGGATTTATCTAAGAATGAATTGCATTTGAAAACTGCTGATGAAGCTGGCTC
TTCATCAATTAGTCAATCTCAACATCATCACAGTCATCACAATCATCATCACC
ACCACCACCATCATAATGACCATGGCCATCACAACAATACTCTTGGCAATAGG
TTGTCCAAGGCCAGTCAAGATTCAGCAGCΆACAGAAACGACTAATGCTAGCAC
AAATAGTCCAATTACACCAGCTAATGAGTCAAATAATGAAGATGGTGCTGTTT
TGACACGTCAGCAGTCAGCTTCCTCAATATGGTCTACTGATACCACTAATCGT
AGATCATCTTTGGCAATGAAGAGATACACCACCACCACATCAGAGATATCGAA
TTTCAATGCAACAGCCCAGAATCCAAATCGCCTGCCAGTACAAAGAGTTGGTA
TGGCAAGGGCTTTGGTTGGACACCAACGTCAGCAACAATTCCAATCAGAAAAA
TCCTCAATGTATAAAAATGGCAATCCGTCGTTGTATTCTCAAGCTTCAGCTGT
ACCΆCAATTGAAGAATCGTCCTTCATACGATCAAATGAAGAGTTTAAATAAAC
GCTCTTCACGTCAGTCTGTTATATCAAAGGATTCTAGCCACAATGATGATGAT
ATGATTTCGGTGTTGTCATTTGATACTATGAATTTGCCAATGCATGATGAATC
GGACTCCCAACGTTTCAACCAACAAATGGAGGATTTCAATGTTGATGATTATC
AGGATAAATATGATTTAACCTTAGAΆTTGCAAGGATCACCGTATTTGAAAGAA
GGGTTGTTGAAATTGAAAATTTTAAACAATGATTCAGTTGATGAAATAGATGG
CAACTCTAATCCCTCGGCATCATCTACACCAGCTAATCACGGCAAGTTCTTGT
CATTTTTCAGTAGACCAGCTAATTCCAGTTCTTCTACTTCTAACATGAACAAT
CACAAATTTΆCTGAAAATTTTGTGGTTATAAGTAAΆGGAGAATTGTCATTGTA
CTCATTTGATCCAAAAGTTATCAAAAAGTTCAAGAAGAGAAATGGCCACCAAC
AACAACAAACTGAACCCGATGACGATGACATTGTTGGCGATGGTAATTGGTTG
AAAAACGCTGCCAAGATTGGTACCTACAATTTATGCTCTACTTATGCTGATTT
AGAAAAGACAACTTCTCAAGGTAAAGTTTTATGGTCATTAACATTCCCCAAAA
CTTCGAAACGTCAACCCAAAAAATTTATATTTGAGGCTGGTACCAAAGAGGTT
GCTTTGGAGTTTATAAATACTTGTAΆCTTCTGGGCTGCCAAAATAΆCTGCTAT
TCCAACATTGGAAGAAAGTGTAAGCTCATTAGAATATGGATGGACCAATTTGG
ACTATATTATTGCTCATCGCGAGTCATTTAAAAAGTCCAGΆAACATAATGAAA
TΆTGAACCCGTCGTCAAGGGGGTATATTTGTCCAACTATATTGTTAATAGTGA
AGAAACCAATCATTTGGGTATGATGAGACAATTTGTTAAAACTTCAAACTATT
ΆTAACCAATTGAAGAAATTGTATAACGAATTCACTGAAATGAGGCAGAAGTTT
TTGATCAATTTACCTAAATGTCATTTCAATTGTTCAAATCATAGCAAAATCTT
GTCTAATTATGACACCAAGATCAATGACTATAATTTGGAAATGAAAAAATATA
AGAATTATTTGATTATTCTTGGGTTTGGGTTACAATTGAGATTTGATTTAGAA
GAGCAAGATAGACAACAACAATATGATACATCTTTAGAAAATGAAGATGTTGA
TGATGATGATGAΆGGTGAAGAAGATTATGAAACTATTGGTGAAACTTTAGCAA
CCACTGATAGAGCAAGCAGTGCTGGAGCTAAAAGTAATGATACATCTTACCAA
GATGΆTGAGTTGACGAAATTGGTTAAATTTGAGATCAAAAΆGTTATTTTTCAA
TATGAΆAGATATCTCAAAAGTGATTCCAΆCTTTCCGΆTCACTGΆAATCAATTA
AAAACTTGGCTGATTTGGCTCAAGATATTGACAACAAGTTGGTTAAATCACCA
AAGACATTTACTTTAGCAAATTATAATGATAATGAGΆGCCCAATCAACCAATT
ACTTGCTACCACTAACGCCAATCCTACCGTGAAATCCAGTTCAATGATAATGG
AACTGTCAATCGCTGAAGAACCAGAAGATGCTGAAGATAGTGAAACCACTAGA
AGAAGCAGTAAGGTTAΆTAACTCAAAAGATCATTCACCTGCTACAAGTATAAG
TAGTAGTATTAAAAAACCAAATTTAAAGATTGCTAATTCAGAAGTATCAGCAT
TGGTAATTTAA
YFR003C-2; ATGTCTCAACAAAGAGAAAACCAAAGAGGAATAGTTTCACAAACAACTACAAC 225
AACQ01000092; GACTGCCTCGCCTATTTTAAAGCTACGAGCTCAAGAAAGACAAGCTCGTGACG
46436607 TCTCTTGGGATGCAAACGTCGTTGATAATGAACATCTAAATAAGAAAAAGACA AAAΆTATGCTGTATATTTCATCCATCAGATCGGAACTGTGATGAAGAAGATAG TTCAAGTTCCAGTGACTCGTCTAGTGATTCTTCAGΆTAATGAAGΆGGATGATA AAAACACGAAGATAGCCCCGAAATCTAACAATAATAAAAAAAAGTCAAAACCT ΆΆTGCGTACGAAGTTCAGCCCCATTACAAAAACCAATCAAAGGTGCCCGGAAA
ATGA
YGRl61C; ATGGTTAATAATCTCACTTCTGGTATTGCAGCCACGTCGTTTAAACACAATCA 226 AACQ01000039; TCCTCAACATGCAACTTCCCCTCCACCAGCAATTTCTATAAATACCAGTTCAC
Figure imgf000146_0001
ACTCTTTGAAACCATCGGCTAACAAGAAATTTTATCATGATCCACCATCACAT
ATTTTAGTTGATTTCAAATCTGTTΆCTGGTTCCTCAGCTTATCAACCTCCAGG
ATTTGCTGGTATGGTGGCCTATATGTACΆTTCGTAACTCCAAGAAAAGATTAA
CAGAGGCATTTGCCGTACACΆCTAATTCAGTTGAAGATTTTGTTCATGTTGAA
AAAATCAGTGCTGCATTATTTAGΆAATCTTCCTGCCAGTGAAΆTTGAΆAΆCAA
TAGAGTTTACCTTGTTGCTGTTTTAACAGAAGAΆGTTGACTTAAACATTAAAG
GTACGGGGCATACTCCAACAATTAAAAGAGTGAAAAAGGGTGTTGCCGCTGGT
GTAGCTGATATCACCAGAATTTTCCCTAGAGCAGAAGGTTCACTTCAATCTGG
TGAAGCCCATAATTTTTCAATTAAATTGTTTGGTTCTTATTTGAGTAAAAAAG
GTCACAAGAATATGGTGGAAGATCTCAGAGGTCTTAGTAATAATGGTTGGGGT
GAΆCTTGTTGATAGAATTATTGCTGGTTCTAGTCAAGGAGTAGCTGTTAATCC
AAGAGCAGAAAAATTGGTGATCACAGTAAAGGAATTCAAACATCAATTTCAAG
GTAATGTGGCCAATCAATTATCATCTAGTGCACCAATATCTAGAATTAAACCA
ATTTTCTTTGATCCATTGGCGGAAAATTATGAACGTATTTATTTGAAAATGGG
TAAAGTTACTTTATTAGGATCTAATGCCAGAGAAGATTTATTGACATTTGAAG
TCAGTACTCCTAATAATGAATTGATTACCTTTGCCAAAGCTTCCAATCAACAG
GAAAAAAGATATTGGCAATTTATATCTGTCTTCCCCGGTGAATCCATTGGTGA
AATTGTTAAAGTTAATGGAGTTGCATTGAAAAATTCATCTAAAAAATTACCTA
AAGATGATTATATTCTTTTATCATTATATGTTAATGGGGTTCTAGCTGGTGAA
GGAAGATTACTTTATAAATCCGGTAΆTAGATTGGTTGAATTCAATAAGAAAAA
GACTCATACCΆTTGAAATTΆTTTCCGCAACCCATAATGTTCCTATGGCTCATA
TTGAACTTAGTACTGAΆTACGTTGGTAAAGTTTATAATTCTGACGTTTCTATT
GATAATATTTTCCAATACGAAAGATTTTTCCAAAATGGACAAAAAGGTATTGA
TGAACTTTCTAATTCATTGGTTGCTTTCACGAGATTAGATATTGCTCAAGTTG
TCAAATATTTCCCAGAATTATTAAGTTCATTATACGGAATTATTGGATTTTCT
AGTCATCATAGTGGACCTAGTATTGAAATTCTTGAAGATAATACTTTTAAAGC
CGTGATTCATTTGTTAGATACGGTTTTCGGTAΆACAAGATCAATACTTGTATC
TTCTTGATAATTTCATTGCCAAATATAAAAGTCTGAATCAAATTGGTATTTTC
TTATTGACTAAAGTTGAACAAATTTTCAATAGAGCAGGATCAAGTTGGAATTC
GGTTTCTAGATCAGTTTGTCGTGTTCTTTCGΆTTATTTTGAGAATTTCGATTT
TATCAATGAATGCACCAAΆTGAACAAGATTTATATTTACAAACATTGAACAAT
TTATTTAAATCAATTGCTTATCTTCTTACTTTGGATTCCACCAACATGATTGA
TGATCAAGTACTTGTTATGGATATTATTGATTATATTTTTGCCTTTGACGTCA
ATTTCAAAGGATCAGAACTTGTTCAAATAATGATCAATTGTATTGATTCTATT
GGTCTTAAAGGTGTGGGAGTTGATGAACTTAGTATGGAGTCAACTCCGGCTGG
TTCTCGTTCAATTAAAGATCACAAGATCATTATTGGTAAATTATTATTAATTT
TGAGATTACTCAATTCTGATTTAGTCAAAGAGGAAAGTAGTAGATGTATTTTG
ATTCCAAAGGCAATCACATGGGCCGTTGATGTATTCCTTGCCCCTACTGATAT
TGAGGCAACAAGATTGGCATGTAGTGTGCTTAATGCTGCTTGTACAGCTTTAT
GGAATGATGGTGTCATTGGTAAATATCAAGGAGATATGGΆGATTTGTTATTCA
TTGGCCAAGTTTTTACCTGCTATATCGAGAACTTTCATCAAGTATAACAAGTT
TACTAGAGGTAATGGTTCΆTTCAAAAAGAAACGTGTGTTCACTCAATTGTTCC
CATCAACGTATCCTTTCATTGAATTTTCTATTGACCCGGTAGTTAATGATGAA
AGTATGGTTGAAGTTTTAGTTGAACTTGCAATTACATTTTCATTTGTTGCTAG
AGTCGGGAAAGAAGCAGCAGGAAATGAGGGTTATATCACAATTTTGGATTCAC
GAATTGAAAATGATTTTTTCATCCCGGAAAAATATTTGGCATCTGATTTCCAT
GGTGAAGATATACTTACATTACTTTCAGGGATTAGATATATGAGATTGGGTAA
ATATTTCCCTGAAACCAAATGGTATTCAACATATTCTGTCATTATTGAAGGTT
GTTTATGTGCCATTGΆATTGGTGAGACCATTAGTGΆTTATCAATCAATTACCA
GCATTGGATGATTCTGAATCATTTGATAGAACCCTTTGGGGGAACTATCTTAG
AAGTTTGTTTAAATTGGCCGTGTTACCACCTGTGGCAGTCGAGCATTTGTCTG
ATGTTCCAAAAAGTGCTTGTGCCAAAΆTAACCAACGATGTTCGTAAACGGGCT
GCATTTTTAATTAATGAAGCTTGGGATTCTTTAGCTTGGGATGCAΆCTGATGA
AGATATGCTTAGATTTAATTTGAAΆAAATTTGGTGGTTATCAAGTTGAATTTA
TTAATGATGAΆTTTGGAATCTTGCCTGATTTGATGTTACTTGGATTACAAAGA
GATAGTGAATGTCAAAGTGTTGCCATCAAGATTTTATGGTCGATCATGATTTC CGAATATATTTTAAGTGATACTCTTCAAGΆTGTTGAAAGΆCAATGTTTACTTG GTTTACATGAAATTTATCATAATAATTCTTATAAACCAACGTCATTGGATCAA GAAAATTTCATTGAAAGAATGΆAAATGACAGTTAGΆTTGGATAGAGAAGATGA
AGCATTTGATATTATTTATAATTTTATTCAAAATCTTTCATCATTTTTCGGTA
CTCTTAATTATTATATTAGTGTACCATTTGGTCCTGAATATGAΆGAAGATAGA
ATTTTCCATGAAATTAAATTGAAAGCACAAATTAΆAAATGCCGGGAAACCAGA
ACTTTTCAATTCTTATATTCATCAAATGTATGAAΆAGTATCTTTCTCAAAATG
ATTATGTTCAGGCCGCTTTAAGTTTGGAATTACTTGCCAGTACTTΆTTCTTGG
GΆTCATCATATAATTGTΆCCAGCAAGTTTTAGACCAAΆATTCCCAGAACAAAG
TTCATTTGAAΆGAAΆAGAAATATTATTGAAAΆTGATAGCTAATΆATTTTGTTA
AGGGAAATAGTCTTGAAAAAGCAGCTGATACTTATAATGAATTATTAGATTCA
TATAATGAACΆTACTTATGATTTGAAAAGTTTTGCTTATGTTCATAATAAATT
GGCTCAΆTTATATTTGGATATGGAATCTTCAGATΆAATTAACCCCTACATATT
TCAAAGTTGAAGCCATTGGTGGTGGGTTCCCTACTTATTTGACACAAATATCT
CAAATTTTCCAΆGGTTTGCCATTTGAACATΆTCACATCAATTCATGΆACGATT
CCTTAAΆGTTTTCCCTGGTGCTAAAATCATTAGTGATGATGCTGAAGCTATTC
GTCTTAAΆGAAAAΆGCCACTAATGGAAGATATTTATACATTAAAACCGTGGΆA
CCAGTTTATGAGTTTTCTGACAAGTTGATTAATACTTCACTTGGGGTAAGACA
ΆTATGCTAGAAACAΆΆGATTTACGATTTTTCACCAGTTTAAAGAAATTCCCAG
GGGCTACTTCGGTGTTTGATTTATGGACAGAAGAAACTACTTATGAAACATGG
TTATCATTCCCAACTTTAATGAATAGAAGTTTTATTAΆΆGATTCAAAGACCGT
TΆΆATTGTCGCCΆTTGGATAATGCAGTTAGΆACGATAGCTGCCAAGAATGATG
ATTTGATTCAATTAGAAGCGTTTATCΆATGCAGCTCTTAAAGAAAAAACTGAT
TATTCACATTATTTCAATGATTTATCGAGACAATTGGCAGGTACGGTGGATTC
GCCAGTAAATGGAGGGGTTGGCCAATATCGTGCATTTTTCTCCGATAGCAAAT
ATCAAATTAATGAAGAAAGTATTGCTAAAACAGAGTTGTTACGTAATGCATTC
AATGATCTTGCTATTATCTTGTATCGTTGTGTGΆATTTACΆTGGTAGTTTGAT
TGGACTATCGATGAAACTGTCACATCAAGCATTAGTCGAATTGTTTAGAAAGA
ATTTCCAAGAAGAAATTGTTGCTTTACGTTTAGGTGAAGAGGCGΆCAATTACA
GCTCCATCCTCAAGTCGTGTTTCCATTTTCCACAATAAACGTGCTAATGGTTT
AΆTGACTGAACGTGCCAATTCCATTTCAΆACATGTCTGGTGCTGGTTCTACAT
ATTCGGGTTCAAGACTAGCAAGGTCTCCTACTAATGCCTCATCAGTGTCTTCA
AATAATTCATCAATCACTAGATCAGGTAGAGCATCAAΆCACTTCGGGATATCC
TGCAAGTGTTATTCAACCAGGATATACTGGGTTAAAGGGATCATCTCTTAAAA
ATGGTAATGGATCTGTCACTTCTAAATCAATAAACGGATCCGGTAAAACAAAT
GCAATAAATACAAAATGGTAG
YMR029C; ATGCCACCATTCAAATTGAGAAGTAGAAGCAACAGTAGCAGTAGTTCAAATCC 229
AACQ01000069; GCAAACTCAATGGTATAATAATAAAAACCAGAACCAACCCTCAATGTCAGAAC
46438081 CGΆCTTATACGTTACCΆGGCGTTATAAACTATCTAACATCTGAΆTTCACCAAG TTGGAACAΆTTTAAAATTGTAAACAATTTAGAGCGΆAGTGAGATGAAATTCAA AATTAΆGGAATTGGAAGGGGAAΆTTAAAAGTTTAACATTCACAAATAAATTAC AAAAGAAGACAATTGAAAGATTGCAGACAGAAAACAAAAAGCTAAGACTGAGA CTAAACGAAGAAGAAGTCGAAGAAGTCATTATGACTCCATCACCCGAAGAACT ΆGCAAAAATGTCCAAGATTGATTTACAGACGATTAAGAGAACAAGAGΆGCGGT TGGCTAΆTTCGATGAAGGAAATTGTAACATTATTAAAACCACCTACTTTAGAA CCAAGTATTTCATTGGCAΆAAACTAGTAΆAAATACGAATGΆTCTAGAATCTTT ATTGGATAAACCTGAGATCAΆCAAGGCAGACGΆCTTTAATTTCAATGTTAAAC CATATAGTTTTGAAAGCAAGGATTATGAATCACCAGTTAGAAACCCAAGTTCC CTAATTTCCCAGTATTTCAACAGTAATACCGACCTTAAGGAGATTTCTAAAGA AΆAGAAAAAGGCTGAAΆTGGAAAACGACAGTATCGTTGATGATGACGAGATCT TΆGACGCAGAATTAGAΆGATGTTTTGGAAAAAGCCATTTCΆGAAACAAGTGAT TCGGCAACAΆTTGTACTCAATGATGACGATGΆTCCTCTTGCTGΆTTTGAATGA TGATGATTTTTCACTTGATGATAGCCCACAAGAGAGAAGTCAAATCAATAATA ACAACAATAATAATAATGATGATGATGATCTTGATTTTGAAGATAAGCTATCG TCATTCCCACTGTTΆGTΆTCTCCACTGTTAGTACTTCCACTGTTAGTACCTCC TCCGTTAAAATCCCCΆCAGTTACAACCCCCACAGTTAGAACCCCCAGTGTTAG
Figure imgf000149_0001

Claims

WHAT IS CLAIMED IS:
1. A method for treating or inhibiting a fungal infection in a mammal, the method comprising: administering to the mammal a composition comprising cells of a fungal strain or an extract thereof, wherein the cells are genetically modified to have at least one altered filamentation property.
2. The method of claim 1 wherein the cells having the altered filamentation property are hypofilamentous.
3. The method of claim 1 , wherein the cells are genetically modified to alter the expression or activity of at least one polypeptide that regulates filamentation.
4. The method of claim 3, wherein the cells are genetically modified to increase the expression or activity of at least one polypeptide that regulates filamentation.
5. The method of claim 3, wherein the cells are genetically modified to decrease the expression or activity of at least one polypeptide that regulates filamentation.
6. The method of claim 1, wherein the fungal cells are of the same species as the fungus of the fungal infection.
7. The method of claim 1, wherein the fungal cells are of a species other than the fungus of the fungal infection
8. The method of claim 1, wherein the genetic modification of the cells comprises a deletion, insertion, rearrangement or mutation in one or more nucleotides of the cell.
9. The method of claim 8, wherein the deletion, insertion, rearrangement, or mutation causes a deletion, an amino acid change, or a premature truncation of a polypeptide encoded by a nucleic acid in the cell.
10. The method of claim 3, wherein the polypeptide that regulates filamentation is a Crvl polypeptide or a fungal homolog thereof.
11. The method of claim 3, wherein the polypeptide that regulates filamentation is a polypeptide selected from: CdclO, Cdc24, Chk2, Chs3, Cla4, Crkl, Cyrl/Cdc35, Efgl, Erg24, Fas2, Hogl, Hwpl, Ml, Kex2, Nag5, MkI, Pldl, Pmtl, SmI, Sskl, Tpsl, and Vρs34.
12. The method of claim 1, wherein the fungal cells are of the genus Candida.
13. The method of claim 1, wherein the fungal cells are cells of a dimorphic fungus.
14. The method of claim 13, wherein the fungal cells are cells of a dimorphic ascomycete.
15. The method of claim 12, wherein the fungal cells are Candida albicans.
16. The method of claim 1, wherein the composition comprises live fungal cells.
17. The method of claim 1, wherein the composition comprises fungal cells, and wherein at least 80% of the fungal cells of the composition are killed.
18. The method of claim 17, wherein the fungal cells are killed by heat, ultraviolet radiation, mechanical disruption, or chemical inactivation.
19. The method of claim 1, wherein the composition is administered subcutaneously.
20. The method of claim 1, wherein the composition is administered intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally.
21. The method of claim 1, wherein the composition is administered orally.
22. The method of claim 1 , wherein an immune response is elicited in the mammal.
23. The method of claim 22, wherein the immune response is a protective immune response.
24. The method of claim 1, wherein the composition comprises an adjuvant.
25. The method of claim 1, wherein the composition is administered two or more times to the mammal.
26. The method of claim 22, wherein the immune response includes a cell- mediated immune response.
27. The method of claim 22, wherein the immune response includes a humoral immune response.
28. The method of claim 22, wherein the immune response includes both a cell-mediated immune response and a humoral immune response.
29. The method of claim 22, further comprising evaluating the immune response in the mammal.
30. The method of claim 29, wherein a cell mediated immune response or a humoral immune response is evaluated.
31. The method of claim 29, wherein a cell mediated delayed-type hypersensitivity response is evaluated
32. The method of claim 1 , wherein the mammal is at risk for infection by a fungus before the administering.
33. The method of claim 32, wherein the mammal at risk is immunocompromised or at risk for becoming immunocompromised.
34. The method of claim 32, wherein the mammal has impaired neutrophil function.
35. The method of claim 1, wherein the mammal is suffering from a fungal infection prior to the administering.
36. The method of claim 35, wherein the fungal infection is caused by a fungus of a species that is the same as the species of the fungal cells or extract thereof administered to the mammal.
37. The method of claim 35, wherein the fungal infection is caused by a fungus of a species that is a species other than the species of the fungal cells or extract thereof administered to the mammal.
38. The method of claim 1, wherein the cells have been further genetically modified to increase expression of a cell-surface or secreted molecule, or a portion thereof, relative to a wild-type strain.
39. The method of claim 38, wherein the cell-surface or secreted molecule is a lipid, a carbohydrate, a polypeptide, or a portion thereof.
40. The method of claim 39, wherein the cell-surface molecule is a mannoprotein.
41. The method of claim 40, wherein the mannoprotein is mp58, a homolog of mp58, or a portion of mp58 or the homolog thereof.
42. The method of claim 39, wherein the cell-surface or secreted molecule is selected from the polypeptides of Table 9.
43. The method of claim 1, further comprising administering cells or an extract of cells of a second fungus.
44. The method of claim 43, wherein the cells of the second fungus have been genetically modified to increase the expression of a cell surface or secreted molecule, or a fragment thereof.
45. The method of claim 44, wherein the cell-surface or secreted molecule is a lipid, a carbohydrate, a polypeptide, or a portion thereof.
46. The method of claim 45, wherein the cell surface or secreted molecule is a mannoprotein.
47. The method of claim 46, wherein the mannoprotein is mp58 or a homolog thereof.
48. The method of claim 45, wherein the polypeptide is selected from the polypeptides of Table 9.
49. The method of claim 1 , further comprising isolating a composition comprising antibodies from the mammal.
50. The method of claim 49, further comprising administering the composition comprising antibodies to a second mammal.
51. The method of claim 1, wherein the mammal is chosen from a mouse, human, dog, cat, cow, pig, and horse.
52. The method of claim 51 , wherein the fungal strain is chosen from a strain of one of the following: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Saccharomyces spp., Paracoccidioides spp., and Coccidioides spp.
53. The method of claim 7, wherein the fungal infection is caused by a species selected from one of the following: Aspergillus spp., Candida spp.,
Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Saccharomyces spp., Paracoccidioides spp., and Coccidioides spp.
54. The method of claim 3, wherein the polypeptide is a gene product of a gene selected from: SPT3; SSN6; RBFl; RFGl; TUPl; NRGl ; and fungal homologs of SPT3; SSN6; RBFl; RFGl; TUPl; and NRGl.
55. A method for eliciting an immune response to a fungus in a primate, the method comprising: administering to the primate a composition comprising cells of the fungus or an extract of the cells, wherein the cells have decreased expression or activity of CRVl or a fungal homolog of CRVl, thereby inducing an immune response to the fungus in the primate.
56. A method for eliciting an immune response in a mammal, the method comprising: administering to the mammal a composition comprising cells of a Candida species or an extract thereof, wherein the cells are genetically modified to be deficient for expression or activity of at least one polypeptide that regulates filamentation growth, thereby inducing in the mammal an immune response to the Candida strain and a second fungal species selected from: Aspergillus spp., Candida spp., Cryptococcus spp., Fusarium spp., Histoplasma spp., Pneumocystis spp., Trichophyton spp., Paracoccidioides spp., and Coccidioides spp.
57. The method of claim 56 wherein the second fungal species is chosen from: Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, Aspergillus niger,
Candida albicans, Candida ciferrii, Candida dubliniensis, Candida famata, Candida glabrata, Candida guilliermondii, Candida inconspicua, Candida kefyr, Candida krusei, Candida lambica, Candida lipolytica, Candida lusitaniae, Candida norvegensis, Candida par apsilosis, Candida pelliculosa, Candida rugosa, Candida tropicalis, Candida viswanathii, Candida zeylanoides, Coccidioides immitis, Cryptococcus neoformans, Fusarium chlamydosporum, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum var. capsulatum, Histoplasma capsulatum var. duboisii, Paracoccidioides brasiliensis, Pneumocystis carinii, Trichophyton rubrum,
58. A composition comprising:
(a) cells of a fungus or an extract of the cells, wherein the cells are of a strain genetically modified to have at least one altered filamentation property; and
(b) a pharmaceutically acceptable carrier.
59. The composition of claim 58, wherein the cells are genetically modified to reduce expression or activity of at least one polypeptide that regulates filamentation.
60. The composition of claim 59, wherein the cells are genetically modified to reduce expression or activity of a Crvl polypeptide or a fungal homolog thereof.
61. The composition of claim 59, wherein the cells have been further genetically modified to increase expression of a cell surface or secreted molecule, or a portion thereof, relative to a wild-type strain.
62. The composition of claim 61, wherein the cell-surface or secreted molecule is a lipid, a carbohydrate, a polypeptide, or a portion thereof.
63. The composition of claim 62 wherein the cell-surface or secreted molecule is a mannoprotein.
64. The composition of claim 63, wherein the mannoprotein is mp58, a homolog thereof, or a portion of mp58 or the homolog thereof.
65. The composition of claim 58, further comprising an adjuvant.
66. The composition of claim 58, further comprising an extract of cells or cells of a second fungus.
67. The composition of claim 66, wherein the cells of the second fungus are genetically modified to increase expression of cell-surface or secreted molecule, or a fragment thereof, relative to a wild-type strain.
68. The composition of claim 67, wherein the molecule is a mannoprotein.
69. The composition of claim 68, wherein the mannoprotein is mp58.
70. A method for treating or inhibiting a fungal infection in a mammal, the method comprising: administering to the mammal a composition comprising cells of a fungus or an extract thereof, wherein the cells are genetically modified to have increased production of a cell surface or secreted molecule, thereby treating or inhibiting the fungal infection in the mammal.
71. The method of claim 70, wherein the fungal cells are of the same genus as the fungus of the fungal infection.
72. The method of claim 71, wherein the fungal cells are of the same species as the fungus of the fungal infection.
73. The method of claim 70, wherein the fungal cells are of a genus other than the genus of the fungus of the fungal infection
74. The method of claim 70, wherein the fungal cells are of the genus Candida.
75. The method of claim 70, wherein the fungal cells are cells of a dimorphic fungus.
76. The method of claim 75, wherein the fungal cells are cells of a dimorphic ascomycete.
77. The method of claim 74, wherein the fungal cells are Candida albicans.
78. The method of claim 70, wherein the composition comprises live fungal cells.
79. The method of claim 70, wherein the composition is administered subcutaneously.
80. The method of claim 70, wherein the composition is administered intravenously, intramuscularly, intraperitoneally, intradermally, intraepidermally, or mucosally.
81. The method of claim 70, wherein the composition is administered orally.
82. The method of claim 70, wherein an immune response is elicited in the mammal.
83. The method of claim 82 wherein the immune response is a protective immune response.
84. The method of claim 70, wherein the composition comprises an adjuvant.
85. The method of claim 70, wherein the composition is administered two or more times to the mammal.
86. The method of claim 82, wherein the immune response includes a cell- mediated immune response.
87. The method of claim 82, wherein the immune response includes a humoral immune response.
88. The method of claim 82, wherein the immune response includes both a cell-mediated immune response and a humoral immune response.
89. The method of claim 82, further comprising evaluating the immune response in the mammal.
90. The method of claim 89, wherein a cell mediated immune response or a humoral immune response is evaluated.
91. The method of claim 89, wherein a cell mediated delayed-type hypersensitivity response is evaluated
92. The method of claim 70, wherein the mammal is at risk for infection by a fungus before the administering.
93. The method of claim 92, wherein the mammal at risk is immunocompromised or at risk for becoming immunocompromised.
94. The method of claim 92, wherein the mammal has impaired neutrophil function.
95. The method of claim 70, wherein the mammal is suffering from a fungal infection prior to the administering.
96. The method of claim 95, wherein the fungal infection caused by a fungus of a genus that is the same as the genus of the fungal cells or extract thereof administered to the mammal.
97. The method of claim 96, wherein the fungal infection is caused by a fungus of a species that is the same as the species of fungal cells or extract thereof administered to the mammal.
98. The method of claim 95, wherein the fungal infection is caused by a genus or species other than the genus or species of fungus cells or extract thereof that is administered to the mammal.
99. The method of claim 70, wherein the cell-surface or secreted molecule is a lipid, a carbohydrate, a polypeptide, or a portion thereof.
100. The method of claim 70 wherein the cell-surface or secreted molecule is a mannoprotein.
101. The method of claim 100, wherein the mannoprotein is mp58, a honiolog thereof, or a portion of mp58 or the homolog thereof.
102. The method of claim 99, wherein the cell-surface or secreted molecule is a polypeptide selected from the polypeptides of Table 9.
103. Use of the composition of any of claims 58-69 in the manufacture of a medicament for treating or inhibiting a fungal infection in a mammal.
104. Use of the composition of any of claims 58-69 for treating or inhibiting a fungal infection in a mammal.
PCT/US2005/034219 2004-09-24 2005-09-23 Fungal variants and uses thereof WO2006036817A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61311204P 2004-09-24 2004-09-24
US60/613,112 2004-09-24

Publications (2)

Publication Number Publication Date
WO2006036817A2 true WO2006036817A2 (en) 2006-04-06
WO2006036817A3 WO2006036817A3 (en) 2006-07-27

Family

ID=36119465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034219 WO2006036817A2 (en) 2004-09-24 2005-09-23 Fungal variants and uses thereof

Country Status (1)

Country Link
WO (1) WO2006036817A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100119533A1 (en) * 2007-03-07 2010-05-13 Cornelius Joseph Clancy Polynucleotides and Polypeptides Identified by IVIAT Screening and Methods of Use
EP2567688A1 (en) 2007-09-25 2013-03-13 Lesaffre et Compagnie Use of a natural agent in cosmetic compositions
WO2014167335A1 (en) * 2013-04-11 2014-10-16 King's College London Peptides and binding partners therefor
WO2014144211A3 (en) * 2013-03-15 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
US10300120B2 (en) 2002-09-13 2019-05-28 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10513724B2 (en) 2014-07-21 2019-12-24 Glykos Finland Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
US10653757B2 (en) 2011-07-22 2020-05-19 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against Staphylococcus aureus
US10724013B2 (en) 2013-07-04 2020-07-28 Glykos Finland Oy O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof
CN111870683A (en) * 2020-09-17 2020-11-03 北京欣颂生物科技有限公司 Application of antibacterial peptide in preparation of medicines or cosmetics
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN118252898A (en) * 2024-05-30 2024-06-28 四川好培养生物工程有限公司 Gastrodia elata extract and preparation process and culture medium thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039667A1 (en) * 2001-08-27 2003-02-27 Vic Jira Anti-fungal composition
US20030176367A1 (en) * 2000-08-25 2003-09-18 Microbia, Inc. A Delaware Corportion Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections
US6638756B2 (en) * 2000-12-05 2003-10-28 California Institute Of Technology Chimeric cell-targeting pathogenic organism and method of therapeutic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176367A1 (en) * 2000-08-25 2003-09-18 Microbia, Inc. A Delaware Corportion Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections
US6638756B2 (en) * 2000-12-05 2003-10-28 California Institute Of Technology Chimeric cell-targeting pathogenic organism and method of therapeutic use
US20030039667A1 (en) * 2001-08-27 2003-02-27 Vic Jira Anti-fungal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GALE C. A. ET AL.: 'Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INTI' SCIENCE vol. 279, February 1998, pages 1355 - 1358, XP002954887 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300120B2 (en) 2002-09-13 2019-05-28 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20100119533A1 (en) * 2007-03-07 2010-05-13 Cornelius Joseph Clancy Polynucleotides and Polypeptides Identified by IVIAT Screening and Methods of Use
EP2567688A1 (en) 2007-09-25 2013-03-13 Lesaffre et Compagnie Use of a natural agent in cosmetic compositions
US10653757B2 (en) 2011-07-22 2020-05-19 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against Staphylococcus aureus
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
WO2014144211A3 (en) * 2013-03-15 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
CN105407915A (en) * 2013-03-15 2016-03-16 加州大学洛杉矶分校港口医学中心生物医学研究所 Compositions and methods for treating fungal and bacterial pathogens
EA030005B1 (en) * 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Compositions and methods for treating fungal and bacterial pathogens
CN105377883A (en) * 2013-04-11 2016-03-02 伦敦国王学院 Peptides and binding partners therefor
US9969796B2 (en) 2013-04-11 2018-05-15 King's College London Peptides and binding partners therefor
WO2014167335A1 (en) * 2013-04-11 2014-10-16 King's College London Peptides and binding partners therefor
US10724013B2 (en) 2013-07-04 2020-07-28 Glykos Finland Oy O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof
US10513724B2 (en) 2014-07-21 2019-12-24 Glykos Finland Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN111870683A (en) * 2020-09-17 2020-11-03 北京欣颂生物科技有限公司 Application of antibacterial peptide in preparation of medicines or cosmetics
CN118252898A (en) * 2024-05-30 2024-06-28 四川好培养生物工程有限公司 Gastrodia elata extract and preparation process and culture medium thereof

Also Published As

Publication number Publication date
WO2006036817A3 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006036817A2 (en) Fungal variants and uses thereof
RU2771533C2 (en) Immunogenic compositions for immunising pigs against type 3 circovirus and methods for production and application thereof
Shkreta et al. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows
JP4118340B2 (en) Fungal antigen and method for producing the same
AU2010266114B2 (en) HYR1 as a target for active and passive immunization against Candida
US20100104604A1 (en) Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
Muňoz et al. Involvement of penaeidins in defense reactions of the shrimp Litopenaeus stylirostris to a pathogenic vibrio
JPH11137267A (en) New compound
JP2005508613A (en) Mycobacterial antigens expressed during incubation
US11771761B2 (en) Adjuvant for animal and human vaccines
KR20080027289A (en) Porcine circovirus type 2 vaccines
EP2895501A1 (en) Salmonid alphavirus and uses thereof
US11260092B2 (en) Fungal immunogens and related materials and methods
JP2005518784A (en) Mycobacterial genes down-regulated during incubation
WO2018182515A1 (en) Methods of modifying fungi and uses thereof
TWI362271B (en) Protein from photobacterium damselae and use thereof
CN113329765A (en) Immunogenic composition for paratuberculosis
US20090081196A1 (en) Medicaments for fungal infections
Nelson et al. Cryptococcus neoformans pathogenicity
CZ200249A3 (en) Antimycotics and fungicidal agents, process of their preparation and use
WO2017109028A1 (en) Recombinant aspartyl protease antigen or antibody thereto for use in immunotherapy of fungal diseases
WO2010112707A1 (en) Use of a bartonella adhesin fragment for a vaccine
Jensen 15 ChaPtEr animal Models in Mycology
Ngo ECM33P is an Aspergillus fumigatus immunodominant antigen with cross reactivity to Rhizopus oryzae
Segal Antigenicity and immunity.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase